Index

2023

ABS Global, Inc. v. Cytonome/St, LLC, **1:381**

Actelion Pharmaceuticals LTD v. Mylan Pharmaceuticals Inc., **1:382**

Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC, **1:383**

AlterWAN, Inc. v. Amazon.com, Inc., **1:384**

Amgen Inc. v. Sandoz Inc., **1:385**

Apple Inc. v. Corephotonics, Ltd., **1:386**

Apple Inc. v. Vidal, **1:387**

Arbutus Biopharma Corporation v. ModernaTX, Inc., **1:388**

Axonics, Inc. v. Medtronic, Inc., **1:389; 1:390**

Baxalta Incorporated v. Genentech, Inc., **2:203**

Blue Gentian, LLC v. Tristar Products, Inc., **2:204**

Bot M8 LLC v. Sony Interactive Entertainment LLC, **2:205**

ChromaDex, Inc. v. Elysium Health, Inc., **3:245**

Columbia Sportswear North America, Inc. v. Seirus Innovative Accessories, Inc., **3:246**

Corephotonics, Ltd. v. Apple Inc., **3:247**

Cyntec Company, Ltd. v. Chilisin Electronics Corp., **3:248**

CyWee Group Ltd. v. Google LLC, **3:249**

Dionex Softron GmbH v. Agilent Technologies, Inc., **4:133**

Elekta Limited v. ZAP Surgical Systems, Inc., **5:156**

Finjan LLC v. SonicWall, Inc., **6:108**

FS.com Inc. v. International Trade Commission, **6:109**

Grace Instrument Industries, LLC v. Chandler Instruments Company, LLC, **7:144**

H. Lundbeck A/S v. Lupin Ltd., **8:166**

2023—Cont'd

Hawk Technology Systems, LLC v. Castle Retail, LLC, **8:167**

Hip, Inc. v. Hormel Foods Corporation, **8:168**

Incept LLC v. Palette Life Sciences, Inc., **9:522**

Inguran, LLC v. ABS Global, Inc., **9:523**

In re: Cellect, LLC, **9:516**

In re Couvaras, **9:517**

In re Float 'N' Grill LLC, **9:518**

In re Google LLC, **9:519**

In re PersonalWeb Technologies LLC, **9:520**

In re Stingray IP Solutions, LLC, **9:521**

Intel Corporation v. PACT XPP Schweiz AG, **9:524**

Ironburg Inventions Ltd. v. Valve Corporation, **9:525**

K-fee System GmbH v. Nespresso USA, Inc., **11:91**

Malvern Panalytical Inc. v. TA Instruments-Waters LLC, **13:254**

Medtronic, Inc. v. Teleflex Innovations S.a.r.l., **13:255; 13:256**

Medtronic, Inc. v. Teleflex Life Sciences Limited, **13:257**

Medytox, Inc. v. Galderma S.A., **13:258**

Minerva Surgical, Inc. v. Hologic, Inc., **13:259**

Netflix, Inc. v. DivX, LLC, **14:109; 14:110**

OneSubsea IP UK Limited v. FMC Technologies, Inc., **15:62**

Parkervision, Inc. v. Vidal, **16:188**

Parus Holdings, Inc. v. Google LLC, **16:189**

Personalized Media Communications, LLC v. Apple Inc., **16:190**

Philip Morris Products S.A. v. International Trade Commission, **16:191**

Purdue Pharma L.P. v. Collegium Pharmaceutical, Inc., **16:192**

2023—Cont'd

Regents of the University of Minnesota v. Gilead Sciences, Inc., **18:134**

Rembrandt Diagnostics, LP v. Alere, Inc., **18:135**

Roku, Inc. v. Universal Electronics, Inc., **18:136**

Salazar v. AT&T Mobility LLC, **19:344**

Sanderling Management Ltd. v. Snap Inc., **19:345**

Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc., **19:346**

Schwendimann v. Neenah, Inc., **19:347**

Sequoia Technology, LLC v. Dell, Inc., **19:348**

Sisvel International S.A. v. Sierra Wireless, Inc., **19:349; 19:350**

SNIPR Technologies Limited v. Rockefeller University, **19:351**

SSI Technologies, LLC v. Dongguan Zhengyang Electronic Mechanical LTD., **19:352**

Trinity Info Media, LLC v. Covalent, Inc., **20:165**

UCB, Inc. v. Actavis Laboratories UT, Inc., **21:92**

United Cannabis Corporation v. Pure Hemp Collective Inc., **21:93**

United Therapeutics Corporation v. Liquidia Technologies, Inc., **21:94**

VLSI Technology LLC v. Intel Corporation, **22:68**

Volvo Penta of the Americas, LLC v. Brunswick Corporation, **22:69**

2024

AI Visualize, Inc. v. Nuance Communications, Inc., **1:391**

AlexSam, Inc. v. Aetna, Inc., **1:392**

Allergan USA, Inc. v. MSN Laboratories Private Ltd., **1:393**

Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., **1:394**

Astellas Pharma, Inc. v. Sandoz Inc., **1:395**

Backertop Licensing LLC v. Canary Connect, Inc., **2:206**

Beteiro, LLC v. DraftKings Inc., **2:207**

Broadband iTV, Inc. v. Amazon.com, Inc., **2:208**

2024—Cont'd

Brumfield, Trustee for Ascent Trust v. IBG LLC, **2:209**

Celanese International Corporation v. International Trade Commission, **3:250**

Chewy, Inc. v. International Business Machines Corporation, **3:251**

Cloudofchange, LLC v. NCR Corporation, **3:252**

Contour IP Holding LLC v. GoPro, Inc., **3:253**

Crown Packaging Technology, Inc. v. Belvac Production Machinery, Inc., **3:254**

Cytiva BioProcess R&D AB v. JSR Corp., **3:255**

CyWee Group Ltd. v. ZTE (USA), Inc., **3:256**

DDR Holdings, LLC v. Priceline.com LLC, **4:134**

DexCom, Inc. v. Abbott Diabetes Care, Inc., **4:135**

Dragon Intellectual Property LLC v. DISH Network L.L.C., **4:136**

EcoFactor, Inc. v. Google LLC, **5:157**

Edwards Lifesciences Corporation v. Meril Life Sciences Pvt. Ltd., **5:158**

Freshub, Inc. v. Amazon.com, Inc., **6:110**

Galderma Laboratories, L.P. v. Lupin Inc., **7:145**

Google LLC v. EcoFactor, Inc., **7:146**

Inline Plastics Corp. v. Lacerta Group, LLC, **9:526**

Intellectual Tech LLC v. Zebra Technologies Corporation, **9:527**

IOENGINE, LLC v. Ingenico Inc., **9:528**

Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., **10:55**

LKQ Corporation v. GM Global Technology Operations LLC, **12:124**

Luv n' Care, Ltd. v. Laurain, **12:125**

Maxell, Ltd. v. Amperex Technology Limited, **13:260**

Miller Mendel, Inc. v. City of Anna, Texas, **13:261**

Mirror Worlds Technologies, LLC v. Meta Platforms, Inc., **13:262**

2024—Cont'd
Mobile Acuity Ltd. v. Blippar Ltd., **13:263**
Natera, Inc. v. NeoGenomics Laboratories, Inc., **14:111**
NexStep, Inc. v. Comcast Cable Communications, LLC, **14:112**
Osseo Imaging, LLC v. Planmeca USA Inc., **15:63**
Packet Intelligence LLC v. NetScout Systems, Inc., **16:193**
Palo Alto Networks, Inc. v. Centripetal Networks, LLC, **16:194**
ParkerVision, Inc. v. Qualcomm Incorporated, **16:195**
Pfizer Inc. v. Sanofi Pasteur Inc., **16:196**
Platinum Optics Technology Inc. v. Viavi Solutions Inc., **16:197**
Promptu Systems Corporation v. Comcast Corporation, **16:198**
Provisur Technologies, Inc. v. Weber, Inc., **16:199**
PS Products Inc. v. Panther Trading Co. Inc., **16:200**
Rai Strategic Holdings, Inc. v. Philip Morris Products S.A., **18:137**
Roku, Inc. v. International Trade Commission, **18:138**
Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., **19:353**
Sanho Corp. v. Kaijet Technology International Limited, Inc, **19:354**
SnapPower v. Lighting Defense Group, **19:355**
SoftView LLC v. Apple Inc., **19:356**
Speck v. Bates, **19:357**
Telefonaktiebolaget LM Ericsson v. Lenovo (United States), Inc., **20:166**
Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, **20:167**
UTTO Inc. v. Metrotech Corp., **21:95**
Vascular Solutions LLC v. Medtronic, Inc., **22:70**
Virtek Vision International ULC v. Assembly Guidance Systems, Inc., **22:71**
Voice Tech Corp. v. Unified Patents, LLC, **22:72**

2024—Cont'd
Weber, Inc. v. Provisur Technologies, Inc., **23:103**
Wisconsin Alumni Research Foundation v. Apple Inc., **23:104**
Zircon Corp. v. International Trade Commission, **26:17**
ZyXEL Communications Corp. v. UNM Rainforest Innovations, **26:18**

2025
Agilent Technologies, Inc. v. Synthego Corp., **1:398**
AliveCor, Inc. v. Apple Inc., **1:400**
Alnylam Pharmaceuticals, Inc. v. Moderna, Inc., **1:401**
AMP Plus, Inc. v. DMF, Inc, **1:402**
Ancora Technologies, Inc. v. Roku, Inc, **1:403**
Apple Inc. v. Gesture Technology Partners, LLC, **1:405; 1:406**
Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., **1:407**
BearBox LLC v. Lancium LLC, **2:212**
CQV Co., Ltd. v. Merck Patent GmbH, **3:262**
Dolby Laboratories Licensing Corporation v. Unified Patents, LLC, **4:137**
EcoFactor, Inc. v. Google LLC, **5:159**
Eye Therapies, LLC v. Slayback Pharma, LLC, **5:163**
Fintiv, Inc. v. PayPal Holdings, Inc., **6:112**
Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V. v. Sirius XM Radio Inc., **6:115**
HD Silicon Solutions LLC v. Microchip Technology Inc., **8:169**
Honeywell International Inc. v. 3G Licensing, S.A., **8:170**
ImmunoGen, Inc. v. Stewart, **9:530**
Incyte Corporation v. Sun Pharmaceutical Industries, Inc., **9:537**
Ingenico Inc. v. IOENGINE, LLC, **9:538**
In re Entresto, **9:531**
In re Forest, **9:532**
In re Kostic, **9:534**
In re Riggs, **9:535**
In re Xencor, Inc., **9:536**
IQRIS Technologies LLC v. Point Blank Enterprises, Inc., **9:542**

2025—Cont'd
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, **10:54**
Kroy IP Holdings, LLC v. Groupon, Inc., **11:92**
Lashify, Inc. v. International Trade Commission, **12:127**
Lynk Labs, Inc. v. Samsung Electronics Co., Ltd., **12:128**
Maquet Cardiovascular LLC v. Abiomed Inc., **13:265**
Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., **13:267**
Micron Technology, Inc. v. Longhorn IP LLC, **13:268**
Mitek Systems, Inc. v. United Services Automobile Association, **13:269**
Odyssey Logistics & Technology Corp. v. Stewart, **15:64**
Optis Cellular Technology, LLC v. Apple Inc., **15:65**
PowerBlock Holdings, Inc. v. iFit, Inc., **16:201**
Qualcomm Incorporated v. Apple Inc., **17:14**
Realtek Semiconductor Corporation v. International Trade Commission, **18:139; 18:140**
Recentive Analytics, Inc. v. Fox Corp., **18:141**
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., **18:142; 18:143**
Regents of the University of California v. Broad Institute, Inc, **18:144**
Restem, LLC v. Jadi Cell, LLC, **18:145**
Rex Medical, L.P. v. Intuitive Surgical, Inc., **18:146**
Sage Products, LLC v. Stewart, **19:358**
Sierra Wireless, ULC v. Sisvel S.p.A., **19:361**
Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc., **19:362**
Steuben Foods, Inc. v. Shibuya Hoppmann Corporation, **19:364**
United Services Automobile Association v. PNC Bank N.A., **21:96**
US Synthetic Corp. v. International Trade Commission, **21:98**
Wash World Inc. v. Belanger Inc., **23:105**

2025—Cont'd
Wuhan Healthgen Biotechnology Corp. v. International Trade Commission, **23:107**

2026
Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc., **1:408**
AGI SureTrack LLC v. Farmers Edge Inc., **1:409**
A.L.M. Holding Company v. Zydex Industries Private Ltd., **1:410**
Apple Inc. v. International Trade Commission, **1:411**
Apple Inc. v. Squires, **1:412**
Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc., **1:413**
Barry v. DePuy Synthes Companies, **2:214**
Bissell, Inc. v. International Trade Commission, **2:215**
Constellation Designs, LLC v. LG Electronics Inc., **3:263**
Crocs, Inc. v. International Trade Commission, **3:264**
Definitive Holdings v. Powerteq, **4:139**
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., **5:164**
Enviro Tech Chemical Services, Inc. v. Safe Foods Corp., **5:165**
Exafer Ltd v. Microsoft Corporation, **5:166**
Federal Express Corporation v. Qualcomm Incorporated, **6:117**
Fortress Iron, LP v. Digger Specialties, Inc., **6:118**
Genuine Enabling Technology LLC v. Sony Group Corporation, **7:148**
Global Tubing LLC v. Tenaris Coiled Tubes LLC, **7:149**
GoTV Streaming, LLC v. Netflix, Inc., **7:150**
Gramm v. Deere & Company, **7:151**
Hafeman v. Google LLC, **8:172**
Implicit, LLC v. Sonos, Inc., **9:543**
Ingevity Corporation v. BASF Corporation, **9:544**
Insulet Corp. v. EOFlow, Co. Ltd., **9:545**
International Medical Devices, Inc. v. Cornell, **9:546**
Ironburg Inventions Ltd. v. Valve Corporation, **9:547**

2026—Cont'd
IronSource Ltd. v. Digital Turbine, Inc., **9:548**
Magnolia Medical Technologies, Inc. v. Kurin, Inc., **13:271**
MCom IP, LLC v. City National Bank of Florida, **13:272**
Netflix, Inc. v. DivX, LLC, **14:113**
Ollnova Technologies Ltd. v. ecobee Technologies ULC, **15:66**
Range of Motion Products, LLC v. Armaid Company Inc., **18:147**
REGENXBIO Inc. v. Sarepta Therapeutics, Inc., **18:148**
Sound View Innovations, LLC v. Hulu, LLC, **19:365**
Teva Pharmaceuticals International GmbH v. Lilly, **20:169**
Trustees of Columbia University in City of New York v. Gen Digital Inc., **20:170**
US Patent No. 7,679,637 LLC v. Google LLC, **21:99**
Versata Software, LLC v. Ford Motor Company, **22:73**
VLSI Technology LLC v. Intel Corporation, **22:74**
Willis Electric Co., Ltd. v. Polygroup Ltd. (Macao Commercial Offshore), **23:108**

"A"
Generally, **1:85; 1:130; 3:96; 11:46**
Claim interpretation, **2:127; 20:90**
One or more than one, **5:44**

ABANDONMENT
Delay, unreasonable delay, **12:21**
Earlier devices, defendant's abandonment of, **3:3**
Law question, **1:111**
Mandamus, changing filing date on abandoned application, **9:54**
Revival, **1:177**
Suppression, **3:59; 6:33**
Time, length of, **4:65**
Unreasonable delay, **12:21**

ABBREVIATED NEW DRUG APPLICATION (ANDA)
Generally, **1:116; 2:54; 2:74; 4:40; 7:55; 7:139; 13:107; 19:182; 20:79**

ABBREVIATED NEW DRUG APPLICATION (ANDA)—Cont'd
Amendments, infringement, **6:90**
Attorney fees, **25:7**
Certification pledging, **19:247**
Conduct before FDA, **5:95**
Covenant not to sue, **3:132**
Damages, **1:280**
Declaratory judgment, **10:39**
Dependent claims, **15:31**
Disclose, obligation to, **2:81**
Double patenting, **1:166**
Enablement, **3:169**
Exclusivity period, **4:98**
Infringement
generally, **2:88**
amendments, **6:90**
Jurisdiction over orange book, **1:135**
Labeling, indications and usage, **2:152**
Obviousness, **6:91; 16:108; 19:271**
180-day exclusivity period, **4:98**
Paragraph IV, **3:132; 13:113; 20:78**
Preliminary injunction, **1:202**
Reasonable royalty, **1:280**
Repetitive filing, **1:156**
Reverse doctrine of equivalents, **18:80**
Safe harbor provision of Hatch-Waxman, **13:187**
Sec. 271(e)(2)(A), **9:312**
Sec. 1337(a), **1:175**
Settlement agreements, **9:309**
Subject matter, **20:100**
30-month period, **1:120; 5:95**
Use different than claimed in method claims, **1:128**
Willful, **7:81**

"ABOUT"
Generally, **15:27**
Doctrine of equivalents, **3:136**

ABOUT CLAIM TERMINOLOGY
Generally, **10:26; 13:80**
Meaning thereof, **5:20**

ABS GLOBAL, INC. V. CYTONOME/ST, LLC
2023, **1:381**

ABSOLUTE
Intervening rights, **13:168; 19:137**

ABSOLUTE PREDICTABILITY
Obviousness, **9:52; 13:18**

ABSOLUTE RULES
Claim preamble, **7:61**

ABSTENTION
Generally, **23:100**

ABSTRACT
Generally, **8:73**
Claim interpretation, **8:73**
Sec. 101, abstract ideas, **1:95; 1:253; 1:285; 1:286; 1:290; 1:333; 2:163; 3:143; 3:212; 4:104; 5:128; 6:94; 9:286; 9:308; 13:188; 19:298; 19:301; 19:323; 20:143; 21:61; 22:58**
Sec. 112, abstract ideas, **18:85**
Statutory subject matter, **21:57**

ABSTRACTIONS
Graver Tank, **20:6**

ABSURD RESULTS
Statutory construction, **2:39**

ABUSE
Anticipation, **18:20**
Fraud, **16:25**

ABUSE OF DISCOVERY
FRCP 37, **7:23**
FRCP 37(a)(4), **13:48**
Monetary sanctions, **13:6**

ABUSE OF DISCRETION
Generally, **12:76; 13:41**
Appellate review, **13:1**
Attorney fees award, **16:24**
Dismissal of pendent state law claim for unfair competition, **22:2**
Examiner's deposition, **23:5**
Found, **2:27**
FRCP 26, **8:9**
FRCP 56(f), **13:154**
Inequitable conduct, **18:78**
Interference, **5:68**
Motion for new trial, **23:10**
Motion to compel discovery, **19:17**
Permanent injunction, **1:219; 9:315**
Prejudgment interest, **3:96; 8:20**
Preliminary injunction, **1:155; 1:169; 13:89**

ABUSE OF DISCRETION—Cont'd
Sec. 271(e)(1), **5:3**
Sec. 285, **1:299; 2:170; 7:20**
Written description, **3:197; 9:318**

ABUSE OF PROCESS
State tort claim, **1:42**

ACCEPTABLE SUBSTITUTES
Generally, **19:96**
Availability, **7:47**
Lost profits, **13:45**
Panduit, **3:8; 4:90**

ACCEPTED WISDOM, CONTRARY TO
Generally, **23:11**
Obviousness, **3:3**

ACCESS AND ACCESSIBILITY
Public access, **4:101; 9:261; 12:89; 19:207; 22:42**

ACCESSORY SALES
Damages base, **11:21**

ACCIDENTAL DUPLICATION
Anticipation, **19:107**

ACCORD AND SATISFACTION
Discharge of claim, **3:48**

ACCOUNTING AND ACCOUNTING PHASE
Attorney, authoritative opinion of, **11:15**
Damages, **1:20; 1:38; 11:15**
Enhanced damages, **11:15**
Final judgment rule, **18:104**
Jurisdiction, **16:72**
Law of the case, **11:15**
Lost profits, defendant's profits as measure of, **11:15**
Nonparty's motion to quash discovery subpoena, **20:17**

ACCURACY
Claim interpretation, **19:155**

ACCUSTOMED MEANING
Ordinary and Accustomed Meaning (this index)

ACORDA THERAPEUTICS, INC. V. ALKERMES PLC
2025, **1:396**

ACTELION PHARMACEUTICALS LTD V. MYLAN PHARMACEUTICALS INC.
2023, **1:382**
2026, **1:408**

ACTING ON BEHALF OF
Sec. 119(a), **2:125**

ACTIVE INGREDIENT
Patent term extension, **16:125**

ACTUAL CASE
Subject matter jurisdiction, **12:22**

ACTUAL COMBINATION
Sec. 271(f)(2), **23:53**

ACTUAL COMMERCIAL CONSEQUENCES
Sec. 102(e) v. sec. 102(g), **19:41**

ACTUAL CONTROVERSY
Declaratory judgment, **1:94; 2:122; 3:69; 6:35; 6:38; 7:38; 7:55; 8:66; 9:324; 23:22**
Declaratory judgment of infringement, **20:26**
Subject matter jurisdiction, **12:22**

ACTUAL DEVICE SOLD
Blonder-Tongue, **1:13**

ACTUAL NOTICE AND KNOWLEDGE
Infringement, **12:61**
Willful infringement, **3:80; 14:24**

ACTUAL REDUCTION TO PRACTICE
Interference, **14:3**
Law question, **4:27**

ACTUAL REPORTS OF FAILURE
Obviousness, **2:101**

ACTUAL SKILL
Invention, **19:34**

ACTUAL WORDS
Claim interpretation, **4:53**

ADDENDA
Motion to strike, **6:10**
Strike, motion to, **6:10**

ADDITIONAL COMPONENTS OR ELEMENTS
Compare claims with accused product, **12:18**
Consisting of claim language, **13:7**
Gist, **12:18**
Good faith prosecution, **12:18**
Infringement not avoided, **12:18**
Prosecution history, **12:18**
Reverse doctrine of equivalents, **12:18**

ADDITIONAL EVIDENCE
Generally, **21:36**

ADDITIONAL PRECISION
Claim interpretation, **16:55; 22:40**

ADDITIONAL REFERENCES
Sec. 102(b), **9:18**

ADDITIONS
After entry of judgment, **15:13**
CIP, **19:28**
Correcting inventorship, **1:54**
Cross-appeal to reverse validity or infringement component of judgment, **18:2**
Factual findings to support jury verdict presumed, **2:15**
FRCP 15(c), **6:11**
Infringement, **9:186; 14:8**
Judgment, after entry of judgment, **15:13**
Obviousness, **21:8**
Transfer of appeal, **7:14**

ADDRESS OF CLAIMS
Court findings, **1:9**

ADJUSTMENT OF PATENT TERM
Generally, **3:232; 7:116; 9:484; 13:205; 13:237; 19:321**
Equitable tolling, **14:74**
Sec. 154(b), **23:69**
Summary judgment, **1:315**

ADMINISTRATIVE AGENCY
Patent and Trademark Office (PTO) (this index)

ADMINISTRATIVE BOARD
Factual underpinning, **2:37**
Review, standard of, **13:49; 22:9**

ADMINISTRATIVE BOARD—Cont'd
Substantial evidence standard, factual determinations reviewed under, **8:34**

ADMINISTRATIVE LAW
Appeal and review, **4:38; 15:8**
Cross-examination, right to, **4:38**
Discretionary agency decision, standard of review of, **4:38**
Inter parties review, **19:282**
Limitation of actions, **13:62**
Presumption that government officials perform their duties properly and in good faith, **13:70**
Sec. 101 patentability, **3:143**
Vitalness thereof, **4:38**

ADMINISTRATIVE NULLIFICATION
Final judgment, **9:354**

ADMINISTRATIVE PATENT JUDGES
Generally, **21:85**
Appointment, **9:311**

ADMINISTRATIVE PROCEDURE ACT (APA)
Generally, **2:202; 5:81; 15:59; 19:176**
Comprehensive record, **2:126**
Good cause exception under, **14:17**
Interference, **9:263**
Judicial review of PTO decisions under APA, **16:134**
Notice requirement, **9:344**
Own regulations, **19:180**
Restriction requirement, **8:165**
Sec. 553, **1:45**
Sec. 703(c), **13:51**
Sec. 706(2), **13:50**
Sec. 7513, **1:354**
Sec. 7703, **2:32**
Sec. 7703(c), **8:31; 11:26**
Substantial evidence standard, administrative board's factual determinations reviewed under, **8:34**

ADMISSIBILITY OF EVIDENCE
Claim interpretation, **19:16**
Discretion of court, **3:57**
Expert testimony, **1:42; 1:43; 7:29**
FRAP 28(e), **12:11**
Inventor's testimony, **8:106**

ADMISSIBILITY OF EVIDENCE —Cont'd
PTO examination, evidence withheld during, **8:111**
Sec. 145, **8:118**

ADMISSIONS
Antedate reference, failed attempt to, **3:54**
Choice of law, **13:121**
Dismissal, **3:19**
Ex parte test, **3:10**
MPEP, **16:6**
Obviousness, **9:125; 18:70**
Own work, **18:70**
Presumption of validity, **18:10**
Specifications, **16:109**

ADNEXUS INC. V. META PLATFORMS, INC.
2025, **1:397**

ADR PROCEEDING
Discovery, **8:37**

ADVERSARINESS, LACK OF
Jurisdiction, **7:8**

ADVERTISING
Abstract ideas, **1:285**

ADVICE OF COUNSEL
Willful infringement, **14:5; 19:154**

ADVISORY JURY
Obviousness findings, **11:69**
Substantial evidence standard, **18:14**
Verdict, **20:39**

ADVISORY OPINION
CAFC jurisdiction, **20:2**
Declaratory judgment, **9:92**

ADVOCACY
FRCP 15(c), **6:11**

AESTHETICS DETERMINATION
Sec. 171, **9:73**

AFFIDAVIT
Antedating reference, **7:19**
Appreciation or recognition by inventor of invention of interference counts, **9:23**
Claims construed, **9:77**
Declaration, **9:177**

AFFIDAVIT—Cont'd
Evidence, how treated, **9:23**
Inequitable conduct, **7:34**
Intent to deceive, **18:37**
Protested reissue, **9:23**
Reissue, protested, **9:23**
Rule 131, **7:19; 17:2**
Sec. 1.192(a), **9:142**
Sham affidavit doctrine, **17:12**
Skill in the art, level of, **9:23**

AFFIRMATIVE DEFENSES
Collateral estoppel, **4:3**
Double patenting, **3:4**
FRCP 8(c), **3:24**
Patent misuse, **23:9**

AFFIRMATIVE DUTY
Anticipation, **18:20**
Willful infringement, **18:29**

AFTER-THE-FACT TESTIMONY
Earlier writings, **14:12**

AFTERTHOUGHT
Secondary considerations, **9:82**

AGENCY
Patent and Trademark Office (PTO) (this index)

AGILENT TECHNOLOGIES, INC. V. SYNTHEGO CORP.
2025, **1:398**

AGI SURETRACK LLC V. FARMERS EDGE INC.
2026, **1:409**

AGREEMENT ON TRIPS
Enforcement of patents, **22:36**

AGREEMENTS
Contracts and Agreements (this index)

AI VISUALIZE, INC. V. NUANCE COMMUNICATIONS, INC.
2024, **1:391**

AKAMAI TECHNOLOGIES, INC. V. MEDIAPOINTE, INC.
2025, **1:399**

ALEXSAM, INC. V. AETNA, INC.
2024, **1:392**

ALGORITHM
Mathematical Algorithm (this index)

ALICE DECISION
Inventive concept, **1:253; 1:277; 2:163; 2:167; 2:168; 4:104; 4:105; 5:124; 5:128; 7:118; 9:383; 9:414; 12:22; 15:46; 19:292; 20:139**

ALIENS
State immunity from suit under Eleventh Amendment, **10:11**

ALIVECOR, INC. V. APPLE INC.
2025, **1:400**

ALL ELEMENTS RULE
Generally, **6:26; 10:7**
Claim interpretation, **10:7; 16:118; 16:119**
Claim preamble, **3:22**
Conflicting precedent, **10:7**
Doctrine of equivalents, **1:82; 5:86**
Law question, **10:7**

ALLERGAN USA, INC. V. MSN LABORATORIES PRIVATE LTD.
2024, **1:393**

ALL EVIDENCE
Generally, **16:36**
Obviousness, **1:80; 5:5; 18:15**

ALLGENESIS BIOTHERAPEUTICS INC. V. CLOUDBREAK THERAPEUTICS, LLC
2023, **1:383**

ALLOWANCE OF COSTS
Claim construction, **1:5**
Deposition transcripts, **19:45**
Transcripts, deposition transcripts, **19:45**

"ALL THE CIRCUMSTANCES"
Declaratory judgment, **13:155**

ALL WRITS ACT
Generally, **1:75**
Sec. 1651, **9:157**

A.L.M. HOLDING COMPANY V. ZYDEX INDUSTRIES PRIVATE LTD.
2026, **1:410**

ALNYLAM PHARMACEUTICALS, INC. V. MODERNA, INC.
2025, **1:401**

ALTER EGO DOCTRINE
FRCP 25(a), **13:25**
Piercing corporate veil, **13:50**

ALTERWAN, INC. V. AMAZON.COM, INC.
2023, **1:384**

ALTVATER
JNOV motion, **6:6**
Mootness, **13:46; 22:4**
Vacating judgment of patient invalidity, **13:46**

AMARIN PHARMA, INC. V. HIKMA PHARMACEUTICALS USA INC.
2024, **1:394**

AMBIGUITY
See also Certainty and Definiteness (this index)
Assignment, **5:99**
Claim interpretation, **2:98; 4:51; 16:53; 19:115**
Contract drafter, **9:132**
Contract interpretation, **3:44; 7:43; 9:160**
Judicial inquiry complete, **23:29**
PTO fact findings, **9:80**
Raises duty to inquire, **9:132**
Sec. 156, **21:6**
Statutory construction, **1:76; 6:24; 7:55; 8:45**

AMEND, LEAVE TO
Choice of law, **3:92**
Defective notice, **4:25**
FRCP 15(a), **20:5**

AMEND, MOTION TO
Generally, **19:6**
Denial, when appropriate, **7:33**
FRCP 15, **3:24**

AMENDMENT
Substitution of claims, **9:421**

AMENDMENT, NARROWING
Claim interpretation, **8:80; 12:83; 19:210**

AMENDMENT, NARROWING —Cont'd
Prosecution history estoppel, **2:128; 7:69; 18:77**

AMENDMENT OF 1984
Sec. 103, **11:23**
Sec. 116, **11:23**

AMENDMENT OF CLAIMS
Burden of proof, **1:305**
CIP, **19:28**
Competitor's device, **13:91; 16:72**
Consisting of claim language, **13:7**
Doctrine of equivalents, **5:53; 6:64; 8:65; 8:66**
Incorporation by reference, **8:113**
Inter partes review, **1:305**
Motion for prejudgment interest, **10:14**
Prosecution history, **5:44**
Prosecution history estoppel, **2:9; 2:128; 3:130; 4:73; 6:48; 8:13; 20:29**
Reexamination, **3:102; 6:8; 16:115; 17:6; 20:4**
Sec. 112, **20:6**

AMENDMENT OF DECISION
Special master, **16:37**

AMENDMENT OF JUDGMENT
Review, standard of, **1:102**

AMENDMENT OF PLEADINGS
Choice of law, **1:107**
FRCP 15(a), **20:24**
FRCP 15(b), **2:40**
FRCP 15(c), **6:11**

AMENDMENTS
ANDA, infringement, **6:90**
Doctrine of equivalents, **9:108; 9:235; 12:51**
Eleventh Amendment (this index)
Incorporation by reference language, clarification, **8:124**
Indefiniteness, **1:21; 8:86**
Prosecution history estoppel, **2:66; 8:47; 18:40; 19:146**
Sec. 120, **8:19**
Seventh Amendment (this index)

AMERICA INVENTS ACT
Compulsory counterclaim, **9:430**

AMERICA INVENTS ACT—Cont'd
Constitutionality, standing, **13:191**
False marking, **16:134**
Inter partes review, **19:282**
Joinder in patent cases, **9:359**
Partial institution, **19:282**
Person challenging, **18:127**
Qui tam provision, retroactive elimination, **2:151**
Selective institution, **19:282**

AMERICAN RULE
Party-prepared findings not improper, **13:12**
Shifting fees, **1:62**

AMGEN INC. V. SANDOZ INC.
2023, **1:385**

AMICUS CURIAE
Intervention, motion for leave to intervene, **9:67**
Motion for leave to intervene, **9:67**
Volunteer, as, **1:41**

AMINO ACID SEQUENCE
Written description, **3:133; 9:264; 9:306**

AMP PLUS, INC. V. DMF, INC
2025, **1:402**

"AN"
Generally, **3:96**
Claim interpretation, **2:127; 20:90**

ANALOGOUS ART
Generally, **9:78; 9:114; 9:127; 19:253**
Anticipation, irrelevant, **19:154**
Anticipation, irrelevant to, **9:201**
Criteria, **23:25**
Disclosure, familiar with all that references disclose, **9:78**
Factors, **9:168**
Fact questions, **8:42; 9:121; 9:154; 10:15**
Familiar with all that references disclose, **9:78**
Field of endeavor test, **9:256**
Inventor's reference, **19:36**
Obviousness, **9:338; 11:70; 18:23**
Ordinary skill in the art, hypothetical person of, **9:78**
Prior art, **1:329**
Reference, **9:78; 19:36**

ANALOGOUS ART—Cont'd
Sec. 102(b), **19:7**
Summary judgment, **6:1; 21:7**

ANCILLARY PROCEEDING
Discovery from nonparty, **13:37**

ANCILLARY TO PRIORITY
Interference, **13:31; 16:16**

ANCORA TECHNOLOGIES, INC. V. ROKU, INC
2025, **1:403**

ANDA
Abbreviated New Drug Application (ANDA) (this index)

ANIMALS
Interference, **3:28**
Sec. 101, **1:45**

ANSWER
FRCP 41(a)(1), voluntary dismissal when neither answer nor summary judgment motion filed, **5:18**

ANTEDATING REFERENCE
Generally, **9:163; 13:251**
Reduction to practice, **9:341**
Rule 131 affidavit, **7:19**

ANTICIPATED PROFITS
Lost profits, **13:131**
Reasonable royalty, **13:131**

ANTICIPATION
Generally, **1:101; 1:131; 1:154; 1:340; 1:341; 2:190; 3:77; 3:211; 3:212; 4:31; 5:55; 5:77; 8:71; 9:44; 9:201; 9:262; 9:280; 9:391; 9:408; 11:57; 12:13; 13:122; 14:85; 15:15; 15:51; 16:47; 16:72; 16:96; 16:145; 18:14; 19:60; 20:63; 20:72; 20:144; 21:50; 22:25**
Abuse, unfounded defenses as, **18:20**
Accidental duplication of invention, **19:107**
Addition, **1:33**
Affirmative duty of due care, **18:20**
All elements, **3:83; 19:249**
Alternatives, **2:86**
Analogous art, **9:201; 19:154**
Burden of persuasion and quantum of proof required, court must state, **18:7**

ANTICIPATION—Cont'd
Burden of production, **20:88**
Burden of proof, **9:201**
Change of ingredient, **1:33**
Chemical compound, **10:26**
Claim, **18:20**
Claim construction, **5:142; 8:96; 8:146; 8:148; 9:285; 20:67**
Claim differentiation, **11:2**
Claim preamble, **3:22; 4:15; 13:164**
Claim-supporting vs. claim-anticipating disclosures, **22:7**
Claim terms, **8:148**
Clearly erroneous standard, **18:20**
Commercial success, **1:10; 1:227**
Conception, **1:255**
Concepts, **16:4**
Continuation with new matter, **1:127**
Copying as indicium of nonobviousness, **4:15**
Corroboration, **14:94**
Covered business method patents, **2:168**
Damages, **5:138**
Defenses, unfounded defenses as abuse, **18:20**
Design patent, **4:64; 8:62; 9:325**
Discovery of properties, **9:257**
Dismissal, **3:19**
Disparagement following disclosure, **2:143**
Doctrine of last antecedent, **6:68**
Dominating patent, **18:20**
Double patenting, **3:4; 21:76**
Due care, affirmative duty of, **18:20**
Duplication, accidental, **19:107**
Enablement, **1:202; 2:82; 9:291; 13:120; 20:156**
Entire market value rule, **18:35**
Evidence, anticipation that certain thing may result in insufficient to proof, **5:19**
Examiner's rejection, **9:427**
Exclusion, **1:33; 1:98**
Existence and recognized, **1:92**
Extrinsic evidence considered, **19:51**
Fact question, **7:34; 8:49; 9:96; 9:111; 9:154; 9:363; 13:45; 19:249; 20:11; 20:56**
Factual determination, **20:63**
File history estoppel, **4:15**
Filing date, **26:12**

ANTICIPATION—Cont'd
Good faith, subjective, **18:20**
Hatch-Waxman Act, **21:76**
Hybrid sec. 102, **9:104**
Hypothetical claim, **1:115**
Identity of invention, **7:33; 20:20**
Incorporation by reference, prior art, **1:238**
Indefiniteness, **5:107**
Inducement, **5:138**
Inequitable conduct, **1:25; 18:20**
Inherency
generally, **1:106; 5:61; 9:242; 20:73**
characteristics, **3:41; 8:58; 9:220; 13:101; 18:56**
claim limitation, **19:56**
combination of prior art, **12:81**
factual question, **20:56**
inevitability, **9:360**
prior art, recognition of, **8:148; 19:150; 19:154**
Injunctions, **1:219**
Interference, **3:32**
Inter partes review, **5:139; 11:80; 11:81; 23:86**
Ipsissimis verbis test, **1:10**
ITC, **1:17**
Judgment as a matter of law, determination of invalidity, **23:87**
Jury instructions, **10:4; 19:249**
Knowledge available to public, **23:48**
Limitation, inherent, **19:56**
MPEP, **16:6**
Multiple different patents, **16:156**
Nonobviousness, copying as indicium of, **4:15**
Objective, **18:20**
Obviousness, **1:255; 3:167; 3:203; 5:139; 9:442; 9:461; 10:8; 11:77; 13:204; 13:227; 20:67; 21:76**
Oral testimony, **5:47**
Ordinary observer test, **9:321**
Ordinary skill in the field of the invention, recognized by, **3:103**
Possible to alter prior device, **19:129**
Potential claim unpatentable, **8:142**
Presumption of validity, **19:37**
Printed publication, **9:322; 9:327; 14:94**
Prior art
arranged as in claim, **14:56**

ANTICIPATION—Cont'd
Prior art—Cont'd
burden of production, **20:88**
incorporation by reference, **1:238**
inherent anticipation does not require recognition in, **19:150; 19:154**
means-plus-function claim, **6:68; 20:116**
method claims, **9:48**
single reference, must be found in, **7:48; 19:38**
Prior device, possible to alter prior device, **19:129**
Priority, **5:142**
Proper claim construction first, **20:67**
Public, knowledge available to, **23:48**
Public use, **16:167; 26:13**
Read in teachings not in reference, **13:85**
Reexamination, **9:314; 9:340; 19:225**
Reference, **5:66; 7:48; 7:94; 9:291; 13:85; 19:38; 19:201**
Relevance, analogous art irrelevant, **19:154**
Review, standard of, **3:54; 9:169; 18:44; 19:12**
Sec. 101, **1:368; 3:207**
Sec. 102, hybrid, **9:104**
Sec. 102(b), **7:99; 9:18; 9:129**
Sec. 102(c), **5:65**
Sec. 102(e), **9:28; 20:115**
Sec. 284, **16:167**
Sec. 285, **3:212**
Secondary considerations, **4:15**
Single prior art reference, must be found in, **7:48**
Subjective good faith, **18:20**
Subject matter jurisdiction, lack of, **1:7**
Two-step analysis, **11:43**
Unfounded defenses as abuse, **18:20**
Validity, **16:167**
Verbatim findings of counsel adopted, **8:22**
Witnesses, oral testimony, **5:47**

ANTITRUST
Generally, **9:282**
Choice of law, **5:30; 7:73; 9:219; 14:21; 14:25**
Citizen petition, **20:127**
Common law fraud, based on, **3:83**

ANTITRUST—Cont'd
Competitors disadvantage, changing product to, **3:83**
Enforcement of patent, **21:45**
Fraud, **3:83; 14:25; 16:48**
Inequitable conduct, **6:5; 14:21**
Jurisdiction, **3:69**
Jury, **1:16**
Licensing activities, **7:25**
Mandamus, **9:41**
Market power, **9:219; 13:133**
Monopoly power, **7:73**
Noerr immunity, **3:46; 5:108; 20:127**
Patent misuse, **16:126**
Private party, **5:30**
Quoting material out of context, **11:16**
Relevant market determination, **9:349**
Reverse settlement agreements, **6:86**
Sanctions, timing of request for, **11:16**
Sec. 1338(a), **21:13**
Settlement agreements, **9:309**
Standing, **9:89**
Timing of request for sanctions, **11:16**
Walker Process, **1:25; 1:42; 4:84; 11:16; 18:97**

ANY CLAIM AMENDMENT
Prosecution history estoppel, **6:48**

ANY METHOD OF ANALYSIS
Claim interpretation, **6:46**

ANY USE OF DEVICE
Claim interpretation, **16:120**

AORTIC INNOVATIONS LLC V. EDWARDS LIFESCIENCES CORPORATION
2025, **1:404**

APA
Administrative Procedure Act (APA) (this index)

APPARATUS
Claim interpretation, indefiniteness, **9:280; 13:220**
Entire market value rule, **6:36**
Functional language in apparatus claims, **20:110**
Marking, **3:146**
Obviousness, **4:74; 16:19**
Sec. 103 rejection, **9:101**

APPEALABILITY
Generally, **8:31**
Attorney disqualification, **16:3; 23:12**
Board decision with remand, **9:31**
CAFC jurisdiction, **7:8; 19:50; 22:2**
Cohen tripartite test, **19:71**
Contempt, **3:85; 5:85; 19:118**
Discovery, **8:9; 17:3**
Dismissal on merits vs. lack of subject matter jurisdiction, **1:39**
Finality rule, **13:23**
Infringement determination, **2:31**
Interlocutory order, **7:21; 17:3; 20:5**
Interlocutory partial judgment, **7:16**
Jurisdiction, **8:15**
Mandamus writ, **2:2**
Partial judgment, **3:9; 7:16**
Preliminary injunction, **11:19**
Quashing discovery, **8:9**
Remand, board decision with, **9:31**
Remand order, **8:97**
Sanctions simultaneously imposed on party and its attorney, **19:64**
Sec. 271(e)(1), **5:13**
Sec. 1292(a)(1), **18:11; 23:13**
Sec. 1292(c)(2), **10:12; 13:5**
Stay order, **11:1**
Stipulation, **10:37; 10:38**
Willful infringement, **3:26**

APPEAL AND REVIEW
Generally, **11:19; 16:37; 21:5**
Abuse of discretion, **13:1**
Administrative law, **4:38; 15:8**
All arguments presented below, **2:87**
APA, **8:34; 16:134**
Assessment of costs, Sec. 145, **14:4**
Attorneys, **6:12; 14:55; 16:29; 19:16**
Attorneys' fees, **4:16; 18:19; 19:8**
Board, **4:39; 7:23; 9:191; 9:195**
Burden, **12:11**
CAFC jurisdiction, **7:14**
Certification of order, **20:28**
Claim interpretation, **19:16**
Clearly erroneous standard, **12:2**
Clear or manifest error, **4:6**
Collateral order doctrine, **9:343**
Commission, not raised before, **6:40**
Confidential information, unsealing, **1:239**

APPEAL AND REVIEW—Cont'd
Considerations involved, **19:49**
Consolidation of claims, **19:95**
Cross-Appeal (this index)
Damages, **1:20**
Dann Amendment, **19:30**
Date of decision, **13:162**
Decision by implication, **5:41**
Declaratory judgment, **9:233**
Defined on theory never presented, **4:67**
Definitions, **10:19**
De novo, **9:7; 11:32**
Dependent claims not separately argued, **9:100**
Deposition testimony introduced on appeal, **13:183**
Design patent, **19:8; 21:4**
Discretionary authority, Board's exercise of, **7:23**
Dismissal, **9:47**
District Court, **6:9; 9:1; 12:36; 16:19**
Enhanced damages, **9:125**
Equitable tolling, **7:32**
Escrow, **3:21**
Examination, **9:2**
Examiner's rejection, **9:64**
Exhaustion, **2:143**
Expanding scope of, **4:25**
Ex parte test, **3:10**
Explained, **12:43**
Favorable judgment, **8:82**
Filing, **10:3; 23:28**
Final decision, **8:82**
FRAP 2, **10:20**
FRAP 4(a)(2), **16:110**
FRAP 4(a)(4), **10:14**
FRAP 30(b), **6:10**
FRAP 39(c), **3:29**
FRCP 26, **8:9**
FRCP 52(a), **3:45; 12:6; 16:25**
FRCP 60(b) motion, **3:5**
Frivolous Appeal (this index)
Immediate appeal, 28 USC Sec. 1291, **11:10**
Implication, decision by, **5:41**
Inequitable conduct, **23:47**
Infringement, award to prevailing infringer, **18:19**
Interference, **4:11; 5:68; 7:26; 7:74; 12:99; 13:119**

APPEAL AND REVIEW—Cont'd
Interlocutory appeal, **9:6; 13:61; 14:9**
ITC, **1:15; 1:129; 1:254; 2:117; 6:2; 7:104; 7:105; 19:25**
Judgment Notwithstanding Verdict (JNOV) (this index)
Jurisdiction. Appellate Jurisdiction (this index)
Jury, **5:41; 19:60**
Jury verdict, generally, **4:18**
License, **21:5**
Limitations and restrictions, **2:9; 7:2; 7:58; 9:59**
Mandamus, **9:41; 9:63**
Mandate, **12:47**
Manifest or clear error, **4:6**
Meaningful appellate scrutiny, **15:40**
Means-plus-function claim, **22:26**
Mootness (this index)
Motion, **9:38; 23:10**
New ground of rejection, **9:22**
9 cir, **19:51**
Notice, **4:25; 9:169; 10:14; 10:18**
Obviousness, **9:15; 9:52; 9:56; 15:40**
Opinions or findings, **19:42**
Overturn on appeal, **23:33**
Patent and Trademark Office (PTO), **9:2; 13:162**
Pendency of appeal, **19:25**
Post-trial motions, **18:3**
Prejudgment interest, no award of, **8:20**
Preliminary injunction, **2:16; 7:81; 8:2**
Preservation of issue, **3:54**
Prima facie case, **9:37**
Privilege, **9:184**
Prosecution history estoppel, **2:9**
Raising argument or issue
generally, **7:58; 8:44; 13:85; 16:32**
first time, **2:34**
not before trial court not considered on appeal, **16:35**
not presented below, **2:33**
not raised below, **8:44; 13:85**
Reconsideration, request for, **20:21**
Reexamination, **9:206**
Rejection, examiner's, **9:64**
Relationship between, **11:13**
Removal, Sec. 1447(d), **22:46**
Reply brief, first mentioned in, **23:23**
Reprehensible conduct, **9:159**

APPEAL AND REVIEW—Cont'd
Reviewed without deference, **21:42; 21:44**
Scope, no restriction on
Sec. 141 proceedings, **9:59**
Sec. 142 proceedings, **9:59**
Sec. 143 proceedings, **9:59**
Sec. 144 proceedings, **9:59**
Sec. 145 proceedings, **9:59**
Scope of judgment appealed from, **5:43**
Sec. 102(b), de novo review from PTO, **9:7**
Sec. 112, **9:40**
Sec. 141, **22:44**
Sec. 145, **6:9; 14:4**
Sec. 146, interference, **7:26**
Sec. 271(e)(1), **5:3**
Sec. 285, award of attorney fees, **4:16**
Sec. 337, appellate function, **3:23**
Sec. 1292(b), **9:97; 14:9**
Sec. 1292(c)(2), interlocutory appeal, **9:6; 13:61**
Sec. 1447(d), removal, **22:46**
Secondary considerations, **9:82**
Separate argument, **9:173**
Special interrogatories, **8:84**
Special master's decision, **13:24**
Standard of review
generally, **7:2; 9:165**
administrative agency, **3:50**
administrative board action, **22:9**
administrative board's decision, **13:49**
amend the judgment, **1:102**
anticipation, **3:54; 9:169; 18:44; 19:12**
arbitration, **4:33; 6:45**
attorney fees award, **9:161**
bankruptcy court decisions, **9:213**
best mode, **26:4**
board, **9:166; 9:208; 9:217**
claim construction and interpretation, **3:74; 12:35; 12:103; 19:12; 19:121; 20:64; 20:130**
claims court, **6:29; 19:67**
commission factual findings, **15:18**
conclusion of obviousness, **9:26**
construction of count, **7:74**
contempt, **3:56**
contract interpretation, **8:41**
contracts, **1:76**

APPEAL AND REVIEW—Cont'd
Standard of review—Cont'd
damages, **18:35; 19:96; 20:39; 21:23**
declaratory judgment, **19:86**
directed verdict, **1:46; 1:71**
disclosure dedication, **20:74**
discovery matters, **11:7**
discretion of court, **7:72**
dismissal, **2:44; 12:44**
disputed material facts, **19:120**
district court, **7:33; 7:72**
enablement, **2:79**
evidentiary rulings, **13:71**
experimental use, **13:109**
fact finding, **4:41; 9:217**
factual determination, PTO, **4:56**
factual findings, commission, **15:18**
finding, **7:27; 7:33; 9:217**
FRAP 38, **16:29**
FRCP 11, **1:42; 8:75; 16:76; 19:87**
FRCP 52(a), **3:39**
indefiniteness, **1:119; 12:61**
inequitable conduct, **2:59; 3:72; 6:50; 9:35; 10:31; 11:11; 13:84; 14:19; 18:37; 18:40; 20:39**
infringement, **3:43; 5:36; 9:254; 16:11**
injunction, **3:56; 15:6**
instructions, **5:30; 8:47; 21:27**
interference, **5:46**
inter partes review, **9:418; 13:213; 19:286**
inventorship, **5:40**
ITC, **2:117; 7:52; 8:28; 8:86; 19:25**
JMOL, **2:91; 3:96; 5:30; 6:46; 12:61; 13:85; 13:101; 14:21; 14:25; 18:62**
JNOV, **4:2; 6:36; 9:186; 12:31; 13:34; 19:12; 19:60; 22:2**
judgment as a matter of law (JMOL), **5:21; 12:45; 13:75; 20:41**
jury findings, **7:27**
jury instructions, **1:136; 4:32; 5:52; 10:4; 20:64**
jury trial, **2:34; 7:28; 23:25**
jury verdict, **2:49; 6:26; 8:51; 21:27**
laches, **5:30; 5:53; 8:50**
Lanham Act, **9:249**
license agreement, **19:104**
limitation of actions, **12:46**
litigation misconduct, **1:112**

APPEAL AND REVIEW—Cont'd
Standard of review—Cont'd
long-felt need, **19:12**
mandamus, **9:128**
material fact, disputed, **19:120**
means-plus-function claim, **14:38**
merit system board, **8:48**
motion, JNOV, **9:186**
new trials, **2:99; 5:54; 13:85; 14:25; 16:87**
obviousness, **2:59; 9:26; 9:168; 9:174; 9:195; 9:202; 9:418; 16:19; 22:13**
on-sale bar, **1:119; 22:20**
oral testimony of anticipatory devices, **19:12**
personal jurisdiction, **6:50**
preliminary injunction, **7:70; 8:46; 13:89; 20:61**
PTO, **4:56; 4:69; 9:43; 9:165; 9:196**
punitive damages, **18:58**
reduction to practice, **19:90**
regulations, **19:137**
remittitur, **15:10**
sanctions, **9:161**
Sec. 112(2), **9:240**
Sec. 145, **13:115**
Sec. 146, **23:52**
Sec. 282, **18:6**
Sec. 314(d), **9:418**
secondary considerations, **9:207; 19:12**
special verdicts, **20:35**
specification, use of, **19:12**
state claim, failure to, **4:29**
statutory construction, **2:54; 3:58; 6:44; 9:162; 9:176; 16:30; 19:88**
statutory interpretation, **13:59**
substantial evidence, **16:31**
summary judgment, **1:67; 1:82; 1:87; 2:44; 2:52; 2:63; 4:29; 7:7; 7:35; 9:162; 15:12; 17:5; 18:33; 19:84; 22:7; 23:36; 23:43**
willful infringement, **19:96**
willfulness, **5:54**
witnesses, **19:12**
Standard of review on appeal
interference, **13:119**

APPEAL AND REVIEW—Cont'd
Standard of review on appeal—Cont'd
preliminary injunction, **2:62; 7:50; 8:71; 12:16; 16:46; 20:53; 22:16**
Standing, **7:39; 19:48; 20:75**
Stay of injunction pending appeal, **5:2**
Subject matter jurisdiction, **1:37; 6:19**
Subordinate, **9:2**
Summary judgment, **8:17; 21:29**
Supporting evidence , citing only, **13:45**
Theory not raised below, **8:44**
37 CFR Sec. 1.191, **9:2**
Timeliness, **10:3; 11:38; 13:162**
Tolling, equitable, **7:32**
Transfers
generally, **16:45**
action, distinction between claim, **7:14**
addition of bona fide patent claim, **7:14**
bona fide patent claim, addition of, **7:14**
CAFC jurisdiction, **7:14**
claim, distinction between action, **7:14**
jurisdiction, CAFC jurisdiction, **7:14**
well-pleaded complaint rule, **1:160; 7:14**
Trial de novo, not, **6:12**
Trial of issues not presented to jury, **5:41**
28 USC § 1291, immediate appeal, **11:10**
Validity
generally, **7:61; 8:49; 18:39**
review of jury verdict, standard of, **8:62**
review of jury verdict thereon, standard of, **21:26**
Verdict, generally, **4:18; 16:14**

APPEAL BRIEF
File, failure to, **7:23**
Improper, **12:22**
Substitute for notice, **10:14**
Summary judgment, **2:29**
Supporting argument in, failure to provide any, **4:36**

APPELLATE COURT
Appendix documents not of record, improper to include in, **2:3**

APPELLATE COURT—Cont'd
Inequitable conduct, **6:4**
Infringement, **2:95**
Law of the case doctrine, **20:34**

APPELLATE JURISDICTION
Attorney fees award, **3:11**
Determination of, **8:1**
District Court, **1:31; 12:36**
Diversity of citizenship, not solely, **3:11**
Finality of judgment, **9:300**
FRCP 21, **1:31**
FRCP 42(b), **1:31**
Frivolous appeal, **3:11**
Infringement, threatened, **3:11**
Judgment as appealable, **8:15**
Pendent, **5:85**
Post-trial injunction pending appeal, denial of stay of, **19:9**
Preliminary injunction, **3:12**
Review of Board decision by expanded panel, **9:147**
Rumors, **3:11**
Sec. 1292, **1:31; 16:116**
Separately tried claims, **1:31**
Threatened infringement, **3:11**
Timeliness of appeal, **2:5; 13:8**
Transfer of appeal, **3:152; 21:12**

APPENDIX DOCUMENTS
Appellate court may consider only the record as it was made before the district court, **2:3**

APPLE INC. V. COREPHOTONICS, LTD.
2023, **1:386**

APPLE INC. V. GESTURE TECHNOLOGY PARTNERS, LLC
2025, **1:405; 1:406**

APPLE INC. V. INTERNATIONAL TRADE COMMISSION
2026, **1:411**

APPLE INC. V. SQUIRES
2026, **1:412**

APPLE INC. V. VIDAL
2023, **1:387**

APPLICATION
Abbreviated New Drug Application (ANDA) (this index)
Assignor estoppel doctrine, **17:4**
Claim interpretation, applicants' inaccurate statement, **19:155**
Confidence, high degree of confidence and trust between PTO and patent applicants, **10:5**
Continuation Application (this index)
Continuation-in-Part Application (this index)
Design patent issued as division of earlier utility application may be entitled to latter's priority date, **18:1**
Double patenting, **1:115**
Earlier filing date, **13:53; 26:12**
Estoppel, **23:30**
Obviousness, **9:29; 9:152**
Original application, meaning of term, **3:139**
Prima facie case, **9:150**
Prima facie obviousness, **2:25; 9:152**
Priority analysis, **9:340**
Provisional, **5:88**
Reissuance, 37 CFR Sec. 1.175(a)(4), **9:25**
Res judicata, **11:35**
Retroactive application of judicial decision, **23:33**
Sec. 119, **9:143**
Sec. 120, **8:19; 12:10**
Specification, **9:189**
Statutory construction, **15:7**
Substitute, must be obvious to, **9:29**
37 CFR Sec. 1.175(a)(4), **9:25**
Unrelated applications, **13:108**

APPOINTMENT
Administrative patent judges, **9:311**
Clause, **9:509**

APPORTIONMENT
Damages, **1:376; 13:224; 15:61**
Delay, **23:27**
Infringement, **13:224**
Reasonable royalty, **14:5**

APPRECIATION
Affidavit describing work of third party at reasonably contemporaneous time, **9:23**

APPRECIATION—Cont'd
Conception, **13:105**

APPREHENSION, REASONABLE
Generally, **6:35**

ARBITRATION
Generally, **13:127; 18:131**
Agreement to arbitrate, **4:85; 16:136; 22:55; 23:91**
Anti-suit injunction, **19:239**
CAFC, **18:3**
Choice of law, **9:278**
District court order compelling arbitration, **16:136; 22:55**
International Trade Commission, **9:380**
9 USC § 3, **18:13**
Review, standard of, **4:33; 6:45**

ARBUTUS BIOPHARMA CORPORATION V. MODERNATX, INC.
2023, **1:388**

ARITHMETICAL ERROR
Generally, **13:45**

ARO
Contributory infringement without direct infringement, none, **13:29**
Repair doctrine, **19:56**

ARRANGED AS IN CLAIM
Printed publication, **14:56**

ART CLASS
Interference, **4:21**

ARTICLE III
Judicial error, **19:55**

ARTICULATED REASON FOR DECISION
Agency, **12:64**

AS A WHOLE
Generally, **19:34**
Chemical, **9:60**
Claim preamble, **16:58**
Combination patent, **13:15**
Double patenting, **5:111**
Focus on one facet, **18:28**
FRCP 52(a), **12:6**
Infringement, **3:100**
Jury instructions, **10:15**

AS A WHOLE—Cont'd
New prior art not considered by PTO, **5:11**
Obviousness, **2:8; 2:171; 5:111; 7:17; 9:46; 9:86; 9:179**
Prima facie obviousness, **9:86**
Printed matter and substrate, no specific type of functional relationship needed between, **9:32**
Prior art references, **9:59**
Sec. 102(g), **11:9**
Special master's decision, **13:24**
Statutory construction, **3:63**
Summary judgment, **12:15**

ASCENDIS PHARMA A/S V. BIOMARIN PHARMACEUTICAL INC.
2026, **1:413**

ASSERTION OF ONLY CERTAIN CLAIMS
Entire patent not in issue, **3:46**

ASSESSMENT OF COSTS ON APPEAL
Sec. 145, **14:4**

ASSIGNMENT
Generally, **19:324**
Ambiguity, **5:99**
Bayh-Dole Act, **2:135**
Exclusive ownership, **20:134**
License, **13:79; 13:87; 19:154**
On-sale, **13:87**
Patent claims, **12:84**
Patentee status, **4:115**
Patent rights, generally, **4:86; 13:28**
PTO, failure to record assignment, **1:60**
Reassignment, **5:82**
Requirements, **7:39; 13:79**
Standing, **1:191; 1:196; 1:218; 1:264; 5:38; 13:87**

ASSIGNOR ESTOPPEL
Generally, **3:117; 8:158; 8:163; 13:223; 16:89; 17:4**
Application, **17:4**
Challenges to validity of contract, **21:38**
Contradictory, **19:47**
Damages, reservation of, **19:47**
Defenses, equitable, **19:47; 19:241**
Equitable defenses, **19:47**

ASSIGNOR ESTOPPEL—Cont'd
Equities weighed, **3:46**
Infringement, inefficient, **19:47**
Judgment, **19:47**
Less advantageous, **19:47**
License back, **1:43**
Privity, **9:118; 13:88; 19:47**
Public policy, **4:13**
Remand, **6:96**
Removal, **6:96**
Reservation of damages, **19:47**
Sec. 1447(d), **6:96**
Statements in declaration, **19:47**
Summary infringement, **13:207**
Validity of contract, challenges to, **21:38**

ASSUMPTIONS
Jurisdiction, **4:44**
Sec. 1400(b), control of litigation, **9:11**

ASTELLAS PHARMA, INC. V. SANDOZ INC.
2024, **1:395**

"AT LEAST ONE"
Generally, **18:50**

"AT LEAST TWO"
Plurality, **18:67**

ATTORNEY-CLIENT PRIVILEGE
Generally, **6:57; 7:52**
Choice of law, **1:19; 9:184**
Crime fraud exception, **21:58**
Interview of third-party inventor, **19:60**
ITC, **23:55**
Mandamus writ, **9:184; 9:293**
Order to produce communications, **23:74**
Record of invention, **9:221**
Third party interview, **19:60**

ATTORNEY FEES
Generally, **1:349; 18:132; 19:336.50**
Bad faith, **18:121**
Exceptional cases, **1:342**

ATTORNEYS
Appealability, **16:3; 19:64; 23:12**
Appeal and review, **6:12; 14:55; 16:29; 19:16**
Attorney-Client Privilege (this index)
Attorneys' Fees (this index)
Awards. Attorneys' Fees (this index)

ATTORNEYS—Cont'd
Claim interpretation, **9:94**
Client bound by acts or omissions of, **4:36**
Criticism by court, **14:55**
Disclosure, duty of, **9:43**
Disqualification
generally, **4:124; 11:6**
appealability, **9:343; 16:3; 23:12**
attorney, **11:6**
canons, **20:3**
confidences, sharing client's, **16:3**
defined, procedure, **16:3**
law firm, **5:12**
merged firms, **16:18**
presumption, **16:3**
procedural, **1:32**
procedure defined, **16:3**
rebuttal, **16:3**
screening, effectiveness of, **16:3**
settlement agreement, **19:40**
Drafting claims specifically directed to competitor's device, **9:158**
Evidence, **7:33; 19:6; 19:209**
FCR 7(a), **18:15**
Flagrant misrepresentations of record, **16:9**
FRCP 11, **18:95**
FRCP 37, **16:71; 21:69**
Inequitable conduct, **15:3**
Infringement, neither intent nor preparation constitutes, **12:22**
ITC, **13:40**
JNOV, **23:4**
Mandamus, **9:57**
Merged firms, **16:18**
Misconduct, **8:35; 11:13**
Obviousness, **3:104; 16:19**
Opinion of counsel
generally, **19:101**
accounting phase, **11:15**
appeal is review and not trial de novo, **6:12**
competency, **4:6; 13:45**
competency requirement, **3:80; 10:21**
damages, **1:20**
inference that adverse, failure to introduce supports, **5:30**
issue preclusion, **4:9**
marketing, prior to, **3:72**

ATTORNEYS—Cont'd
Opinion of counsel—Cont'd
no adverse effect, **11:56**
prior to marketing, **3:72**
willful infringement, **1:62; 8:50; 9:125; 10:15; 12:32**
willfulness, **21:18**
Personal jurisdiction, attorney-client relationship, **18:90**
Preliminary injunction, denial of, **12:16**
Qualifications. Disqualification, above
Reissue, **9:84**
Role of counsel, generally, **19:6**
Root, **12:24; 16:4**
Sanctioning counsel
Rule 11, **8:122**
Sec. 1292(c)(2), **9:6**
Sec. 10.57(b), **13:69**
Sec. 32, **23:15**
Sec. 1292(c)(2), **9:6**
Settlement agreement, **19:40**
Verbatim findings of counsel adopted, **8:22**
Willful infringement
generally, **14:5; 19:92; 19:154; 23:26**
advice of counsel, **14:5; 19:154**
opinion of counsel, **1:62; 8:50; 9:125; 10:15; 12:32; 19:92; 23:26**

ATTORNEYS' FEES
Generally, **1:364; 2:61; 7:81; 19:8; 23:56**
Abuse of discretion explained, **16:24**
ANDA, **25:7**
Appellate jurisdiction, **3:11**
Clearly erroneous standard, **19:23**
Collateral estoppel, **4:3**
Conflict of laws, **17:7; 19:163**
Cost-plus-overhead vs. private firm market rate for in-house counsel fee award, **16:24**
De novo review, **3:171**
Design patent, **19:8; 21:4**
Divided infringement, refusal to deem unreasonable, **13:208**
Enforcement order, **4:20**
Enhanced damages, **1:43**
Exceptional case, **1:62; 1:299; 2:85; 4:83; 5:109; 5:143; 9:316; 9:328; 9:377; 9:455; 9:483; 11:16; 12:24;**

ATTORNEYS' FEES—Cont'd
12:32; 12:110; 13:175; 13:197; 14:58; 18:9; 19:92; 19:249; 20:87; 20:115; 20:122; 23:65
Experience, reliance upon, **19:65**
Expert witness fees, **15:48**
Findings, for remand when no express findings, **3:46**
Fixed sum, **19:57**
Frivolous appeal, **16:20; 18:11; 20:16**
Inequitable conduct, **1:193; 8:18; 10:2; 13:19; 18:43; 20:97**
Infringement, **18:19**
In-house counsel, **16:24**
Joint liability of inventor, **8:18**
Jury trial, **1:300**
Litigation misconduct, **13:167; 13:197; 19:100; 20:87**
Local rules, **1:260**
Mandamus, **9:68**
Market rate, **16:24**
Mootness, **19:200**
Non-patent issues, **7:54**
Other circumstances may support, **19:26**
Party-prepared findings not improper, **13:12**
Prevailing party, **3:35; 13:73**
Prior experience, **19:65**
Private firm, **16:24**
Privity, **11:14**
Prosecution aggressiveness, **13:116**
Public service, **10:2**
Rate calculation, **22:22**
Reissue proceedings, **16:24; 18:82**
Reliance upon his prior experience, **19:65**
Remand, **3:46**
Restitution of award improperly granted, **19:58**
Review, standard of, **9:161**
Routine assessment, **18:12**
Sanctions, **12:36; 19:42**
Sec. 85, **9:159**
Sec. 145, **14:80**
Sec. 285, **1:300; 2:170; 3:42; 3:196; 4:16; 4:32; 5:109; 5:137; 7:20; 7:27; 8:18; 8:38; 8:130; 9:328; 9:455; 12:4; 13:38; 13:175; 16:5; 18:121; 18:123; 19:3; 19:33; 19:35; 19:51; 19:58; 19:313; 23:6**
Sec. 1117(a), **18:121**

ATTORNEYS' FEES—Cont'd
Sec. 2412(b), **13:48**
Settlement negotiations, failure to engage in, **15:37**
Success in sustaining validity of valid patent is public service, **10:2**
Summary judgment, **1:2; 2:71**
Two-prong inquiry, **13:85**
Two-step analysis required, **7:37**
Two-step process, **6:53**
Validity of valid patent is public service, **10:2**
Willfulness finding not upheld, **19:103**

ATTRIBUTION
Infringement, **20:141**

AVAILABLE TO THE PUBLIC
Printed publication, **9:386**

AXIOMATIC
Case or controversy requirement, **1:113**

AXONICS, INC. V. MEDTRONIC, INC.
2023, **1:389; 1:390**

AZURITY PHARMACEUTICALS, INC. V. ALKEM LABORATORIES LTD.
2025, **1:407**

BACKERTOP LICENSING LLC V. CANARY CONNECT, INC.
2024, **2:206**

BAD AXIOM
Sec. 102(g), **11:9**

BAD FAITH
Attorney fees, **13:167; 18:121; 20:115**
Damages, **20:19**
Exceptional case, **9:328; 13:69**
Litigation misconduct, **18:29**
Objectively baseless, **4:88; 7:92**
Settlement, **12:39**
Willful infringement, **10:21**

BANKRUPTCY
Choice of law, **9:213**
11 USC § 1141, **2:21**
Infringement, **8:94**
Jurisdiction, **9:213**
Review, standard of, **9:213**
Standing analysis, **13:148**

BANKRUPTCY—Cont'd
Summary judgment, **2:21**

BARRETTE OUTDOOR LIVING, INC. V. FORTRESS IRON, LP
2025, **2:210**

BARRY V. DEPUY SYNTHES COMPANIES
2026, **2:214**

BATCH PROCESS
Inequitable conduct, **10:2**

BAXALTA INCORPORATED V. GENENTECH, INC.
2023, **2:203**

BAYER PHARMA AKTIENGESELLSCHAFT V. MYLAN PHARMACEUTICALS INC.
2025, **2:211**

BAYH-DOLE ACT
Generally, **3:108**
Assignment, **2:135**

BEARBOX LLC V. LANCIUM LLC
2025, **2:212**

BED OF ITS OWN MAKING
FRCP 15(c), **6:11**

BEST MODE
Generally, **1:80; 1:161; 2:70; 3:109; 9:125**
Claimed invention, **20:63**
Commercial mode, **26:4**
Concealment, **2:34; 19:231**
Defined by scope of claimed invention, **14:30**
Deposit, **1:44; 19:51**
Design patent, **18:1**
Disclosure, **7:37; 7:47; 9:357; 23:72**
Enablement, **2:90; 3:31; 9:177**
Fact-law question, mixed, **3:31**
Fact question, **14:8; 20:35**
Interference, **4:8; 13:3**
JNOV motion, denial of, **13:13**
Knowledge, only disclose what aware of, **7:47**
Law-fact question, mixed, **3:31**
Mixed law-fact question, **3:31**
Only disclose what aware of, **7:47**

BEST MODE—Cont'd
Possessed best mode, **5:55**
Review, standard of, **26:4**
Sec. 112, **1:161; 1:194; 2:14; 4:2; 5:16; 19:21; 19:60**
Sec. 112(1), **7:34; 20:33; 23:19**
Sec. 120, **8:19**
Specification, **9:357**
State of mind of inventor not sole focus, **3:31**
Time of belief, **1:246**
Trade name alone, **18:5**
Two component analysis, **1:91; 7:41; 13:79; 21:25**
Two factual inquiries, **5:49; 6:36; 14:21; 18:42; 23:41; 25:4**
Unclaimed subject matter, **13:101**
Unintentional omission, **8:87**
Verbatim findings of counsel adopted, **8:22**

BETEIRO, LLC V. DRAFTKINGS INC.
2024, **2:207**

BEYOND EXPRESS TERMS
Consent judgment, **14:28Z**

BIAS
Generally, **16:29**
See also Prejudice (this index)

BIFURCATION
Sec. 287, **4:12**
Trial, **19:195**
Willfulness, **17:3**

BIOGENIC
DNA technology, **1:44**

BIOLOGICAL ACTIVITY
Chemical, **9:60**

BIOLOGICAL DEPOSITS
Description, **5:69**

BIOLOGICAL PROCESSES
Enablement, **5:66**

BIOLOGICS PRICE COMPETITION AND INNOVATION ACT (BPCIA)
Generally, **1:273**
Doctrine of equivalents, **1:337**
Infringement, **1:337**
Preemption, **1:303; 19:294**

BIOSIMILAR PRODUCTS
Preliminary injunction, **1:291**

BISSELL, INC. V. INTERNATIONAL TRADE COMMISSION
2026, **2:215**

BLEAK HOUSE
Dickens, **19:83**

BLOCK DIAGRAM
Combination patent, **13:15**

BLOCKING PATENT
Obviousness, **1:314**

BLONDER-TONGUE
Generally, **1:13**
Actual device sold, **1:13**
Collateral estoppel, **1:47; 13:26; 13:61; 19:33**
Delay in disclaiming, **1:13**
Earlier adjudication, not augmented by, **1:13**
FRCP 52(a), **1:13**
Inequitable conduct, **1:13**
Infringement proof, **1:13**
Law question, **1:13**
Lear, **20:9**
Obviousness, **1:13**
Presumption of validity, **1:13**
Repair parts, **1:13**
Royalty, **1:13**
Subjective good faith, **1:13**

BLUE GENTIAN, LLC V. TRISTAR PRODUCTS, INC.
2023, **2:204**

BLUEPRINT
Obviousness, **9:90**

BOARD
Appealable, **9:31**
Appropriate, when, **11:26**
Clearly erroneous standard review of facts, **9:191**
EIC, **7:23**
Explanation, sufficient, **9:218**
Fact findings, **9:195**
Filings, late, **18:56**
Findings, review for, **9:195**
Grounds relied upon, **1:348**
Interference, dissolution of, **16:7**

BOARD—Cont'd
Invention ownership vs. inventorship, **2:36**
Late filings, **18:56**
Merit Systems Protection Board standard of review thereof, **4:39**
Review, standard of, **2:126; 9:166; 9:208; 9:217**
Sec. 135(a), **9:116**
Sufficient explanation required, **9:218**
37 CFR Sec. 1.191, **9:2**

BOARD OF PATENT APPEALS
Scope of review, **9:265**

BOARD OF PATENT APPEALS AND INTERFERENCES
Jurisdiction, **2:150**

BONA FIDE PATENT CLAIM
Transfer of appeal, **7:14**

BONA FIDE PURCHASER
Generally, **1:46; 8:63**
Choice of law, **18:61**
License agreement, **18:61**

BORN VALID
Sec. 282, **6:10**

BOT M8 LLC V. SONY INTERACTIVE ENTERTAINMENT LLC
2023, **2:205**

BRIEFS
Appeal Briefs (this index)
Commissioner's brief not prior art, **9:140**
Confidentiality markings, **9:337**
Filing, **7:23**
First time develop fraud allegation, **12:3**
Sec. 143, **9:116**
Waiver by not raising issue, **23:25**

BRIGHT-LINE TEST
Fitness for intended use, **6:23**
Intent, **6:23**
On-sale bar, **3:83**
Owner's right to preserve patented machine's fitness for its intended use, **6:23**
Repair vs. reconstruction, **2:75**

BRITA LP V. INTERNATIONAL TRADE COMMISSION
2025, **2:213**

BROADBAND ITV, INC. V. AMAZON.COM, INC.
2024, **2:208**

BROAD DISCRETION
Injunctive relief, **10:23**

BROADEN BEYOND CORRECT SCOPE
Claim differentiation, **13:91; 20:51**

BROADENED CLAIMS
Reissue, **9:192; 17:6**

BROADENING REISSUE
Filing, timely filed, **9:3**
Objective intent to claim is not criterion, **9:109**
Prosecution history, **9:368**
Sec. 251, **1:52**
Summary judgment, **20:10**
Timely filed, **9:3**

BROADENING SCOPE
Injunction, **19:48**

BROADEN TERM
Reexamination, **1:90**

BROADEST REASONABLE INTERPRETATION
Claim construction, **3:201; 9:350**
Claim interpretation, **9:149; 9:256**
Claim not read in vacuum, **9:58**
Claims construed, **9:77**
Examiner's rejection, **9:427**
Interference, **9:88; 23:14**
Interference counts, **18:56**
Inter partes review, **3:201; 4:112; 9:400; 9:448; 22:56**
Obviousness, **3:201**
Reexamination, **9:8; 9:154; 9:255**

BROAD STATUTORY LANGUAGE
Statutory construction, **20:31**

BRUMFIELD, TRUSTEE FOR ASCENT TRUST V. IBG LLC
2024, **2:209**

BURDEN
Appeal, **12:11**

BURDEN—Cont'd
Challenger, **16:12; 18:4**
Coming forward, **10:18**
Establish, PTO's burden to establish, **9:140**
Heavy burden
challenging validity, **1:9**
FRCP 26, **8:9**
obviousness question, **16:19**
reasonable royalty, **8:51**
validity, **23:48**
Interference, **15:1; 19:70**
Mandamus writ, **9:193**
Obviousness, **1:30**
Prima facie obviousness, **9:153**
Prior art, noting differences from, **4:6**
Rebut, **9:152**
Show, **2:96; 22:18**
Summary judgment, **13:90; 18:47**
Willful infringement, **16:22**

BURDEN OF PERSUASION AND QUANTUM OF PROOF
Generally, **12:74; 18:7**
Anticipation, **18:7**
Burden of proof, **19:68**
Claim element, **18:7**
Court must state, **18:7**
Dependent, independent vs. dependent claims, **18:7**
Independent vs. dependent claims, **18:7**
Means-plus-function, **18:7**
Obviousness, **9:357; 18:7**
Validity, **15:15**

BURDEN OF PRODUCTION
Anticipatory prior art, **20:88**
Reduction to practice, **12:63**

BURDEN OF PROOF
Generally, **9:282**
See also Presumptions (this index)
Amendment of claims, **1:305**
Anticipation, **9:201**
Burden of persuasion, **19:68**
Circumstantial evidence, carried by, **4:33**
Copying claims from patent, **2:26**
Declaratory judgment, **13:179; 13:194**
Defenses, **9:118; 19:48**
Disclosure, **13:10**
Evidence required, **5:83**

BURDEN OF PROOF—Cont'd
Exceptional case, **15:45**
Indefiniteness, **1:21**
Inequitable conduct, **19:92**
Infringement, **1:123; 7:31; 13:179; 13:194**
Interference, **2:47; 2:107; 4:8; 5:52; 13:31; 16:36**
Invalidity, **2:92**
ITC, **19:25**
Jury, **1:16**
Laches, **23:46**
License defense, **3:56; 9:118**
New prior art, **5:11**
Obviousness, **14:71**
On-sale bar, **9:171; 12:98**
Preliminary injunction, **3:76; 5:92; 14:20; 19:235**
Printed publication, **13:72**
Prior art, **5:11**
Reverse doctrine of equivalents, **19:24**
Sec. 282, **9:80**
Summary judgment, **1:35; 10:4**
Validity, **14:21; 20:35; 20:39; 21:25**

BURYING REFERENCE
Relevancy of foreign patent prosecution, **13:69**

BUSINESS DAMAGE
Mandamus, **9:76**

BUSINESS DAY
Timely appeal, failure to file, **23:28**

BUSINESS METHODS EXCEPTION
Estoppel, **3:202**
Statutory subject matter, **9:308; 19:112; 19:297**

BUSINESS RECORDS EXCEPTION
Evidence, **3:67; 13:71**

BUSINESS SYSTEMS
Sec. 101, **1:293; 9:286**

BUSY COURT
FRCP 15(a), **20:5**

BUT FOR CAUSATION
Panduit guidelines, **3:62**

BUT FOR TEST
Lost profits, **5:54; 6:36; 7:47; 8:51; 11:32; 13:121; 16:40; 18:35; 20:52**

BUT ONE FACTOR FOR REJECTING
Intent to claim, **9:39**

CAFC
Court of Appeals for the Federal Circuit (CAFC) (this index)

CAMOUFLAGED ATTACK
Claim interpretation, **20:8**

CANATEX COMPLETION SOLUTIONS, INC. V. WELLMATICS, LLC
2025, **3:257**

CANCELLATION
Claim interpretation, **16:118; 16:119**
Doctrine of equivalents, **13:106**
Prosecution history estoppel, **5:36**
Reissue claim, **9:364; 12:31**

CANDOR
Generally, **11:11**
Inequitable conduct, **12:55**

CANONS
Attorney disqualification, **20:3**

CAPACITOR
Generally, **8:58; 9:220**

CASE OR CONTROVERSY
Generally, **1:274; 16:144; 19:160; 20:79**
Axiomatic, **1:113**
Declaratory judgment
inducement, **1:319**
plaintiff must establish, **19:86**
Escrow, **3:21**
Infringement, **7:10**
Medicare Prescription Drug, Improvement, and Modernization Act, **20:78**
Orange book, **20:78**
Patent Office issuance of final decisions, challenging, **19:290**
Summary judgment, **7:7**

CATALOG OF PARTS
Generally, **12:13**

CAUSAL RELATION MUST BE SHOWN
Lost profits, **5:71**

CAUSAM ENTERPRISES, INC. V. ECOBEE TECHNOLOGIES ULC
2025, **3:258**

CAUSAM ENTERPRISES, INC. V. INTERNATIONAL TRADE COMMISSION
2025, **3:259**

CAUSATION
Lost profits, **13:79; 15:10**
Permanent injunction, **7:121**

CAUSATION, BUT FOR
Lost profits, **3:96**

CAUSE OF ACTION
Generally, **13:62**

CCPA DECISIONS
Binding precedent, **9:74**
Fast moving industry, **9:74**
Long-felt need, **9:74**
Secondary considerations, **9:74**

CD-ROM
FRAP 25, **25:5**

CEASE AND DESIST LETTERS
Corporate officers, **6:67**
Importation, **19:221**
Minimum contact, **18:45**
Personal jurisdiction, **24:5**

CEILING
Factual findings to support jury verdict presumed, **2:15**

CELANESE INTERNATIONAL CORPORATION V. INTERNATIONAL TRADE COMMISSION
2024, **3:250**

CELLS
Hepatocytes, freeze-thaw cycles, **18:109**
Microbiology field, **9:53; 18:109**

CENTRIPETAL NETWORKS, LLC V. PALO ALTO NETWORKS, INC.
2025, **3:260**

CERTAINTY AND DEFINITENESS
Generally, **2:166; 3:237; 4:111; 5:122; 8:93; 9:252; 9:396; 9:473; 14:103; 14:105 to 14:107; 15:50; 16:127; 19:161; 19:337**
See also Ambiguity (this index)
Amenable to construction, **5:58**
Amendments, **1:21; 8:86**
Antecedent basis, **5:81**
Anticipation, **5:107**
Apparatus method, mixed, **13:220**
Appeal and review, **21:44**
Basic and novel properties, **8:156**
Burden of proof, **1:21**
Claim construction, **3:193; 7:120; 20:99**
Claim language as precise as subject matter permits, **16:47**
Claim preclusion, indefiniteness, **4:110; 13:223**
Clarity, **19:213**
Competitor, potential competitor cannot determine infringement, **13:57**
Construction, **5:58; 5:81; 8:86; 8:103**
Damages, indefiniteness, **1:275**
Deference, reviewed without, **21:44**
De novo review, **9:328**
Design patent, indefiniteness, **1:275; 5:126**
Difficulty in determining scope of claim by one skilled in the art, **9:156**
Discretion of court, **19:60**
Enablement, versus, **16:60; 20:121**
Essentially factual, when issues are, **2:99**
Explicit antecedent basis, failure to provide, **2:84**
Express definition of terms, **2:105**
Extrinsic evidence, **2:156**
Indefiniteness. See entries throughout this topic
Infringement, **13:57**
Inherent, **9:486**
Intervening rights, **16:161**
Language
claim language as precise as subject matter permits, **16:47**
indefinite, **2:169**
Legal conclusions, **1:118; 9:253**
Means-plus-function claim, **1:289; 5:112; 9:330; 13:200; 18:107; 26:15**

CERTAINTY AND DEFINITENESS —Cont'd
Method and apparatus of claim, **9:280**
Noninfringement, **21:68**
Not amendable to construction, **8:86**
Obviousness, **2:160**
Opposing views of experts, **1:21**
Ordinary artisan, **8:103**
Ordinary skill, hypothetical person of, **5:106**
Potential competitor cannot determine infringement, **13:57**
Prosecution history estoppel, **1:21**
Question of law, **9:328**
Reasonably apprise of the scope of invention, **15:21**
Review, standard of, **1:119; 12:61**
Sec. 112, **1:21; 1:44; 1:161; 16:114; 19:4**
Sec. 112(1), **3:54**
Sec. 112(2), **3:37; 5:106; 13:55; 14:12; 14:66; 14:72**
Skilled in the art, **9:156**
Standard to apply, **9:389**
Subject matter, **16:47**
Summary judgment, **2:175; 5:141; 19:131**
Technical terms, **13:80**
Those skilled in the art would understand the scope, **1:99**
Understand, hard to, **19:131**

CERTIFICATE OF CORRECTION
Generally, **3:224; 8:154; 19:126**
Clear and convincing standard, **3:128; 19:142**
Material limitation omission, **8:132**
Reasonable debate, subject to, **14:39**
Recapture rule, **3:187**
Sec. 254, **19:56**
Subject to reasonable debate, **14:39**
Terminal disclaimer, **10:44**
Written description, **3:187**

CERTIFICATES AND CERTIFICATION
Choice of law, **19:155**
Correction. Certificate of Correction (this index)
FRCP 54(b), **19:141; 19:191**
Order for appeal, **20:28**
Reexamination, **9:239**

CERTIFICATION PLEDGING
Abbreviated New Drug Application (ANDA), **19:247**

CERTIFIED APPEAL
Limitation thereon, **6:17**

CERTIFIED QUESTION
Generally, **8:55**
Federal patent policy, **6:17**

CERTIORARI
Sec. 135(c), **3:29**

CFR 1.601(n)
Generally, **5:68**

CHAIN OF RELATED APPLICATIONS
Sec. 120, **12:10**

CHALLENGE
Assignor estoppel, **21:38**
Burden, heavy, **1:9**
Burden on patent challenger, **16:12**
Claim preclusion, **8:76**
Executive Order 10096, **8:10**
Interference, **13:3**
Jurisdiction, **19:46**
Liquidated damages, **4:46**
Public policy, **4:13**
Sec. 112, **18:4**

CHEMICAL
Biological activity, **9:60**
Contemporaneous invention as evidence of knowledge level, **9:60**
Medicinal drug, **9:60**
Obvious to try, **9:60**
Reference read in combination with prior art as a whole, **9:60**
Structural similarity, **9:60**

CHEMICAL CASES
Doctrine of equivalents, **26:2**
Infringement, **13:46**
Interference, **3:28**
Obviousness, showing of nonobviousness, **9:44**
Showing of nonobviousness, **9:44**

CHEMICAL COMPOSITION
Obviousness, prima facie obviousness, **9:98**
Prima facie obviousness, **9:98**

CHEMICAL COMPOUND
Anticipation, **10:26**
Disclosure, encompassed by disclosed generic formula, **9:148**
Encompassed by disclosed generic formula, **9:148**
Exact compounds, **21:33**
Generic formula, encompassed by disclosed generic formula, **9:148**
Infringement, **5:29**
Interference, **15:1**
Obviousness, **5:90; 5:91**
Obviousness-type double patenting, **15:41**

CHEMICAL GENUS
Disclosure, **9:126**

CHEMICAL INTERFERENCE
Sec. 112, **2:14**

CHEMICAL PROCESS
Define, process defined, **9:20**
Each statutory claim class to be considered independently, **9:20**
Obvious, otherwise, **9:20**
Process defined, **9:20**

CHEVRON DEFERENCE
Statutory construction, **4:45; 6:31; 13:77; 26:3**

CHEWY, INC. V. INTERNATIONAL BUSINESS MACHINES CORPORATION
2024, **3:251**

CHINESE WALL
Confidences acquired, **5:12**

CHOICE OF FORUM
License agreement, **23:2**

CHOICE OF LAW
Generally, **2:34; 2:116; 6:78; 18:32; 19:61**
Admitting evidence, **13:121**
Advertising, false, **2:132**
Amend, leave to, **3:92**
Amendment of pleadings, **1:107**
Antitrust, **5:30; 7:73; 9:219; 14:21; 14:25**
Arbitration award, **9:278**
Attorney-client privilege, **1:19; 9:184**
Attorneys' fees, **17:7; 19:163**

CHOICE OF LAW—Cont'd
Bankruptcy, **9:213**
Bona fide purchaser, **18:61**
CAFC, **5:67; 6:51; 7:75; 19:156; 21:44**
Certification, **19:155**
Civil contempt, **5:59**
Claim preclusion, **13:65**
Collateral estoppel, **2:88; 4:71; 16:57; 20:72; 22:24**
Common law, federal common law, **18:38**
Competition, unfair, **7:55; 16:48**
Compliance with court rules, **5:54**
Conflicts with other federal statutes, **13:92**
Consent judgment, **14:28Z**
Contracts, **19:134; 20:53**
Co-pending actions, **12:67**
Copyright, **1:151**
Cost awards, **11:51**
Counterclaim, infringement, **22:18**
Deference to regional circuit law, **2:31**
Discovery, **1:19; 4:47; 19:114**
Dismissal, without-prejudice, **8:82**
Evidence, admitting, **13:121**
Evidentiary rulings, **1:92; 15:14; 19:142**
Factors considered, **13:73**
Federal common law, **18:38**
FRCP, **19:16**
FRCP 11, **22:14**
FRCP 15(b), **19:105**
FRCP 26(c)(7), **1:19**
FRCP 37, **16:71; 21:69**
FRCP 51, **5:60**
FRCP 56(f), **5:83; 14:50**
FRCP 60(b), **13:93**
Implied-in-fact contract, **20:40**
Inconsistent jury verdicts, **13:105**
Infringement counterclaim, **22:18**
Insurance policy, **21:31**
Interpretation, **1:132**
JMOL, **2:91; 19:137**
Joinder, **9:268**
Judgment disposes of fewer than all issues, **19:95**
Judicial estoppel, **21:24**
Jury verdict, inconsistent, **13:105**
Justiciability, **13:30**
Misconduct, sanctions for, **19:114**
Motion for new trial, **5:56; 5:65; 19:165**

CHOICE OF LAW—Cont'd
Motion to remand, **19:45**
New trial, **5:56; 5:65; 13:101; 19:126; 19:165**
Nonparty's motion to quash discovery subpoena, **20:17**
Patent tying, **9:276**
Personal jurisdiction, **1:70; 4:49; 8:69; 8:79; 9:226; 18:45**
Postjudgment interest, **20:49**
Prejudice, without-prejudice dismissal, **8:82**
Preliminary injunction, **13:89; 16:33**
Pre-trial order, **19:149**
Procedural issues, **8:21; 19:42; 20:4**
Purely procedural issues, **12:58**
Recusal, **2:55**
Regional circuit court, case transferred by, **24:1**
Rule 60(b)(6), **6:49**
Sanctions for misconduct during discovery, **19:114**
Sec. 285, **23:57**
Settlement agreement, **1:100; 7:54; 16:99**
Sixth Circuit, **1:42**
State law, **18:64; 18:66**
Subject matter jurisdiction, **20:66**
Supreme Court case law as controlling precedent, **23:24**
Trade dress, **9:161; 15:11**
Trade secrets, **12:65; 18:39**
Transfer of case, **24:1**
Unfair competition, **7:55; 16:48**
Uniformity objective, **23:37**
Without-prejudice dismissal, **8:82**

CHROMADEX, INC. V. ELYSIUM HEALTH, INC.
2023, **3:245**

CHUTZPAH
Design patent, **19:8**

CIP
Continuation-in-Part Application (this index)

CIRCUMSTANTIAL EVIDENCE
Burden of proof, **4:33**
Direct evidence versus, **13:28**
Inducement, **2:130**
Infringement, **12:90**

CIRCUMSTANTIAL EVIDENCE —Cont'd
Process performable by person, **1:12**
Rule of reason, **3:82**

CITATION TO RECORD
FRAP 28(e), **12:22**

CITED ART
Presumption re uncited art, **12:13**
Sec. 282, **12:6**

CITED PRIOR ART
Generally, **13:28**
Inequitable conduct, **8:29**

CITING EVIDENCE
Only supporting evidence on appeal, **13:45**

CITIZEN PETITION
Antitrust, **20:127**

CIT (UNITED STATES COURT OF INTERNATIONAL TRADE)
Procedural rule corresponds to FRCP, **5:18**

CIVIL ACTIONS
Generally, **3:38**
Interference, **18:49**
Sec. 145, **8:118**

CIVIL CONTEMPT
Choice of law, **5:59**
Criminal distinguished, **19:48**
Damages, **7:11**
Severe remedy, **13:1**

CLAIM AGAINST GOVERNMENT
Just compensation, **12:27**

CLAIM CONSTRUCTION AND INTERPRETATION
Generally, **1:142; 1:144; 1:336; 1:379; 2:72; 2:95; 2:102; 2:110; 2:142; 2:188; 2:192; 3:97; 3:179; 3:214; 3:217; 4:77; 5:123; 5:145; 6:106; 7:91; 7:120; 7:144; 8:104; 8:141; 9:396; 9:399; 9:405; 9:409; 9:424; 9:468; 9:485; 9:494; 9:495; 9:503; 9:513; 11:44; 11:76; 11:84; 11:88; 13:137; 13:228; 13:250; 14:49; 14:51; 14:87; 14:102; 15:22; 15:25; 16:93; 16:165; 16:180; 16:183; 18:74; 19:169; 19:172;**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
19:189; 19:256; 19:270; 19:277; 19:289; 19:343; 20:81; 20:138; 20:142; 21:83; 22:33; 22:47; 23:56; 23:60; 23:79; 23:80; 23:90
"A" and "an," **2:127; 20:90**
Absent meaning interpret as in patent, **9:273**
Abstract, **8:73**
Accuracy, **19:155**
Accused device. Device, below
Accustomed and ordinary meaning, **4:60**
Actual words controlling, **4:53**
Additional precision, **16:55; 22:40**
Adequacy, **5:2**
Admissibility of evidence, **19:16**
Advantages, **7:83**
Affidavit, **9:77**
Aids, **19:19**
All elements rule, **10:7; 16:118**
Allowance during prosecution, positions taken to obtain, **1:5**
Ambiguity, **2:98; 16:53; 19:115**
Amendment, narrowing, **8:80; 12:83; 19:210**
Anticipation, **2:188; 5:142; 8:96; 8:146; 8:148; 9:285; 20:67**
Any method of analysis, **6:46**
Any use of device, **16:120**
Apparatus and method claims, **8:125; 13:220**
Apparatus of claim, **9:280**
Appeal and review, **19:16**
Arguing claim, **1:123; 3:7**
Asserted claims valid, **19:285**
Attorneys, **9:94**
Avoid ensnaring prior art, **8:57**
Beginning with language of claims, **20:71**
Broadening ordinary meaning, **13:156**
Broadest reasonable interpretation, **3:223; 9:77; 9:149; 9:256; 9:350**
Camouflaged attack, **20:8**
Canceled claims, **16:118; 16:119**
Choice between two views of evidence cannot be clearly erroneous, **16:13**
Claim differentiation, **6:93; 23:88**
Claim language, **1:85; 1:125; 5:101**
Claim narrowing, **4:23**
Claim preamble, **1:313; 3:224; 9:94**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
Claim terms, construing, **9:420**
Claim vs., **18:46**
Clearly erroneous, **4:23; 16:13**
Close proximity of terms, **2:105**
Collateral estoppel, **5:113**
Commercial embodiment, **1:192**
Commercial product, comparison to, **9:94**
Commercial success, **9:77**
Common meanings, several, **9:246**
Common term among patents, **13:128**
Comparison to commercial product, **9:94**
"Comprised of" construed, **3:129**
"Comprising" construed, **19:158**
Consistent interpretation, **3:3**
Consistent terms, **3:119**
Consistent with dependent claims, **23:43**
Consisting essentially of, **1:127; 23:3**
Consult sources other than claims, **5:30**
Context of intrinsic record, **16:138**
Contributory infringement, **5:98**
Copies, claim copied from patent to provoke interference, **9:130**
Correction of error by District Court, **3:156**
Corroboration, **9:77**
Cover more than preferred embodiment, **7:57**
Critical claim term construction, **13:169**
Crowded art, improvement in, **20:8**
Customary meaning, **6:51**
Dedication to public, **16:88**
Defining the invention, claim as, **9:267**
Definiteness, **5:114; 8:103; 20:99**
Definition, **7:28; 8:99; 9:253; 14:30**
Dependent claims, consistent with, **1:158; 15:31; 23:43**
Designing around, **3:7**
Device
accused device, generally, **5:83; 23:60**
how works, **12:28**
Dictionary, **1:90; 1:154; 3:105; 6:51; 7:79; 9:253; 9:269; 9:396; 11:53; 13:151; 16:85; 16:94; 20:51**
Different meaning with different words, **24:2**
Direct infringement, **12:108**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
Disavowal of claim scope, **3:140; 5:97; 7:109; 15:47; 16:143; 16:151; 20:112; 20:148; 21:70**
Disfavor argue own construction improves, **11:43**
Doctrine of equivalents, **1:192; 3:170; 3:178; 4:23; 4:87; 5:120; 20:8**
Doctrine of last antecedent, **6:68**
Drawings, **16:82**
Effective amount, **1:122**
Effective filing date
generally, **16:92**
ascertainment on, **16:95**
Elaborating terse claim language, **5:50**
Embodiment, **1:207; 7:57; 7:77; 10:23; 14:34; 16:54; 19:196; 22:12; 22:30; 22:35; 23:49**
Enablement, **19:205; 22:49**
Erroneous remark, **9:94**
Erroneous statement during prosecution, **2:80**
Essential element, **1:119**
Estoppel
argument-based estoppel, **19:320**
marking estoppel, **19:15**
Evidence, **1:79; 4:23; 5:53; 6:37; 16:13**
Evolving claim construction, **15:42**
Examiner, **9:94; 19:184; 20:72**
Exceptional case determination, **8:122; 16:13**
Exclusion, **1:233; 14:34; 19:138; 22:12**
Expand or limit scope of terms, applicant, **7:76**
Experience, **8:52**
Experimental and physical evidence, **6:37**
Expert or opinion evidence, **3:111; 9:77; 13:86; 19:16; 19:279; 19:340; 22:40**
Explicit arguments, **12:54; 18:60**
Expressly redefine claim terms, **5:48**
Extreme skepticism, renders claim inoperable viewed with, **20:60**
Extrinsic evidence, **2:62; 4:51; 4:59; 5:36; 11:43; 14:30; 16:53; 19:115; 20:77; 22:45; 23:79; 25:3**
Fact, mixed question of law and fact, **13:78**
Factors, **1:52; 1:82; 12:35; 16:40**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
Fact question, **26:1**
File history attorney, **9:94**
File history estoppel, **18:29**
File Wrapper (this index)
Filing date. Effective filing date, above
Foreign prosecution activities, relevancy, **1:209; 3:7**
FRCP 12(b)(6), **15:56**
FRCP 52(a), **3:7**
FRCP 56(c), **8:27**
Functional language, **1:124**
Harmless error, **19:15**
Hatch-Waxman Act, **19:314**
Heavy presumption, **5:70; 18:67; 20:63**
Hindsight, **19:15**
History attorney, **9:94**
Identity of invention, **5:2**
Import limitations, **2:92; 5:62**
Improper to inject limitation, **9:94**
Improvement in crowded art, **20:8**
''Including'' and ''comprising,'' **12:83**
Incorporation by reference, **16:128**
Indefiniteness and infringement, **3:193; 13:220; 20:136; 21:68**
Independent/dependent claim infringement, **26:1**
Induced infringement, **5:98**
Inequitable conduct, **1:138; 19:15**
Infringement, generally, **2:82; 2:129; 3:7; 6:93; 16:35; 19:15; 19:167; 19:242; 23:58; 23:88; 26:1**
Ingredients, **13:125**
Inimical, **8:88**
In light of specification vs. into the claim, **1:108**
Injunction, **20:149**
Interference, **1:5; 1:182; 2:172; 9:88; 9:130**
International Trade Commission, **5:98; 12:87; 19:196**
Inter partes review, **1:328; 8:149**
Intrinsic evidence, **1:140; 5:53; 11:40; 16:53; 16:58; 18:51; 19:111; 19:115; 20:117; 22:45**
Intrinsic evidence primary source, **1:140**
Intrinsic record, **11:53; 22:31**
Inventor's testimony, **8:106**
Issue preclusion, **9:151**
JMOL, failure to make, **21:39**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
JNOV motion, **6:6**
Joint infringement, **1:195**
Judge, extrinsic evidence only to educate, **5:36**
Judgment, acquiescence in, **19:16**
Jury verdict, **19:5**
Kessler Doctrine, **19:309**
Knowledgeable in the field, understanding as that of persons, **13:120**
Laches, **8:114**
Language, **18:68; 20:71**
Last antecedent, **6:68**
Law, mixed question of law and fact, **13:78**
Law of the case, evolving claim construction, **15:42**
Law question, **1:50; 1:77; 2:52; 4:17; 4:23; 4:102; 5:22; 8:52; 8:74; 9:131; 12:33; 13:29; 13:45; 13:54; 13:80; 16:40; 18:30; 19:56; 19:266; 20:25; 23:16**
Lexicographer, **1:132; 2:81; 5:94; 9:254; 13:124; 26:1**
Limitations and restrictions
generally, **1:158; 14:32**
applicant may expand or limit scope of terms, **7:76**
attorney's erroneous remark, **9:94**
certificate of correction, **8:132**
disclaimer, **15:38**
file history, **9:94**
import, may not, **5:62**
means plus function claim, **9:339; 20:116**
preferred embodiment, **6:56; 7:77**
read unwritten limitation therein, **11:47**
specification, **9:94; 20:61**
specific examples, **9:298**
Literal infringement, **2:139**
Made inside body, **14:46**
Malpractice, disregard of alternative claim language, **13:184**
Marking estoppel, **19:15**
Markman hearing, **5:100**
Markush claim, **13:218; 19:299**
Meaning, **9:396**
extrinsic evidence to contradict meaning, **4:59**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
Meaning, **9:396**—Cont'd
no meaning removed from context, **7:66**
same meaning, **19:15**
several common meanings, **9:246**
trial testimony not alter established meaning, **10:22**
useful to ascertain claim meaning, **10:32**
words given meaning as would persons experienced in field of invention, **8:52**
Means-plus-function, **20:149**
Method and apparatus claim, **8:123; 9:280; 13:195**
Minority, **5:71**
Mixed question of law and fact, **13:78**
Motion for judgment as matter of law, **5:130**
Motion for new trial, **19:16**
Motions, post-trial mottos, cannot be reserved for, **8:84**
Multiple applications, **14:47**
Multiple constructions for same claim, **1:247**
Multiple definitions of phrase, **7:28**
Multiple dictionary definitions, **9:253**
Multiple embodiments, **22:30**
Narrowing amendment, **8:80; 12:83; 19:210**
Negative claim construction, **19:234**
New property, **5:2**
New trial, motion for, **19:16**
Nexus, **9:77**
No meaning removed from context, **7:66**
Noninfringement stipulated, **1:130; 23:80**
Nonsensical result, **3:113**
Not limited to preferred embodiment, **6:56; 7:77**
Objection, waiver of, **3:200; 19:16**
Obviousness, **1:223; 1:365; 2:183; 2:185; 2:189; 3:178; 9:397; 9:459; 9:504; 19:11; 19:243; 19:315; 20:8**
Obviousness to try, **9:459**
Obviousness-type double patenting, **19:226**
"Or," **2:86; 19:145**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
Ordinary and Accustomed Meaning (this index)
Ordinary skill in the art, **2:88; 5:110; 8:88; 8:112; 20:99**
Overturn, easily, **16:13**
Patentability, reason related to, **11:49**
Patent drawings, **16:82**
Patent marking, **18:118**
Petition to make special, **7:57**
Phrase, multiple definitions of, **7:28**
Physical and experimental evidence, **6:37**
Physically combinable, references need not be, **9:77**
Pioneer invention, **20:8**
Plain meaning, **19:167**
Plain meaning of specification, **21:9**
Plurality, **1:372**
Policy driven, **19:161**
Post-trial mottos, cannot be reserved for, **8:84**
Preamble, **9:478; 16:86; 19:335; 20:131**
Preferred embodiment, **1:116; 1:207; 5:31; 6:56; 7:57; 7:77; 16:54; 22:12; 23:49**
Preferred embodiment, exclusion, **1:233**
Prejudicial error, **14:2**
Preliminary injunction, **1:241; 3:135**
Present invention, **18:64**
Presumption, **1:161; 4:73; 4:74; 5:70; 9:94; 11:48; 18:67; 20:63**
Prevailing party, JMOL, **3:161**
Printed publication, **1:313**
Prior art, **1:103; 8:57; 13:63; 19:15**
Prior art, unpatentable in view of, **19:281**
Priority, **5:142**
Priority claim, **1:199**
Priority date, **20:102**
Process, **21:61**
Prosecution disclaimer, **1:309; 7:140; 15:21; 19:336; 20:138**
Prosecution history, **1:77; 2:77; 11:12; 12:31; 14:57; 19:84; 19:193; 23:51**
Prosecution history estoppel, **9:94; 15:30; 22:37; 26:1**
PTO interpretation during prosecution, **9:199**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
Publication, unpublished paper, **20:8**
Purely legal question, **3:84**
Read unwritten limitation therein, **11:47**
Reasonable interpretation, **9:77; 16:60**
Reasonable royalty, **19:279**
Reason related to patentability, **11:49**
Redefine, expressly redefine claim terms, **5:48**
Redraft claims, **18:91**
Redundancy, **22:67**
Reexamination, broadest reasonable interpretation, **9:87; 9:154; 9:255; 9:424**
References need not be physically combinable, **9:77**
Reissue, **9:77**
Relevant, problem inventor was attempting to solve is, **3:75**
Renders claim inoperable viewed with extreme skepticism, **20:60**
Repeatedly and consistently characterizing claims, **7:120**
Reservation, **8:84**
Reverse doctrine of equivalents, **3:7; 19:24; 19:51**
Review, standard of, **3:74; 12:35; 12:103; 19:12; 19:121; 20:64**
Rewriting, specification, use to rewrite claim language, **18:68**
"Rewritten" claims, **16:91**
Same meaning, **19:15**
Same term, **1:106; 5:63; 6:43**
Same way construction, **23:11**
Scope of invention, **8:112**
Sec. 102(g), **11:9**
Sec. 103, **20:8**
Sec. 112, **4:23; 9:40; 20:6**
Sec. 112(6), **9:339; 11:28**
Sec. 116, **19:15**
Sec. 285, **1:5**
Sec. 291, **1:5**
Sequences, **9:326**
Several common meanings, **9:246**
Skill in the art, **3:75; 4:61; 4:66; 9:232; 20:8**
Special, petition to make special, **7:57**
Special definition, **14:30**
Specification, **1:134; 3:80; 5:2; 9:94; 13:86; 13:104; 14:57; 18:68;**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
19:26; 19:191; 19:196; 20:61; 21:9; 25:4
Specifications, limitations, **12:68**
Standard of review, **3:74; 12:35; 12:103; 19:12; 19:121; 20:64; 20:130**
Standing, **1:264**
Statements describing whole invention, **22:32**
Statement that claims not include feature, **19:136**
Stipulated judgment, **10:37**
Strong presumption ordinary meaning, **4:73**
Substantial evidence vs. clearly erroneous, **20:1**
Substantiality, **12:70**
Substantially, **12:61; 13:134**
Suggestion in prior art, **19:15**
Summary judgment, **1:256; 2:24; 8:17; 20:10**
Technical terms, **14:44; 16:56**
Terms, **3:91; 5:48; 6:43; 7:31; 7:76; 9:338**
Terse claim language, elaborating, **5:50**
Timing, **3:123**
Timing of analysis, **22:18**
Trial testimony not alter established meaning, **10:22**
True inventor, **19:15**
Two-step analysis, **19:15; 20:62**
Unambiguous meaning, extrinsic evidence not contradict, **4:51**
Unclaimed elements, **6:58**
Understood by person in field, **22:25**
Uniform interpretation, **9:130**
Useful to ascertain claim meaning, **10:32**
Use of evidence, **1:92; 1:129; 25:3**
Use of prosecution history, **19:84**
Vacating, **1:5**
Vacuum, claims not interpreted in, **9:58; 19:13**
Validity (this index)
Varied use of a term, **2:78**
Vitiation, **3:178**
Waiver, **3:174; 3:200; 4:99; 9:234; 15:29; 19:16; 19:279**
Whereby clause, **8:91; 20:29**

CLAIM CONSTRUCTION AND INTERPRETATION—Cont'd
Wherein clauses, **1:331**
Wired and wireless technologies, limitation of claims to, **18:114**
Witnesses, **10:22; 19:16; 22:17**
Words, **1:136; 8:52; 10:24**
Written description, **6:93; 22:49**

CLAIM DIFFERENTIATION
Generally, **1:293; 2:45; 2:82; 5:5; 6:58; 6:92; 7:70; 8:141; 11:2; 11:44; 11:48; 12:35; 12:121; 13:8; 14:43; 14:48; 22:30; 23:16**
Anticipation, **11:2**
Broaden beyond correct scope, **13:91; 20:51**
Claim construction and interpretation, **6:93; 23:88**
Claim terms, construing, **9:420**
Combinations, hypothetical, **11:2**
Covenant not to sue, **9:411**
Covered business method, **1:293**
Defer to PTO, no reason to, **11:2**
Dependent claim, **5:60; 9:237**
Dictionaries, **19:261**
Different words not mandate different interpretations, **20:52**
FRCP 56(c), **8:27**
Hard and fast rule, **19:157**
Hindsight reconstruction, **11:2**
Hypothetical combinations, **11:2**
Identity of invention, **11:2**
Immutable fixed rule, **4:17**
Independent claims, **5:60; 9:237**
Infringement, **6:93; 23:88**
Inventor's theory, **6:10**
Law question, **11:2**
Limitations, **3:89; 9:370**
Means-plus-function, **18:17; 23:54**
Plain language, cannot overcome, **13:105**
Presumption of different scope, **3:80; 19:171**
Prosecution history, **1:162**
PTO, defer to PTO, no reason to, **11:2**
Reading dependent claim into independent claim, **9:237**
Reconstruction, hindsight, **11:2**
Reverse doctrine of equivalents, **11:2; 19:24**

CLAIM DIFFERENTIATION—Cont'd
Sec. 112(6) equivalency, **12:26**
Sec. 112 equivalency, **16:2**
Separate claims have different scope is not rigid, **1:92**
Uncited art, **11:2**
Words, **19:261**
Written description, **6:93**

CLAIMED INVENTION
Best mode, **20:63**

CLAIMED METHOD
Infringement, **2:52**

CLAIMED RANGES
Obviousness, **9:277**

CLAIM LANGUAGE
Generally, **3:41**
Claim interpretation, **1:85; 1:125; 5:101**
Controlling language, **18:30**
Design patent, **7:59**
Doctrine of equivalents, **3:136**
Indefiniteness, **2:169; 5:114; 16:47**
Means-plus-function claim, **2:137; 3:97; 5:112**
Sec. 112, **9:72**

CLAIM NOT READ IN VACUUM
Generally, **19:13**
Broadest reasonable interpretation, **9:58**

CLAIM PREAMBLE
Generally, **1:80; 2:82; 2:115; 4:128.50; 7:74; 9:123; 9:272; 12:28; 16:142; 18:47; 19:130; 19:145**
Absolute rules, none, **7:61**
All elements rule, **3:22**
Anticipation, **3:22; 4:15; 13:164**
As a whole, **16:58**
Burden on patent challenger, **16:12**
Claim construction and interpretation, **1:313; 9:94; 16:86; 19:210; 20:131**
Claim limitation, **1:198; 9:154; 13:164; 22:41**
Combining prior art teachings, **9:79**
Deposition, **1:338**
Derive antecedent basis, **5:65**
Doctrine of equivalents, **3:22; 7:80**
Effect, **3:22**
Function, **3:22**

CLAIM PREAMBLE—Cont'd
Genus, **3:22**
Import that claim as whole suggests, **2:52; 16:58**
Intent, **1:103; 2:101; 9:79**
Inter partes review, **1:338**
Jepson claim, **5:63**
Life and meaning, **9:154; 22:41**
Limitations, **1:119; 3:22; 7:16; 9:154; 18:44; 19:210; 22:41**
Litmus test, **9:242**
Meaning, **7:113; 9:154; 16:20; 22:41**
Obviousness, **9:79**
Printed publication, **1:313**
Prior art, combining, **9:79**
Reasonable diligence, **1:338**
Reciting structural limitations, **18:44**
Redrafting claim, **3:22**
Species, **3:22**
Statement of intended purpose, **9:79**
Statement of purpose, **1:208; 5:63**
Structural limitations, **1:198; 18:44**
Suggestions, **16:58**
Verdict, **16:14**

CLAIM PRECLUSION
Generally, **1:170; 2:159; 13:117; 24:8**
Certainty and definiteness, **4:110**
Challenge to validity when second action involves different device, **8:76**
Choice of law, **13:65**
Claim limitations unchanged, **14:61**
Essentially the same, **1:170**
Identical parties, not limited to, **13:65**
Inter partes review, **23:86**
Law question, **8:76**
Material differences in claim limitation, **14:64**
Privity, **23:86**
Reexamination, **19:255**
Res judicata, **19:255**
Reverse doctrine of equivalents, **18:80**

CLAIMS COURT
Generally, **13:50; 19:65; 23:28**
Binding precedent, **19:63; 23:33**
Dismissal for lack of subject matter jurisdiction, **20:27**
Findings of special master, **3:49**
FRCP 12(b)(4), **13:56**

CLAIMS COURT—Cont'd
Limitation of actions, **2:53; 3:55**
Review, standard of, **6:29; 19:67**
RUSCC 60(b) motion, **3:40**
Sec. 1498, **16:38**
Sec. 2412(b), **13:48**
Special master's findings, **3:49**
Subject matter jurisdiction, **2:41; 20:27; 21:21**
Summary judgment, **16:30**

CLAIM TERMS
Anticipation, **8:148**
Consistently interpreted, **18:30**
Construction of critical claim term, **13:169**
Essentially, **26:2**
Expand or limit scope of terms, **7:76**
Expressly redefine, **5:48**
Inequitable conduct, **18:116**
Limitations, **21:53**
Means for cross-referencing, **20:110**
Ordinary meaning unless used differently by inventor, **3:91; 7:31; 11:61**
Same terms appearing in different portions, **6:43**
Scope, **11:61**

CLAIM WORDS
In first instance, **5:7**

CLAM INDEFINITENESS
Sec. 112(2), **2:45**

CLASSIC TEST
Sec. 102, **12:12**

CLEAR AND CONCISE
Prosecution history estoppel, **23:42**
Sec. 112, **15:2**

CLEAR AND CONVINCING EVIDENCE
Certificate of correction, **3:128; 19:142**
Conception, **7:46**
Defined, **9:118**
Exceptional case, **9:161**
Inequitable conduct, **1:71; 7:68; 13:141; 15:3; 19:38**
Infringement, **3:158**
Obviousness, **2:171; 14:9**
On-sale bar, **2:23**

CLEAR AND CONVINCING EVIDENCE—Cont'd
Validity, **5:49; 5:64; 19:132; 19:142**
Willful infringement, **16:129; 20:39**

CLEAR AND UNAMBIGUOUS
Plain and ordinary meaning, they must be given their, **1:56**

CLEAR-CUT GROUNDS
Frivolous appeal, **19:90**

CLEAR DEMARCATION
Sec. 121, **7:75**

CLEARLY ERRONEOUS
Generally, **2:59; 19:23**
Anticipation, **18:20**
Appeal and review, **4:6; 7:2; 12:2**
Attorney fees, **19:23**
Board, **9:191**
Claim construction, **4:23; 16:13**
Defense, implied license, **19:23**
Definition, **4:41**
Due care, duty of, **19:23**
Equitable estoppel, **19:23**
Findings, PTO fact, **9:80**
Identity of invention, **20:20**
Implied license defense, **19:23**
Increased damages, **19:23**
Interference, **4:11**
Legal, **19:23**
License, **19:23**
Literal infringement, **19:23**
Mandamus, **9:57**
Means-plus-function, **19:23**
New evidence introduced, **6:9**
On-sale bar, **2:23**
Per se rule, **19:23**
PTO fact findings, **9:80**
PTO standard of materiality, **9:43**
Substantial evidence versus, **20:1**
Willful infringement, **19:23**

CLEARLY LINK
Means-plus-function claim, **13:118**

CLEAR MEANING
FRCP 52(a), **12:6**

CLEAR UNEQUIVOCAL LEGAL OPINION
Generally, **3:8**

CLERICAL MISTAKE
Sec. 255, **19:142**

CLOSED GROUP
Markush group, **1:122**

CLOSE EXAMINATION
Prosecution history estoppel, **8:13**

CLOSE PROXIMITY OF TERMS
Claim interpretation, **2:105**

CLOSEST ART
Expectation, unexpected results, **9:111**
Unexpected results, **9:111**

CLOUDOFCHANGE, LLC V. NCR CORPORATION
2024, **3:252**

COHEN COLLATERAL ORDER EXCEPTION
Final judgment rule, **20:28**

COHEN TRIPARTITE TEST
Appealability of interlocutory nonfinal decision, **19:71**

CO-INVENTORS
Generally, **16:48**
Collaboration required, **5:40; 6:35; 22:39**
Correcting inventorship, **6:79**
Deceptive intent, **1:106**
Freedom to license, **19:98**
Interference, **4:31**
Inventorship, **8:81; 22:54**
License, freedom to license, **19:98**
Non-joinder, **14:59**
On-sale bar, **2:85**
Ownership, **9:303**
Physically work together or at same time, **20:68**
Presumption named properly, **7:79**
Requirements, **16:50**
Same time, **20:68**
Scope of claims first, **5:73**
Sec. 116, **22:39**
Sec. 262, **8:5**

COLIBRI HEART VALVE LLC V. MEDTRONIC COREVALVE, LLC
2025, **3:261**

COLLABORATION
Co-inventors, **5:40; 6:35; 22:39**

COLLATERAL ESTOPPEL
Generally, **1:152; 1:325; 7:142; 9:143; 13:111; 13:231; 14:93; 16:38; 16:160; 16:170; 19:274; 19:338; 20:68; 21:65; 21:90; 22:24; 22:60**
Adoption of party's findings, **4:9**
Affirmative defenses, **4:3**
Agency acting in judicial capacity, **20:41**
Alternative position, taking, **10:3**
Applicable, when, **3:62**
Attorney fee award, relevant to, **4:3**
Attorneys, opinion of counsel, **4:9**
Blonder-Tongue, **1:47; 13:26; 13:61; 19:33**
Choice of law, **2:88; 4:71; 16:57; 20:72; 22:24**
Claim construction, effect of prior litigation on, **9:151**
Claim construction and interpretation, **5:113**
Construction, narrow, **1:3**
Cross-examine, right to, **13:53**
Damages, measure of, **4:9**
Declaratory judgment, **10:6**
Defenses, affirmative defenses, **4:3**
Description, **1:249**
Expert's conclusion not controlling, **4:9**
Factors, **4:71**
Fair, full and fair opportunity to litigate, **16:57**
Findings, adoption of party's findings, **4:9**
Full and fair opportunity to litigate, **2:50; 16:57**
Holding of patent invalidity, **4:3**
Hypothetical judicial statements, **1:3**
Identical parties, **9:232**
Inequitable conduct, **4:3**
Infringement, **1:3; 1:155; 25:10**
Infringement, willful, **4:9**
Issues of law differ, **21:24**
ITC decision, **2:17**
ITC's decision, **20:41**
Judicial capacity, **20:41**
Lost profits, **4:9**
Multi-defendant cases, **9:310**
Non-mutual, **9:296**

COLLATERAL ESTOPPEL—Cont'd
Non-parties, **9:296**
Obviousness, claims are focus of, **10:3**
Opinion of counsel, **4:9**
Opportunity, **16:57**
Pleaded, must be, **4:3**
Prior adjudication, **9:90**
Prior decision or validity, **8:73; 13:105**
Prior litigation, effect on claim construction, **9:151**
Raise claim in second proceeding, **7:65**
Res judicata, **4:9; 7:99; 9:122; 13:51; 16:35**
Sec. 101, **22:61**
Second proceeding, raise claim in second proceeding, **7:65**
Specific devices before court, not embrace more than, **11:35**
Test thereof, **16:31**
Unique application to patent law, **1:244**
Validity, **4:3; 8:73; 13:105**
Willful infringement, **4:9**

COLLATERAL ORDER DOCTRINE
Generally, **2:190; 3:85; 3:115; 5:25; 6:84; 21:80**
Appeal of order disqualifying counsel, **9:343**
Confidential information, unsealing, **1:239**
Final judgment rule, **1:302; 20:28**
Protective order, **13:249**

COLLATERAL SALES
Entire market value rule, **18:35**

COLUMBIA SPORTSWEAR NORTH AMERICA, INC. V. SEIRUS INNOVATIVE ACCESSORIES, INC.
2023, **3:246**

COMBINATION
Generally, **5:5; 9:118**
As a whole, invention, **13:15**
Block diagram, **13:15**
Burden on patent challenger, **16:12**
Claim differentiation, **11:2**
Claim preamble, **9:79**
Combination patent, **12:13; 13:15; 19:52**
Cross-appeal, **18:2**
Declaratory judgment, **10:6**

COMBINATION—Cont'd
Essence, **13:15**
Expert testimony, motivation, **23:68**
Hindsight, **13:15**
Inherency, **12:81**
Inventor's theory, **6:10**
Is obvious, **18:22**
Jury verdict, **3:17**
Means-plus-function claim, **3:89**
Modification, **9:51**
Motion to remand, **19:45**
Obviousness (this index)
Pioneer invention, **13:1**
Prior art, **13:18**
Reference (this index)
Repair, **19:79**
Sec. 271(f)(2), **16:141; 23:53**
Sec. 282, **6:10; 18:6**
Simplification of reference, **13:15**
Sophistication as nonobviousness, **13:15**
Summary judgment, **3:1**
Synergism, **19:36**

COMBINING REFERENCES
Obviousness, **9:372; 23:11**

COMBINING TEACHINGS
Known or used by others, **3:2**
Prior art references related to one another, **9:74**

COMITY
Generally, **9:238**

COMMERCIAL BUYERS
Design patent infringement, **1:165**

COMMERCIAL CONSEQUENCES
Sec. 102(e) v. sec. 102(g), **19:41**

COMMERCIAL EMBODIMENT
Generally, **12:3; 26:2**
Claim construction, **1:192**
Comparing claims with accused device, **13:9**
Costs on appeal, **1:20**
Obviousness, **1:4**
Patent misuse, **23:9**
Reverse doctrine of equivalents, **19:24**
Verdict, **16:14**

COMMERCIALIZATION
Prior art, noting differences from, **4:6**

COMMERCIALLY AVAILABLE
MPEP, **16:6**

COMMERCIAL MARKETPLACE
Generally, **12:77**
Enablement, **3:104**

COMMERCIAL MODE
Best mode, **26:4**

COMMERCIAL OFFER FOR SALE
On-sale bar, **13:102; 19:113**

COMMERCIAL OFFER TO SELL
On sale bar, **5:72; 8:145; 19:179**

COMMERCIAL PRODUCT
Claim interpretation, **9:94**
Infringement, **1:124**

COMMERCIAL SALE
On-sale bar, **1:177; 1:179; 8:145; 13:122; 19:133**

COMMERCIAL SUCCESS
Generally, **1:87; 13:18; 13:137**
Anticipation, **1:10; 1:227**
Appeal is review and not trial de novo, **6:12**
Burden on patent challenger, **16:12**
Claims construed, **9:77**
Inequitable conduct, **11:4**
New features, where it includes several, **23:7**
Nexus, **9:168; 18:28; 23:68**
Nexus required, **2:76**
Nonparty's motion to quash discovery subpoena, **20:17**
Number of units sold is weak showing, **9:181**
Obviousness, **7:108; 9:154; 9:311; 13:166; 18:15; 18:83; 20:107; 23:75**
Presumption, **23:52**
Results from claimed invention, **10:22**
Sales alone, **9:111; 20:50**
Secondary considerations, **3:41; 9:82; 9:331**

COMMERCIAL TRANSACTIONS
Statutory subject matter, **9:308**

COMMERCIAL USE
Public use bar, **11:12**

COMMISSIONER
Authority, **1:45**
Brief not prior art, **9:140**
Mandamus, **9:54**
Reexamination, **9:194**
Sec. 6(a), **23:15**
Sec. 41(a)(7), **13:32**

COMMON KNOWLEDGE
References, **9:154**

COMMON LAW
Generally, **12:27**
Antitrust, **3:83**
Choice of law, **18:38**
Good faith, **1:64**
Presumption, **9:154**

COMMONLY OWNED PATENTS
Prosecution history estoppel, **1:115**

COMMON MEANINGS
See also Ordinary and Accustomed Meaning (this index)
Claim interpretation, **9:246**

COMMON NUCLEUS OF OPERATIVE FACT
Sec. 1376, **22:36**

COMMON OCCURRENCE
Examiner's initial rejection of all claims, **17:4**

COMMON SENSE
Obviousness, **9:297; 9:450**
Reasonable royalty estimation, **9:213**

COMMUNICATION
Attorney-client privilege, **23:74**
Domestic disclosure, **1:224**
Injunction, **7:92**
Objectively baseless, **4:88**

COMPANIES
Sec. 102(g), **14:7**

COMPARATIVE DATA
Obviousness, **9:56**

COMPCO
Sears, **21:11**

COMPENSATION
Adjudicated infringer, **11:10**
Claim against government, **8:116; 12:27**

COMPENSATION—Cont'd
Damages, **16:40**
Prejudgment interest, **15:10; 23:73**

COMPETENCE
Generally, **10:18**
Attorney, opinion of counsel, **3:80; 4:6; 10:21; 13:45**
Ordinary skill, hypothetical person of, **9:65**
Prosecution history estoppel, **23:41**

COMPETITION
Amendment, **16:72**
Amendment of claims, **13:91**
Antitrust, **3:83**
Attorney drafting claims specifically directed to competitor's device, **9:158**
Choice of law, **7:55; 16:48**
CIP, **19:28**
Drafting claims covering competitor's product, **11:11**
Estoppel, **1:345**
Indefiniteness, **13:57**
Inducing infringement, **18:48**
Infringement, **19:87**
Inter partes review, **1:345**
ITC, **13:40**
9 Cir, **22:2**
Patent misuse, **19:227**
Patent prosecution bar, disclosure, **5:110**
Preemption, **26:7**
Prosecution history estoppel, **8:38**
Sears, **21:11**
Sec. 43(a), **15:5; 16:21**
Sec. 112, **20:6**
Standing, **1:345**
Summary judgment, **12:15**
Unfair Competition (this index)

COMPETITIVE DECISION MAKING
Definition, **4:94**

COMPLAINT
Generally, **8:66; 13:59; 13:107; 19:14; 19:55; 19:66**
Appropriate, when, **19:14**
Dismissal with prejudice, **19:14**
Facts before court, **12:44**
Form 16, **13:142**
FRCP 15(c), **6:11**

COMPLAINT—Cont'd
FRCP 37(b), **23:34**
Jurisdiction, **7:38**
Prejudice, dismissal with prejudice, **19:14**
Res judicata, **11:35**
Sec. 41(a)(7), **13:32**
Sec. 102(b), **19:31**
Transfer of appeal, **7:14**

COMPLETE ARTICLES
Sec. 171, **9:73**

COMPLETENESS
Conception, **2:48**
Reexamination, **9:239**

COMPLEXITY
Master, use of, **19:37**
Reverse doctrine of equivalents, **19:24**

"COMPONENT" OF PATENTED INVENTION
Reasonable royalty rate, **12:97**
Sec. 271(c), **18:79**
Sec. 271(f), **1:146; 12:113**

COMPOSED OF
Generally, **1:109**

COMPOSITION
Generally, **9:129; 16:72**
Discovery of inherent properties, **20:11**
Infringement, **4:51**
Obviousness issue, **9:12**
Patentable, **9:104**
Prima facie obviousness, **9:17**

COMPOUND
Generally, **9:103**

COMPOUND INTEREST
Delay damages, **4:24**
Prejudgment interest, **18:35**

"COMPRISED OF"
Construction of phrase, **3:129**

COMPRISING
Cancellation of claims, **9:435**

"COMPRISING"
Generally, **3:96**
Claim interpretation, **5:102; 12:83**
Construction of phrase, **19:158**
Improvement, **3:37**

"COMPRISING"—Cont'd
Open claim language, **13:174**
Presumption, **4:84**

COMPROMISING
Generally, **1:109; 7:49; 9:254; 13:28; 22:18**

COMPULSORY ARBITRATION
District court order, **16:136; 22:55**

COMPULSORY COUNTERCLAIM
America Invents Act, **9:430**
FRCP 13(a), **2:36; 9:430**

COMPUTATION
Patent term extension, **13:144; 23:70**

COMPUTER
Generally, **16:11**
Detailed disclosure thereof unnecessary, **9:154**
Display, infringement, **20:118**
Embodied in tangible medium, **9:164**
Infringement, **19:220**
Means-plus-function claim, **1:176; 6:68; 20:116**
New way is physically different machine, **9:153**
Organization of information, **9:153**
Programmer's skill, **14:8**
Sec. 101, **1:251; 1:286; 2:147; 5:128; 6:80; 19:292**
Sec. 120, **8:19**
Statutory subject matter, **9:175**
Tangible medium, embodied in, **9:164**

COMPUTER-FACILITATED PROCESSES
Sec. 101 patent-eligible subject matter, **6:71; 19:292**

CONCEALMENT
Best mode, **1:246; 2:34**
Sec. 102(g), **16:9**
Unreasonable delay, **12:21**

CONCEPTION
Generally, **1:44; 3:94; 5:40; 19:149; 19:152; 21:42**
Anticipation, **1:255; 20:115**
Appreciation, recognition and, **13:105**
Clear and convincing evidence, **7:46**
Complete, when, **19:72**
Completeness, **2:48**

CONCEPTION—Cont'd
Corroborating evidence, **3:160**
Corroboration, **4:74**
Definition, **2:126; 4:100**
Evidence, proven by, **9:244**
Facts supported by clear and convincing evidence, **7:46**
Fixed ideas, **13:72; 20:65**
Idea must be fixed and permanent, **13:72; 20:65**
Interference, **3:15; 9:244; 15:1; 19:240**
Inter partes review, **1:323; 18:110**
Inventorship, **2:99; 2:164; 6:35; 19:72; 19:195; 20:126; 21:55**
Law question, **2:47; 2:96; 6:18; 6:20**
Offer for sale, **1:216**
Only ordinary skill necessary to reduce to practice, **19:124**
Oral testimony, **16:70; 19:151**
Ordinary skill, **19:124**
Permanent ideas, **13:72; 20:65**
Recognition and appreciation, **13:105**
Reduction to practice, **9:407; 13:105; 19:124**
Requirements thereof, **11:41**
Sec. 131, **9:407**
Simultaneous reduction to practice, **13:105**
Testing, when required, **3:82**
Verbatim findings of counsel adopted, **8:22**
Willful infringement, **2:164**
Witnesses, oral testimony, **16:70; 19:151**

CONCEPTS
Anticipate, do not, **16:4**
Inventive, **1:290; 13:210**

CONCERNED PARTY
Inventorship, **3:93**

CONCESSION
Double patenting, **15:6**
Filing of CIP, **23:30**

CONCLUSIONS OF LAW
FRCP 52(a), **3:45**

CONCLUSORY STATEMENT
Evidence, **2:80**
Routinely built, well-known and, **9:113**
Summary judgment, **3:13; 20:62**

CONCLUSORY STATEMENT —Cont'd
Well-known and routinely built, **9:113**

CONCURRENT LITIGATION
Preliminary injunction, **11:19**
Same parties and same issues requirement, **9:116**

CONDITIONAL CROSS-APPEAL
Claim construction, **14:53**

CONDITIONAL NEW TRIAL
District court has wide discretion, **13:34**

CONDUCT AND MISCONDUCT
See also Inequitable Conduct (this index)
Attorneys, **11:13**
Choice of law, **19:114**
Exceptional case, litigation misconduct, **18:64**
FDA, conduct before, **5:95**
Flagrant misrepresentations of record, **16:9**
Litigation Misconduct (this index)
Res judicata, continuing conduct, **1:229**

CONFIDENCE
Attorney disqualification, **16:3**
Chinese Wall, **5:12**
High degree of confidence and trust between PTO and patent applicants, **10:5**

CONFIDENTIAL BUSINESS INFORMATION
Preliminary injunction, **6:7**

CONFIDENTIAL INFORMATION
Discovery, **1:10**
Motion to compel discovery, **19:17**
Protective order, **13:40**
Public use, **1:174; 2:106**
Unsealing, appeal and review, **1:239**

CONFLICT OF LAWS
Choice of Law (this index)

CONGRESS
Agency's authority limited by, **11:26**
Prejudgment interest, **19:83**
Sec. 156, **6:3**
Sec. 282, **12:5**

CONGRESS—Cont'd
Statutory Construction and Interpretation (this index)

CONGRESSIONAL INTENT
Statutory construction and interpretation, **1:61; 7:24; 8:39; 19:75**

CONJECTURE
Generally, **9:125**

CONNECTED
Generally, **7:49**

"CONNECTED TO" OR "COUPLED TO"
Claim construction, **7:104**

CONSENT
FRCP 60(b), **23:23**
Judicial Panel on Multi-District Litigation (JPMDL), **7:6**
Personal jurisdiction, **8:79; 13:114; 16:124**
Res judicata effect, **6:17**
Standing, **19:263**
Stipulated judgment, **8:6**

CONSENT ORDER AND JUDGMENT
Generally, **11:28**
Beyond express terms, **14:28Z**
Choice of law, **14:28Z**
Contract law, **4:58; 5:60; 21:64**
Express terms, beyond, **14:28Z**
FRCP 60(b)(6), **3:29**
International Trade Commission, **4:108**
Interpreted under contract law, **4:58**
Relitigating patent validity, **5:8**
Validity, **5:8**
Written agreement, need for, **3:64**

CONSISTENCY
Generally. Inconsistency (this index)

CONSISTENT INTERPRETATION
Generally, **3:3; 3:119**
Claim terms to be interpreted consistently, **18:30**

CONSISTENT TERMS
Claim interpretation, **3:119**

"CONSISTING ESSENTIALLY OF"
Prosecution history disclaimer, **5:94**

"CONSISTING OF"
Generally, **1:109**
Doctrine of equivalents, **3:124**

CONSISTING OF CLAIM LANGUAGE
Generally, **13:7**
Additional elements, presence of, **13:7**
Amendment, **13:7**
Presence of additional elements, **13:7**
Prosecution history estoppel, **13:7**

CONSOLIDATED PRETRIAL PROCEEDINGS
Judicial Panel on Multi-District Litigation (JPMDL), **7:6**

CONSOLIDATION OF CLAIMS
Appeal, **19:95**

CONSOLIDATION ORDER
Sec. 1651, **9:128**

CONSONANCE
Generally, **1:80**
Obviousness-type double patenting, **19:246; 20:29**
Restriction requirement, **2:140; 16:112**

CONSTELLATION DESIGNS, LLC V. LG ELECTRONICS INC.
2026, **3:263**

CONSTITUTIONALITY
Decided only when court compelled to do so, **3:209; 8:31**
IPR, **13:246.50**
Jurisdiction, **13:191; 18:34**
Jury trial, **16:8**
New art, reexamination over, **16:8**
Patent system, purpose of, **16:8**
Property, patents are, **16:8**
Public concern, patent grant is, **16:8**
Punitive damages, **20:58**
Reexamination proceeding, **10:16; 16:8**
Retroactive application of reexamination statutes, **16:8**
Retroactive elimination of qui tam action under AIA, **2:151; 3:195**
Sec. 303, **16:8**
Seventh Amendment (this index)
Standing, **13:191**
Waiver, **3:33**

CONSTRUCTION AND INTERPRETATION
As to claims. Claim Construction and Interpretation (this index)
Generally, **1:54; 9:36; 9:132; 12:31; 18:30; 21:19**
CAFC, **12:47**
Choice of law, **1:132**
Claim Construction and Interpretation (this index)
Claim interpretation. Claim Construction and Interpretation (this index)
Collateral estoppel, **1:3**
Consent judgments, **4:58**
Contract Construction and Interpretation (this index)
Design patent, **7:59**
Entitled to deference, **11:27**
FRCP generally, **23:34**
Indefiniteness, **5:58; 8:86**
Information disclosure statement, **5:31**
Interference, **7:49; 7:74**
Interference estoppel by judgment, **23:14**
Inventor's theory, **6:10**
Law question, **3:54; 4:31; 9:120; 9:132**
Means-plus-function claim, **3:166; 5:110; 9:199; 20:56**
Method claims, **9:223**
Performance of government contract, **8:8**
Reduction to practice, **8:67**
Review, standard of, **7:74**
Sec. 41(a)(7), **13:32**
Sec. 112(6), **22:10**
Sec. 120, **9:13**
Settlement agreement, **10:9**
Statutory Construction and Interpretation (this index)
Summary judgment, **8:17; 21:46**
Validity, **19:145**
Waiver of sovereign immunity, **10:19**

CONSTRUCTIVE NOTICE
Generally, **19:172**

CONSTRUCTIVE POSSESSION
Written description, **3:157**

CONSULTANCY AGREEMENT
Generally, **1:46**

CONSULT SOURCES OTHER THAN CLAIMS
Claim interpretation, **5:30**

CONSUMER BEHAVIOR
Market demand, **19:6**

CONTEMPORANEOUS ACTS AND MATTERS
Generally, **3:49**
Chemical, **9:60**
Evidence of level of skill in the art, **9:23**
Invention, **19:34**
Obviousness issue, **9:12**

CONTEMPT
Generally, **5:117; 9:271; 12:3; 16:142; 19:129; 19:342**
Appealable decision, create, **3:85; 5:85**
Appealable when opportunity to purge has passed, **19:118**
Civil vs. criminal distinguished, **19:48**
Communications protected by attorney-client privilege, refusal to produce, **23:74**
Contributory infringement, **16:25**
Criminal, civil vs. criminal distinguished, **19:48**
Infringement, injunctive relief against infringer is norm, **11:17**
Injunction, **1:156; 1:234; 5:119; 11:17; 14:69; 16:25**
Modified device, infringement by, **2:119**
Motion, two-step procedure on ruling on motion, **11:17**
Proof, standard of, **1:73**
Reinstatement of license agreement, **16:23**
Review, standard of, **3:56**
Sec. 271(c), **16:25**
Sec. 283, **11:17**
Severe remedy, **13:1**
Substantial open issues, **1:88**
Third persons, conduct of, **20:54**
Two-step procedure on ruling on motion, **11:17**

CONTINUATION
Generally, **3:114; 7:89; 12:54**
Anticipation, **1:127**
Description, **20:47**
Gorham infringement test, **12:17**
Interference, **13:31**

CONTINUATION—Cont'd
License duration, **9:369**
Necessary conditions, **9:419**
Prosecution history, **13:100**
Sec. 112, **18:4**
Sec. 120, **20:88**
Sec. 1292(a)(1), **23:13**

CONTINUATION APPLICATION
Generally, **9:166**
Claims adequately described in prior application, **19:105**
Design patent, **9:205**
Means-plus-function, **4:51**
Reexamination inter partes, **3:139; 13:213**

CONTINUATION-IN-PART APPLICATION (CIP)
Added matter, newly, **19:28**
Amending claims to read on competitor's product, **19:28**
Benefit of earlier filing date, **1:80; 20:35**
Competitor's product, amending claims to read on, **19:28**
Date, **20:35; 20:59**
Different filing dates, **20:59**
Earlier filing date, **5:20; 20:35**
Filing
concession, not concession of inadequate disclosure in parent case, **23:30**
MPEP, **16:6**
parent case, not concession of inadequate disclosure in, **23:30**
Filing date, **5:20; 20:35; 20:59**
Gorham infringement test, **12:17**
MPEP, **16:6**
Newly added matter, **19:28**
Restriction requirement, **16:112**
Sec. 120, **9:73**

CONTINUING CONDUCT
Res judicata, **1:229**

CONTINUOUS PROCESS
Inequitable conduct, **10:2**

CONTOUR IP HOLDING LLC V. GOPRO, INC.
2024, **3:253**

CONTOURS OF CORRESPONDING STRUCTURE IS LAW QUESTION
Means-plus-function claim, **19:119**

CONTRACT CONSTRUCTION AND INTERPRETATION
Generally, **2:65; 9:160; 9:236; 11:28; 13:76**
Ambiguity, **3:44; 7:43; 9:160**
Contract law, **13:47; 15:9**
Ejusdem generis, **20:38**
Law question, **1:56; 1:57; 3:70; 4:41; 4:42; 8:33; 9:132; 9:145; 9:159; 11:29; 17:5; 23:36**
License agreement, **15:9**
Meaning to all parts, **2:65; 13:47; 13:76**
Review, standard of, **8:41**
Spirit and purpose, **14:26**

CONTRACTS AND AGREEMENTS
Generally, **2:36; 13:64**
Ambiguities are resolved against contract drafter, **9:132**
Arbitration agreement, **4:85; 23:91**
Assignment, **1:46; 4:86**
Breach accrues, **8:44**
Choice of law, **19:134; 20:53**
Companies do not intend to be bound until written agreement is executed, **23:21**
Consent judgments, **4:58; 5:60; 21:64**
Damages, **8:43**
Deference, **9:132**
Depriving court of jurisdiction, **21:14**
Elements of contract-based claim, **8:43**
Enforcement in settlement agreement, **3:107**
FNERDA, **6:18**
Formation, **20:44**
Good faith implied, **12:39**
Government, **4:59**
Illegality, **7:36**
Implicates inequitable conduct, **4:54**
Implied, **9:482**
Implied, good faith, **12:39**
Implied-in-fact contract, **12:38; 20:40**
Inequitable conduct, implicates, **4:54**
ITC, **13:20**
Latent ambiguity, **3:48**
Lear, **18:8**
License agreement, **15:9**

CONTRACTS AND AGREEMENTS —Cont'd
Mistake of fact, **4:34**
Mutual mistake, **2:44; 4:34**
On-sale bar, **26:8**
Patent right clause, **8:8**
Personal jurisdiction, **13:114**
Public use, confidentiality agreement, **2:106**
Qui tam provision, Government and relator, **2:151**
Res judicata, **4:71**
Review, standard of, **1:76**
Settlement agreement, enforcement in, **3:107**
Standard agreement, **9:252**
Subject matter jurisdiction, **18:13; 25:1**
Suit against former employees to obtain title to patent, **1:49**
Trade secrets, **18:14**
Unilateral contract, **23:39**

CONTRADICTORY
Assignor estoppel doctrine, **19:47**

CONTRA PROFERENTUM RULE, EXCEPTION TO
Patent ambiguity, **9:160**

CONTRARY TO ACCEPTED WISDOM
Generally, **23:11**

CONTRARY TO PRIOR ART TEACHINGS
Obviousness, **9:31**

CONTRIBUTION
Inventorship, **6:50**

CONTRIBUTORY INFRINGEMENT
Generally, **2:195; 3:199; 5:10; 8:83; 16:20; 19:56**
ARO, **13:29**
Claim construction, **5:98**
Contempt, **16:25**
Customer end user as parties at trial, no necessity to have, **18:11**
Damages, **20:23**
Direct infringement, need for, **11:36; 19:100**
Evidence, **18:11**
FRCP 52(a), **7:82**
Implied license, **13:21**

CONTRIBUTORY INFRINGEMENT —Cont'd
Importance of an element, **1:129**
Inducement, **7:130**
Inducing infringement, **8:24; 9:356**
Inequitable conduct, **1:210**
Noninfringing use, existence, **20:113**
Notice, single use notice, **19:79**
Obviousness, **7:130**
Patent misuse, **8:14**
Process claims, **1:222**
Sec. 271(c), **6:23; 18:79**
Sec. 337, **19:222**
Single use notice, **19:79**
Summary judgment, **3:36**
Utility, **7:130**

CONTROL
Direct infringement, ''control'' by one party over entire process, **1:222**
System use, infringement by, **3:156**

CONTROLLING PRECEDENT
CAFC, **19:18**

CONTROVERSY
Declaratory judgment, **6:35; 6:38; 7:38; 7:55**

CONVENTIONAL
Well-understood, Routine and Conventional (this index)

CONVERSION
Proper notice required, **2:41**

CONVEYANCE
Damages, **3:56**

CONVOYED SALES
Lost profits, **1:174**
Sec. 284, **2:31**

CO-OWNERS
Generally, **19:98**
JNOV, **23:4**
Standing, **5:40; 19:221**

CO-PENDENCY
Interference, **2:70**
Markush claim rejection, **9:105**
Sec. 2201, **13:41**
Validity, **8:7**

COPIES
Generally, **1:87; 19:36**
Anticipation definition, **4:15**
Burden of proof, **2:26**
Costs, **11:51**
Damages, **19:29**
Designing around versus, **18:29**
Infringement, willful, **8:47**
Interference, **3:92; 4:8**
Interpretation thereof, **9:130**
Jepson format, **13:15**
Obviousness, as relevant to, **1:119**
Reissue, **11:5**
Seas and Compco decisions, **7:3**
Silence, **1:48**
Willful infringement, **8:47**

COPYRIGHT
Infringement, **16:110**

COREPHOTONICS, LTD. V. APPLE INC.
2023, **3:247**

CORPORATE OFFICERS AND DIRECTORS
Cease and desist order, **6:67**
FRCP 15(c), **6:11**
Sec. 112, **15:2**

CORPORATE VEIL, PIERCING
Piercing Corporate Veil (this index)

CORPORATION APPEARANCE BY NONLAWYER
FCR 7(a), **18:15**

CORRECTION
Accrual of claim for correction of inventorship, **16:131**
Adding co-inventor, **1:54; 6:79**
Claim construction error, **3:156**
Inventorship, **1:54; 6:35; 6:79; 16:131; 19:195; 19:218; 20:68**
Obviousness conclusion, **9:15**
Sec. 101, **18:6**

CORRESPONDENCE
Customers as infringement threats, letters to, **13:41**
Doctrine of equivalents, **5:39**

CORRESPONDING FUNCTION
Means-plus-function claim, **10:36; 18:48**

CORRESPONDING STRUCTURE
Means-plus-function claim, **1:114; 2:61; 2:123; 7:70; 11:42; 19:119; 19:238**
Sec. 112(6), **2:123; 14:38; 14:56**

CORROBORATING EVIDENCE
Generally, **3:117**
Conception, **3:160**
Inventorship, **19:132; 21:42**

CORROBORATION
Generally, **12:63; 19:152**
Activities for proof, **2:118**
Anticipation, **14:94**
Claims construed, **9:77**
Conception, **4:74**
Criteria, **23:48**
Evidence, forms of, **2:118; 5:40**
Factors, **20:75**
Inurement, **14:83**
Invalidity and noninfringement, declaratory judgment, **20:133**
Inventor's testimony, **8:30**
New interference rules, **8:3**
Non-party inventors, **20:48**
Obviousness, **5:133**
Oral testimony, **10:31**
Physical exhibit, not necessary for, **2:96**
Printed publication, **14:94**
Rule of reason analysis, **9:288; 11:41; 12:92; 13:72; 19:132**
Sec. 102(g), **20:48**
Sec. 102 in general, **6:40**
Witnesses, **8:30; 10:31; 20:64**

COST AWARD
Generally, **11:58**
28 USC § 1920, **9:342**

COST-PLUS-OVERHEAD
Attorney fees award, **16:24**

COST SAVINGS
Sec. 284, **8:4**

COSTS OF ACTION
Allowance of Costs (this index)
Commercial embodiment, comparison with, **1:20**

COSTS OF ACTION—Cont'd
Copies, exemplifications and copies, **11:51**
Cost Award (this index)
Deposition transcripts, **13:73; 19:45**
Distortion of record, **1:20**
Doctrine of equivalents, **1:20**
E-discovery costs, **3:156**
Exemplifications and copies, **11:51**
Expert witness fees, **19:77**
FRAP 39, **11:24**
FRCP 54(d), **4:32; 15:32**
Inequitable conduct, **1:193**
Infringement, **1:20**
Local rules, **1:260**
Prevailing Party (this index)
Process claims, irrelevant with, **1:20**
Sec. 145, **10:16; 14:4**
Sec. 2412(b), **13:48**
Trial and deposition transcripts, **13:73**

COUNTERCLAIM
Choice of law, **22:18**
Declaratory judgment, **13:46**
Immunity, **19:141**
Infringement, by licensee, **13:179**
Jurisdiction, **4:57; 7:73**
Sec. 1631, **19:2**
Sec viii statement, **14:63**
Substantive merit not basis for refusal to accept, **22:18**
Validity, **13:91**
Well-pleaded complaint, **2:31**

COUNTS
Generally, **3:43; 13:10**
Affidavit describing work of third party at reasonably contemporaneous time, **9:23**
Broadest reasonable interpretation, **18:56**
Interference, **7:49; 7:74; 9:88; 9:141; 9:230; 13:31; 19:151**
Interference estoppel, **9:49**
Interference estoppel by judgment, **23:14**
Law question, **4:31**

COURT ERROR
JNOV motion, **6:6**

COURT FINDINGS
All claims not addressed, **1:9**

COURT NOT LIMITED TO REASONABLE ROYALTY FIGURES URGED BY PARTIES
Generally, **19:53**

COURT OF APPEALS FOR THE FEDERAL CIRCUIT (CAFC)
Arbitration, ultimate arbiter, **18:3**
Choice of law, **5:67; 6:51; 7:75; 19:156; 21:44**
Controlling precedent, **19:18**
Declaratory judgment, **19:22**
Disregarding precedent, **1:52**
District court, **6:9**
Diversity jurisdiction determined at time action filed, **2:11**
Effect thereof, **17:2**
Evidence, failure to submit, **18:3**
Exclusive jurisdiction, **5:8**
Factfinder, **18:3**
Frivolous appeal, **2:11**
General verdict, **18:3**
Inter partes reexamination, **18:103**
Interpretation of own mandate, **12:47**
Interrogatories, **18:3**
Judge, **18:3**
Jurisdiction
generally, **1:69; 2:11; 2:67; 2:69; 2:111; 3:60; 3:73; 5:33; 6:57; 7:70; 8:66; 8:70; 9:213; 11:50; 14:29; 16:45; 16:68; 16:73; 19:95; 19:141; 19:170; 19:175; 20:2; 20:45; 20:82; 21:35; 21:37; 22:14**
advisory opinion, **20:2**
appealability, **7:8; 10:43; 19:50; 22:2**
contempt, **1:263**
appeal and review, **7:14**
arising under, **10:43; 13:14**
equitable estoppel, **13:14**
exclusive jurisdiction, **5:8**
ex parte tests, **9:63**
facts vs. law, **20:2**
FDCA, **1:332**
interlocutory order, **5:85; 13:219; 22:2**
inventor not required to understand, **9:63**
ITC, **1:15**

COURT OF APPEALS FOR THE FEDERAL CIRCUIT (CAFC) —Cont'd
Jurisdiction—Cont'd
lack of, **2:11**
law vs. facts, **20:2**
mandamus, **9:54; 9:63; 9:292**
nonpatent claims, **9:161**
notice, **9:63**
opinion, advisory, **20:2**
reexamination, **7:8**
repeal of jurisdictional statute, **6:30**
repeal of jurisdictional statute, after, **6:30**
Sec. 1651, **9:128**
special dispatch, conducted with, **7:8**
stipulation, **20:2**
threshold question, **23:15**
transfer of appeal, **7:14**
understand, inventor not required to understand, **9:63**
without notice to other party, **9:63**
Jury, obviousness question to, **18:3**
Late claiming, **18:3**
Motion to publish cafc decision, **9:1**
MPEP, **9:10**
New ground of rejection, **9:22**
Obviousness question to jury, **18:3**
Opinions or findings, **19:42**
Parties, **21:22**
Precedent, **22:7**
Preemption, **21:42**
Purpose, **9:76**
Repeal, **6:30**
Sec. 145 proceeding in district court, **6:9**
State immunity from suit under Eleventh Amendment, **10:11**
Submit evidence, failure to, **18:3**
Trial conduct, **18:3**
Ultimate arbiter, **18:3**

COURT OF CLAIMS
Claims Court (this index)

COURT OF INTERNATIONAL TRADE STANDARD
Summary judgment, **20:38**

COVENANT NOT TO SUE
ANDA, **3:132**
Claim differentiation, **9:411**
Dismissal, **7:90**

COVENANT NOT TO SUE—Cont'd
Jurisdiction, **18:81**
Statement of nonliability, **19:55**
Subject matter jurisdiction, **4:95**
Summary judgment, **1:306; 13:244**

COVERED BUSINESS METHOD REVIEW
Generally, **1:293; 19:297; 19:318; 19:330; 21:71; 22:51**
Complimentary to, **21:71**
Estoppel, **3:202**
Final judgment, **9:415**
Incidental to, **21:71**
Obviousness, **21:72**
Sec. 101, **1:293; 18:119; 20:154; 21:71**
Sec. 329, **7:117**
Statutory definition, **21:71**
Stay, **2:158; 9:415; 22:48; 22:52**
Transitional program, **2:168**

CREDIBILITY OF EVIDENCE
Weight and Credibility of Evidence (this index)

CREDITING EXPERT
Sec. 145, **7:9**

CREDIT ONE WHEN CONFLICTING TESTIMONY
Witness' testimony, **7:47**

CRIME FRAUD EXCEPTION
Attorney-client privilege, **21:58**

CRIMINAL CONTEMPT
Generally, **19:48**

CRITICAL CLAIM TERM
Construction, **13:169**

CRITICAL DATE
Exceptional case, **18:9**

CRITICALITY
ITC, **1:17**
Obviousness, **9:107**

CROCS, INC. V. INTERNATIONAL TRADE COMMISSION
2026, **3:264**

CROPS FROM SECOND GENERATION SEEDS
Replication of patented technology, **13:173**

CROSS-APPEAL
Generally, **2:87; 13:8; 14:53; 18:2; 22:4**
Conditional, **14:53**
Different claims in issue, **8:46**
Equitable estoppel, **18:98**
JNOV, **22:4**
Law of the case, **7:28**
Reverse validity or infringement component of judgment
generally, **18:2**
adding features, **18:2**
combination, **18:2**
doctrine of equivalents, **18:2**
fact question, **18:2**
jury instruction error, **9:317**
liability not avoided, **18:2**
means-plus-function claim, **18:2**
old combination rejection, **18:2**
rejection, **18:2**
secondary considerations must be considered, **18:2**

CROSS-EXAMINATION
Administrative law, **4:38**
Collateral estoppel, **13:53**

CROSS MOTIONS
Noninfringement, **1:66**
Summary judgment, **2:36**

CROSS-READING
Design patent, **19:8**

CROWDED ART
Claim interpretation, **20:8**

CROWN PACKAGING TECHNOLOGY, INC. V. BELVAC PRODUCTION MACHINERY, INC.
2024, **3:254**

CULPABILITY
Intent to mislead, **20:35**

CULPABLE INTENT
Inequitable conduct, **5:16; 15:34; 16:32; 20:25**

CUMULATIVE PRIOR ART
Inequitable conduct, **7:1**

CUMULATIVE REFERENCE
Generally, **5:16; 18:40**
Inequitable conduct, **19:51**

CUMULATIVE REFERENCE—Cont'd
Materiality, **19:59**
Prior art, **12:61**

CURE
Damages, **1:20**

CUSTOM
Mandamus, **9:57**

CUSTOMER
Contributory vs.direct infringement, **18:11**
Patent license, **12:14**
Statutory notice under Sec. 287(b)(5), **13:41**
Use of system, infringement, **3:156**

CYNTEC COMPANY, LTD. V. CHILISIN ELECTRONICS CORP.
2023, **3:248**

CYTIVA BIOPROCESS R&D AB V. JSR CORP.
2024, **3:255**

CYWEE GROUP LTD. V. GOOGLE LLC
2023, **3:249**

CYWEE GROUP LTD. V. ZTE (USA), INC.
2024, **3:256**

DAMAGES
Generally, **1:152; 1:350; 1:373; 11:88; 18:62; 19:38; 20:157; 21:44; 22:65**
Accounting, **1:20; 1:38**
Accounting phase, **11:15**
Adequate to compensate for infringement, **16:40**
Amended complaint, **1:350**
Anticipation, **5:138**
Appeal and review, **1:20; 6:12; 18:35; 19:96; 20:39; 21:23**
Apportionment, **13:224; 15:61**
Assembly of completed machine after patent term, **16:5**
Assignor estoppel doctrine, **19:47**
Bad faith, **20:19**
Breach of contract limited to those reasonably foreseeable, **8:43**
Civil contempt, **7:11**
Compensation, adequate, **16:40**

DAMAGES—Cont'd
Compound interest, **4:24**
Conflicting expert testimony, **1:20**
Contributory infringement, **20:23**
Conveyed sales vs. derivative sales, **3:56**
Copying, **19:29**
Cure trial mistakes, cannot find facts de novo or, **1:20**
Delay, **23:27**
Derivative sales, conveyed sales vs., **3:56**
Design, **20:15**
Design patent, **1:275; 3:98**
Discretion of court, **7:15; 13:45**
District court, affirm on grounds not relied upon by, **2:15**
Divided infringement, **1:270; 1:271**
Double recovery, **1:148**
Doubts resolved against infringer, **19:92**
Dual-sided subject, **12:24**
Egregiousness of defendant's conduct, **5:54**
Enhanced damages during appeal, **9:125; 19:289**
Equitable defense, **2:19**
Exceptional case, **3:180**
Expert testimony, **12:88; 22:43**
Fact question, **6:26; 15:10; 21:18**
Fact question with underlying discretionary decisions, **13:45**
Foreign countries, invention not sold in US, **20:23**
Foreseeability, **7:63; 13:79**
FRCP 52(a), **1:18; 19:4**
FRCP 60(b), **1:20**
Good faith challenge, **16:5**
Harm to reputation, **18:32**
Hypothetical negotiation, **1:296; 12:97**
Inadequacy of money damages, **14:9**
Inducement, **5:138; 9:410**
Infringement, **5:121; 13:146; 13:224; 16:40; 19:92; 22:35**
Injunction, **1:20; 1:262**
Invalidity, **3:180**
Issue preclusion, **4:9**
JNOV, **23:4**
Jury, **1:16; 1:199; 2:80; 23:73**
Laches, **2:19; 3:180**
Law of the case, **20:23**

DAMAGES—Cont'd
Lear, **18:8**
Lost profits, **1:20; 1:59; 2:19; 2:40; 3:8; 7:15; 7:63; 13:157; 16:5; 18:2; 19:52; 20:23; 23:3; 23:82**
Lump sum royalty payment, **9:235**
Machine, assembly of completed machine after patent term, **16:5**
Mandamus, **9:76**
Mandate, **18:105**
Marking, **4:89; 14:24; 18:2**
Master, special master, **20:19**
Maximum recovery rule, **19:137**
Method, notice required for, **19:154**
Methodology, **1:105; 11:10; 12:90; 13:75**
Modified item, **1:20**
Multi-component products, **22:47**
Negotiations, hypothetical, **1:296; 2:189; 20:23**
Notice, **7:66; 19:154**
Obviousness, **19:228**
Opinion of counsel, **1:20**
Other damages, **23:73**
Panduit, **16:40; 19:56**
Payment, lump sum royalty, **9:235**
Pre-issuance damages with no actual notice of patent, **18:113**
Prejudgment interest, **2:15; 7:15; 16:5; 18:2**
Prejudice, **8:50**
Price erosion, **22:26**
Prior judgment, **20:23**
Process, notice required for method or process, **19:154**
Punishment, not, **1:20**
Punitive damages, **9:161; 18:14**
Question of fact, **3:96; 5:71**
Reasonable royalty
generally, **8:20; 13:146; 16:163; 19:16; 23:25**
ANDA, **1:280**
apportionment, **14:5**
floor on damages, **18:35**
future lost sales, **6:74**
hypothetical negotiation, **1:296; 12:90; 16:129**
redetermination, **18:86**
30 percent, **20:19**
willfulness, **21:57**
Reasonably foreseeable, **13:79**

DAMAGES—Cont'd
Reexamination, **12:50**
Remand, **18:105**
Requirement, **20:19**
Reversal of award, **5:102**
Royalty, lump sum royalty payment, **9:235**
Royalty, reasonable royalty, **8:20**
Sale, **3:180**
Sears, **21:11**
Sec. 101, **6:97**
Sec. 271(a), **1:270; 3:180; 8:138**
Sec. 271(f), **23:82**
Sec. 289, **14:77; 19:293**
Sec. 102(e), **19:41**
Sec. 112, **8:7; 19:7**
Sec. 271(c), **20:23**
Sec. 284
generally, **2:31; 4:6; 4:7; 8:4; 11:21; 12:4; 19:29; 19:35; 19:53; 20:23**
enhanced damages, **2:30; 9:323**
nominal damages, **12:24**
precision, not ascertainable with, **2:30**
Sec. 286, **1:47**
Sec. 287, **4:12**
Sec. 1498, **13:35**
Simple v. compound interest, **4:24**
Special master, **20:19**
Standard essential patents, **3:186**
Standing, **23:82**
State law punitive damages, **9:161**
Testimonial evidence alone, **7:11**
30 percent reasonable royalty, **20:19**
Two-step analysis, **10:21**
Two-step process, **13:101**
Unpatented accessory sales part of damages base, **11:21**
Validity, **12:45**
Willful infringement
generally, **1:20; 2:19; 2:148; 13:145; 16:5; 18:2; 19:29**
determination, **18:2**
increased damages, **9:323; 11:10; 15:14**
reasonable royalty, **21:57**

DANN AMENDMENT
Appeals from judgments, **19:30**
Defect reissue, **19:30**
Opinions, **19:30**

DANN AMENDMENT—Cont'd
Reissue, **9:47; 19:30**

DATE
Time and Timeliness (this index)

DDR HOLDINGS, LLC V. PRICELINE.COM LLC
2024, **4:134**

DEAD INVENTOR'S VIDEOTAPE DEPOSITION
FRE 403, **13:4**

DECEPTION
Intent to Deceive (this index)

DECLARATION
Affidavit, **9:177**
Foreign, **19:118**
Inequitable conduct, **9:378; 13:129**

DECLARATORY JUDGMENTS
Generally, **1:243; 5:74; 16:103**
Actual controversy
generally, **1:94; 2:122; 3:69; 4:103; 6:35; 6:38; 7:38; 7:55; 8:66; 9:324; 15:24; 19:250; 23:22**
infringement, **20:26**
patented transgenic seeds, **15:44**
Advisory opinion, **9:92**
"All the circumstances," **13:155**
ANDA disputes, **10:39**
Appeal and review, **9:233; 19:86**
Appropriateness, **9:92**
Burden of proof, **13:179; 13:194**
CAFC, **19:22**
CAPC, **3:132**
Case or controversy requirement, **1:319; 19:86; 20:111**
Collateral estoppel, **10:6**
Combination invention, **10:6**
Discretion of court, dismissal is within, **5:24; 19:198**
Dismissal, **5:24; 19:81**
District court follows CAFC patent law, **19:22**
Escrow, **3:21**
Exceptional case, **1:159**
First to file, **3:226; 6:89**
Immediacy requirement, **3:134; 13:177; 19:250**
Inducement, **1:319**

DECLARATORY JUDGMENTS—Cont'd
Infringement, **13:194; 19:81; 19:101**
Inventorship, **12:86**
Jurisdiction, **1:27; 2:122; 8:109; 13:194; 19:192; 23:9**
Justiciable controversy, **19:61**
Justifiable controversy, **2:42**
Law question, **19:265**
Licenses
generally, **13:133**
license agreement, **7:79; 13:143; 19:192**
licensee, **13:132**
Limitations in specification, **10:6**
Notice of infringement, **19:101**
Opinion, advisory, **9:92**
Patented transgenic seeds, actual controversy, **15:44**
Pendent jurisdiction, **23:9**
Personal jurisdiction, **1:374**
Redundant judgment to patentee's suit, **13:46**
Regional circuit law, **19:22**
Registration, trademark, **23:9**
Requirements, **4:40; 16:42**
Reversal of court ruling, **9:92**
Sec. 2201, **7:25; 9:89; 9:92; 10:6; 12:23; 13:41; 19:22; 19:55; 23:9**
Sovereign immunity, **7:25**
Specification, limitations in, **10:6**
Standing, **16:113**
Subject matter jurisdiction, **1:297; 1:301; 8:109; 16:130; 19:250**
Summary judgment, **7:7**
Synergism, **10:6**
Trademark registration, **23:9**
Unasserted claims, **19:236**
Validity, **1:312**

DECREES
See index topics Judgments; Orders (this index)

DEDICATION TO PUBLIC
Claim interpretation, **16:88**
Doctrine of equivalents, disclosure-dedication, **19:233**
Unclaimed subject matter, intent, **20:74**

DEFAULT JUDGMENT
Dismissal, **20:7**

DEFAULT JUDGMENT—Cont'd
FRCP 60(b), **9:144**
Interference, **1:60**

DEFAULT PROOF
Generally, **4:76**

DEFECTS
Dann Amendment, **19:30**
FRCP 12(b)(7), **21:56**
Sec. 251, **7:21**

DEFENSES
Anticipation, **18:20**
Assignor estoppel doctrine, **19:47; 19:241**
Burden of proof, **9:118; 19:48**
Clearly erroneous standard, **19:23**
Collateral estoppel, **4:3**
Exhaustion of patent rights, **5:93**
Factual overlap of issues, **23:24**
Implied license, **1:100**
Inconsistent jury findings, **2:10**
Infringement, **5:60**
Inherent element of every government contract, **8:41**
Interrelationship of issues, **20:5**
Invalidity, **1:177**
Jury trial, **20:55**
Jury verdict, **3:75**
Laches, **8:114**
Licensee agreement, **18:58**
Obviousness, **16:4**
Patent misuse, **23:9**
Repair, **4:1**
Sec. 282, **16:50**
Sec. 1631, **19:2**
Sovereign acts, **15:8**
Waiver, **9:159**
Willfulness, **3:96**

DEFERENCE
Agency's interpretation of contract, **9:132**
Agency's interpretation of own regulations, **11:27**
Certificate of correction, **10:44**
Choice of law, **2:31**
Claim differentiation, **11:2**
Indefiniteness, **21:44**
Inventorship, **21:42**
ITC, **5:37**

DEFERENCE—Cont'd
Patent term extension, **8:25**
Sec. 41(a)(7), **13:32**
Special master's decision, **13:24**
Statutory construction
generally, **2:51; 4:30; 11:39; 14:17; 14:22; 19:74; 19:82**
chevron deference, **6:31; 26:3**
ITO agency, **23:31**
own statute, **11:30**
permissible construction, **12:34**
silent or ambiguous statute, **6:24**
Timing of agency's decision making, **20:88**

DEFINITENESS
Certainty and Definiteness (this index)

DEFINITE STRUCTURE
Means-plus-function claim, **6:36**

DEFINITIONS
Abuse of discretion, **8:9**
Appeal, **4:67; 10:19**
Best mode, **14:30**
Certainty and definiteness, failure to define term, **2:105**
Claim interpretation, **8:99**
Clearly erroneous standard, **4:41**
Competitive decision making, **4:94**
"Comprising," **19:158**
Conception, **2:126; 4:100**
Extrinsic evidence rarely probative of special definition, **14:30**
Machine, **9:290**
Manufacture, **9:290**
Markush claim, **13:218**
Mathematical algorithm, **9:42**
Multiple definitions of phrase, **7:28**
Multiple dictionary definitions, **9:253**
Ordinary skill, hypothetical person for, **19:26**
Original application, **3:139**
Precise proportions, **8:74**
Preponderance of the evidence, **4:33**
Procedure, **16:3**
Process, **9:20; 18:85**
Prosecution history defining claim terms, **19:84**
Relationship, **9:34**
Substantial evidence, **2:37; 3:23; 4:33; 6:31; 6:32; 7:43; 7:44; 8:31;**

DEFINITIONS—Cont'd
9:231; 10:31; 13:68; 20:22
Summary judgment, **20:10**
Trade secret, **12:27**
Undefined terms given their ordinarily understood meaning, **8:61**

DEFINITIVE HOLDINGS V. POWERTEQ
2026, **4:139**

DELAY
Laches or Delay (this index)

DELISTING
Federal Food, Drug and Cosmetic Act, **1:120**

DELIVERY
Judicial notice, **11:24**

DEMAND
Entire market value rule, **20:50**
Sanctions, **17:2**

DEMEANING
Reprehensible conduct, **9:159**

DEMONSTRATION
Infringement, **13:53**

DE NOVO REVIEW
Generally, **3:53**
Attorney fee ruling, **3:171**
Evidence, **11:32**
Explained, **12:43**
Prima facie obviousness, **2:133**
Sec. 102(b), **9:7**
Sec. 145, **14:4**
Sec. 252, **19:4**
Standard of review, **11:19**
Standing, **7:39**

DEPENDENT CLAIMS
Generally, **12:28**
Burden of persuasion and quantum of proof, **18:7**
Claim differentiation, **5:60; 9:237**
Claim interpretation, **15:31; 23:43**
Dependent claim tail cannot wag independent claim dog, **14:12**
Design patent, **19:8**
Doctrine of equivalents, **5:6; 18:65**
Independent claims, generally, **9:100; 9:123**

DEPENDENT CLAIMS—Cont'd
Infringement, **10:26; 13:100; 13:147; 23:17; 23:35**
Obviousness, **9:24; 16:4; 18:23; 19:245**
Prosecution history estoppel, **8:105**
Reissue, **9:336**
Sec. 1.192(c), **9:154**
Summary judgment, **2:29**
Validity, **8:7; 9:345**

DEPOSIT
Best mode, **1:44; 19:51**
Microbiology field, **9:53**
Recombinant DNA technology, **19:121**

DEPOSITION
Allowance of costs, **19:45**
Appeal, introduction on, **13:183**
Costs, **13:73**
Declaration in conflict with prior deposition testimony, **19:62**
Discovery, **23:5**
FRE 403, **13:4**
Inter partes reexamination, **1:232**
Inter partes review, **1:338**

DERIVATION OF INVENTION
Another, **12:122**
Claim preamble, **5:65**
Damages, **3:56**
Interference, **4:11**
Inurement versus, **3:82**
Law questions, **16:36**
Obviousness, **3:204**
Sec. 102(f), **14:10**
Two prong test, **7:46**

DESCRIPTION
Generally, **16:80**
Biological deposits, **5:69**
Collateral estoppel, **1:249**
Continuation, **20:47**
Continuation application, **19:105**
Design patent, **9:205**
DNA, **1:131; 2:143**
Drawings constitute an adequate description, **3:101**
Enablement, **21:9**
Enablement vs. description requirement, **22:7**
Fact question, **1:118; 9:177**

DESCRIPTION—Cont'd
Failure to meet requirements for written description, **21:67**
Genus claim, **2:143; 2:144**
Haec verba, not, **3:103**
Inherency, **5:56**
Limitations, **12:50**
MPEP, **16:8**
Obvious for continuation, patent only renders, **20:47**
Obviousness, **6:99**
Possession, **13:124**
Precision, reasonable precision, **6:33**
Primarily factual, **21:33**
Reasonable precision, **6:33**
Sec. 112, **9:85; 18:40; 20:6**
Secondary considerations, **6:99**
Written description
generally, **3:210; 5:75; 9:488; 11:57; 12:73; 13:126; 14:42; 14:97; 18:120; 19:178; 19:283; 20:118; 20:123; 20:146**
abuse of discretion, **3:197; 9:318**
adequacy of disclosure, **1:185**
amino acid sequence, **3:133; 9:264; 9:306**
bacteria, **1:330; 3:114**
certificate of correction, **3:187**
claim construction, **1:215; 6:93; 19:283; 22:49**
claim differentiation, **6:93**
constructive possession, **3:157**
design patent, **9:376**
disclosure, **16:133; 17:11**
DNA, **2:143; 3:116**
doctrine of equivalents, **1:164**
enablement, **1:304; 9:476; 14:101; 22:49**
enablement requirement vs., **19:236; 21:46; 21:47**
fact question, **6:20; 7:112; 9:373; 21:14**
failure to meet requirements, **21:67**
features, **19:254**
genus claim, **2:143; 2:144**
genus when only disclose species, **2:107**
induced infringement, **22:59**
infringement, **9:453**
inherent capabilities, **13:53**
in haec verba, **12:54; 16:65**

DESCRIPTION—Cont'd
Written description—Cont'd
injunction, **1:304**
injunctions, **22:59**
interference, **1:182; 2:172; 7:123; 11:65; 18:88**
inter partes review, **11:80**
jurisdiction, **22:59**
jury taint, **1:215**
lack of written description, **11:62; 19:249**
means-plus-function, **1:262**
negative limitations, **9:412**
obviousness, **14:101**
ordinary and accustomed meaning, **18:46**
priority filing date, **4:117; 19:120**
provisional application, **14:36**
public availability, **3:144**
recapture rule, **3:187**
reissue, **9:479**
Sec. 112, **1:188; 1:252; 1:258; 1:304; 8:101; 9:46; 18:4; 25:11**
Sec. 112(1), **1:200; 2:144; 9:125; 9:130; 19:254; 22:7; 23:25**
species, need not describe all, **3:106**
sufficiency, **1:185**
summary judgment, written description and enablement requirement, **2:144; 21:46**

DESIGN
See also Design Patent (this index)
Combined references showing only components not overall appearance of, **9:137**
Damages, **20:15**
Double patenting, **3:4**
Inequitable conduct, **6:4**
Injunction against use, purpose of, **20:15**
Modification, **20:15**
Same, Sec. 171, **9:73**
Sec. 171, **9:73; 9:106**

DESIGNER OF ORDINARY SKILL
Obviousness, **12:32**

DESIGNING AROUND PATENT
Generally, **4:35; 8:47**
Claim interpretation, **3:7**
Copying, versus, **18:29**
Sec. 102(g), **11:9**

DESIGNING AROUND PATENT —Cont'd
Subject matter jurisdiction, **25:1**
Willful infringement, **19:52**

DESIGN IN PUBLIC DOMAIN
Jurisdiction, **12:48**

DESIGN PATENT
Generally, **2:112; 3:208; 3:218; 8:157; 9:464; 12:118; 16:101; 19:333; 19:341**
Anticipation, **3:216; 4:64; 8:62; 9:325; 9:500**
Appeal and review, **19:8; 21:4**
Attorneys' fees, **19:8; 21:4**
Best mode requirement, **18:1**
Case, **1:73**
Chutzpah, **19:8**
Claim language, **7:59**
Construe claim language, **7:59**
Continuing application, **9:205**
Cross-reading, **19:8**
Damages, **1:275; 3:98**
Dependent vs. independent claims, **19:8**
Description, **9:205**
Double patenting, **19:8**
Drawings, **9:137**
Estoppel, **1:318**
Evidence, validity for each claim, **19:8**
Exhibits superior characteristics over single predecessor device, **18:63**
Experimental use, **3:81**
FRAP 38, **19:8**
Functional elements, **18:29**
Functionality, **1:151; 12:32**
Functional vs. non-functional aspects, **5:21**
Genuine issue, **16:17**
Gorham test, **2:33; 12:29; 15:5; 16:33; 19:8**
Improper to use reference's drawing to negate patentability, **9:137**
Indefiniteness, **1:275; 5:126**
Inequitable conduct, **7:59; 16:1**
Infringement
generally, **3:98; 3:100; 8:126; 15:11; 19:85; 21:4**
elements, **1:165**
Gorham test, **15:5; 19:8**
ordinary observer test, **1:151; 1:165; 5:89; 9:321; 18:96**

DESIGN PATENT—Cont'd
Infringement—Cont'd
patentability distinguished, **11:25**
tests, **1:165; 5:89; 12:8**
Inventor, **8:81**
Issued as division of earlier utility application may be entitled to latter's priority date, **18:1**
Materiality, **16:1**
Obviousness, **1:226; 3:227.50; 8:128; 9:120; 9:135; 9:178; 9:227; 12:17; 13:198; 16:17**
Ordinary designer standard, **4:48**
Ordinary observer test, **1:151; 1:165; 5:89; 6:88; 9:321; 18:96**
Ornamentality requirement, **1:151; 2:58; 8:62; 8:128; 18:87**
Overall design standard, **18:96**
Overall similarity compared, **2:63**
Patentability, **9:137; 11:25**
Points of novelty, **2:106; 9:325**
Preliminary injunction, **1:226; 3:34; 20:93**
Presumption not augmented by previous validity holding, **19:8**
Primarily functional, **16:21**
Priority claim, **9:376**
Profits and Sec. 284, not receive both, **3:98**
Prosecution history estoppel, **16:139**
Reference, improper to use reference's drawing to negate patentability, **9:137**
Scope, **9:55**
Sec. 102(b), **20:32**
Sec. 103, **9:8**
Sec. 284 and profits, not receive both, **3:98**
Sec. 1337 industry requirement, **3:154**
Stipulated judgment of noninfringement, **19:288**
Summary judgment, **1:35; 16:17**
Supervisory authority, **16:17**
Two-part test, **21:28**
Utility patent, **1:356**
Validity, **19:8**
Visible, not required to be, **19:118**
Written description sufficiency, **9:376**

DESIRABILITY
Obviousness (this index)

DESTROY
Presumption of validity, **13:81**

DESTRUCTION OF DOCUMENTS
Evidence, **5:1**

DETAIL
Sec. 112, **19:7**

DEVICES
Claim interpretation. Claim Construction and Interpretation (this index)
Claim preclusion, **8:76**
Doctrine of equivalents, **7:40**
Equivalent device, not necessarily, **11:22**
Infringement, **8:46**
MPEP, **16:6**
Obviousness, **20:72**
Refining, **13:8**
Sec. 103 rejection on single reference device capable of being operated like claimed apparatus, **9:101**
Suggestion or motivation to modify, must be, **9:101**

DEVOID
Generally, **13:98**

DEXCOM, INC. V. ABBOTT DIABETES CARE, INC.
2024, **4:135**

DICKENS
Bleak House, **19:83**

DICTA
Generally, **11:37**

DICTIONARY
Generally, **4:67; 22:19**
Claim interpretation
generally, **7:79; 9:269; 16:85; 16:94**
definitions, **1:90; 13:151**
intrinsic record trumps dictionary, **11:53; 19:196**
less useful than patent itself, **20:51**
multiple dictionary definitions, **9:253**
not always customary meaning, **6:51**
sole use improper, **3:105**
Extrinsic evidence, **22:19**
Technical terms, use technical dictionary for, **1:109**

DIFFERENTIATION
Claim Differentiation (this index)

DILIGENCE
Generally, **2:118; 11:82; 13:103**
Experiment, laboratory, **19:144**
Laboratory experimentation, **19:144**
Reasonable, **13:105**
Sec. 102(g), **14:7; 16:148**

DIMENSIONS
Jury verdict, **19:5**

DIONEX SOFTRON GMBH V. AGILENT TECHNOLOGIES, INC.
2023, **4:133**

DIRECT APPEAL
District court, **6:9**

DIRECTED TO FACTS
Interrogatories, **23:7**

DIRECTED VERDICT
Generally, **5:22**
FRCP 50(a), **2:31**
JNOV, **22:4**
JNOV motion, **4:32**
Jury instructions, **10:4**
Renewal, **14:1**
Review, standard of, **1:46; 1:71**
Sufficiently specific, when, **23:17**
Summary judgment, **10:4**
Waiver, **10:15**
Willful infringement, **16:22**

DIRECT EVIDENCE
Generally, **13:28**
Disclosure, duty of, **12:52**
Inducement, **2:130**

DIRECT INFRINGEMENT
Generally, **5:63**
ARO, **13:29**
Claim construction, **12:108**
Contributory infringement, **11:36; 19:56**
Contributory requires direct infringement, **16:20**
''Control'' or ''direction'' by one party over entire process, **1:222**
Customer end user as parties at trial, no necessity to have, **18:11**
Divided, **12:108**
Evidence, **18:11**
If none, then no contributory or induced infringement, **5:10**

DIRECT INFRINGEMENT—Cont'd
Implied license, **13:21**
Inducing infringement, **5:63; 5:102; 12:104**
Intent not required, **9:118**
Joint infringement, party in control, **2:124**
Method claims, performance of all steps, **1:222; 5:121; 12:108**
Single direct infringer requirement, **1:222**
Single entity performing all steps, **1:242**

DIRECTORY STATUTES
Statutory construction, **5:17**

DISAVOWAL OF CLAIM SCOPE
Claim construction and interpretation, **3:140; 5:97; 15:47; 16:143; 16:151; 20:112; 20:148; 21:70**

DISBELIEF BY EXPERTS
Generally, **5:5**

DISCHARGE OF CLAIM
Accord and satisfaction, **3:48**

DISCLAIMERS
Disavowal of claim, **3:137; 21:70**
Doctrine of prosecution disclaimer, **3:137**
Double patenting, **15:6**
Fundamental precept in claim construction, **1:309; 15:21; 20:138**
Interference, **7:45**
Inter partes review, **1:326; 1:327**
Patent marking, **18:118**
Patent term extension, **13:144**
Prior art, **19:216**
Prosecution history, **1:298; 2:155; 4:84; 13:209; 19:169; 19:193; 20:157.70; 22:35**
Prosecution history estoppel, **19:153**
Purpose, **9:110**
Recapture, **8:96**
Reissue, **22:15**
Rejection, **17:2**
28 USC § 1295, **1:327**

DISCLOSURE
Analogous art, **9:78**
ANDA, **2:81**
Best mode, **7:37; 7:47; 9:357; 23:72**
Chemical compound, **9:148**

DISCLOSURE—Cont'd
Chemical genus, **9:126**
Claim-supporting vs. claim-anticipating, **22:7**
Computer, **9:154**
Conception, **3:160**
Doctrine of Equivalents (this index)
Double patenting, **9:45; 9:307**
Duty of, **9:43; 12:52; 14:19; 20:76**
Enablement, **1:102; 1:167; 10:23**
Exceptional case, **18:9**
Expert testimony, **3:141; 13:183**
Filing of CIP, **23:30**
FRCP 26, **3:141**
FRCP 52(a), **12:6**
Generic, **19:201**
Inequitable conduct, **3:98; 6:13; 19:128**
Infringement, **9:4**
Inherent, **25:12**
Intent to mislead, **8:51**
Interference, **7:13**
Inventor's admission of invention by another, **1:8**
ITC domestic disclosure communication, **1:224**
Later reference, discredited by, **9:117**
Means-plus-function, **2:134; 4:17**
MPEP, **16:6**
Obviousness, **9:107; 16:4; 19:243**
Obviousness-type double patenting, **19:226**
Original claims, **14:8**
Patent prosecution bar, **4:94; 5:110**
Preemption, **21:30**
Prior art, **4:84; 7:68; 13:18**
Production specification, **5:16**
References, **15:28; 15:33**
Relative terms in claims given broadest reasonable interpretation during prosecution, **9:36**
Rule 26(a) expert testimony disclosure, **13:183**
Sec. 1.56, **8:29**
Sec. 10.57(b), **13:69**
Sec. 102(b), **9:18**
Sec. 102(e), **9:28**
Sec. 112, **2:123; 13:10; 16:10**
Sec. 145, **7:9**
Sec. 282, statutory outer limits, **23:76**

DISCLOSURE—Cont'd
Specification need not disclose what is well known, **9:113**
Standard of review, disclosure dedication, **20:74**
Standard setting organizations, **17:9**
Substitute, must be obvious, **9:29**
Sufficiency of
corresponding structure, **2:123**
enablement, **1:102**
good faith explanation of failure to disclosure, **6:80**
interference, **3:25**
Sec. 112(1), **23:30**
Sec. 120, **11:8**
some claims but not all, **22:7**
Trade name information as failure to comply with best mode requirement, **20:33**
Written description, **1:185**

DISCOVERY
Abuse of Discovery (this index)
ADR proceeding, documents pertaining to ADR proceeding, **8:37**
Ancillary proceeding, **13:37**
Anticipation, discovery of properties, **9:257**
Appealability, **8:9**
Choice of law, **1:19; 19:114; 20:17**
Confidential information, **1:10; 19:17**
Documents pertaining to ADR proceeding, **8:37**
E-discovery costs, **3:156**
Enhanced damages, **21:3**
Examiner's deposition, **23:5**
Exceptional case discovery, **4:83**
Foreign countries, **3:65**
FRCP 26, **23:76**
FRCP 37(b), **23:34**
FRCP 45, **11:24**
FRCP 56(f), **13:154**
Interference estoppel by judgment, **23:14**
Monetary sanctions, **13:6**
New property or new use cannot impart patentability to known composition, **9:129**
New property or use of known composition, **9:104**
New trial, **22:26**

DISCOVERY—Cont'd
Nonparty's motion to quash discovery subpoena, **20:17**
Old composition, **20:11**
Prosecution disclaimer, **3:137**
Protective order, **13:40**
Record of invention, **9:221**
Review, standard of, **11:7**
Sanctions, **2:27; 18:94**
Summary judgment, **1:35**

DISCOVERY ORDER
Appealability, **17:3**
Choice of law, **4:47**
Mandamus review, **9:362; 9:430**

DISCOVERY SANCTIONS
FRCP 37(b), **20:4**
Respond, failure to, **13:25**

DISCRETION
Abuse of Discretion (this index)
Court's. Discretion of Court (this index)
Damages, **13:45**
Difficulty of showing, **19:57**
Injunctive relief, **10:23**

DISCRETIONARY
Enhanced damages award, **15:14**
Injunction, **15:14**
28 USC § 1292(b), **14:40**

DISCRETIONARY AGENCY DECISION
Standard of review, **4:38**

DISCRETIONARY AUTHORITY
Review of EIC, standard of, **7:23**

DISCRETIONARY EXERCISE
Mandamus, **6:19; 9:430**

DISCRETION OF COMMISSIONER
Interference, **2:67**

DISCRETION OF COURT
Conditional new trial, **13:34**
Damages, **7:15**
Declaratory judgment, **5:24; 19:198**
Evidence, **3:57**
FRE 403, **7:5**
Inequitable conduct, **7:33; 13:38; 13:45**
JMOL, **26:9**
Laches, **14:11**
Pendent jurisdiction, **11:20**

DISCRETION OF COURT—Cont'd
Preliminary injunction, **2:60; 6:21; 8:81; 12:29; 23:20**
Review, standard of, **7:72**
Rule 60(b), **12:100**
Sec. 252, **19:4**
Sec. 283, **18:18**
Summary judgment, **7:7**
Supplemental jurisdiction, **7:39**
Trial management, **20:25**

DISCRETION TO APPLY
Doctrine of equivalents, **13:80**

DISEASE TREATMENT METHODS
Bacterial species, **18:109**
Cells, **18:109**
DNA (this index)
Recombinant DNA (this index)

DISMISSAL
Generally, **8:95**
Abuse of discretion, **22:2**
Accessibility to public, **3:19**
Admission of prior art in specification, **3:19**
Anticipation, **3:19**
Appealable final order, **1:39**
Choice of law, **8:82**
Claims court, **20:27**
Complaint dismissed for mootness in view of settlement of controversy, **19:14**
Covenant not to sue, **7:90**
Declaratory judgment, **5:24; 19:81**
Default judgment, **20:7**
Factual allegations taken as true, **12:46**
Failure to state claim, **3:19; 4:121; 7:36; 10:42; 20:44**
Federal, **22:5**
Final decision, **8:82**
Final judgment, **16:62**
FRCP 12(b)(6), **1:42; 1:248; 3:147; 7:90; 8:102; 12:112; 19:237; 23:29**
FRCP 12(b)(7), **21:54**
FRCP 19(a), **22:8**
FRCP 37, **18:24**
FRCP 37(b), **23:34**
Harsh remedy, **7:52**
ITC, **25:2**
Joint motion, **20:95**

DISMISSAL—Cont'd
Jurisdiction
all patent claims dismissed, **3:112**
dismissal for lack of, **1:189; 6:30**
Jury trial, right to, **3:19**
Lexicographer, **3:19**
Limitations from specification, reading into claims, **3:19**
Merits vs. lack of subject matter jurisdiction, **12:38**
More pertinent prior art, **3:19**
Motion (this index)
9 Cir, **22:2**
Printed publication, **3:19**
Prior art, **3:19**
Reissue application, **9:47**
Sanctions, **12:36**
Sec. 285, **3:42**
Sec. 1338(b), **13:58**
Sec. 1631, **19:2**
Sec. 2201, **7:25; 13:41**
Specification, admission of prior art in, **3:19**
State claim, failure to, **3:19; 4:121; 7:36; 10:42; 20:44**
Subject matter jurisdiction, merits vs. lack of, **12:38**
Summary judgment, **3:19**
Validity, **16:54**
Weapon of last resort, **1:60; 7:23**

DISPOSITIVE MOTIONS
Executive Order 10096, **8:10**

DISSOLUTION
Interference, **16:7**

DISTINCTIVENESS
Sec. 112, **12:28; 19:26; 21:17**

DISTORTION OF RECORD
Costs on appeal, **1:20**

DISTRICT COURT
Appellate jurisdiction, **1:31; 12:36**
Conditional new trial, **13:34**
Correction of error in claim construction, **3:156**
Damages, **2:15**
Declaratory judgment, **19:22**
Evidence, **6:12**
Findings by, need for, **18:32**

DISTRICT COURT—Cont'd
Inherent power to control its own docket, **12:36**
Injunctive relief pending appeal after patentee has prevailed, **16:19**
Mandamus, **9:41**
Preliminary injunction, **8:81**
PTO will not cite as authority district court decision reversed on appeal, **9:1**
Reexamination, **9:180**
Review, standard of, **7:33; 7:72**
Sec. 41(a)(7), **13:32**
Sec. 145 proceeding, **6:9**

DIVERSITY JURISDICTION
CAFC, **2:11**

DIVERSITY OF CITIZENSHIP
Appellate jurisdiction, **3:11**

DIVIDED INFRINGEMENT
Refusal to deem unreasonable, **13:208**
Summary judgment, **13:211**

DIVISIONAL APPLICATION
Generally, **2:106**

DIVORCE
Standing, **5:105**

DNA
Generally, **6:20**
Biogenic, **1:44; 18:109**
Deposit of DNA, **19:121**
Description, **1:131; 3:116**
Interference, priority of invention, **19:240**
Isolated DNA molecules, **1:228; 9:383**
Prima facie obviousness, **9:133**
Recombinant DNA (this index)
Sec. 101, **1:228; 1:245; 9:383**
Sec. 112(1), **18:40**
Subject matter jurisdiction, **1:214**
Typing, **13:139**
Written description, **2:143; 3:116**

DOCKET
District court's inherent power to control its own, **12:36**

DOCTRINE OF EQUIVALENTS
Generally, **1:93; 1:132; 1:142; 1:145; 1:356; 2:74; 2:84; 2:114; 4:78; 5:59; 5:144; 7:41; 7:78; 8:100; 11:42; 11:46; 12:26; 12:65; 12:66; 12:123; 13:229; 14:46; 16:53; 16:99; 16:102; 16:104; 20:47; 21:18; 22:23; 26:9**

DOCTRINE OF EQUIVALENTS —Cont'd
"About," **3:136**
Additional step, **5:36**
All elements rule, **1:82; 5:86**
Amendment, narrowing, **6:70; 7:80; 8:87; 19:162**
Amendment of claims, **5:53; 6:64; 8:65; 8:66**
Amendments, **9:108; 9:235; 12:51**
Apply, no discretion to, **1:79**
Cancellation of claim and replacement with another claim, **13:106**
Chemical case, **26:2**
Claim construction and interpretation, **1:192; 3:170; 3:178; 4:23; 4:87; 5:120; 20:8**
Claiming process not perfect, **1:80**
Claim preamble, **3:22**
Claim vitiation, **18:106**
Complete identity not required, **14:1**
Correspondence, **5:39**
Costs on appeal, **1:20**
Criticism of prior art, **16:106**
Cross-appeal, **18:2**
Dependent claim, **5:6; 18:65**
Device, cannot cover prior art device, **7:40**
Direct, if none, **13:28**
Disclosure
disclosure dedication, **5:152; 19:233; 20:74**
unclaimed disclosed material, **13:75; 25:6**
Discretion to apply, none, **13:80**
Double patenting, **3:4**
Element-by-element analysis required, **7:61; 20:41; 22:16**
Element missing, **4:53**
Ensnarement, **4:90; 7:121**
Equivalence to non-means-plus-function limitation, **11:48**
Equivalent, generally, **1:93**
Equivalents versus, **5:32; 11:47**
Estoppel, scope of, **1:119**
Every claim limitation must be met, **9:131**

DOCTRINE OF EQUIVALENTS —Cont'd
Evidence, **7:51**
Exception, Graver Tank is exception not rule, **12:28**
Experts, **1:164**
Fact question, **5:28; 9:108; 10:10**
File wrapper estoppel, **9:108**
Findings on function, **3:39**
Foreseeability, **6:52; 6:64; 18:106**
FRCP 8(a)(2), **14:91**
FRCP 12(b)(6), **14:91**
FRCP 56(c), **8:27**
Function, **5:26; 6:37; 19:84; 21:28**
Function-way-result test, **19:52; 19:199**
Generalized testimony, **3:80**
Graver Tank, **12:28; 13:39; 16:11**
Hatch-Waxman Act, **9:438**
Human, infringement of human product by structurally different nonnatural one, **7:28**
Hypothetical claim, **23:17**
Hypotheticals, **14:18**
Identity, complete identity not required, **14:1**
Independent claims, **5:6; 18:65**
Inducement, **14:91**
Inducing infringement, **13:28**
Information disclosure statement, **5:31**
Infringement
generally, **4:35; 13:55; 20:6**
see also other entries throughout this topic
Biologics Price Competition and Innovation Act, **1:337**
equivalence, **12:7; 13:28**
human product by structurally different nonnatural one, **7:28**
inducing infringement, **13:28**
insubstantial differences, **22:47**
inventorship, **4:125**
judgment of invalidity must be vacated when no infringement, **5:6**
method claim, **13:186**
Inspection of patentee's product, **16:15**
Insubstantial differences, **1:84; 2:101; 3:86; 4:50; 4:62; 5:30; 9:225; 15:16 to 15:18; 19:97; 19:135; 20:57; 21:33; 22:47; 23:41; 26:6**
Interchangeability, **12:42; 13:91**

DOCTRINE OF EQUIVALENTS —Cont'd
Inventorship, **4:125**
Judgment as a matter of law, **5:44**
Judgment of invalidity must be vacated when no infringement, **5:6**
Jury instructions, **19:227**
Jury verdict, **8:47**
Limitations and restrictions
generally, **11:45**
equivalence to limitation, **16:133**
equivalence to non-means-plus-function limitation, **11:48**
every claim limitation must be met, **9:131**
patentee has duty to submit evidence for limitations not literally met, **7:51**
Literal scope of claims, outside of, **5:6; 7:51**
Matter of law, judgment as, **5:44**
Meaningful claim limitations, not to be used to erase, **3:51**
Means-plus-function claims, **1:125; 4:50; 9:215; 11:48**
Narrowing amendment, **6:70; 7:80; 8:87; 19:162**
1952 Patent Act, survives, **23:42**
Numerical ranges, effect of, **1:115**
Obviousness, **3:178**
One-to-one correspondence not required, **5:39; 6:39**
Outside literal scope of claims, **5:6; 7:51**
Patentability, **8:60; 12:51**
Patent Act of 1952, **23:42**
Patentee has duty to submit evidence for limitations not literally met, **7:51**
Pen and pencil analogy, **18:29**
Perspective, **12:69**
Presumption, **8:60; 21:11**
Prior art, **7:40; 9:118; 12:78; 13:93; 20:61**
Prosecution history, **9:108**
Prosecution history estoppel, **1:164; 6:48; 6:64; 9:186; 9:377; 12:62; 15:29; 16:27; 20:69; 20:89; 21:77; 22:37**
Public, unclaimed disclosed material dedicated to, **13:75**

DOCTRINE OF EQUIVALENTS —Cont'd
Recapture, surrendered, cannot recapture what has been, **13:63; 13:95**
Replacement with another claim, cancellation of claim and, **13:106**
Reverse Doctrine of Equivalents (this index)
Rewriting dependent claim into independent form, **18:65**
Same location, substitute need not be in exact, **26:4**
Sec. 112(6) equivalent, **9:149**
Sec. 112 equivalency, **16:2**
Separate patentability, **7:77**
Serving same function is very different ways, **1:66**
Spectrum of effect, **9:108**
Submission of evidence, **7:51**
Substantial difference, **16:40**
Substantiality of differences standard, **1:82; 8:47; 19:94**
Substantiality test, **6:26; 18:39; 23:40**
Substantial reason, **6:41; 8:60**
Substation of features, **14:45**
Substitute need not be in exact same location, **26:4**
Summary judgment, **2:20; 2:66; 2:114; 4:62; 8:40; 11:46; 12:42; 20:13; 22:21; 23:64**
Surrendered, cannot recapture what has been, **13:63; 13:95**
Tangential, **3:130; 18:74; 18:77**
Three-part inquiry, **22:10**
Timing, **23:63**
Two components viewed to serve as one element, **18:62**
Unclaimed disclosed material, **13:75; 25:6**
Unclaimed subject matter, **10:30**
Validity, judgment of, **5:6**
Verdict, **16:14**
Vitiation, **1:267; 3:178; 18:106**
Wilson hypothetical claim, **3:52; 10:15; 11:22; 23:20**
Witnesses, generalized testimony, **3:80**
Written description, **1:164**

DOCTRINE OF IMPOSSIBILITY OF PERFORMANCE
Excuse, **8:43**

DOCUMENTARY EVIDENCE
Oral testimony, **3:49**
Thesis, weight accorded testimony in conflict with, **13:34**

DOCUMENTS
Discovery, documents pertaining to ADR proceeding, **8:37**
Responses possible, document request, **2:27**
Retention policy, **13:168**
Sec. 287, documents not marked, **4:12**
Summary judgment, trial by documents, **19:51**

DOLBY LABORATORIES LICENSING CORPORATION V. UNIFIED PATENTS, LLC
2025, **4:137**

DOMESTIC INDUSTRY
International Trade Commission (ITC), **12:105**

DOMINATING PATENT
Anticipation, **18:20**
Overbreadth, **21:10**

DOMINATION
Generally, **5:49**
Double patenting, **9:45**

DOUBLE PATENTING
Generally, **7:111; 9:45; 14:96; 19:246**
Affirmative defenses, **3:4**
Anticipation, **3:4; 21:76**
Applications, two non-related, **1:115**
Concession, terminal disclaimer as concession of obviousness, **15:6**
Design, **3:4**
Design patent, **19:8**
Disclaimer, **15:6**
Disclosure, **9:45; 9:307; 19:226**
Doctrine of equivalent, **3:4**
Domination, **9:45**
FRCP 8(c), **3:4**
Hatch-Waxman Act, **21:76**
Inducement, **5:132**
Later developed processes, **20:92**
Law question, **9:190**
Monopoly, **9:45**
Obviousness (this index)
Prior art, **9:45**

DOUBLE PATENTING—Cont'd
Purpose, **1:80**
Reissue, **7:115**
Same invention, **7:75**
Sec. 101, **9:463**
Sec. 121, **7:115**
Separate and patentably distinct inventions, **7:22**
Terminal disclaimer as concession of obviousness, **9:384; 15:6**
Two limitations, **3:4**
Use of applicant's own invention disclosure as prior art against him, **9:45**
Validity, **8:7**
Variation amount, **5:103**

DPCA
Drug Price Competition Act (DPCA) (this index)

DRAFTING CLAIMS
Generally, **11:11**

DRAGON INTELLECTUAL PROPERTY LLC V. DISH NETWORK L.L.C.
2024, **4:136**

DRASTIC REMEDY
Mandamus writ, **9:180**
Preliminary injunction, **9:95**

DRAWINGS
Generally, **8:150**
Claim interpretation, **16:82**
Description, **3:101**
Design patent, **9:137**
Inequitable conduct, **11:4**
Over reliance, **11:71**
Physical exhibit, **16:36**
Precise proportions, do not define, **8:74**
PTO fact findings, **9:80**
Speak louder than words, **9:137**

"DRIVE DEMAND" FORMULATION
Irreparable injury, **7:122**

DRUG APPLICATION
Abbreviated New Drug Application (ANDA) (this index)
New Drug Application (this index)

DRUG PRICE COMPETITION ACT (DPCA)
Generally, **4:40; 7:55**
Extension of patent term, **7:18; 13:77**
Sec. 271(e)(1), **20:26**

DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT (DPCPTRA)
Generally, **3:109; 13:77**

DRUG PRODUCT
Patent term extension, **16:125**

DRUGS
Medicare Prescription Drug, Improvement, and Modernization Act, **20:78**
Sec. 271(e)(1), **1:175; 5:3**

DUE CARE
Anticipation, **18:20**
Clearly erroneous standard, **19:23**
Notice of infringement, **3:96**
Summary judgment, **1:35**

DUE PROCESS
Generally, **18:27**
Claim selection procedure, **11:66**
Fraudulent inducement liability, not relevant to, **18:69**
FRCP 15(c), **6:11**
Secondary considerations, **5:131**
Self-executing statutes, **18:33**

DUKE UNIVERSITY V. SANDOZ INC.
2025, **4:138**

DUPLICATE LITIGATION DOCTRNE
Generally, **1:375**

DUPLICATION
Anticipation, **19:107**

DURDEN CASE
Method claims, **9:98**

"EACH AND EVERY" LIMITATION
Interference, **25:11**

"EACH CLAIM"
Sec. 263, **15:6**
Sec. 1498, **12:11**
Separate invention, **10:8**

"EACH MOTION"
Summary judgment, **5:48**

"EACH PATENT"
Property, **11:35**
Validity, **5:45**

"EACH STATUTORY CLAIM CLASS"
Chemical process, **9:20**

EARLIER ADJUDICATION
Blonder-Tongue, **1:13**

EARLIER FILING DATE
Generally, **13:53**
CIP, **5:20; 20:35**
Sec. 120, **12:99; 18:85; 20:33; 20:88; 26:12**

EARLIER PATENT
Prosecution estoppel, **12:3**

EARLIER SUIT
Infringement, **16:35**

EARLIER WRITINGS
After-the-fact testimony of inventor, **14:12**

EARLY DISCLOSURE
Interference, **7:13**

ECOFACTOR, INC. V. GOOGLE LLC
2024, **5:157**
2025, **5:159**

ECONOMIC POSITION
Prejudice, **7:30**

ECONOMIC PREJUDICE
Prejudice, **1:67**

EDUCATION OF INVENTOR
Inequitable conduct, **15:3**

EDWARDS LIFESCIENCES CORPORATION V. MERIL LIFE SCIENCES PVT. LTD.
2024, **5:158**

EFFECTIVE AMOUNT
Generally, **7:75**
Claim interpretation, **1:122**

EFFECTIVE DATE
Reexamination, **13:79**
Reference, sec. 102(e) reference, **9:110**

EFFECTIVE DATE—Cont'd
Sec. 102(e) reference, **9:110**

EFFECTIVE FILING DATE
Interference, **19:144**
Sec. 112, **18:4**

EGENERA, INC. V. CISCO SYSTEMS, INC.
2025, **5:160**

EGREGIOUSNESS
Damages, enhanced, **5:54**

EIC
Board's exercise of discretionary authority, **7:23**
Sec. 1.645(b), **1:60**

8 CIR
Sec. 43(a), **10:15**

EJUSDEM GENERIS
Contract interpretation, **20:38**

ELABORATING TERSE CLAIM LANGUAGE
Claim interpretation, **5:50**

ELECTION
Sec. 120, **12:10**
Voiding, **3:61**

ELEKTA LIMITED V. ZAP SURGICAL SYSTEMS, INC.
2023, **5:156**

ELEMENT-BY-ELEMENT ANALYSIS
Doctrine of equivalents, **7:61; 20:41; 22:16**

ELEMENTS
Generally, **8:43**
Defined, **4:35**
Doctrine of equivalents, **4:53**
Equitable estoppel, **13:44**
Infringement, **19:111**
Inspection of patentee's product, **16:15**
Laches, **13:44; 23:45**
Reduction to practice, **13:105**
Sec. 282, **6:10**

11 USC § 1141
Bankruptcy discharge, **2:21**

ELEVENTH AMENDMENT
Generally, **3:79; 7:56; 18:66**

ELEVENTH AMENDMENT—Cont'd
Immunity, state, **2:120; 9:128**
Inventorship, **24:3**
Nonresidents, not limited to suits by, **10:11**
State as defendant, **18:40**
State immunity, **2:120; 9:128**

EMBELLISHMENT
Prior art, noting differences from, **4:6**

EMBODIMENT
Generally, **5:19; 12:3; 26:2**
Claim interpretation, **1:233; 7:57; 7:77; 10:23; 14:34; 16:54; 19:196; 22:12; 22:30; 22:35; 23:49**
Comparing claims with accused device, **13:9**
Computer program, **9:164**
Enablement, **3:103**
Exclusion of preferred embodiment, claim interpretation, **1:233**
Parallel, **1:132**
Patent misuse, **23:9**
Preferred embodiment, scope of invention, **1:207**
Reduction to practice, **19:144**
Sec. 271, **10:17**
Verdict, **16:14**

EMERGING TECHNOLOGIES
Statutory subject matter, **9:308**

EMINENT DOMAIN
Reasonable royalty, **8:56**
Valuation determinations, **8:56**

EMPLOYMENT
Executive Order 10096, **8:10**
Motion to remand, **19:45**
Ownership, **2:73**
Preliminary injunction, denial of, **12:16**
Title dispute, **6:15**

ENABLEMENT AND ENABLEMENT REQUIREMENT
Generally, **1:150; 1:362; 2:70; 2:90; 2:103; 2:192; 3:114; 5:152; 8:57; 8:130; 9:259; 9:283; 9:404; 11:57; 12:13; 13:243; 16:181; 18:72; 19:59; 19:152; 19:181; 19:304; 22:7; 23:59**
Abbreviated new drug application (ANDA), **3:169**

ENABLEMENT AND ENABLEMENT REQUIREMENT—Cont'd
Anticipation, **1:202; 2:82; 9:291; 13:120**
Anticipatory reference, **2:82**
Best mode, **2:90; 3:31; 9:177; 12:80**
Biological processes, factual premises for, **5:66**
Claim construction and interpretation, **22:49**
Commercial marketplace, not success in, **3:104**
Date of filing, determined at, **5:45**
Description, **14:101; 21:9**
Determined at date of filing, **5:45**
Disclosure, **1:102; 1:167; 10:23**
Embodiments, inoperative, **3:103**
Experiment, **3:169; 9:177; 23:77**
Factual premises for biological processes, **5:66**
Factual underpinnings, **21:36**
Filing, determined at date of, **5:45**
Germ of idea not sufficient, **7:50**
How to use, **14:4**
Indefiniteness, **16:60; 20:121**
Inequitable conduct, **20:101**
Inoperative, **9:222**
Inoperativeness, **3:103; 14:12**
Interference, **3:28; 4:8; 13:3**
Jury, **1:14; 5:110**
Later broader claims of previous nonenabled claims, **1:78**
Law question, **1:80; 1:117; 1:127; 9:150; 9:154; 9:210; 16:47**
Means-plus-function, **5:124**
Objective factors, **9:375**
Obviousness, **14:101**
One mode required, **1:131**
Only as of issue date of patent, **9:53**
Open claim language, **13:174**
Patent must be enabled, **1:197; 4:67**
Pioneering, **16:80**
Plant patents, **9:259**
Practice invention without undue experimentation, **9:177**
Prior art reference, **9:305; 19:207**
Priority, **19:304**
Review, standard of, **2:79**
Scope of claim, **14:27; 19:205**
Sec. 101, **18:6**

ENABLEMENT AND ENABLEMENT REQUIREMENT—Cont'd
Sec. 102(b), **9:18**
Sec. 112, **1:167; 1:252; 1:304; 2:34; 3:14; 9:83; 12:80; 13:56; 14:8; 17:1; 19:21; 21:14; 23:8**
Sec. 112(1), **1:200; 6:20; 9:113; 9:115; 9:134; 9:142; 9:143; 13:55; 16:141; 19:51**
Sec. 145, **7:9**
Specifications, **23:77**
Summary judgment, **2:144; 14:75; 15:26; 21:46**
Time to be satisfied, **21:39**
Undue experimentation, **1:44; 2:99; 9:177; 9:305; 19:201**
Utility, versus, **9:319; 16:60**
Validity of claim, **19:206**
Verbatim findings of counsel adopted, **8:22**
Written description, **9:476; 22:49**
Written description vs., **1:200; 19:236; 20:119; 21:46; 21:47**

ENANTA PHARMACEUTICALS, INC. V. PFIZER INC.
2026, **5:164**

ENFORCEMENT AND ENFORCEABILITY
Generally, **13:69**
Agreement on TRIPS, **22:36**
Antitrust, **21:45**
Arbitration agreement, **16:136; 22:55**
Attorney fees, **4:20**
Consent of co-owners, **19:264**
Contracts, **3:107**
FRCP 59(e), **19:42**
Inequitable conduct, **7:101; 8:12; 19:30**
International Trade Commission, **22:29**
Judicial estoppel, **23:21**
Lear distinguished, **8:11**
On-sale bar, **13:42**
Res judicata effect, **6:17**
Restrictions, **13:42**
Sanctions, **4:20**
Sec. 262, **19:264**
Seizure, **4:20**
Settlement and settlement agreement, **2:138; 8:48; 9:159**
Single use only restriction on sale of patented device, **13:42**

ENFORCEMENT AND ENFORCEABILITY—Cont'd
Validity, **12:40**

ENGLISH GRAMMAR
Sec. 112, **9:40**

ENHANCED DAMAGES
Generally, **9:125; 19:289; 19:336.50**
Accounting phase, **11:15**
Attorney fees, **1:43**
Discovery, newly discovered prior art, **21:3**
Discretionary, **15:14**
Egregiousness of defendant's conduct, **5:54**
Intervening rights, **21:3**
Newly discovered prior art, **21:3**
Prejudgment interest, **21:3**
Principal considerations same as willfulness, **19:101**
Prior art, newly discovered, **21:3**
Seagate test, **8:137**
Sec. 252, **21:3**
Sec. 284, **1:62; 2:30; 2:40; 18:29**
Subject matter jurisdiction, **25:1**
Two-step analysis, **10:21**
Willful infringement, **21:3; 23:85**
Willfulness, **12:47**

ENHANCEMENT
Prior art, noting differences from, **4:6**

ENSNAREMENT
Doctrine of equivalents, **4:90; 7:121**

ENTIRE MARKET VALUE RULE
Generally, **9:275; 11:32**
Anticipated collateral sales vs. reasonable royalty rate, **18:35**
Apparatus, value of entire, **6:36**
Collateral sales, **18:35**
Demand, **20:50**
Patented feature is reason for demand, **20:50**
Reasonable royalty rate, **12:97; 18:35; 22:43**
Value of entire apparatus, **6:36**

ENTIRE PATENT
Assertion of only certain claims, **3:46**

ENTIRETY
Direct infringement, ''control'' by one party over entire process, **1:222**
Graver Tank, **20:6**
References considered, **16:4**

ENTITLEMENT
Generally, **9:243**
Estoppel, **23:30**
ITC, **5:37**
Sec. 120, **11:8**

ENVIRO TECH CHEMICAL SERVICES, INC. V. SAFE FOODS CORP.
2026, **5:165**

EQUAL, NOT EQUAL TO SAME THING
Preliminary injunction, **4:5**

EQUAL, THINGS EQUAL TO EACH OTHER
Preliminary injunction, **4:5**

EQUITABLE CONDUCT
Inequitable Conduct (this index)

EQUITABLE DEFENSE
Generally, **6:14**
Assignor estoppel doctrine, **19:47**
Damages, **2:19**

EQUITABLE ESTOPPEL
Generally, **6:53; 6:103; 7:141; 10:49; 19:252; 22:28**
CAFC jurisdiction, **13:14**
Clearly erroneous standard, **19:23**
Cross-appeals, **18:98**
Delay, unreasonable, **8:50**
Elements, **13:44**
Government, **26:8**
Implied license, **13:67; 19:35; 23:55**
Inventorship, **16:131**
Jury verdict, **13:4**
Misleading conduct, **1:201; 19:108**
Performance of government contract, **8:8**
Prejudice, **19:252**
Summary judgment, **8:140; 19:108**
Three-part test, **2:61; 5:53**
Timeliness of appeal filing, **2:5**

EQUITABLE ISSUES
Jury trial, **2:61**

EQUITABLE REMEDY
Restitution, **20:34**

EQUITABLE TOLLING
Appeal, of time for, **7:32**
Limitation of actions, **23:38**
Patent term adjustment, **14:74**

EQUITIES WEIGHED
Assignor estoppel, **3:46**

EQUITY POWERS
Sec. 112, **19:4**

EQUIVALENCE AND EQUIVALENTS
Generally, **3:39; 12:26; 16:174; 16:175; 23:35**
Amendment, effect of, **12:1**
Doctrine of Equivalents (this index)
Fact finding, **7:12**
Fact question, **5:7; 19:59**
Infringement, **8:51; 23:40**
Insubstantial differences, **1:93; 19:114**
Interchangeable device, **11:22**
Invention, **19:34**
Jury verdict, **19:5**
Means-plus-function claim, **9:96; 21:44**
More pertinent art, **5:7**
Present, not, **10:10**
Presumption of validity, **5:7**
Processes, **3:87**
Sec. 112, **8:7; 11:10; 20:6**
Sec. 282, **18:6**
Separate patentability, **6:42**
Validity, presumption of, **5:7**

EQUIVALENTS, DOCTRINE OF
Doctrine of Equivalents (this index)

EQUIVOCAL OPINION OF COUNSEL
Willful infringement, **23:26**

ERRONEOUS JURY INSTRUCTIONS
Indirect infringement, **3:173**
Special verdict, **14:7**

ERRONEOUS STATEMENT
Claim interpretation, **2:80**

ERROR
Appeal and review, **19:16**

ERROR—Cont'd
Claim interpretation, **9:94**
Obviousness, **12:79**
Reissue, **8:64; 19:110; 19:137**
Sec. 287, **4:12**

ERROR IN RECORD
Prosecution history, **22:23**

ESCAPEX IP, LLC V. GOOGLE LLC
2025, **5:161**

ESCROW
Arising under jurisdiction, **3:21**
Case or controversy, **3:21**
Declaratory judgment, **3:21**
Future royalty payments, **3:21**
Interlocutory, **3:21**
Preliminary injunction, **3:21**
Review, scope of, **3:21**
Royalty, future, **3:21**
Sec. 1292(d)(2), **3:21**
Stay of patent action, **9:91**

ESSENCE
Combination patent, **13:15**
Inspection of patentee's product, **16:15**

ESSENTIAL ELEMENTS
Claim interpretation, **1:119**
Heart, **5:10**
New legal test, not, **3:101**

ESSENTIALLY FACTUAL
Indefiniteness, **2:99**

ESSENTIALLY THE SAME
Claim preclusion, **1:170; 2:159**

ESTIMATED COST SAVINGS
Sec. 284, **8:4**

ESTOPPEL
Generally, **2:98; 3:222; 5:116; 8:40; 9:216; 12:3; 22:62; 23:14**
See also Waiver (this index)
Argument-based estoppel, **19:320**
Assignor estoppel, **19:241**
Business methods, **3:202**
Claim construction, **19:320**
Claim interpretation, **19:15**
Covered business methods, **3:202**
Design patent, **1:318**
Doctrine of equivalents, **1:119**

ESTOPPEL—Cont'd
Elements thereof, **7:30**
Entitlement to priority date of parent application, **23:30**
Equities weighed, **3:46**
Exhaustion of appeals, **2:143**
File Wrapper (this index)
FRE 103(a)(1), **23:27**
Hatch-Waxman Act, **9:438**
Interference (this index)
Inter partes review, **1:344**
ITC, **25:2**
Laches, **1:48; 19:38; 22:8**
Marking estoppel, **6:86**
Privity, **9:118; 13:88**
Prosecution History Estoppel (this index)
Regulation, **19:63**
Sec. 101, **19:320**
Sec. 285, **19:320**
Standing, **1:344**
Statutory estoppel, **1:344**
Summary judgment, **10:4**
Three-part test, **8:32**
Three requisite elements, **1:67**

ETHANOL BOOSTING SYSTEMS, LLC V. FORD MOTOR COMPANY
2025, **5:162**

EVERY CLAIM
Generally, **23:35**
Doctrine of equivalents, **9:131**
Infringement, **1:52; 1:84; 19:111; 23:40**

EVERYDAY MECHANICAL CONCEPTS
Judicial notice, **9:127**
Notice, judicial notice, **9:127**

"EVERY SUCH OFFENSE"
Civil penalty for false marking, **6:72**

EVIDENCE
As to particular evidence, see more specific topics throughout this index
Generally, **3:49; 9:29; 9:481; 10:18; 12:24; 13:9; 13:28; 13:45; 13:53; 14:2; 16:36; 18:7; 23:18**
Additional evidence at trial, **19:232; 21:36**

EVIDENCE—Cont'd
Admissibility of Evidence (this index)
Affidavit, **9:23**
APA, **8:34**
Appeal and review, **6:12; 11:32**
Attorney argument not substitute for substantive evidence, **7:33**
Burden of Persuasion and Quantum of Proof (this index)
Burden of Proof (this index)
Business records exception, **3:67; 13:71**
CAFC, **18:3**
Chasm, Sec. 145, Sec. 146, **20:125**
Chemical, **9:60**
Choice of law, **1:92; 13:121; 15:14; 19:142**
Circumstantial Evidence (this index)
Claim construction and interpretation, **1:79; 4:23; 5:53; 6:37; 16:13; 23:11**
Clear and Convincing Evidence (this index)
Conception, **9:244**
Conclusory statement, **2:80**
Contributory vs. direct infringement, **18:11**
Corroboration, **1:159; 2:118; 5:40**
Counsel's arguments, **3:3**
Counsel's statements, **19:6**
Credibility of witnesses, **19:57**
Delay, **23:27**
De novo, **11:32**
Design patent, **19:8**
Destruction of documents, **5:1**
Disclosure, duty of, **12:52**
Discretion of court, admissibility is within, **3:57**
Doctrine of equivalents, **7:51**
Document retention policy, **13:168**
Exception, business records, **13:71**
Expert opinion on obviousness, **13:53**
Expert or Opinion Evidence (this index)
Extrinsic Evidence (this index)
Good cause under 37 CFR Sec. 1.617(b) justifying, **8:35**
Hearsay, **1:70**
Identity of invention, **20:20**
Inequitable conduct, **2:68; 2:103; 5:42; 7:46; 13:19; 15:43; 20:106**
In limine, **21:41**
Integration, **13:76**

EVIDENCE—Cont'd
Interference, **2:70; 14:3**
Invention, **19:34**
Inventorship, **19:132; 21:42**
ITC, **23:55**
JMOL, **19:126**
JNOV, **6:6; 13:4; 13:13; 25:4**
Jurisdiction, **1:76**
Jury verdict, **3:75; 4:18**
Linking evidence in general, **13:103**
Mandamus, **9:41**
Means-plus-function claim, **3:83**
Newly discovered, **1:101; 19:235**
New trial, **22:26**
Objective Evidence (this index)
Obviousness (this index)
Post-trial motions, **18:3**
Prejudice, **18:39**
Preliminary injunction, **8:2**
Presumptions (this index)
Prima facie obviousness, **9:99; 9:152**
Prosecution laches, **3:155**
PTO initial rejection, **7:19**
Quality vs. quantity, **12:37**
Reduction to practice, **13:110**
Rejection, **7:19**
Retired, **14:11**
Review, standard of, **13:71**
Scientific opinion, within reasonable range of difference of, **2:79**
Sec. 1.324, **23:55**
Sec. 102(b), **9:7; 9:18**
Sec. 102(e), **1:22**
Sec. 112, **19:7**
Sec. 112(2), **19:125**
Sec. 112 vs. validity, **19:125**
Sec. 145, Sec. 146, chasm, **20:125**
Sec. 252, **19:4**
Sec. 287, **4:12**
Sec. 1292(a)(1), **23:13**
Secondary considerations, **13:17; 13:45**
Skill in the art, level of, **9:23**
Special province of trier of fact, **18:12**
Spoliation, **8:120**
Substantial Evidence (this index)
Summary judgment, **14:33**
Technological evidence, **14:32**
Thesis, **13:34**
35 USC § 146, **19:232**
Unexpected results, **9:197**

EVIDENCE—Cont'd
Validity, **4:19; 13:169; 19:125**
Verbatim findings of counsel adopted, **8:22**
Weight and Credibility of Evidence (this index)
Witnesses (this index)

EXACT COMPOUNDS
Chemical compounds, **21:33**

EXACT IDENTITY
Verdict, **16:14**

EXAFER LTD V. MICROSOFT CORPORATION
2026, **5:166**

EXAMINATION
Generally, **8:42**
Prosecution history estoppel, **8:13; 8:47; 18:40**
Reexamination (this index)
Review, Board must, **9:2**
Subject matter jurisdiction, lack of, **6:19**

EXAMINER
Appellate review, **9:64**
Claim interpretation, **9:94; 20:72**
Common occurrence, **17:4**
Deposition
abuse of discretion, **23:5**
discovery, **23:5**
inequitable conduct, **23:5**
materiality, **23:5**
occurring, when, **23:5**
Excuse, **11:3**
FRE 706, **7:21**
Infringement, **20:72**
Interference, **4:21**
Materiality, **12:43**
Obviousness, **11:42**
Prosecution history estoppel, **12:49**
Sec. 112, **16:10**
Sec. 121, **2:140**
37 CFR Sec. 1.196(a), **9:106**
Validity, **3:77**

EXCEPTIONAL CASE
Generally, **2:112; 5:79; 5:149; 6:61; 9:280; 10:35; 17:7**
Attorney fees, **1:62; 2:85; 4:83; 4:128; 9:316; 9:377; 9:455; 9:483; 11:16; 12:24; 12:32; 14:58; 15:45; 18:9; 19:92; 20:87; 20:115; 23:65**
Bad faith, **13:69**
Basis, **8:75**
Burden of proof, **15:45**
Claim construction, **16:13**
Clear and convincing evidence required, **9:161**
Critical date, **18:9**
Damages, **3:180**
Declaratory judgment, **1:159**
Enhanced attorney fees, **12:110**
Exceptional finding, **3:84**
Factors to be considered, **13:91**
Fact question, **13:46**
Frivolous infringement claims, **8:122**
Inconsistent jury findings, **2:10**
Inequitable conduct, **13:19; 15:13; 16:78; 18:9; 18:55**
Invalidity, **3:180**
Judgment must be considered, **16:59**
Laches or delay, **3:180**
Litigation misconduct, **5:63; 17:9; 18:64; 20:87**
Merely losing, **11:18**
Misconduct, litigation, **13:197; 18:64**
Negligence, **18:9**
Prosecution aggressiveness, **13:116**
Purpose of, **1:105**
Sale, **3:180**
Sec. 102(b), **9:93**
Sec. 271(a), **3:180**
Sec. 285, **1:201; 2:33; 2:181; 5:14; 5:109; 6:13; 8:130; 9:455; 13:2; 13:175; 14:88; 15:3; 15:45; 19:52; 19:269; 20:151; 21:75**
Simple negligence not enough, **18:9**
Timeliness of appeal filing, **2:5**
Two-step process, **5:45**

EXCEPTIONAL CIRCUMSTANCES STANDARD
Mandamus, **1:302; 9:63**

EXCEPTIONAL FINDING
Exceptional case, **3:84**

EXCEPTIONAL SKILL IN THE ART
Obviousness, **14:67**

EXCEPTIONS, EXCLUSIONS, AND EXEMPTIONS
Generally, **5:8; 8:40; 9:110; 13:10**
Anticipation, **1:33; 1:98**
Claim interpretation, **14:34; 19:138; 22:12**
Crime fraud exception, **21:58**
Doctrine of equivalents, **12:28**
Evidence, **8:111; 13:71**
Experimental use, **3:142; 5:50; 8:98**
Final judgment rule, **20:28**
FRCP 13(a), **9:430; 16:81**
FRCP 19, **9:71**
FRCP 56(c), **8:27**
Good cause exception under APA, **14:17**
In banc hearing, **1:52**
ITC, **8:28; 9:118; 19:222**
Law of the case doctrine, **7:36; 13:61**
Mandamus, **9:63**
Noerr, **6:27**
On-sale bar, **19:140**
Patent ambiguity, **9:160**
Patent prosecution bar, **4:94**
Public use, **14:35**
Reverse doctrine of equivalents, **19:24**
Sec. 102(b), **19:140**
Sec. 271(e)(1), **9:299**
Sec. 287, **4:12**
Sec. 337, **3:23; 25:9; 25:10**
Secondary considerations, **13:17**
Statutory subject matter, **19:112**

EXCLUSIONARY RIGHTS
Preliminary injunction, **12:111**

EXCLUSIONS
Exceptions, Exclusions, and Exemptions (this index)

EXCLUSIVE ENTERPRISE
Standing, **9:301**

EXCLUSIVE JURISDICTION
Sec. 207(a)(2), **14:9**
Standing, **16:64**

EXCLUSIVE LICENSEE
Generally, **21:87**
Immunity, **1:190**
Standing, **1:190; 1:196; 13:157; 19:223; 23:67**

EXCLUSIVE VENDOR
Sec. 284, **11:18**

EXCUSABLE DELAY
Jury verdict, **13:4**

EXCUSE
Doctrine of impossibility of performance, **8:43**
PTO examiner's lapse, **11:3**

EXECUTION
Considerations involved, **19:49**
Written agreement, **23:21**

EXECUTIVE ORDER 10096
Generally, **8:10**

EXEMPLIFICATIONS
Costs, **11:51**

EXEMPTIONS
Exceptions, Exclusions, and Exemptions (this index)

EXHAUSTION OF PATENT RIGHTS
Generally, **1:133; 6:76; 8:134; 9:440; 10:45; 12:76; 13:139; 15:25**
Defense of, **5:93**
First sale doctrine, **13:67**
Preliminary injunctions, **12:102**
Repair vs. reconstruction, **10:27**
Sale of patented article, **12:107**
Sales of product, **20:105**
Specific claims, reservation, **11:72**

EXHIBIT
Design patent, **18:63**
Drawing, **16:36**
New interference rules, **8:3**

EX PARTE TEST
Admit, party's responsibility to, **3:10**
Appeal, **3:10**
CAFC jurisdiction, **9:63**
Divest court, **3:10**
Evidentiary weight, **3:10**
Expenses award, **3:10**
Fair trial, **3:10**
FRCP 37(c), **3:10**
FRCP 56(e), **3:10**
Hearsay, **9:150**
Perfect one, not, **3:10**
Summary judgment, **3:10**

EXPECTATION
Generally, **9:100; 9:191**
Closest art, compared with, **9:111**
Established by factual evidence not argument, **9:174**
Factual evidentiary inquiry, **9:197**
Obviousness, **9:52; 9:228; 9:250; 12:55; 16:108**
Obvious to try, **1:44**
On-sale bar, **5:35**
Prima facie obviousness, **9:86**
Secondary considerations, **16:4**
Showing of nonobviousness, **9:44**
Unexpected Results (this index)

EXPENSES AWARD
Ex parte test, **3:10**

EXPERIENCE
Attorneys' fees, award by special master, **19:65**
Claim construction, **8:52**

EXPERIMENTAL USE
Generally, **14:52; 19:91**
Design patent, **3:81**
Exception, narrow, **3:142; 5:50; 8:98**
Experimental stage, **19:107**
Factors, **1:119; 21:16**
Inequitable conduct, **5:137**
Invention, **7:12**
Lease, **13:123**
Narrow exception, **5:50**
On-sale bar, **1:59; 1:177; 1:179; 2:178; 5:64; 5:137**
Prima facie case of public use, **1:71**
Public use, **2:178; 14:35**
Ready for patenting, **5:64**
Reduce to practice, **7:12**
Review, standard of, **13:109**
Sec. 102(b), **7:12; 12:30**
Sec. 285, **5:137**
Totality of circumstances standard, **2:57; 12:45; 16:44**

EXPERIMENTS
Generally, **19:113**
Claim interpretation, **6:37**
Diligence, **19:144**
Enablement, **3:169; 9:177; 23:77**
Experimental use, **19:107**
Reduction to practice, **26:11**

EXPERIMENTS—Cont'd
Sec. 112(1), **10:23**
Sec. 282, **6:10**
Undue experimentation, **10:23; 23:11**

EXPERT
Experts (this index)

EXPERT OR OPINION EVIDENCE
Generally, **9:113; 13:10; 14:9; 19:38; 21:13**
Admissibility, **1:42; 1:43; 7:29**
Claim interpretation, **3:111; 9:77; 13:86; 19:16; 19:279; 19:291; 22:40**
Claims construed, **9:77; 22:40**
Claims must be construed same way, **23:11**
Clarify patented technology, **1:104**
Costs award, **19:77; 20:87**
Damages, **22:43**
Disclosure, **3:141; 18:102**
Fees of expert witness, **13:175; 15:48**
FRE 702, **19:209**
FRE 705, **19:38**
FRE 706, **7:21; 13:161**
Imported product, **7:96**
Infringement, **3:90; 9:320; 14:18; 18:43; 19:242**
Motivation to combine, **23:68**
Obviousness, **1:235; 13:53; 19:244**
Patent attorney, **5:32**
Reasonable royalty, **19:279**
Removal of expert testimony, **2:80**
Sec. 252, **19:4**
Summary judgment, **1:6; 3:20; 3:150**
Waiver, **19:279**

EXPERTS
Generally, **5:5; 8:160; 11:90; 14:50; 16:11; 19:340; 21:17**
Appointment, **13:163**
Doctrine of equivalents, **1:164**
Fee award, **13:175**
Infringement, **9:125; 13:28**
Issue preclusion, **4:9**
Non-attorney, **15:42**
Prima facie obviousness, **2:25**
Report, **20:160**
School, still in, **23:11**
Sec. 145, **7:9**
Sec. 285, **5:14**

EXPERTS—Cont'd
Summary judgment, **3:1; 8:14**

EXPIRED PATENT
Interference, **7:102**
Reexamination proceedings, during, **9:424**
Royalties, **11:79**
Standing, **11:78**

EXPLANATORY NOTES
Binding effect, **20:38**

EXPRESSIO UNIUS
Maxim, **4:30**
Statutory interpretation, **1:57**

EXPRESSLY REDEFINE CLAIM TERMS
Claim interpretation, **5:48**

EXPRESS TERMS
Consent judgment, **14:28Z**

EXTENSION OF TERM
Calculation of extension, **23:70**
Drug Price Competition Act (DPCA), **7:18**
Medical device, **16:117**
Obviousness-type double patenting, **9:112**
Patent term
generally, **14:95**
restoration, **13:77**
Sec. 156, **6:3**
Sec. 156(a)(4), **8:25; 15:35; 16:125**
Sec. 156(f), **16:125**
Sec. 156(g), **23:70**

EXTRANEOUS CLAIM LIMITATION
Generally, **9:154**

EXTRATERRITORIAL ACTIVITIES
Generally, **18:54**
Infringement, **16:138**
Sec. 271(a), **13:135**
Subject matter jurisdiction, **12:82**

EXTRATERRITORIAL INJUNCTION
Generally, **9:271**

EXTRATERRITORIALITY
Sec. 271(f)(2), **23:93**

EXTRINSIC EVIDENCE
Anticipation, **19:51**

EXTRINSIC EVIDENCE—Cont'd
Appellate review, **1:294**
Claim interpretation, **2:62; 4:51; 4:59; 5:36; 11:43; 14:30; 16:53; 19:115; 20:77; 23:79; 25:3**
Dictionary, **22:19**
Indefiniteness, **2:156**
Latent ambiguity vs. patent ambiguity, **9:160**

EYE THERAPIES, LLC V. SLAYBACK PHARMA, LLC
2025, **5:163**

FACILITATION
Permission, versus, **20:54**

FACT FINDING
Generally, **8:31**
Board, **9:195**
CAFC, **18:3**
Equivalence, **7:12**
FRCP 52(a), **1:18; 12:6; 13:16; 19:4**
ITC, **1:10; 8:28**
Judge role, **10:15**
Jury role, **10:15**
Jury verdict presumed, supporting
generally, **2:15**
added features, **2:15**
ceiling, not, **2:15**
infringement, do not avoid, **2:15**
interrogatories or written opinion not required, **2:15**
lost profits, **2:15**
Panduit, **2:15**
royalty established, **2:15**
timely objection to instructions, **2:15**
New evidence introduced, **6:9**
Obviousness, **1:4**
Review, standard of, **4:41; 9:217; 15:18**
Sec. 112, **8:7**

FACT-LAW QUESTION
See also Law Question (this index)
Best mode, **3:31**
Claim construction, **13:78**
JNOV, **22:4**
Obviousness-type double patenting, **9:52**

FACT QUESTION
See also Law Question (this index)

FACT QUESTION—Cont'd
Analogous art, **8:42; 9:121; 9:154; 10:15**
Anticipation, **7:34; 8:49; 9:96; 9:111; 9:154; 9:363; 13:45; 20:11; 20:56**
Best mode, **14:8; 20:35**
Claim construction, **26:1**
Cross-appeal, **18:2**
Damages, **3:96; 5:71; 6:26; 13:45; 15:10; 21:18**
Description, **1:118; 9:177**
Doctrine of equivalents, **5:28; 9:108; 10:10**
Equivalence and equivalents, **5:7; 19:59**
Exceptional case, **13:46**
Indirect infringement, **13:190**
Infringement, **3:101; 7:10; 7:37; 8:51; 19:19; 21:17**
Inherency, **9:31; 9:172**
Interference, **3:32; 4:8**
JNOV motion, denial of, **13:13**
Known or used by others, **3:2**
Literal infringement, **12:1**
Marking, **7:66**
Motion for new trial, **23:10**
Obviousness, **9:182; 9:217; 23:52**
Reference, **9:119; 9:133; 9:148; 9:166; 9:169; 19:56**
Sec. 112, **8:7**
Utility, **13:28**
Verbatim findings of counsel adopted, **8:22**
Well-understood, routine and conventional, skilled artisan, **1:311**
Willful infringement, **7:37; 8:52; 13:45; 16:40**
Willfulness, **3:96**
Written description, **6:20; 7:112; 21:14**
Written findings and conclusions prepared by prevailing party, **21:2**

FACTUAL DETERMINATION
Anticipation, **20:63**
APA, **8:34**
Review, standard of, **4:56**

FACTUAL EVIDENCE
Expectation, unexpected results, **9:197**
Obviousness conclusion, **9:15**
Unexpected results, **9:174; 9:197**

FACTUAL UNDERPINNING
Administrative board's decision, **2:37**
Enablement, **21:36**

FAILURE TO STATE CLAIM
State Claim, Failure to (this index)

FAIR TRIAL
Ex parte test, **3:10**

FALSE ADVERTISING
Choice of law, **2:132**

FALSE AND FORGED DOCUMENTS
Fraudulent conduct, **6:22**
Inequitable conduct, **7:34**

FALSE PATENT MARKING
Generally, **1:23; 19:278**
America Invents Act, **16:134**
Misuse, **10:42**
Sec. 292, **1:23; 2:151; 3:118; 9:329; 12:23; 19:224; 19:262**

FALSE STATEMENTS
Inventorship, **16:61**

FAST MOVING INDUSTRY
CCPA decisions, **9:74**

FATAL WOUND, STAUNCHING
Sec. 102(b) on-sale bar, **4:16**

FAULTY JURY INSTRUCTION
Remand, when appropriate, **7:27**

FCR 7(A)
Corporation appearance by nonlawyer, **18:15**

FCR 12
Generally, **21:22**

FCR 35
In banc rehearing, **1:52**

FCR 36
Generally, **21:27**

FCR 38
Frivolous appeal, **8:37**

FDA
Generally, **1:83; 7:141**
Conduct before, **5:95**
Delay in approval, **20:100**
Infringement, **1:85**

FDA—Cont'd
Obviousness, FDA approval, **1:235; 1:236**
Patent term extension, **15:35; 23:70**
Use code, counterclaim to force correction, **14:68**

FEATURES ADDED
Infringement not avoided, **14:8**

FEDERAL CIRCUIT LAW
Generally, **6:17**

FEDERAL COMMON LAW
Choice of law, **18:38**

FEDERAL COURTS
Jurisdiction, **23:77**
state universities, **21:63**

FEDERAL EXPRESS CORPORATION V. QUALCOMM INCORPORATED
2026, **6:117**

FEDERAL FOOD, DRUG, AND COSMETIC ACT
Generally, **2:54; 13:107**
Court of Appeals of Federal Circuit, **1:332**
Delisting, **1:120**
International Trade Commission, **1:332**
Jurisdiction, **1:332**
Sec. 271(e)(1), **3:182**

FEDERAL GOVERNMENT
Sovereign immunity, **3:95**

FEDERAL LAW
Sec. 261, **18:58**

FEDERAL NONNUCLEAR ENERGY RESEARCH AND DEVELOPMENT ACT (FNERDA)
Research performed under government contract, **6:18**

FEDERAL PATENT CODE
Generally, **6:17**
Certified question, **6:17**
Preemption, **3:68**
Sec. 1292(c)(1), **6:17**

FEDERAL QUESTION JURISDICTION
Sec. 291, **1:11**

FEDERAL RULES
Spirit, **3:24**

FEDERAL RULES OF APPELLATE PROCEDURE
See entries beginning: FRAP

FEDERAL RULES OF CIVIL PROCEDURE
See entries beginning: FRCP

FEDERAL RULES OF EVIDENCE
See entries beginning: FRE

FEDERAL UNFAIR COMPETITION CLAIMS
Preemption, **26:7**

FEDERAL VACANCIES REFORM ACT
Preemption, **1:376**

FERTILE SOURCE OF ERROR
Inequitable conduct, **6:5**

FEW MACHINES HAVE NO UTILITY
Prima facie obviousness, **9:17**

FFDCA
Federal Food, Drug, and Cosmetic Act (this index)

FICTITIOUS FACTS
Stipulation, **13:68**

FIELD OF ENDEAVOR TEST
Analogous art, **9:256**

FIELD OF USE
Standing of licensee, **9:301**

FILE BRIEF
Generally, **7:23**

FILE HISTORY ATTORNEY
Claim interpretation, **9:94**

FILE HISTORY ESTOPPEL
Anticipation definition, **4:15**
Claim interpretation, **18:29**

FILE WRAPPER
Doctrine of equivalents, **9:108**
Estoppel, **21:66**
Inventor's theory, **6:10**
Prosecution history estoppel, **4:26**
Summary judgment, **10:13**

FILING
CIP (continuation-in-part application.) Continuation-in-Part Application (this index)
Complaint, jurisdiction, **7:38; 13:59; 19:66**
Counterclaim, immunity, **19:141**
Disclaimer, reissue, **22:15**
First-filed suit rule, **6:89; 7:25**
Interference, **16:9**
Late filing, Board, **18:56**
Motions
Executive Order 10096, **8:10**
FRCP 41(a)(1), **5:18**
Only as of issue date of patent, **9:53**
Party's argument will not be addressed, **10:18**
Performance of government contract, filing application, **8:8**
Reexamination, **9:180**
Timeliness of
appeal dismissal, **10:3**
broadening reissue, **9:3**
first business day after weekend or holiday, filing made on, **23:28**
reissue, broadening reissue, **9:3**

FILING DATE
CIP, **5:20; 20:35; 20:59**
Claim Construction and Interpretation (this index)
Description, **19:120**
Earlier Filing Date (this index)
Enablement, **5:45**
First business day after weekend or holiday, **23:28**
Interference, **6:20; 19:144; 19:164**
Mandamus, **9:54**
Microbiology field, **9:53**
On-sale bar, **1:97; 4:93; 20:102**
Priority filing date, **9:258**
Sec. 102(d), **9:136**
Sec. 111, **19:32**
Sec. 112, **18:4; 23:11**
Sec. 119, **9:143**
Sec. 120, **5:104; 11:8; 20:33**

FINAL DECISION
Appeal without-prejudice dismissal, **8:82**
Director of Board of Patent Appeals and Interferences, **2:150**

FINAL DISPOSITION
FRCP 54(b), **1:289; 8:55**

FINALITY
Appealability, **13:23**
Appellate jurisdiction, **9:300**
Law of the case doctrine, **19:14**

FINAL JUDGMENT
Generally, **14:40; 16:90; 16:177; 19:175; 23:60**
Cohen collateral order exception, **20:28**
Collateral order, Cohen collateral order exception, **1:302; 20:28**
Covered business method review, **9:415; 21:71**
Dismissal, **16:62**
Exception, Cohen collateral order exception, **20:28**
Form, consent to, **20:98**
FRCP 60(b)(2), **19:14**
Interference estoppel by judgment, **23:14**
Jurisdiction, **18:104**
Nullification, **9:354**
Order staying case, **19:110**
Partial summary judgment, **3:86**
Preliminary injunction, **9:304**
Reexamination, **5:25; 6:84; 6:85; 9:353**
Sec. 1292(c)(2), **13:8**
Stay, **9:415**
Staying, order staying case, **19:110**
Summary judgment, **21:29**
Withdrawal of claims, **19:233**

FINAL ORDER
Summary judgment, denial of, **12:41**

FINDINGS
Generally, **8:22; 13:12**
Attorney fees, **3:46**
Board, **9:195**
Claims court, **3:49**
Clearly erroneous standard, **9:80**
Doctrine of equivalents, **3:39**
FRCP 41(b) motion, FRCP 50 vs. FRCP 41(b) motion, **12:11**
FRCP 50 vs. FRCP 41(b) motion, **12:11**
FRCP 52(a), **3:45; 12:13; 13:16; 16:25**
Improper, **21:2**
Interference, **4:11; 7:48**
Is obvious, **18:22**

FINDINGS—Cont'd
Issue preclusion, **4:9**
ITC, **1:17; 8:28**
Jury verdict, **20:39**
Motion, FRCP 50 vs. FRCP 41(b), **12:11**
Preliminary injunction, denial of, **12:16**
Review, standard of, **7:27; 7:33; 9:217**
Sec. 112, **8:7**
Sec. 271(e)(1), **5:13**

FINES
Sanctions (this index)

FINESSE WIRELESS LLC V. AT&T MOBILITY LLC
2025, **6:111**

FINE TUNING
Offer for sale, **19:130**

FINJAN LLC V. SONICWALL, INC.
2023, **6:108**

FINTIV, INC. V. PAYPAL HOLDINGS, INC.
2025, **6:112**

FIRST-FILED
Generally, **6:89; 7:25; 17:2**
Customer suit exception, **19:230**
Stay order, **11:1**

FIRST IDENTIFY CLAIMED FUNCTION
Means-plus-function claim, **12:62; 13:100**

FIRST MENTIONED IN REPLY BRIEF
Issue on appeal, **23:23**

FIRST SALE DOCTRINE
Generally, **6:59**
Exhausts patent rights, **13:67**
Foreign products, **10:27**
Timeliness of appeal filing, **2:5**

FITNESS FOR INTENDED USE
Bright-line test, **6:23**

FIXED IDEAS
Conception, **13:72; 20:65**

FIXED SUM
Attorney fees award, **19:57**

FLAGRANT MISREPRESENTATIONS OF RECORD
Conduct of counsel, **16:9**

FLAWED OPINION OF COUNSEL
Willful infringement, **19:92**

FMC CORPORATION V. SHARDA USA, LLC
2025, **6:113**

FNERDA (FEDERAL NONNUCLEAR ENERGY RESEARCH AND DEVELOPMENT ACT)
Research performed under government contract, **6:18**

FOCUS ON ONE FACET
Invention to be considered as a whole, **18:28**

FOCUS PRODUCTS GROUP INTERNATIONAL, LLC V. KARTRI SALES CO., INC.
2025, **6:114**

FOOD, DRUG, AND COSMETIC ACT
Federal Food, Drug, and Cosmetic Act (this index)

FOOD AND DRUG ADMINISTRATION
FDA (this index)

FORCE OF LAW
MPEP, **18:1**
Sec. 6(a), **23:15**

FOREIGN CORRUPT PRACTICES ACT
Sec. 292, qui tam provision, **2:151**

FOREIGN COUNTRIES
Generally, **8:42; 12:13**
Burying reference in prior art statement, **13:69**
Choice of law, **6:78**
Claim interpretation, **3:7**
Damages, **20:23**
Date of invention, **9:61**
Declaration, **19:118**
Discovery, **3:65**
First sale doctrine, **10:27**
FRCP 52(a), **13:16**

FOREIGN COUNTRIES—Cont'd
German Geschmacksmuster as prior art reference under Sec. 102(a), **9:120**
Interference, **6:20; 6:66**
ITC, **13:20**
Jurisdiction, **7:60; 22:36**
MPEP, **16:6**
New prior art not considered by PTO, **5:11**
Offer for sale, infringement, **8:129**
Ownership, **1:172; 9:238**
Personal jurisdiction, **1:181; 1:186; 1:189; 2:142; 8:79; 14:15**
Preliminary injunction, **19:32**
Prior art, German Geschmacksmuster as prior art reference under Sec. 102(a), **9:120**
Reference, **9:120; 17:1**
Reissue, claim construction, **1:209**
Sec. 102(a), **9:120**
Sec. 102(g), **19:10**
Sec. 104, **8:30**
Sec. 112, **17:1**
Sec. 119, **2:125; 6:66; 9:143; 19:144**
Sec. 271(f), **21:52**
Subject matter jurisdiction, **12:81**
Summary judgment, **20:38**

FOREIGN SALES
Patent exhaustion, **12:107**

FORESEEABILITY
Generally, **8:43**
Damages, **7:63; 13:79**
Doctrine of equivalents, **6:52; 6:64**
Prosecution history estoppel, **4:96**
Unexpected Results (this index)

FORESEEABILITY PLUS TEST
Personal jurisdiction plus something more, **1:221**

FORFEITURE
Generally, **9:492; 12:27**

FORGERY
Fraudulent conduct, **6:22**

FORM
Final judgment, **20:98**
Jury verdict, **22:4**

FORM 8
Complaint, **11:73**

FORM 16
Complaint, **13:142**

FORM 18
State claim, motion to dismiss for failure to, **12:114**

FORMER
See index topics beginning: ''Prior''

FORM-OF-CLAIM REQUIREMENT
Sec. 1.153, **9:137**

FORTRESS IRON, LP V. DIGGER SPECIALTIES, INC.
2026, **6:118**

FORUM NON CONVENIENS
Generally, **2:116; 8:136**
Public interest factors, **13:58**

FOUND
Abuse of discretion, **2:27**

FOUNDRY ARRANGEMENT
Semiconductor chip, **9:145**

FRAP
Sec. 1927, **1:41**

FRAP 2
Summary disposition of appeal, **10:20**

FRAP 3
Notice of appeal, **9:317**

FRAP 3(c)
FRAP 4(a)(4), **4:25**
Notice of appeal, **2:46**

FRAP 4
Timeliness of appeal filing, **9:317**

FRAP (4)
Generally, **19:170**

FRAP 4(a)
FRCP 7(b)(1), **18:25**
Timeliness of appeal filing, **2:5**

FRAP 4(a)(2)
Appeal and review, **16:110**

FRAP 4(a)(4)
Generally, **11:38**
Appeal and review, **10:14**
FRAP 3(c), **4:25**
Notice of appeal, **10:14**

FRAP 4(a)(4)—Cont'd
Renders of no effect any prior notice of appeal, **10:14**

FRAP 4(a)(5)
Generally, **20:132**

FRAP 25
CD-ROM, **25:5**

FRAP 28(a)(6)
Generally, **7:60**

FRAP 28(e)
Generally, **12:11**
Admissibility of evidence, failure to argue, **12:11**
Citation to record, need for, **12:22**

FRAP 28(g)
Page limit, circumvention of, **12:22**

FRAP 30(b)
Raising issues, only issues raised in appellant's statement may properly be presented on appeal, **6:10**

FRAP 35
Generally, **9:182**

FRAP 36
Collateral estoppel, **16:160**

FRAP 38
Design patent, **19:8**
Frivolous appeal, **1:28; 2:31; 3:40; 3:42; 4:36; 5:14; 6:16; 13:43; 14:16; 16:4; 18:24; 18:27; 19:42; 19:57; 19:87**
Infringement, **12:22; 16:4**
Injunctions, **16:29**
Jury verdict, **3:17**
Meaning, **16:4**
Purpose, **16:29**
Representative claims, **16:4**
Review, standard of, **16:29**
Sanctions, **9:102**
Settlement agreement, **19:1**

FRAP 39
Costs award, **11:24**

FRAP 39(a)
FRAP 39(b), **18:19**

FRAP 39(b)
FRAP 39(a), **18:19**

FRAP 39(c)
Appeal, reimbursable costs on, **3:29**

FRAP 41
Cause for stay, **1:349**

FRAP 47.6(b)
Generally, **2:72**

FRAP 50
Generally, **9:185**

FRAP 289(c)
Generally, **5:37**

FRAUD
Generally, **12:3**
Abused, much, **16:25**
Antitrust, **3:83; 14:25; 16:48**
Fraud upon the court, **1:163**
Inequitable conduct, **5:5; 6:4; 6:5; 10:2; 11:4; 18:19**
Intent, specific intent to deceive, **6:28**
Interference, **4:21**
Jury, **1:16**
Law of the case doctrine, **19:14**
Malpractice, **12:96**
Obviousness, **22:1**
Ownership, **13:150**
Patent prosecution, applied to, **3:83**
Sec. 282, **8:23**
Sec. 285, **15:3**
Specific intent to deceive, **6:28**

FRAUDS, STATUTE OF
Settlement agreement, **19:40**

FRAUDULENT CONCEALMENT
Generally, **19:93**

FRAUDULENT CONDUCT
False and forged documents, **6:22**

FRAUDULENT INDUCEMENT
Due process clause, **18:69**

FRAUDULENT NON-DISCLOSURE
Preemption, **21:30**

FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. V. SIRIUS XM RADIO INC.
2025, **6:115**

FRCP
Generally, **5:78; 19:16**
All civil actions, generally, **3:38**
Choice of law, **19:16**
CIT, procedural rule corresponds to FRCP, **5:18**
Interpretation, **23:34**
New trial, motion for, **18:111**

FRCP 4
Personal jurisdiction, **13:181**

FRCP 4(k)(2)
Generally, **19:212; 19:215**
Personal jurisdiction, **13:234**

FRCP 7(b)(1)
FRAP 4(a), **18:25**

FRCP 8
Statement of claim, **9:356**

FRCP 8(a)(2)
Doctrine of equivalents, **14:91**
FRCP 12(b)(6), **14:91**
Inducement, **14:91**
Short and plain statement of claim, **11:73**

FRCP 8(c)
Affirmative defense, **3:24**
Double patenting, **3:4**

FRCP 11
Generally, **1:121**
Attorney's inquiry reasonable under circumstances, **18:95**
Bad faith, **4:88**
Choice of law, **22:14**
Infringement analysis, **22:22**
Review, standard of, **1:42; 8:75; 16:76; 19:87**
Sanctions, **1:41; 3:150; 5:109; 9:125; 18:24; 18:95**

FRCP 12(b)
Generally, **2:69; 18:54**
Joint infringement, **12:112**
Rule 12(b)(1) versus Rule 12(b)(6), **8:66**

FRCP 12(b)(1)
Rule 12(b)(6) versus, **8:66**
Subject matter jurisdiction, lack of, **1:7**

FRCP 12(b)(4)
Generally, **8:45**
Claims court, **13:56**

FRCP 12(b)(6)
Generally, **1:45; 1:143; 3:95; 3:229.50; 16:62; 16:81; 21:38; 24:3**
Claim construction and interpretation, **15:56**
Dismissal, **1:42; 3:147; 7:90; 19:237; 23:29**
Doctrine of equivalents, **14:91**
FRCP 8(a)(2), **14:91**
Inducement, **14:91**
Motion to dismiss, **1:54; 1:248; 2:41; 19:237; 23:29**
Res judicata, **7:99**
Rule 12(b)(1) versus, **8:66**
State claim, failure to, **2:41; 7:99; 8:102; 19:237; 23:29**
State claim, motion to dismiss for failure to, **2:41; 7:99; 8:102; 12:114; 19:237; 23:29**

FRCP 12(b)(7)
Dismissal, **1:45**
Dismissal without prejudice, **21:56**

FRCP 12(f)
Materials outside pleadings, consideration of, **4:13**

FRCP 12(g)(2)
Venue, **9:447**

FRCP 12(h)(1)(A)
Venue, **9:447**

FRCP 13(a)
Generally, **7:56; 21:24; 22:18**
Compulsory counterclaim, **2:36**
28 USC § 2202, exception of, **16:81**

FRCP 15
FRCP 21, **11:18**
Motion to amend pleadings, **3:24**

FRCP 15(a)
Generally, **6:27; 6:28; 11:58**
Amending pleading, **20:5; 20:24**
Busy court need not allow to be imposed upon by presentation of theories seriatim, **20:5**
FRCP 21, **4:28**

FRCP 15(b)
Generally, **19:105**
Amendment of pleadings, **2:40**
Choice of law, **19:105**

FRCP 15(c)
Adding party, amendment of complaint to add party, **6:11**
Advocacy, **6:11**
Amendment of complaint to add party, **6:11**
Bed of its own making, **6:11**
Complaint, amendment of complaint to add party, **6:11**
Corporate officers and directors, **6:11**
Due process, **6:11**
Personal liability, **6:11**
Road tryout, not, **6:11**
Scattergun approach, **6:11**
Trial should be main event, **6:11**

FRCP 16
Pretrial order, **19:14**

FRCP 19
Joinder of patentee with exclusive licensee, **9:71**

FRCP 19(a)
Generally, **1:68**
Dismiss, motion to dismiss, **22:8**
Involuntary joinder, **11:19; 19:264**
Motion to dismiss, **22:8**
Standing, **9:302**
Voluntariness, involuntary joinder, **11:19; 19:264**

FRCP 19(b)
Patent holding subsidiary, **4:49**

FRCP 21
Generally, **1:135; 13:101**
Appellate jurisdiction, lack of, **1:31**
FRCP 15, **11:18**
FRCP 15(a), **4:28**
Mandamus review, **9:359**

FRCP 24
Motion to intervene, **3:38**

FRCP 24(b)
Intervention, **8:36**
Motion to intervene, **8:36**

FRCP 25(a)
Alter ego, **13:25**
In personam jurisdiction, **13:25**
Piercing corporate veil, **13:25**
Venue, **13:25**

FRCP 26
Abuse of discretion defined, **8:9**
Appellate review, standard for, **8:9**
Burden, heavy burden, **8:9**
Defined, abuse of discretion defined, **8:9**
Disclosure, **3:141; 18:102**
Discovery, **23:76**
Discretion, abuse of discretion defined, **8:9**
Heavy burden, **8:9**

FRCP 26(a)
Disclosure of written expert report, **13:183**

FRCP 26(c)
FRCP 45(d), **13:37**

FRCP 26(c)(7)
Choice of law, **1:19**

FRCP 26(e)
FRCP 37(b), **18:22**

FRCP 36
Imposition of discovery sanctions, **18:94**

FRCP 37
Abuse, discovery abuse, **7:23**
Attorney, pro se lawyer, **16:71**
Choice of law, **16:71; 21:69**
Discovery abuse, **7:23**
Dismissal of action, **18:24**
Pro se lawyer, **16:71**
Regional circuit law, **21:69**

FRCP 37(a)(4)
Abuse of discovery, **13:48**
Discovery abuse, **13:48**

FRCP 37(b)
Discovery sanctions, **20:4**
Dismissal of complaint for failure to comply with discovery deadlines, **23:34**
FRCP 26(e), **18:22**
Sanctions, **14:14**

FRCP 37(c)
Ex parte test, **3:10**

FRCP 41(a)
Voluntary dismissal without prejudice, **18:76**

FRCP 41(a)(1)
Voluntary dismissal when neither answer nor summary judgment motion filed, **5:18**

FRCP 41(a)(1)(B)
Inducement, **1:279**
Sec. 1498, **1:279**

FRCP 41(b)
Generally, **11:35**
Findings, **12:11**
Sec. 102(b), **19:31**

FRCP 42(b)
Appellate jurisdiction, lack of, **1:31**
Mandamus, **9:41**

FRCP 45
Quashing of discovery of nonparty, **11:24**

FRCP 45(d)
FRCP 26(c), **13:37**

FRCP 49(a)
Generally, **2:49; 7:27**
Jury verdict, **19:5**
Special verdict, **19:37; 23:1**
Validity of claims not infringed, **19:21**
Waiver of jury trial, **19:21**

FRCP 49(b)
Inconsistent jury findings, **1:50**
Jury instructions, **19:60**
Jury verdict, **13:4**

FRCP 50
Findings, **12:11**
Motion for judgment as matter of law, **7:27**

FRCP 50(a)
Generally, **1:71; 2:49; 5:77; 10:35; 13:72**
Directed verdict motion, **2:31**
JMOL, **2:48**
Judgment as a matter of law, **2:34**
Jury, **11:12**

FRCP 50(a)(1)
Generally, **3:98; 5:21**
JMOL, **16:106**

FRCP 50(b)
Generally, **6:98; 7:27; 8:52; 14:25**
JMOL motion, **13:54**
JNOV, prerequisite for, **23:25**
JNOV motion, **1:43**
Motion for judgment, **2:33**

FRCP 51
Generally, **1:101; 5:73; 18:70; 19:60; 19:185**
Choice of law, **5:60**
Jury instructions, **12:20**
Means-plus-function, **12:106**

FRCP 52
Generally, **20:40**

FRCP 52(a)
Generally, **11:32; 18:63**
Adopted findings, **12:13**
Appeal and review, **3:45; 12:6; 16:25**
As a whole, invention, **12:6**
Blonder-Tongue, **1:13**
Claim interpretation, **3:7**
Clear, meaning clear in specification, **12:6**
Conclusions of law, **3:45**
Contributory infringement, **7:82**
Damages, increased, **1:18**
Damages methodology, **19:4**
Disclosure, use of inventor's testimony to supplement, **12:6**
Fact findings, **12:6; 19:4**
Factual findings, **1:18; 13:16**
Findings, **3:45; 12:13; 13:16; 16:25**
Foreign proceedings not relevant, **13:16**
FRCP 65, **4:14**
Lexicographer, **12:6**
Meaning clear in specification, **12:6**
Need for findings, **1:52**
Preliminary injunction, **3:12; 15:5; 16:26**
Remand necessary when inadequate factual findings, **1:59**
Review, standard of, **3:39**
Royalty offered when coupled with infringement charge, **1:18**
Specification, meaning clear in, **12:6**

FRCP 52(a)—Cont'd
Specific factual findings, failure to make, **13:16**
Summary judgment, **20:26**
Trial court, **3:45**
Willful infringement, **1:18**
Witnesses, **12:6**

FRCP 52(b)
Generally, **7:88**

FRCP 52(c)
Generally, **25:7**

FRCP 53(e)
Generally, **6:26**

FRCP 54
Generally, **11:85; 16:87**
Entry of single judgment order for all claims not necessary, **6:16**

FRCP 54(b)
Generally, **14:40; 19:155; 19:301**
Certification, **19:141; 19:191; 23:24**
Final disposition, **8:55**
Motion in limine, **21:41**

FRCP 54(d)
Generally, **11:58**
Costs award, **4:32; 15:32**

FRCP 54(d)(1)
Generally, **18:55; 19:190**

FRCP 56
Generally, **4:79; 14:18**
High degree of confidence and trust between PTO and patent applicants, **10:5**
Material information defined, **13:158**
Summary judgment, **2:29; 9:89; 13:36; 16:28; 16:32; 19:44**

FRCP 56(c)
Generally, **2:52; 3:103; 19:135**
Claim differentiation, **8:27**
Claim interpretation, **8:27**
Doctrine of equivalents, **8:27**
Exclusion, expansion of right to exclude, **8:27**
Expansion of right to exclude, **8:27**
Infringement, summary judgment of noninfringement, **3:52; 9:131**

FRCP 56(c)—Cont'd
Summary judgment, **3:36; 3:52; 4:26; 8:27; 9:131; 11:25; 16:35; 18:28; 21:13**
Term thereof, **8:27**

FRCP 56(d)
Partial summary judgment, **7:5**

FRCP 56(e)
Generally, **19:135**
Ex parte test, **3:10**
Summary judgment, **3:1**

FRCP 56(f)
Generally, **19:93**
Abuse of discretion, **13:154**
Choice of law, **14:50**
Rejection of submissions, **2:80**
Submissions, rejection of, **2:80**
Summary judgment, oppose, **11:7**
Summary judgment appropriateness, **19:20**

FRCP 59
Generally, **11:38; 12:43; 12:61; 21:43**
Order ambiguous, **19:50**
Willful infringement, **3:26**

FRCP 59(a)
Generally, **1:101**

FRCP 59(e)
Generally, **1:102; 6:98; 13:123**
Limitations, **19:42; 19:58**
Mootness, **19:42**
Motion for prejudgment interest, **10:14**
Post-judgment motion, **2:46; 4:25**
10 day limit on modifying judgment, **19:42**
Time limit, **19:58**
Vacating judgment of invalidity and unenforceability when noninfringement finding undisturbed, **19:42**

FRCP 60
Generally, **11:38**

FRCP 60(a)
FRCP 60(b), **21:19**
Post-judgment relief, **16:37**

FRCP 60(b)
Generally, **5:78; 7:32; 22:23**
Appeal, untimely, **3:5**

FRCP 60(b)—Cont'd
Choice of law, **6:49; 13:93**
Consent, **23:23**
Damages, **1:20**
Default judgment, **9:144**
FRCP 60(a), **21:19**
Injunction, **23:23**
Judgment, relief from, **1:29; 13:59**
Master, **16:54**
Modification of injunction under consent under entered pursuant to settlement, **23:23**
Motion, **2:43; 6:22; 9:144**
Post-judgment relief, **16:37**
Set aside, motion, **6:22**
Settlement, **23:23**
Untimely appeal, **3:5**

FRCP 60(b)(2)
Final judgment, relief from, **19:14**

FRCP 60(b)(3)
Fraud upon court, **1:163; 3:229**

FRCP 60(b)(6)
Generally, **6:49**
Choice of law, **6:49**
Motion to modify consent judgment, **3:29**

FRCP 61
Generally, **1:101; 19:94**
Harmless error, **4:7**

FRCP 65
FRCP 52(a), **4:14**
Injunction, **7:3**

FRCP 65.1
Motion to execute on bond, **2:30**

FRCP 65(d)
Generally, **1:75; 1:88; 9:270; 15:20**
Injunction, **1:53; 5:4**

FRCP 68
Generally, **19:99**

FRCP 79(a)
Separate document, **5:45**

FRCP 391(c)(1)
Advisory jury, **11:69**

FRCP FORM 18
Pleading requirements, **19:237**

FRCP FORM 18—Cont'd
Sample complaint for direct patent infringement, **9:356**

FRE 103(a)(1)
Estoppel, **23:27**

FRE 403
Generally, **13:53; 13:81; 25:4**
Dead inventor's videotape deposition, **13:4**
Discretion of court, **7:5**

FRE 407
Generally, **16:40**

FRE 408
Generally, **14:18**

FRE 501
Privileges, **9:362**

FRE 701
Generally, **19:59**

FRE 702
Generally, **13:121; 19:209**
Damages award, **12:88**

FRE 705
Expert opinion, **19:38**
Prima facie case of infringement, **19:59**

FRE 706
Generally, **20:62**
Appointment of expert, **13:163**
Examiners as expert witnesses, **7:21**
Expert or opinion evidence, **13:161**

FRE 801(C)
Hearsay, **23:27**

FRE 803(6)
Generally, **23:101**

FRE 803(24)
Generally, **3:67**

FRE 804(B)(5)
Generally, **3:67**

FREEDOM TO LICENSE
Co-inventors, **19:98**

FREEMAN-WALTER-ABELE TEST
Generally, **1:95; 19:112**

FRESHUB, INC. V. AMAZON.COM, INC.
2024, **6:110**

FRIVOLITY OR FRIVOLOUSNESS
Mandamus, **9:68**
Rehearing, request for, **9:97**

FRIVOLOUS APPEAL
Generally, **14:19**
Appellate jurisdiction, **3:11**
Attorney fees, **16:20; 18:11; 20:16**
CAFC, **2:11**
Clear-cut grounds, based on, **19:90**
FCR 38, **8:37**
FRAP 38, **1:28; 2:31; 3:40; 3:42; 4:36; 5:14; 6:16; 13:43; 14:16; 16:4; 18:24; 18:27; 19:42; 19:57; 19:87; 23:89**
JNOV, **22:4**
Jury verdict, **3:17**
New argument, **13:46**
Non-final order, **18:11**
Pro se litigant, **2:38**
Sanctions, **3:150; 5:96; 13:71**
Settlement agreement, **19:1**
Standard, **19:127**
Unsupported allegation, **1:52**
Venue, **23:98**

FS.COM INC. V. INTERNATIONAL TRADE COMMISSION
2023, **6:109**

FULL AND FAIR OPPORTUNITY TO LITIGATE
Collateral estoppel, **2:50; 16:57**

FUNCTIONAL ASPECTS
Design patent, **5:21**

FUNCTIONALITY
Construction, **2:154**
Design patent, **12:32; 18:29**
Preliminary injunction, **2:16**
Suggestion or motivation to modify, must be, **9:101**

FUNCTIONAL LANGUAGE
Apparatus claims, **20:110**
Claim interpretation, **1:124**

FUNCTIONAL LIMITATION,
Means-plus-function claim, **23:54**

FUNCTIONAL RECITATION
Generally, **9:201**

FUNCTIONAL RELATIONSHIP
Obviousness, **9:32**

FUNCTIONAL REQUIREMENTS
Preliminary injunction, **3:34**

FUNCTION-WAY-RESULT TEST
Doctrine of equivalents, **19:52; 19:199**

FUNDAMENTAL PRINCIPLE
Sec. 101, **1:95**

FUTILITY
Interference, **13:31**

FUTURE ACTS AND MATTERS
Claims must be construed same way, **23:11**
Escrow, **3:21**
Interference, **18:49**
Lost profits, **19:137**
Lost sales, **6:74**
Sec. 286, **19:27**

FUTURE LINK SYSTEMS, LLC V. REALTEK SEMICONDUCTOR CORPORATION
2025, **6:116**

GALDERMA LABORATORIES, L.P. V. LUPIN INC.
2024, **7:145**

GENERALIZED TESTIMONY
Doctrine of equivalents, **3:80**

GENERAL VERDICT
Generally, **12:20; 19:259**
CAFC, **18:3**

GENERIC, TRADEMARK
Patent misuse, **23:9**

GENERIC CLAIM
Generally, **1:44**
Premarketing approval, Sec. 271(e)(1), **3:159**
Sec. 102(e), **9:28**

GENERIC FORMULA
Chemical compound, **9:148**

GENUINE ENABLING TECHNOLOGY LLC V. SONY GROUP CORPORATION
2026, **7:148**

GENUINE ISSUE
Design patent, **16:17**

GENUS
Generally, **9:126**
Claim preamble, **3:22**
Interference, **9:88**
Obviousness, **3:167**
Species, **2:107; 18:40**
Written description, **2:143; 2:144**

GERM
Enablement, **7:50**

GERMAN GESCHMACKSMUSTER
Prior art reference under sec. 102(a), **9:120**

GIST
Additional components, **12:18**
Heart, **22:7**
Heart of invention, **23:11**

GLOBAL HEALTH SOLUTIONS LLC V. SELNER
2025, **7:147**

GLOBAL TUBING LLC V. TENARIS COILED TUBES LLC
2026, **7:149**

GOOD CAUSE
Evidence, **8:35**
Exception under APA, **14:17**
Later submission of evidence, **8:35**
New interference rules, **8:3**

GOOD FAITH
Additional components, **12:18**
Administrative law, **13:70**
Anticipation, **18:20**
Common law definition thereof, **1:64**
Contract law, **12:39**
Explanation of failure to disclosure, **6:80**
FRCP 11, **4:88**
Induced infringement, invalidity, **3:185**
Inequitable conduct, **11:3; 13:138**
Inventorship, **3:59**
Notice, **7:92**

GOOD FAITH—Cont'd
PTO rejection of claims, **1:43**
Summary judgment, **16:54**

GOOGLE LLC V. ECOFACTOR, INC.
2024, **7:146**

GORHAM
CIP, **12:17**
Continuation, **12:17**
Design patent, **12:29; 15:5; 16:33; 19:8**
Design patent infringement, **2:33**
Infringement, generally, **12:32**
Novelty must be appropriated, **12:17**
Summary judgment, **1:35**
Trade dress, **12:17**

GOTV STREAMING, LLC V. NETFLIX, INC.
2026, **7:150**

GOVERNING LAW
Conflict of Laws (this index)

GOVERNMENT
Contract, **4:59**
Equitable estoppel doctrine, **26:8**
FNERDA, **6:18**
Just compensation, **8:116; 12:27**
Prejudgment interest, **19:83**
Regulation, **19:63**
Sec. 207(a)(2), **14:9**
Sec. 1498, **9:398; 20:18**
Sec. 2412(b), **13:48**

GOVERNMENT CONTRACT
Patent right clause, **8:8**
Sovereign act doctrine as defense, **8:41**

GOVERNMENT EMPLOYEES
Executive Order 10096, **8:10**

GOVERNMENT LIABILITY
Method claims, **26:10**

GOVERNMENT OFFICIALS
Administrative law, **13:70**
Regulations, **19:78**

GRACE INSTRUMENT INDUSTRIES, LLC V. CHANDLER INSTRUMENTS COMPANY, LLC
2023, **7:144**

GRAHAM
Generally, **9:170; 13:17**

GRAHAM—Cont'd
Obviousness, **2:8; 3:30; 19:244**
Rule 131 affidavit, **7:19**
Secondary considerations, **13:17**

GRAMMATICAL STRUCTURE AND SYNTAX
Interference, **1:117**

GRAMM V. DEERE & COMPANY
2026, **7:151**

GRAVER TANK
Abstractions, **20:6**
Doctrine of equivalents, **12:28; 13:39; 16:11**
Entirety of technology test, **20:6**
Inventing around, **20:6**
Same result, **20:6**

GROSS NEGLIGENCE
Inequitable conduct, **3:104; 6:4; 8:26; 14:8**
Intent to mislead, **2:68**

GUARANTEE
Same invention-type, **19:39**

GVR ORDER
Generally, **6:39; 8:65**

H. LUNDBECK A/S V. LUPIN LTD.
2023, **8:166**

HAEC VERBA
Description, **3:103**

HAFEMAN V. GOOGLE LLC
2026, **8:172**

"HALF THE PRACTICE OF A DECENT LAWYER"
Root or roots, **1:20; 12:24; 16:4**

HARD AND FAST RULE
Claim differentiation, **19:157**

HARDWARE AND SOFTWARE
Interchangeability, **15:16**

HARMFUL ERROR
JNOV, **22:4**
Procedural errors, **4:37**

HARMLESS ERROR
Claim interpretation, **19:15**
FRCP 61, **4:7**

HARMLESS ERROR—Cont'd
Summary judgment, **3:1**

HARMONIZATION
Enforcement, **22:36**

HARM TO REPUTATION
Adequacy of monetary damages, **18:32**

HARSH REMEDY
Dismissal, **7:52**

HATCH-WAXMAN ACT
Generally, **1:120; 5:144; 13:144**
Anticipation, **21:76**
Claim construction and interpretation, **19:314**
Doctrine of Equivalents (this index)
Double patenting, **21:76**
Obviousness, **21:76**
Patent information, **14:62; 14:63**
Subject matter jurisdiction, **3:159; 19:247**

HAVING
Generally, **3:96**

HAWK TECHNOLOGY SYSTEMS, LLC V. CASTLE RETAIL, LLC
2023, **8:167**

HD SILICON SOLUTIONS LLC V. MICROCHIP TECHNOLOGY INC.
2025, **8:169**

HEADINGS
Statutory interpretation, **7:25**

HEARING
Generally, **1:41**
Markman hearing, **5:100**
Panel hearing or rehearing en banc, **11:67**

HEARSAY
Generally, **1:70**
Ex part proceeding, use in PTO proceeding, **9:150**
FRE 801(c), **23:27**
PTO ex part proceeding, use in, **9:150**

HEART
Essential elements, **5:10**
Gist, **22:7; 23:11**
Inspection of patentee's product, **16:15**

HEART—Cont'd
Obviousness, **16:41**
Sec. 102(g), **19:10**

HEAVY BURDEN
FRCP 26, **8:9**
Obviousness question, **16:19**
Reasonable royalty, **8:51**
Validity, **23:48**

HEAVY LINES
Sec. 1.84, **9:137**

HEAVY PRESUMPTION
Claim interpretation, **5:70; 18:67; 20:63**

HIGH DEGREE OF CONFIDENCE AND TRUST BETWEEN PTO AND PATENT APPLICANTS
Generally, **10:5**
Materiality, **10:5**
Rule 56, **10:5**

HIGHLY RELEVANT PRIOR ART
Inequitable conduct, **13:69**

HINDSIGHT
Claim differentiation, **11:2**
Claim interpretation, **19:15**
Combination patent, **13:15**
Infringement, **7:10**
Obviousness, **3:103; 3:109; 4:91; 5:47; 9:274; 13:185; 15:42; 16:4; 19:92; 21:8**
Reference, **9:16**
Template, use as, **9:114**
Use as template, **9:114**

HIP, INC. V. HORMEL FOODS CORPORATION
2023, **8:168**

HIRED TO INVENT
Standing, **10:47**

HISTORY ATTORNEY
Claim interpretation, **9:94**

HOLDER OF LEGAL TITLE
Standing, **1:68**

HOLDING OF PATENT
Collateral estoppel, **4:3**

HONEYWELL INTERNATIONAL INC. V. 3G LICENSING, S.A.
2025, **8:170**

"HOW TO DO IT"
Sec. 145, **7:9**

"HOW TO MAKE"
Interference, **13:3**

"HOW TO USE"
Enablement, **14:4**

HUMAN
Doctrine of equivalents, **7:28**

HYATT V. STEWART
2025, **8:171**

HYBRID NATURE
Interference, **3:6**

HYBRID SEC. 102
Anticipation, **9:104**

HYPOTHETICAL CLAIM
Generally, **21:32**
Anticipated by single prior art reference, **1:115**
Doctrine of equivalents, **23:17**
Wilson, **9:146**

HYPOTHETICAL COMBINATIONS
Claim differentiation, **11:2**

HYPOTHETICAL INVENTOR
Ordinary skill, hypothetical person for, defined, **19:26**

HYPOTHETICAL JUDICIAL STATEMENTS
Collateral estoppel, **1:3**

HYPOTHETICAL NEGOTIATION
Reasonable royalties, **12:90; 16:129**
Sec. 284, **1:296**

IDEAS
Generally, **10:8**
Analysis begins with claims, **10:8**
Conception, **13:72; 20:65**

IDENTICAL ACTS AND MATTERS
Claim preclusion, **13:65**
Issue preclusion, **9:232**
Means-plus-function claim, **11:32**

IDENTICAL ACTS AND MATTERS —Cont'd
Means without substantive change, **12:25**
Product-by-process claims, **9:58; 9:81**
Reexamination, **6:8**

IDENTIFIABLE BENEFIT
Useful, **10:25**

IDENTIFICATION OR DESCRIPTION
Description (this index)

IDENTIFIED, FUNCTION MUST BE
Means-plus-function, **1:125**

IDENTIFY FACTS
Summary judgment, **22:21**

IDENTIFY FUNCTION
Means-plus-function claim, **1:125; 7:67; 7:79; 12:66**

IDENTITY
Anticipation, **20:20**
Applicable, where, **20:20**
Claim construction, **5:2**
Claim differentiation, **11:2**
Clearly erroneous standard, **20:20**
Court can decide validity differently from PTO on same evidence, **20:20**
Doctrine of equivalents, **14:1**
Evidence, **20:20**
Law question, **9:90**
Verdict, **16:14**

IDENTITY OF INVENTION
Anticipation, **7:33**

IF CLAIM LIMITATION OR EQUIVALENT
Present, not, **10:10**

IGNORANCE
Mandamus, **9:57**
Reissue, **9:84**

IGT V. ZYNGA INC.
2025, **9:529**

IMMEDIATE APPEAL
28 USC § 1291, **11:10**
Sec. 1292(a)(1), **23:13**

IMMUNITY
Antitrust, Noerr immunity, **3:46; 5:108**
Counterclaim, filing of counterclaim, **19:141**
Eleventh Amendment, **2:120; 9:128**
Exclusive immunity, **1:190**
Filing of counterclaim, **19:141**
Nonresidents, not limited to suits by, **10:11**
Sovereign Immunity (this index)
Strictly construed, **10:19**

IMMUNOGEN, INC. V. STEWART
2025, **9:530**

IMMUTABLE FIXED RULE
Claim differentiation, **4:17**

IMPLICATES INEQUITABLE CONDUCT
Intentional interference with contractual relations, **4:54**

IMPLICATIONS
Appeal, **5:41**
Narrow vs. broad claims, **13:39**
Statutory construction, **18:34**

IMPLICIT, LLC V. SONOS, INC.
2026, **9:543**

IMPLICIT DECISIONS
Mandate, **12:47**

IMPLICIT REPEALS
Statutory construction, **6:30; 19:80**

IMPLIED GOOD FAITH
Contract law, **12:39**

IMPLIED-IN-FACT CONTRACT
Generally, **20:40**
Choice of law, **20:40**
Contract law, **12:38**

IMPLIED LICENSE
Generally, **8:59**
Clearly erroneous standard, **19:23**
Contributory infringement, **13:21**
Defense to infringement, **1:100**
Direct infringement, **13:21**
Equitable estoppel, **13:67; 19:35; 23:55**
Factors, **23:41**
Inducing infringement, **13:21**
Infringement, **7:62; 13:21**

IMPLIED LICENSE—Cont'd
Law question, **3:56**
Public use, **26:13**
Repair, **4:1; 11:36**
Restrictions, upon unrestricted sale of unpatented article, **13:21**
Sec. 287, **4:12**
Third party production, **3:147**
Timeliness of appeal filing, **2:5**

IMPLIED ORDER
Method claims, **9:234**

IMPLIED WAIVER
Standard setting organization, **3:206**
Standard setting organizations, **8:120**

IMPORTS
Expert testimony, **7:96**
Sec. 337 (this index)

IMPROVEMENT
Claim interpretation, **20:8**
Comprising, **3:37**
Obviousness, **18:23**
Refining, **13:8**
Secondary considerations, **9:82**
Special master's decision, **13:24**
Surprising results, **9:118**

INCENTIVE
Generally, **9:96**
Modification, **9:51**
Subject matter jurisdiction, **25:1**

INCEPT LLC V. PALETTE LIFE SCIENCES, INC.
2023, **9:522**

INCLUDING
Generally, **20:51**

"INCLUDING" AND "COMPRISING"
Claim interpretation, **12:83**

INCONSISTENCY
Generally, **2:47**
Agency's interpretation of own regulations, **22:9**
Injunction, **16:5**
Jury, **1:14**
Jury findings, **2:10**
Jury verdicts, **13:105; 18:14**
Procedural issue, **8:21**

INCORPORATION BY REFERENCE
Generally, **1:101; 8:143; 13:80; 20:56; 24:4**
Amendment, **8:113**
Anticipation, International Trade Commission, **1:238**
Disclosure-dedication to public, **19:233**
Interference, **8:113; 8:119**
Inter partes review, **8:143**
Obviousness, **16:164**
Particularity, **26:12**
Reasonable examiner standard, **8:124**
Sec. 102(b), **1:101**
Sec. 120, **4:122**
Specification, **16:128**

INCREASED DAMAGES
Clearly erroneous standard, **19:23**
Injunction, **16:5**
Willful infringement, **15:14**

INCREASING SUPERSEDEAS BOND
Sec. 1291, **19:42**

INCYTE CORPORATION V. SUN PHARMACEUTICAL INDUSTRIES, INC.
2025, **9:537**

INDEFINITENESS
Generally, **7:144**
Certainty and Definiteness (this index)

INDEMNIFICATION AGREEMENT
Deterrent effect of patent laws, **8:24**

INDEPENDENT CLAIMS
Generally, **3:41; 9:123; 12:28; 14:12**
Chemical process, **9:20**
Claim construction, **26:1**
Claim differentiation, **5:60; 9:237**
Court must state burden of persuasion and quantum of proof required, **18:7**
Dependent claims, **10:26; 13:100**
Doctrine of equivalents, **5:6; 18:65**
Infringement, **23:35**
Sec. 282, **13:55**
Substantial evidence test, **19:43**
Validity, **5:45; 8:7; 19:86**

INDEPENDENT RIGHT
Property, **11:35**

INDEXING
Public accessibility, **22:42**

INDIRECT INFRINGEMENT
As to infringement, generally. Infringement (this index)
Generally, **4:75**
Anticipation, **21:73**
Claim construction, **16:153**
Inequitable conduct, **21:73**
Question of fact, **13:190**
Summary judgment, **3:36**
Verdict form, **16:153**

INDUCED INFRINGEMENT
Generally, **1:129; 1:142; 2:195; 3:96; 4:80; 5:10; 6:59; 7:135; 8:24; 18:133; 19:295; 19:322; 20:157**
Active inducement, **5:102**
Case or controversy, **1:319**
Claim construction, **5:98**
Competition, **18:48**
Contributory infringement, **8:24; 9:356**
Damages, **9:410**
Declaratory judgments, **1:319**
Direct infringement, **1:222; 5:63; 5:102; 12:104**
Direct or circumstantial evidence, **2:130**
Divided infringement, **1:222**
Doctrine of equivalents, **13:28; 14:91**
Double patenting, **5:132**
Due process clause, **18:69**
FRCP 8(a)(2), **14:91**
FRCP 12(b)(6), **14:91**
FRCP 41(a)(1)(B), **1:279**
Good faith belief invalidity, **3:185**
Implied license, **13:21**
Inference, **1:202**
Infringement, **8:24**
Injunctions, **22:59**
Intent, **1:133; 13:135; 19:217**
Intent for infringement cases, **23:87**
Interference, **18:48**
Jurisdiction, **22:59**
Knowingly, **1:222; 7:103; 23:3**
Limitation to actions by single entity, **1:222**
Manual, instructions in, **13:186**
Obviousness, **8:24**
Operational differences over prior art, lack of, **8:24**

INDUCED INFRINGEMENT—Cont'd
Personal liability, invoke, **19:92**
Pre-issuance inducement, **14:18**
Prior art, **8:24**
Sec. 172(b), **26:2**
Sec. 271(b), **1:157; 7:103; 8:24; 11:60; 16:22**
Sec. 271(c), **8:24**
Sec. 1498, **1:279**
Snuggle use doctrine, **19:79**
Specific intent, **18:79**
Tortious interference and unfair competition, versus, **18:48**
Unfair competition, **18:48**
Written description, **22:59**

INDUCEMENT
Anticipation, **5:138**
Contributory infringement, **7:130**
Damages, **5:138**
FRCP 46, **15:57**
Obviousness, **7:130**
Utility, **7:130**

INDUSTRIAL AND COMMERCIAL BUYERS
Design patent infringement, **1:165**

INDUSTRY REQUIREMENT
Design patent, Sec. 1337, **3:154**
Validity, **19:206**

INDUSTRY STANDARD
Infringement, **6:77**
Patent misuse, **16:126**

INEQUITABLE CONDUCT
Generally, **1:9; 1:116; 1:131; 1:138; 2:43; 2:139.50; 3:234; 4:72; 4:79; 5:65; 6:60; 7:138; 9:272; 10:31; 11:58; 13:250; 16:105; 18:117; 19:19; 23:55; 23:59**
Abuse of discretion, **18:78**
Affidavit, **7:34**
Anticipation, **1:25; 18:20; 21:73**
Antitrust, **6:5; 14:21**
Appeal and review, **6:4; 23:47**
Attorney, **15:3**
Attorney fees, **1:193; 8:18; 10:2; 13:19; 18:43; 20:97**
Balancing materiality and intent, **6:5**
Batch process, continuous vs., **10:2**
Blonder-Tongue, **1:13**

INEQUITABLE CONDUCT—Cont'd
Burden of proof, **19:92**
Candor with PTO, **12:55**
Cited prior art, **8:29**
Claim interpretation, **19:15**
Claim terms, **18:116**
Clear and convincing evidence, **1:71; 7:68; 13:141; 15:3; 19:38**
Collateral estoppel, **4:3**
Commercial success, **11:4**
Consider, **6:4**
Continuous vs. batch process, **10:2**
Contracts, **4:54**
Contributory infringement, **1:210**
Costs of action, **1:193**
Culpable intent, **5:16; 16:32; 20:25**
Cumulative prior art, **7:1**
Cumulative reference, **19:51**
Deception. Intent to Deceive (this index)
Decisions, **1:25; 11:4**
Declaration, **9:378; 13:129**
Design, **6:4**
Design patent, **7:59; 16:1**
Disclosure, **3:98; 6:13; 19:128**
Discretion of court, **7:33; 13:38; 13:45**
Distinguished from fraud, **1:25**
Drawings of hypothetical devices, **11:4**
Education of inventor, **15:3**
Enablement, **20:101**
Enforceability, **1:210; 7:101; 8:12; 19:30**
Evidence, **2:68; 2:103; 5:42; 7:46; 13:19; 15:43; 20:106**
Examiner's deposition, **23:5**
Exceptional case, **13:19; 15:13; 16:78; 18:9; 18:55**
Experimental use, **5:137**
False, **7:34**
Fertile source of error, **6:5**
Fraud, **5:5; 6:4; 6:5; 10:2; 11:4; 18:19**
Good faith, **11:3; 13:138**
Gross negligence, **3:104; 6:4; 8:26; 14:8**
Highly relevant prior art, withholding, **13:69**
Induced infringement, **5:102**
Inference, **1:3; 1:102; 12:92**
Infringement, **6:4; 7:10**
Intent, **1:169; 1:257; 2:33; 2:68; 4:54; 5:16; 6:4; 6:5; 7:34; 7:46; 9:378; 13:19; 13:91; 13:141; 16:32; 20:25**
Interference, **4:21; 4:54**
Invalidity and noninfringement, declaratory judgment, **20:133**
Inventorship, **16:48**
Jury, **1:14; 1:16; 2:49**
Knowledge of reference, **13:101**
Law of the case doctrine, **19:14**
Litigation misconduct, **1:112; 1:180**
Maintenance fees, **14:70; 21:40**
Manifest injustice, **14:58**
Material, **2:85**
Materiality (this index)
Mention, failure to, **6:4**
Mere knowledge of reference, **13:101**
Misrepresentations, **8:85**
Misrepresentations or omissions material to patentability, **15:49**
Motion to compel discovery, **19:17**
Negligence, gross, **6:4; 14:8**
Nondisclosure of known prior art, **1:3**
Non-final judgment, **1:237**
Obviousness, **1:231; 18:84; 19:202; 22:1**
Omissions, **7:46**
On-sale bar, **5:137; 12:30**
Other circumstances may support, **19:26**
Patentability, **18:116**
Patent prosecution, **6:42**
Per se materiality rule, none, **12:20**
Petition to make special, **7:29**
Presumption, **13:19**
Printed publication, **15:34**
Prior art, **7:1; 8:29; 8:62; 12:30; 19:128**
Process, continuous vs. batch, **10:2**
Procurement, **13:19**
Prosecution irregularities, **3:149; 13:81**
PTO, **1:203; 7:19; 9:43; 10:2; 12:55; 12:85; 16:114; 19:118**
Raised on appeal, must review if, **23:47**
Reasonableness of examiner's rejection, **1:3**
Reference, **6:80; 13:101; 19:51**
Reissue, **8:26**
Relevant prior art, withholding highly relevant prior art, **8:62**
Resubmitting references, **1:92**

INEQUITABLE CONDUCT—Cont'd
Review, standard of, **2:59; 3:72; 6:50; 9:35; 10:31; 11:11; 13:84; 14:19; 14:54; 18:37; 18:40; 20:39**
Sec. 102(b), **5:80; 9:7; 13:35**
Sec. 112, **8:7**
Sec. 282, **8:23**
Sec. 285
generally, **16:59**
attorney fees, **5:137; 18:43**
Secondary considerations, **4:10; 11:4**
Separate nonjury trial, **7:1**
Several patents, one of, **12:3**
Sham litigation, **8:98**
Skill, level of, **15:3**
Special, petition to make, **7:29**
Standard of review, **19:202**
Starting point, **7:1**
Summary judgment, **2:24**
Surprising results, **11:4**
Synergism, **11:4**
Threshold intent, **6:4**
Threshold level, **1:44; 21:36**
Translation, **1:154**
Two step analysis, **1:89**
Two-step analysis, **16:61; 16:70**
Unclean hands doctrine, **3:35**
Unfair competition, **16:48**
Very material omissions require less evidence to show intent, **7:46**
Walker process, **3:71; 14:21; 14:25**
Withheld prior art, **8:29; 8:62; 12:30**
Withholding reference, **6:80**
Witnesses, **11:4**

INFERENCE
Inequitable conduct, **1:3; 1:102; 12:92**
Intent to deceive, **13:69**
Intent to induce infringement, **1:202**
Intent to mislead, **8:51; 20:35**
Opinion of counsel, **5:30**
Sec. 285, **5:14**

INFERIOR INFRINGEMENT
Special verdict, **23:1**

INFORMATION DISCLOSURE STATEMENT
Doctrine of equivalents, **5:31**
Interpret scope of claims, used to, **5:31; 7:113**

INFORMATION DISCLOSURE STATEMENT—Cont'd
Prior art, no admission material, **1:122; 18:86**

INFRINGEMENT
Generally, **1:137; 1:147; 1:161.50; 1:356; 2:94; 2:109; 2:114; 2:162; 2:195; 3:99; 3:232.50; 5:62; 5:65; 6:55; 9:287; 9:477; 10:10; 10:36; 12:72; 13:52; 13:53; 13:125; 14:45; 14:48; 14:51; 14:73; 16:87; 16:91; 16:93; 16:95; 16:178; 18:2; 18:13; 18:62; 19:53; 19:159; 19:168; 20:77; 23:18; 23:96**
Abbreviated new drug application (anda), **6:65; 19:247**
Abbreviated new drug application (ANDA), **2:146; 13:233**
Access validity not examiner's potential act, **20:72**
Actual controversy required, **20:26**
Actual notice, **12:61**
Add elements, avoided if, **9:186**
Additional components, **12:18**
ANDA, **1:252; 2:88; 2:146; 6:65**
Appeal and review, **2:95**
Appellate jurisdiction, **3:11**
Appropriate, when, **23:35**
ARO, **13:29**
As a whole, visual appearance, **3:100**
Asserted equivalents need not be known, **20:6**
Assignor estoppel doctrine, **19:47**
Attorney fee on appeal, **18:19**
Attorneys, **12:22**
Attribution, **20:141**
Avoidance, inefficiency does not avoid, **6:26**
Awareness of material prior art insufficient by itself, **7:10**
Bankruptcy, **8:94**
Basic, **20:6**
Blonder-Tongue, **1:13**
Burden of proof, **1:123; 7:31; 13:179; 13:194**
Capable of modified to operate infringing means, **20:56**
Capable of operating in infringing mode, **6:74**
Careful consideration, **12:29**
Case or controversy, **7:10**

INFRINGEMENT—Cont'd
Chemical case, **13:46**
Chemical compound, **5:29**
Choice of law, **22:18**
Circumstantial evidence, **12:90**
Claim, **8:61**
Claim construction and interpretation, **2:82; 2:129; 3:7; 6:93; 16:35; 19:15; 19:167; 19:242; 23:58; 23:88; 26:1**
Claim differentiation, **6:93; 23:88**
Claimed method, sometimes embodies, **2:52**
Claim preclusion, **1:170**
Claims must be construed same way, **23:11**
Clear and convincing evidence, **3:158**
Collateral estoppel, **1:3; 1:155; 25:10**
Commercial product, **1:124**
Composition of process or product undisputed, **4:51**
Computer claims, **19:220**
Contempt, **11:17**
Contributory Infringement (this index)
Copyright, **16:110**
Costs on appeal, **1:20**
Counterclaim, **13:179**
Court can observe with its own eyes, **9:4**
Customer end user as parties at trial, no necessity to have, **18:11**
Damages, **5:121; 13:146; 16:40; 16:135; 19:92; 22:35**
Declaratory judgment, **13:194; 19:81**
Defense, practicing the prior art not, **5:60**
Dependent claim, **10:26; 13:100; 13:147; 23:17**
Design patent, **1:165; 3:98; 3:100; 8:126; 11:25; 12:8; 15:5; 15:11; 19:8; 19:85; 21:4**
Device alterable so as to infringe, **8:46**
Direct Infringement (this index)
Disclosure, not measure of what is discloses, **9:4**
Divided infringement, **1:270; 1:271**
Doctrine of equivalents, **4:125; 7:121**
Doctrine of Equivalents (this index)
Earlier suit, preclusive effect on claim construction of, **16:35**
Elements, every claim element must be present, **19:111**

INFRINGEMENT—Cont'd
Ensnarement, **7:121**
Equivalency, **8:51**
Equivalent, **23:40**
Every claim, **1:52; 1:84; 19:111; 23:40**
Evidence, **3:158; 8:120; 14:33; 18:11**
Examiner, **20:72**
Expert, technical, **9:125**
Expert testimony, **3:90; 9:320; 14:18; 18:43; 19:242; 19:291**
Extraterritorial production, **16:138**
Fact question, **3:101; 7:10; 8:51; 19:19; 21:17**
Factual findings to support jury verdict presumed, **2:15**
FDA approval, **1:85**
Features added, **14:8**
File wrapper, **10:13**
Final assembler theory, **1:361.50**
First to file, **6:89**
Foreign patent, **22:36**
Foreign sales, **8:129**
FRAP 38, **12:22; 16:4**
FRCP 11, **22:22**
FRCP 49(a), **19:21**
FRCP 59(e), **19:42**
FRE 705, **19:59**
Gorham, **12:32**
Hindsight, **7:10**
Implied license, **7:62; 13:21**
Imported product, **2:80; 11:60**
Improper to compare claims with patent's preferred embodiment or patentee's commercial embodiment, **1:52**
Indefiniteness, **13:57**
Independent v. dependent claims, **23:35**
Induced Infringement (this index)
Industry standard, **6:77**
Inefficiency does not avoid, **6:26**
Inequitable conduct, **6:4; 7:10**
Intent not required, **9:118**
International Trade Commission, **1:17; 3:198; 5:98; 25:2**
Inventorship, **4:125**
Inventor's theory, **6:10**
ITC, **1:17; 25:2**
JNOV, **6:6; 22:4**
Joint infringement, **1:195; 1:222; 2:124; 13:159; 13:160**

INFRINGEMENT—Cont'd
Jurisdiction, **7:73**
Jury verdict, **8:47; 19:5; 20:25**
Law question, **12:31; 13:64; 13:74**
License, implied, **7:62**
Limitations, **23:40; 25:3**
Literal Infringement (this index)
Lost profits, **13:45; 16:135; 26:4**
Manufacture, pre issuance manufacture, **10:23**
Markush claim, **1:155; 19:299**
Means-plus-function claim limitation, **3:46**
Minor differences, **16:33**
Mixed question, **19:19**
Modified device, **2:119**
Mootness, **11:23**
Motion, **12:36; 23:10**
New trial, **8:51**
Nonobviousness, **7:10**
Nonparty's motion to quash discovery subpoena, **20:17**
Notice and knowledge
generally, **1:62; 3:96; 13:42; 20:6**
awareness of material prior art insufficient by itself, **7:10**
declaratory judgment, versus, **19:101**
due care, duty of, **3:96**
knowledge, asserted equivalents need not be known, **20:6**
marking, **4:89**
marking as constructive notice, **6:78**
notice, actual notice, **12:61**
sufficiency, **11:70**
Novelty must be appropriated, **12:17**
Observation, court can observe with its own eyes, **9:4**
Obviousness, **18:23; 19:11; 19:19**
Occurs at place where sales are made, **14:15**
Offer for sale, **8:129**
Only claims may be, **5:6**
Patent misuse, **8:14; 23:9**
Pioneer invention, **20:6**
Pleading, **9:356**
Preclusive effect on claim construction of earlier suit, **16:35**
Pre issuance manufacture, **10:23**
Preliminary injunction, **1:40; 1:155**
Prior art, **5:60; 7:10; 19:19**

INFRINGEMENT—Cont'd
Process, **1:12; 4:51**
Product, composition of process or product undisputed, **4:51**
Prosecution history, **5:84; 13:126**
Prosecution history estoppel, **22:8**
Reconsideration, new theory, **7:113**
Remand for clarification, **10:38**
Replication of patented technology, **13:173**
Review, standard of, **3:43; 5:36; 9:254; 16:11**
Reviewability, **2:31**
Sale of spare parts after patentee fully compensated, **11:10**
Sales, **8:129**
Sample is potent witness, **9:4**
Sanctions on counsel, **12:22**
Sec. 102(b), **19:31**
Sec. 112(6), **9:215**
Sec. 112(6), invoking, **16:51**
Sec. 112 equivalency, **16:2**
Sec. 271(a), **23:53**
Sec. 271(b), **8:24**
Sec. 271(c), **6:23**
Sec. 271(e)(1), **5:13**
Sec. 271(g), **13:105**
Sec. 285, **3:42; 3:212**
Sec. 337, **3:23**
Separate patentability, **8:52**
Settlement on product, effect of, **16:40**
Special master's decision, **1:207; 13:24**
Special verdict, **23:1**
Spoliation of evidence, **8:120**
Standard essential patent, **7:136**
Standing, **13:170; 19:154**
Statutory notice under Sec. 287(b)(5), **13:41**
Step-two analysis, **20:63**
Strict liability offense, **10:21**
Structure, no dispute concerning, **7:57**
Substantial evidence, **25:10**
Substitute, **7:63**
Success on merits, likelihood of, **7:50**
Summary judgment, **1:35; 1:79; 2:29; 3:36; 3:52; 3:189; 4:75; 4:113; 5:10; 8:40; 9:131; 14:14; 16:20; 16:88; 16:155; 21:28; 21:46; 23:58**
Superiority of accused product, **19:38**

INFRINGEMENT—Cont'd
Switching not establish noninfringing substitute during past infringement, **7:63**
Technical expert, **9:125**
Technological advance, **22:32**
Technologic equivalency are fact questions, **8:51**
Two-part analysis, **2:83**
Two-step analysis, generally, **1:118; 1:134; 2:62; 2:78; 3:66; 3:105; 4:66; 5:26; 6:47; 7:40; 7:67; 8:77; 9:269; 10:28; 10:32; 11:44 to 11:46; 12:42; 12:49; 12:65; 12:70; 13:112; 13:118; 14:32; 14:46; 15:12; 15:17; 16:66; 16:77; 16:82; 18:46; 18:51; 18:57; 19:103; 19:135; 19:158; 23:49; 24:2; 26:6**
Two-step inquiry, **2:74**
Two-step process, **14:14; 18:30; 23:35**
Two-step test, **13:75**
Unfair competition, **19:87**
Use of system, **3:156**
Vacate, **7:8**
Validity, **1:113; 1:169; 7:61; 8:49; 12:45; 15:15; 16:74; 18:39; 19:86; 20:72**
Venue, **8:53**
Vicarious liability, **4:75**
Visual appearance as a whole, **3:100**
Willful Infringement (this index)
Withdrawn claims, **7:10**
Within United States, **12:81**
Witnesses, **9:4**
Written description, **1:252; 6:93; 9:453**

INGENICO INC. V. IOENGINE, LLC
2025, **9:538**

INGEVITY CORPORATION V. BASF CORPORATION
2026, **9:544**

INGREDIENTS
Claim construction and interpretation, **13:125**

INGURAN, LLC V. ABS GLOBAL, INC.
2023, **9:523**

INHERENCY
Generally, **5:61; 6:40; 7:81; 9:212; 9:242; 9:486; 12:36; 13:94; 16:172**

INHERENCY—Cont'd
Anticipation (this index)
Certain thing may result is not sufficient, **9:140**
Circumstances insufficient, may result from set of, **3:103**
Composition, discovery of inherent properties, **20:11**
Defense, sovereign act doctrine as defense, **8:41**
Descriptive matter, recognition that missing descriptive matter is necessarily present, **5:56**
Disclosure, **25:12**
Discovery, **20:11**
Escrow, **3:21**
Fact question, **9:31; 9:172**
Must necessarily be present, **20:59**
Necessary function, **2:143**
Necessary present, **20:47**
Obviousness, **5:136; 8:147; 16:140; 19:303; 20:67**
Old composition, **20:11**
On-sale bar, **19:113**
Privity, **11:14**
Recognition that missing descriptive matter is necessarily present, **5:56**
Sec. 112(1), **18:52**
Sec. 120, **11:8**
Sovereign act doctrine as defense, **8:41**
Unexpected properties, **8:147**
Written description requirement, **13:53**

IN-HOUSE COUNSEL
Attorney fees award, **16:24**

IN BANC HEARING
Correction of panel opinions, **16:107**
Exception not rule, **1:52**
FCR 35, **1:52**
Malpractice, **2:152**

IN CAMERA DOCUMENT INSPECTION
Generally, **17:3**

IN FIRST INSTANCE
Claim words, **5:7**

IN HAEC VERBA
Written description, **12:54; 16:65**

IN LIGHT OF SPECIFICATION
Claim interpretation, **1:108**

IN LIMINE
Evidence, **21:41**

"IN THIS COUNTRY"
Sec. 102(g), **1:111**

IN TOTO
Generally, **8:31**

IN VIVO
Generally, **1:44**
Interference, **3:28**

INITIAL BURDEN TO SHOW
Summary judgment, **22:18**

INITIAL CONSIDERATION OF EVIDENCE
Preliminary injunction, **8:2**

INJUNCTIONS
Generally, **1:240; 2:189; 5:8; 5:125; 11:28; 13:136; 16:19; 16:142; 18:14**
Anti-suit injunction, **19:239**
Appealability of interlocutory order having injunction effect, **7:21; 13:219**
Biosimilar products, **1:291**
Broad discretion, **10:23**
Broadening scope, **19:48**
Claim construction, **20:149**
Claims must be construed same way, **23:11**
Communication regarding rights, **7:92**
Considerations involved, **19:49**
Contempt, **1:156; 1:234; 2:119; 5:119; 11:17; 14:69; 16:25**
Damages, **1:20; 1:262**
Design, **20:15**
Discretion, broad discretion, **10:23**
Discretionary, **2:157; 15:14**
Extraterritorial, **9:271**
FRAP 38, **16:29**
FRCP 60(b), **1:173; 23:23**
FRCP 65, **7:3**
FRCP 65(d), **1:53; 5:4**
Inconsistency, **16:5**
Increased damages award, **16:5**
Induced infringement, **22:59**
Interlocutory decision, **12:41; 16:116**
Irreparable Harm or Injury (this index)
Jurisdiction, **1:234; 19:9; 22:50; 22:59**
Jury trial, **20:55**

INJUNCTIONS—Cont'd
Licenses, **22:37**
Means-plus-function, **20:149**
Non-parties, **1:75**
Party enjoined, **16:5**
Patent misuse, **23:9**
Permanent injunction, **1:308; 5:110; 12:88; 19:329**
Preliminary Injunction (this index)
Res judicata, continuing conduct, **1:229**
Review, standard of, **3:56; 15:6**
Same parties and same issues requirement, **9:116**
Sec. 112, **1:304; 19:4**
Sec. 271(e)(1), **5:3; 5:13**
Sec. 283, **10:17; 18:18**
Sec. 337, **19:222**
Sec. 1292(a)(1), **23:13**
Stay, **5:2; 9:91**
Tailoring permanent injunction, **5:110**
Territoriality of U.S. patent laws, **13:181**
Third parties, **1:296**
Willful infringement, **9:323; 16:5**
Written description, **22:59**

INJURY
Standing, **3:177; 4:116**
Standing criteria, **1:45; 4:116**

INLAND DIAMOND PRODUCTS CO. V. CHERRY OPTICAL INC.
2025, **9:539**

INLINE PLASTICS CORP. V. LACERTA GROUP, LLC
2024, **9:526**

INNOVATION
Obviousness, **18:15**

INOPERABLE
Utility, **5:56**

INOPERATIVE
Enablement, **9:222**
Utility, **9:222**

INOPERATIVE EMBODIMENTS
Enablement, **3:103**

INOPERATIVENESS
Enablement, lack of, **14:12**
Utility, lack of, **6:9**

IN PERSONAM
Personal Jurisdiction (this index)

INQUIRE, DUTY TO
Patent ambiguity doctrine, **3:48**

IN RE: CELLECT, LLC
2023, **9:516**

IN RE COUVARAS
2023, **9:517**

IN RE ENTRESTO
2025, **9:531**

IN RE FLOAT 'N' GRILL LLC
2023, **9:518**

IN RE FOREST
2025, **9:532**

IN RE GESTURE TECHNOLOGY PARTNERS, LLC
2025, **9:533**

IN RE GOOGLE LLC
2023, **9:519**

IN RE KOSTIC
2025, **9:534**

IN RE PERSONALWEB TECHNOLOGIES LLC
2023, **9:520**

IN RE RIGGS
2025, **9:535**

IN RE STINGRAY IP SOLUTIONS, LLC
2023, **9:521**

IN RE XENCOR, INC.
2025, **9:536**

INSPECTION
Generally, **16:15**
Concept, no claim on, **16:15**
Doctrine of equivalents, **16:15**
Elements, interchangeability of elements, **16:15**
Essence, **16:15**
Heart of invention, **16:15**
In camera document inspection, **17:3**
Interchangeability of elements, **16:15**
Pioneer invention, **16:15**

INSTITUTION
Inter partes review, **1:328**

INSTRUCTIONAL LIMITATION
Sec. 101, printed matter, **11:64**

INSTRUCTIONAL MANUAL
Template, claimed invention used as, **9:123**

INSTRUCTIONS TO JURY
Jury Instructions (this index)

INSUBSTANTIAL DIFFERENCES
Doctrine of equivalents, **1:84; 2:101; 3:86; 4:62; 5:30; 9:225; 15:16 to 15:18; 19:97; 19:135; 20:57; 23:41; 26:6**
Equivalence, **1:93**
Equivalency, **19:114**

INSULET CORP. V. EOFLOW, CO. LTD.
2026, **9:545**

INSURANCE POLICY
Choice of law, **21:31**

INTEGRAL
Generally, **8:58; 9:199**

INTEGRATION
Parol evidence, **13:76**

INTEL CORPORATION V. PACT XPP SCHWEIZ AG
2023, **9:524**

INTELLECTUAL TECH LLC V. ZEBRA TECHNOLOGIES CORPORATION
2024, **9:527**

INTENT
All facts and circumstances considered, **11:13**
Bright-line test, **6:23**
Broadened reissue, **9:109**
But one factor for rejecting, **9:39**
Claim preamble, **1:103; 2:101; 9:79**
Deceive. Intent to Deceive (this index)
Dedication to public of unclaimed subject matter, **20:74**
Direct infringement, **9:118**
Disclosure, duty of, **12:52**
Fraud, **6:28**

INTENT—Cont'd
Implicates inequitable conduct, **4:54**
Inducement, **1:133; 7:88; 13:135; 19:217**
Inequitable conduct, **1:169; 2:33; 2:68; 4:54; 5:16; 6:4; 6:5; 7:34; 7:46; 9:378; 13:19; 13:91; 13:141; 16:32; 20:25**
Infringement, direct, **9:118**
Jurisdiction, **3:27**
Materiality, **12:93; 14:19**
Mislead. Intent to Mislead (this index)
Performance of government contract, **8:8**
PTO, **7:19; 9:43**
Reduction to practice, **13:72**
References, **12:43**
Rejection, **9:39**
Sec. 102(g), **11:9**
Sec. 282, **12:5**
Sec. 285, **5:14**
Statutory construction, **7:24; 7:55; 8:39; 8:45; 13:60**
Willful infringement, **18:14**
Written agreement is executed, **23:21**

INTENT TO DECEIVE
Generally, **11:58**
Affidavit ipso facto material, **18:37**
Clear and convincing evidence, **1:187**
Coinventors, **1:106**
Conjecture alone does not show intent to deceive, **9:125**
Deception, specific intent to deceive, **6:28**
Inequitable conduct, **1:178; 1:180; 1:187; 3:98; 5:87; 8:42; 11:23; 12:85; 15:42; 19:208**
Inferred, can be, **13:69**
Misrepresentation, **6:28**
Negligence, **19:59**

INTENT TO MISLEAD
Generally, **13:80**
Culpability. inferential culpability doctrine, **20:35**
Disclosure, **8:51; 14:19**
Factors involved, **3:72**
Gross negligence alone insufficient, **2:68**
Inference, not inferred solely from information not disclosed, **8:51**

INTENT TO MISLEAD—Cont'd
Inferential culpability doctrine, **20:35**
Materiality, **12:30; 12:43**
Mere denial, sufficiency thereof, **19:128**
Not inferred solely from information not disclosed, **8:51**

INTERCHANGEABILITY
Generally, **8:47**
Doctrine of equivalents, **13:91**
Equivalent device, not necessarily, **11:22**
Hardware and software, **15:16**
Inspection of patentee's product, **16:15**

INTEREST OF JUSTICE
Sec. 1651, **3:14**

INTEREST RATE
Generally, **4:6**

INTERFERENCE
Generally, **2:118; 4:11; 4:21; 4:132; 8:67; 9:163; 9:198; 13:10; 13:105; 15:1; 18:124; 19:10; 19:149**
Abuse of discretion, permissive rules reviewed for, **5:68**
Actual reduction to practice, evidence of, **14:3**
Administrative Procedure Act, **9:263**
Affidavit describing work of third party at reasonably contemporaneous time, **9:23**
All issues of patentability and priority decided in one proceeding, **16:16**
Already known, no teaching required of what is, **3:6**
Ancillary to priority, **13:31; 16:16**
Animal testing, **3:28**
Anticipation, **3:32**
Appeal and review, **4:11; 5:68; 7:26; 7:74; 12:99; 13:119**
Art class, examiner's search of, **4:21**
Best mode, **4:8; 13:3**
Board has no authority to dissolve interference, **16:7**
Broadest interpretation, **9:88**
Broadest reasonable interpretation, **18:56**
Burden, junior party's burden, **15:1; 19:70**
Burden of proof, **2:47; 2:107; 4:8; 5:52; 13:31; 16:36**

INTERFERENCE—Cont'd
Burden to show date of invention, senior party's, **2:96**
Challenges, **13:3**
Chemical case, **3:28**
Chemical compound, **15:1**
Civil action, **18:49; 19:232**
Claim construction and interpretation, **1:5; 1:182; 2:172; 9:88**
Clearly erroneous standard, reviewed under, **4:11**
Conception, **3:15; 9:244; 15:1; 19:240**
Construction and interpretation, **7:49; 7:74; 9:130**
Continued, proceeding not to be, **13:31**
Co-pending application, standard of proof for, **2:70**
Copies, **3:92; 4:8**
Counts, **7:49; 7:74; 9:49; 9:88; 9:141; 9:230; 13:31; 19:151**
Dates, effective filing dates, **8:122; 19:144**
Default judgment awards, **1:60**
Delay, long delay in filing, **16:9**
Delusion to cite sentence as precedent, **3:6**
Derivation, **4:11**
Disclaimer, statutory, **7:45**
Disclosure, **3:25; 7:13**
Discretion of Commissioner to declare, **2:67**
Dissolve, motion to, **16:7**
"Each and every" limitation, **25:11**
Early disclosure of inventions, **7:13**
Effective filing dates, **8:122; 19:144**
Enablement, **3:28; 4:8; 13:3**
Estoppel
judgment, by, broadest interpretation, **23:14**
section 141, **2:165**
section 146, **2:165**
Evidence, **2:70; 14:3**
Examiner's search of art class, **4:21**
Expired patent, **7:102**
Fact question, **3:32; 4:8**
Filing, long delay in filing, **16:9**
Filing date, **6:20; 8:122; 19:144; 19:164**
Findings, **4:11; 7:48**
Foreign countries, **6:20**
Fraud, **4:21**
Futility, exercise in, **13:31**

INTERFERENCE—Cont'd
Future use of non-contested priority in civil action, **18:49**
Genus, **9:88**
Grammatical structure and syntax, **1:117**
How to make, **13:3**
Hybrid nature, **3:6**
Implicates inequitable conduct, **4:54**
Incorporation by reference, **8:113; 8:119**
Inducing infringement, **18:48**
Inequitable conduct, **4:21; 4:54**
In vivo, **3:28**
Interpretation thereof, **9:130**
Inurement, **3:94**
Inventorship, **3:15; 19:109**
Inventorship proof, **5:73**
Joint inventors deemed single party, **4:31**
Joint vs. sole inventorship, **19:72**
Junior party's burden, **15:1; 19:70**
Lapse, procedural, **5:57**
Late claiming, **3:25**
Law question, **4:8**
Long delay in filing, **16:9**
Lost count, **9:88**
Motions, untimely challenges not raised during motions period, **13:3**
Motion to dissolve, **16:7**
Necessary findings must be expressed with sufficient particularity, **7:48**
New Interference Rules (this index)
New practice, **16:16**
New rules. New Interference Rules (this index)
Obviousness, **18:89**
Overlapping dates, **3:54**
Particularity, **7:48**
Patentability, **9:230; 16:16; 18:44; 23:44**
Patent and Trademark Office (PTO), **7:102**
Patent Cooperation Treaty (PCT), **6:66**
Pending applications, **13:31**
Permissive rules reviewed for abuse of discretion, **5:68**
Phantom count, **9:49**
Physical embodiment must meet every limitation of count, **3:25**
Preamble, **4:8**
Pre-critical date claiming, **16:132**

INTERFERENCE—Cont'd
Preliminary statement with two distinct nonoverlapping dates, **3:54**
Prima facie case of priority, **7:13**
Priority, **2:107; 3:6; 3:82; 6:20; 7:13; 7:100; 8:30; 8:78; 9:88; 11:65; 13:31; 15:1; 16:16; 18:49; 19:90; 19:240**
Prior possession of invention vitiates any contention, **4:11**
Procedural lapse, **5:57**
Production specifications, not, **4:8**
Provocation, **18:88**
Public disclosure, **3:25**
Public policy, **7:13**
Raisable against patent in interference, **13:3**
Raising issues, **13:3**
Reasonable diligence, **2:13**
Reduction to practice, **3:25; 12:2; 14:3**
Reexamination v. litigation, **4:8**
Review, standard of, **5:46**
Sec. 1.633(g), **11:27**
Sec. 1.640, **3:32**
Sec. 1.662(b), **7:23**
Sec. 13(b), **2:93**
Sec. 102(b), **25:11**
Sec. 112, **3:6; 3:28**
Sec. 135(b)(1), **1:220**
Sec. 135(c), **3:29**
Sec. 136, **4:27**
Sec. 146, **1:42; 3:6; 3:53**
Sec. 146 appeal, **7:26**
Sec. 291, **1:11; 7:102; 11:23; 19:149**
Sec. 1346(b), **3:6**
Sec. 2201, **13:41**
Senior party, **2:96; 15:1**
Specifications, **1:182; 2:172; 4:8; 19:151**
Stated time period, acts within, **15:1**
Statutory disclaimer, **7:45**
Subsequent litigation, effect of prior interference on, **2:36**
Sufficiency of disclosure, **3:25**
Third party inventorship, **3:6**
Tie, if, **15:1**
Timeliness, **16:132**
Time period, acts within, **15:1**
Underlying facts found by Board, **4:11**
Utility, **6:33**

INTERFERENCE—Cont'd
Warranty, breach of, **1:58**
Withdrawal, **9:217**
Written description, **1:182; 2:172; 7:123; 11:65; 18:88; 25:11**

INTERLOCUTORY
Escrow, **3:21**

INTERLOCUTORY APPEAL
Collateral order doctrine, **4:129**
Jurisdiction, **16:184**
Sec. 1292(b), **10:43; 14:9**
Sec. 1292(c)(2), **9:6; 13:61**

INTERLOCUTORY DECISION
Cohen tripartite test, **19:71**
Preliminary injunction when seeking permanent injunction, **12:41**

INTERLOCUTORY ORDER
Generally, **7:21**
Appealability, **17:3; 18:75; 20:5**
CAFC jurisdiction, **5:85; 13:219**
CAFC jurisdiction limited, **13:219; 22:2**
Leave to file counterclaim, **2:43**
Preliminary injunction, **11:19**
Question certified, not confined to precise, **21:24**
Sec. 1292(a)(1), **16:116; 18:16; 23:13**
Sec. 1292(b), **9:97**
Sec. 1292(c)(1), **16:116**
Sec. 1292(c)(2), **10:12**
Stay order, **19:230**

INTERLOCUTORY PARTIAL JUDGMENT
Appealability, **7:16**

INTERNATIONAL BUSINESS MACHINES CORPORATION V. ZILLOW GROUP, INC.
2025, **9:540**

INTERNATIONAL MEDICAL DEVICES, INC. V. CORNELL
2026, **9:546**

INTERNATIONAL TRADE COMMISSION
Generally, **6:56; 6:63; 11:54; 22:28**
Access by party's in-house counsel to proprietary information of its competitor, **13:40**
Anticipation, **1:17; 1:238**

INTERNATIONAL TRADE COMMISSION—Cont'd
Appeal and review, **1:129; 1:254; 3:191; 6:2; 7:104; 7:105; 19:25**
Arbitration, **9:380**
Articles, **19:280**
Attorneys, **13:40; 23:55**
Burden of proof, **19:25**
CAFC jurisdiction, **1:15**
Choice of remedy, **3:198**
Claim construction and interpretation, **5:98; 9:513; 12:87; 19:196**
Collateral estoppel, **20:41**
Competitors, **13:40**
Consent order, **4:108**
Contract law, **13:20**
Criticality, **1:17**
Deference, entitled to, **5:37**
Dismissal, prior, **25:2**
Domestic disclosure communication, **1:224**
Domestic industry, **2:200; 12:105**
Enforcement proceedings, **22:29**
Entitled to deference, **5:37**
Estoppel to assert patent, **25:2**
Evidence, **2:117; 8:28; 10:27; 23:55**
Exclusions, **8:28; 9:118; 19:221; 19:222**
Factual findings, **1:10; 3:225; 8:28**
FDCA, **1:332**
Foreign law, **13:20**
Infringement, **1:17; 3:198; 5:98; 25:2**
Initial determination, appeal and review, **1:254**
Invalidity, **13:242**
Inventor's admission of invention by another, **1:8**
Issue preclusion, **2:17**
Jurisdiction, **1:332; 3:183**
Law question, **13:20**
License agreement, **9:379; 20:53**
Limited exclusion order, **8:28**
Modification of orders, **3:73**
Mootness during appeal, **20:6**
New and surprising result, **1:17**
Orders, modification of, **3:73**
Parties, purpose of, **13:20**
Penalties, **4:130; 14:65; 15:52**
Pendency, appeal pendency, **19:25**
Presumption of validity, **19:25**

INTERNATIONAL TRADE COMMISSION—Cont'd
Prior dismissal of earlier infringement suit, effect of, **25:2**
Process patents, **1:184**
Recission, **4:130**
Requirements, **25:2**
Review, standard of, **3:59; 7:52; 8:28; 8:86; 19:25**
Review of initial determinations on matters other than temporary relief, **7:105**
Sec. 102(g) prior invention under pre-AIA law, **1:224**
Sec. 211.54(a), **1:15**
Sec. 271(e)(1) exempt purpose, **1:184**
Sec. 282, **19:25**
Sec. 337, **1:15; 2:12; 3:23; 5:98; 12:5; 18:26; 19:25; 20:105; 21:64**
Sec. 337(a), **1:39**
Sec. 337(c), **6:14**
Sec. 1337, **3:154; 25:2**
Sec. 1337(c), **8:28**
Sec. 1337(d), **8:28**
Sec. 1337(e), **8:28**
Self-initiated investigation, terminating, **2:17**
Standard of review, **2:117**
Substantial evidence, **2:117; 8:28**
Summary determination, **8:58**
Tariff Act, **13:11**
37 CFR Sec. 1.321, **13:20**
Validity, **19:25**

INTERNET
Abstract ideas, Sec. 101, **1:285; 9:437; 13:188**

INTER PARTES REEXAMINATION
CAFC, **18:103**
Jurisdiction of Board of Patent Appeals and Interferences, **2:150**
Subpoena, **1:232**
Third parties, **3:138**

INTER PARTES REVIEW
Generally, **1:266; 1:268; 1:316; 1:339; 1:349 to 1:351; 1:354; 2:176; 2:194; 3:234; 3:238; 3:242; 4:119; 6:95; 7:132; 9:401; 9:441; 9:443; 13:199; 13:203; 13:252; 15:54; 16:146; 16:179; 19:291; 19:308; 19:338; 21:84; 23:95**

INTER PARTES REVIEW—Cont'd
Administrative agencies, **19:282**
Amendment of claims, **1:305; 1:371; 3:237; 8:164**
America Invents Act, **19:282**
Anticipation, **5:139; 11:80; 11:81; 23:86**
Broadest reasonable interpretation, **3:201; 4:112; 9:400; 9:448; 17:13**
Burden of proof, **1:305**
Cancellation of claims
generally, **16:154**
motion to amend to request, **14:78**
Claim construction, **1:328; 8:149; 9:489**
Claims, amendment of, **1:305**
Conception, **1:323**
Conception and reduction to practice, **18:110**
Consolidation, **19:284**
Constitutionality, **13:246.50; 19:325**
Contested cases, **1:232; 13:213**
Deposition, **1:338**
Disclaimers, **1:326; 1:327**
Discontinue, **13:213**
Errors, **12:120**
Estoppel, **1:345**
Expiration of patent, **9:424**
Incorporation by reference, **4:122**
Indefiniteness, **19:323**
Institute review, **8:143**
Institution, **1:328; 9:469**
Joinder, **6:104; 14:86**
Jurisdiction to review, **9:425**
Mandamus, **9:385; 9:469; 9:498.70**
Multiple proceedings, **9:512**
Obviousness, **1:278; 1:295; 1:321; 1:326; 2:173; 3:201; 4:123; 5:134; 5:135; 5:139; 8:139; 9:418; 9:426; 9:428; 13:222; 14:99; 16:166; 19:334; 22:56**
Party in interest, **1:324; 23:97**
Patent and trademark office (PTO), **19:282**
Potential claim unpatentable, **8:142**
Privity, **23:86; 23:94**
Proposed substitute claims, **9:418**
Ranges, **5:134**
Rehearing en banc, **13:214**
Review proceedings, **7:119**
Sanctions, **2:174; 3:237**

INTER PARTES REVIEW—Cont'd
Sec. 101, **14:99**
Sec. 120, **4:122**
Sec. 314, **8:143; 19:260**
Sec. 314(d), **8:143; 9:390; 9:418**
Sec. 315(b), **1:324**
Sec. 316(a)(3), **21:74**
Sovereign immunity, **19:305**
Standard of review, **9:418**
Standing, **1:345; 1:361; 10:50; 16:157**
Substitution of claims, **9:421**
Supplemental information, **21:74**
Takings, **3:228; 3:231**
Third-party petition, **3:194**
Time barred, **12:115; 23:94**
28 USC § 1295, **1:327**
Unpatentable claims, **2:173; 16:152**
Validity of claims, **4:114**
Written description, **11:80; 13:252**

INTERPRETATION
Generally. Construction and Interpretation (this index)
Claim Construction and Interpretation (this index)

INTERRELATIONSHIP OF ISSUES
Defenses, **20:5**

INTERROGATORIES
CAFC, **18:3**
Contention interrogatories, **23:76**
Directed to facts, **23:7**
JNOV, **23:4**
Obviousness, **5:7**
Special Interrogatories (this index)

INTERVENING RIGHTS
Indefiniteness, **16:161**
Protection of investments, **10:51**

INTERVENTION
Generally, **23:26**
Absolute intervening rights, **13:168; 19:137**
Amicus curiae, **9:67**
Enhanced damages, **21:3**
Ex parte reexamination, **13:176**
FRCP 24, **3:38**
FRCP 24(b), **8:36**
Motion, **1:68**
Patent misuse, **23:9**

INTESTACY
Ownership, **1:172**

INTRINSIC EVIDENCE
Claim construction and interpretation, **1:140; 5:53; 11:40; 16:53; 16:58; 18:51; 19:111; 19:115; 20:117**

INTRINSIC RECORD
Claim interpretation, **11:53; 22:31**

INUREMENT
Generally, **3:82; 7:64**
Corroboration, **14:83**
Derivation, **3:82**
Interference, **3:94**
Requirements, **3:94**

INVALIDITY
Validity (this index)

INVENTION SECRECY ACT
Claim against government, **8:116**
Sec. 183 use of invention, **8:117**

INVENTIVE CONCEPT
Generally, **1:355**

INVENTOR
Generally, **6:10; 19:62**
Analogous art, **19:36**
Attorney fee award, **8:18**
CAFC jurisdiction, **9:63**
Claim differentiation, **6:10**
Combinations, **6:10**
Construed by those skilled in art, **6:10**
Corroboration, need for, **8:30**
Design patent, **8:81**
Disavowal of feature, **16:151**
Disclosure, **1:8**
Discovery of new property or use of known composition, **9:104**
Feature, disavowal of, **16:151**
File wrapper, **6:10**
First inventor, Sec. 102(a)(2), **7:98**
Infringement, literal, **6:10**
ITC, **1:8**
Jury verdict, **19:5**
Literal infringement, **6:10**
Presumption, none, **1:8**
Prima facie obviousness, **9:17**
Prior art under Sec. 102(g) and Sec. 103, **1:8**
Public use, **14:36**

INVENTOR—Cont'd
Rebuttal, **1:8**
Reissue, **9:84**
Scientific principles, **6:10**
Sec. 282, **1:8**
Sec. 337, **1:8**
Skilled in art, construed by those, **6:10; 20:126**
Testimony, **8:106**

INVENTORSHIP
Generally, **2:194; 2:201; 3:215; 4:74; 4:126; 5:73; 5:148; 7:79; 7:110; 7:143; 20:159**
Appeal and review, **21:42**
Claim preamble, **19:210**
Conception, **2:99; 2:164; 6:35; 19:72; 19:195; 20:126; 21:55**
Concerned party, **3:93**
Contribution, **6:50**
Correction, **6:35; 6:79; 16:131; 19:195; 19:218; 20:68**
Corroborating evidence, **19:132; 21:42**
Declaratory judgment, **12:86**
Deference, **21:42**
Disclosure to public, **6:83**
Doctrine of equivalents, **4:125**
Eleventh Amendment, **24:3**
Equitable estoppel, **6:103**
Evidence, **19:132; 21:42**
False statements, **16:61**
Good faith error, **3:59**
Inequitable conduct, **16:48**
Infringement, **4:125**
Interference, **3:15; 5:73; 19:72; 19:109**
Joint inventor, **8:81; 22:54**
Laches or delay, **16:131**
Large number of individuals, **3:76**
Law question, **1:106; 3:83**
Means-plus claim, **23:55**
Nonjoinder, **14:59; 16:50**
Ownership, **5:40**
Presumption that correct, **6:35**
Private right of action, challenge, **8:115**
Provisional application, **5:88**
Reissue, **3:83**
Review, standard of, **5:40**
Sec. 102(b), **19:7**
Sec. 256, **12:86**
Standing, **19:272**
Third party, filed in name of, **1:102**

INVENTORSHIP—Cont'd
Touchstone, conception is, **2:99**
Unclean hands doctrine, **16:131**
Willful infringement, **2:164**

INVITED ERROR
JNOV, **23:4**

INVOCATION
Means-plus-function claim, **3:66; 25:3**

IOENGINE, LLC V. INGENICO INC.
2024, **9:528**

IPSISSIMIS VERBIS TEST
Anticipation, **1:10**

IQE PLC V. NEWPORT FAB, LLC
2025, **9:541**

IQRIS TECHNOLOGIES LLC V. POINT BLANK ENTERPRISES, INC.
2025, **9:542**

IRONBURG INVENTIONS LTD. V. VALVE CORPORATION
2023, **9:525**
2026, **9:547**

IRONSOURCE LTD. V. DIGITAL TURBINE, INC.
2026, **9:548**

IRREPARABLE HARM OR INJURY
Evidence, **18:26**
License, **8:46**
Permanent injunction, **4:102; 7:122; 18:93**
Preliminary injunction, **1:169; 1:225; 3:34; 18:21; 19:14**
Presumption, **1:110; 14:9; 18:32; 19:94**
Procedural issue, **8:21**

IS OBVIOUS
Combination, **18:22**
Findings prepared by prevailing party, **18:22**
Improper, **18:22**
Patentable, **18:22**

ISOLATED DNA MOLECULES
Patentability, **1:228; 9:383**
Subject matter jurisdiction, **1:214**

ISOLATION
Claims do not live in, **11:11**

ISSUANCE
Judicial notice, **8:40**
Preliminary injunctions, standard for issuance, **11:67**
Reexamination, **9:239**
Reissue (this index)
Sec. 283, **18:18**

ISSUE DATE
Sec. 112, **9:53**
Sec. 153, **5:17**

ISSUE FEE
Small entity, **4:52**

ISSUE JURISDICTION
Generally, **20:34**

ISSUE PRECLUSION
Collateral Estoppel (this index)

ITC
International Trade Commission (this index)

"IT WOULD BE OBVIOUS"
Verbatim findings of counsel adopted, **8:22**

JANSSEN PHARMACEUTICALS, INC. V. TEVA PHARMACEUTICALS USA, INC.
2024, **10:55**
2025, **10:56**

"JAWBONING" AT LICENSING NEGOTIATIONS
Generally, **19:61**

JAZZ PHARMACEUTICALS, INC. V. AVADEL CNS PHARMACEUTICALS, LLC
2025, **10:54**

JEPSON CLAIM
Generally, **5:28; 11:40; 13:15; 18:44**
Claim preamble, **5:63**
Copying while lauding prior art, **13:15**

JIAXING SUPER LIGHTING ELECTRIC APPLIANCE, CO., LTD. V. CH LIGHTING TECHNOLOGY CO., LTD
2025, **10:58**

JMOL
Judgment as Matter of Law (this index)

JNOV
Judgment Notwithstanding Verdict (JNOV) (this index)

JOINDER
America Invents Act, **9:359**
Choice of law, **9:268**
FRCP 19, **9:71**
FRCP 19(a), **11:19; 19:264**
Inter partes review, **14:86**
Inventorship, **16:50**
Involuntary plaintiff, **9:302; 14:9; 15:9**
Owner, **19:194**
Sovereign immunity, **7:134**

JOINED
Generally, **7:49**

JOINT DEVELOPMENT EXCEPTION
On-sale bar, **2:23**

JOINT INFRINGEMENT
Claim construction, **1:195**
Control or direction over process, **13:159; 13:160**
FRCP 12(b), **12:112**
Performance of different steps by each infringer, **2:124**

JOINT INVENTORS
Generally, **16:48**
Collaboration required, **5:40; 6:35; 22:39**
Deceptive intent, **1:106**
Freedom to license, **19:98**
Interference, **4:31**
Inventorship, **8:81; 22:54**
License, freedom to license, **19:98**
Non-joinder, **14:59**
On-sale bar, **2:85**
Ownership, **9:303**
Physically work together or at same time, **20:68**
Presumption named properly, **7:79**
Requirements, **16:50**
Same time, **20:68**
Scope of claims first, **5:73**
Sec. 116, **22:39**
Sec. 256, **22:54**
Sec. 262, **8:5**

JOINT INVENTORSHIP
Interference, **19:72**
Sec. 116, **2:48**

JOINT LIABILITY
Attorney fee award, **8:18**

JOINT MOTION TO DISMISS
Vacation of lower court decision, **20:95**

JOINT MOTION TO VACATE JUDGMENTS BELOW
Settlement agreement, **21:22**

JOINT VENTURES
Patent misuse, research joint ventures, **16:126**

JPML
Judicial Panel on Multi-District Litigation (this index)

JUDGE
CAFC, **18:3**
Claim interpretation, **5:36**
Disqualification, **1:65; 16:19**
Fact finding, **10:15**
Improper, **16:25**
Judicial disqualification, **16:19**
Presumed jury fact findings, **10:15**
Qualification, judicial, **16:19**
Recusal, **1:65**
Sec. 284, **2:31**
Sec. 455, **8:14**
Weight and credibility of testimony, **19:54**

JUDGMENT AS MATTER OF LAW (JMOL)
Generally, **3:106; 5:54; 5:65; 5:71; 6:62; 9:237; 12:72; 13:99; 13:100; 13:103; 13:105; 13:118; 13:122; 14:45; 16:86; 18:41; 18:58; 18:64; 18:70; 19:123; 19:166; 20:52; 20:63; 20:81; 21:44; 22:23; 23:56; 25:7; 26:11**
Anticipation, **23:87**
Appropriate, when, **3:75; 12:43; 13:64**
Choice of law, **2:91; 19:137**
Claim interpretation, **21:39**
Discretion of court, **26:9**
Doctrine of equivalents, **5:44**
Evidence, effect of, **19:126**
Experimental use, **5:50**

JUDGMENT AS MATTER OF LAW (JMOL)—Cont'd
FRCP 50(a), **2:34; 2:48; 13:194**
FRCP 50(a)(1), **16:106**
FRCP 50(b), **13:54**
Jury findings, **2:45**
Jury verdict, **11:28**
Method claims, **13:195**
Motion, **1:101; 13:54; 13:64; 13:194**
New construction, **8:84**
Obviousness, **1:171; 1:178; 2:136**
Prevailing party, **3:161**
Raising issues, **8:84**
Reissue, **4:64**
Review, standard of, **2:91; 3:96; 5:21; 5:30; 6:46; 12:45; 12:61; 13:75; 13:85; 13:101; 14:21; 14:25; 18:62; 20:41**
Substantial evidence, **10:40**
Wide discretion to trial judge, **26:9**

JUDGMENT NOTWITHSTANDING VERDICT (JNOV)
Appeal and review
generally, **13:38; 21:5; 22:4**
standard of review
generally, **4:2; 12:31; 22:2**
motion, **6:36; 9:186; 13:13; 13:34; 19:12**
new trial motions, **19:60**
Attorney arguments, **23:4**
Co-owners' right to relief, **23:4**
Counsel arguments, **23:4**
Cross-appeal, **22:4**
Damages, **23:4**
Directed verdict, **22:4**
Evidence rules, **13:4**
Fact, infringement mixed fact-law question, **22:4**
FRCP 50(b), **23:25**
Frivolous appeal, **22:4**
Harmful error, **22:4**
Infringement mixed fact-law question, **22:4**
Instructions, **23:4**
Interrogatories, **23:4**
Invited error, **23:4**
Jury and jury trials, **1:14; 19:7; 19:16; 23:17**
Jury findings, **18:29**
Jury instruction, **22:2**

JUDGMENT NOTWITHSTANDING VERDICT (JNOV)—Cont'd
Jury verdict, **3:17; 13:17; 19:56; 20:15**
Law, infringement mixed fact-law question, **22:4**
Law question, **13:38**
Means-plus-function claim language, **4:4**
Motion
generally, **19:37; 23:7**
Altvater, **6:6**
best mode, **13:13**
claim ambiguity, **13:13**
claim construction, **6:6**
Court error, **6:6**
directed verdict, **4:32; 19:41**
evidence, **6:6; 13:13; 25:4**
extrinsic evidence, **13:13**
fact question, **13:13**
fair, **6:6**
FRCP 50(b), **1:43**
infringement, **6:6**
jury and jury trials, **9:125; 13:39**
jury instruction, **6:6**
jury verdict, **5:7**
limitations and restrictions, **13:13**
nonasserted claims, **6:6**
objection, timely, **6:6**
perfect, not, **6:6**
review, standard of, **6:36; 9:186; 13:34; 19:12**
review limited to sufficiency of evidence, **13:13**
same meaning, words to be given, **13:13**
substantial evidence, **6:6**
substantial rights must be affected, **6:6**
timely objection, **6:6**
verdict, **16:14**
New trial, **4:4; 13:4; 19:16; 23:4**
Objections, **22:2; 23:4**
Obviousness, **13:38; 20:15**
Post-trial motions, **1:50**
Presumption of validity, **22:2**
Prevailing party, **22:4**
Procedural, **13:4**
Sec. 112 equivalent, **4:4**
Sec. 284, **23:4**
Submission, **23:4**

JUDGMENT NOTWITHSTANDING VERDICT (JNOV)—Cont'd
Substantial evidence, **15:2**
Summary judgment, **10:4**
Timely objection, **22:2**
Validity, presumption of validity, **22:2**

JUDGMENTS
Generally, **19:171**
See also Orders (this index)
Adding party, **15:13**
Affirmed on any ground supported by record, **19:86**
Appealability (this index)
Appeal and Review (this index)
Appropriate, when, **14:13**
Assignor estoppel doctrine, **19:47**
Choice of law, **19:95**
Claim interpretation, **19:16**
Considerations involved, **19:49**
Cross-appeal to reverse validity or infringement, **18:2**
Dann Amendment, **19:30**
Doctrine of equivalents, **5:6**
Enforcement, court's power, **1:83**
Exceptional case, **16:59**
FRCP 50, **7:27**
FRCP 54, **6:16**
FRCP 59(e), **19:42**
FRCP 60(b), **1:29; 13:59**
Interference estoppel by judgment, **23:14**
Judgment as Matter of Law (JMOL) (this index)
Judgment Notwithstanding Verdict (JNOV) (this index)
No form of words necessary, **16:74**
Opinions or findings, **19:42**
Settlement agreement, **21:22**
Special master's decision, **13:24**
State court decision, **19:45**
Vacation of Judgments (this index)
Validity, **2:169; 14:1**
Verdict, **16:14**

JUDICIAL BIAS
Generally, **16:29**

JUDICIAL CAPACITY
Issue preclusion, **20:41**

JUDICIAL DECISION
Retroactive application, **23:33**

JUDICIAL ERROR
Article III, **19:55**

JUDICIAL ESTOPPEL
Generally, **2:116; 4:43; 11:43; 12:3; 13:122; 14:30; 19:169; 21:24; 23:3**
Choice of law, **21:24**
Enforceability of unexecuted settlement agreement, **23:21**

JUDICIAL FUNCTION
Judicial legislation, **5:3**

JUDICIAL INQUIRY
Unambiguous, if language of statute is, **23:29**

JUDICIAL LEGISLATION
Judicial function, **5:3**

JUDICIAL NOTICE
Generally, **9:139**
Delivery, **11:24**
Everyday mechanical concepts, **9:127**
Issued patent, **8:40**
Mail delivery, **11:24**
Mechanical concepts, everyday, **9:127**
MPEP, **9:374**
Proper subject matter, **6:10**
Stay of execution of judgment and injunction pending appeal, **19:49**
Time required for mail delivery, **11:24**

JUDICIAL PANEL ON MULTI-DISTRICT LITIGATION (JPML)
Generally, **7:6**
Consent, parties cannot confer by, **7:6**
Consolidated pretrial proceedings governed by Sec. 1407(a), **7:6**
Jurisdiction, transfer divests, **7:6**
Sec. 1651, **9:128**
Transfer divests jurisdiction, **7:6**

JUDICIAL POWER
Generally, **3:57**

JUDICIAL REDRAFTING
Summary judgment, **2:29**

JUDICIAL REVIEW
Proper respondent, **19:89**
Restriction of access to, **1:72**

JUNIOR PARTY'S BURDEN
Interference, **15:1; 19:70**

JURISDICTION
Generally, **1:281; 1:352; 2:197; 3:121; 8:144; 11:74; 13:248; 16:184; 19:155; 19:337; 20:83; 21:89; 22:53**
Accounting remains only, **16:72**
Adversariness, lack of, **7:8**
Agreement depriving court, **21:14**
ANDA, **1:135; 3:132**
Antitrust claims, **3:69**
Appellate Jurisdiction (this index)
Arising under, **3:27**
constitutionality, **13:191**
Assumption that party will establish contested, **4:44**
Bankruptcy court, **9:213**
Board of Patent Appeals and Interferences, **2:150**
Case jurisdiction, issue jurisdiction versus, **20:34**
Challenge to PTO determination in reexamination proceeding, **19:46**
Claims not asserted by patentee, **23:26**
Complaint, determined at time filed, **7:38; 13:59; 19:66**
Constitutionality, **13:191; 18:34**
Contempt, **1:263**
Counterclaim, **4:57; 7:73**
Court of Appeals for the Federal Circuit (CAFC) (this index)
Covenant not to sue, **18:81**
Declaratory judgment, **1:27; 2:122; 8:109; 13:194; 19:192; 23:9**
Design in public domain, **12:48**
Discretion of court to assume pendent jurisdiction, **11:20**
Dismissal (this index)
Disputed facts resolved in favor of petitioner, **5:27**
Evidence outside pleadings, consideration of, **1:76**
Federal, **22:5; 23:77**
state universities, **21:63**
Final judgment rule, **18:104**
Foreign defendant, **7:60**

JURISDICTION—Cont'd
Foreseeability plus test, **1:221**
Induced infringement, **22:59**
Infringement, **7:73**
In personam, **4:49; 9:226; 18:45; 22:11; 26:5**
Injunctions, **1:234; 19:9; 22:50; 22:59**
Intentions may change over time, **3:27**
International Trade Commission, **3:183**
Inter partes review, **1:377**
Issue jurisdiction vs. case jurisdiction, **20:34**
Judicial Panel on Multi-District Litigation (JPMDL), **7:6**
Law question, **16:43; 19:66**
Legal malpractice, **1:160**
Mandamus, **9:41; 9:63; 9:292; 23:92**
Non-final appeals from Patent Office, **9:422**
Nunc pro tunc order, **13:59**
Only accounting remains, **16:72**
Out-of-state defendant, **7:60**
Patent Cooperation Treaty (PCT), **2:116**
Pending appeal, **19:9**
Personal jurisdiction, **1:284**
Personal Jurisdiction (this index)
Post-trial injunction pending appeal, denial of stay of, **19:9**
Preliminary injunction, **3:12**
Raised at any time, **2:56**
Reissue application, **9:47**
Sanctions, **20:129**
Sec. 41(a)(7), **13:32**
Sec. 145, **9:394**
Sec. 1267, **7:25**
Sec. 1292(a)(1), **14:6**
Sec. 1338(a), **1:160; 3:150; 4:22; 4:92**
Settlement agreement, breach of, **7:54**
State law claims, **12:91; 12:96; 13:180; 21:60**
State universities, federal courts, **21:63**
Stay, **19:9**
Stream-of-commerce plus theory, **1:221**
Subject Matter Jurisdiction (this index)
Summary judgment and subject matter jurisdiction, **13:216**
Time complaint is filed, determined at, **7:38**
Timely, inquiry is always, **15:8**
Transfer, appeal transferred, **21:12**

JURISDICTION—Cont'd
Walker process claim, **24:6**
Well-pleaded complaint, **1:135; 1:160**
Written description, **22:59**

JURISDICTIONAL GRANTS
Sovereign immunity, **13:66**

JURISDICTIONAL LIMITATION
Limitation of actions, **8:44**

JURISDICTIONAL RULES
Generally, **21:21**

JURISDICTIONAL STATUTE
Statutory construction, **3:60**

JURY AND JURY TRIALS
Antitrust, **1:16**
Appeal, reversal on, **5:41**
Attorneys' fees, **1:300**
Burden of proof, **1:16**
CAFC, **18:3**
Constitutionality, **16:8**
Damages, **1:16; 1:199; 2:80; 23:73**
Defenses, **20:55**
Dismissal, **3:19**
Enablement, **1:14; 5:110**
Equitable issues over objection, **2:61**
Fact findings of, **19:9**
Findings, **2:45; 7:27; 18:29**
Fraud, **1:16**
FRCP 49(a), **19:21**
FRCP 50(a), **11:12**
Inconsistent findings, **1:14**
Inequitable conduct, **1:14; 1:16; 2:49**
Injunction, **20:55**
Instructions, **1:14**
JNOV, **1:14; 19:7; 19:16; 23:17**
JNOV motion, **9:125; 13:39**
Law question, **1:14**
Materiality, **1:14**
Motion, JNOV, **9:125**
Non-advisory, **19:9**
Objection, **1:14; 2:61**
Obviousness, **1:16; 3:153; 18:84; 19:37**
Presumed jury fact findings, **10:15**
Presumption of validity, **1:16**
Priority claim, **1:199**
Prosecution history estoppel, **6:26**
Reissue, **1:16**
Relevant market, **1:16**

JURY AND JURY TRIALS—Cont'd
Reversal on appeal, **5:41**
Reverse doctrine of equivalents, **19:24**
Review, standard of, **2:34; 7:28; 23:25**
Review of verdict, **19:60**
Royalty rate, **20:147**
Sec. 102(e) v. sec. 102(g), **19:41**
Sec. 112, **17:1**
Seventh Amendment, **1:58; 3:71; 9:170; 13:64; 13:74; 19:195**
Special interrogatories, **1:16**
Special verdicts, **13:53; 20:50**
Substantial evidence standard, **18:14**
Synergism, **1:16**
Tainted jury, written description, **1:215**
Validity, **21:26**
Verdict (this index)
Waiver, **20:39**

JURY BIAS
Generally, **3:110**

JURY INSTRUCTIONS
Generally, **8:157; 13:53; 16:104; 19:165**
Anticipation, **10:4**
Directed verdict, **10:4**
Doctrine of equivalents, **19:227**
Error, **3:173; 9:317**
FRCP 49(b), **19:60**
FRCP 51, **12:20**
JNOV, **6:6; 22:2**
Meaning is requirement, **19:156**
New trial, **5:60**
Objection, **1:43; 13:38**
Prejudice, considered as a whole in determination, **10:15**
Prejudicial error, **2:31**
Remand, when appropriate, **7:27**
Review, standard of, **1:136; 4:32; 5:52; 10:4; 20:64**
Same invention, substantially, **10:4**
Special verdict, **6:88; 14:7**
Substantially same invention, **10:4**
Sufficiency, **2:143**
Timely objection, **13:38**

JUST COMPENSATION
Claim against government, **8:116; 12:27**

JUSTICIABILITY
Choice of law, **13:30**

JUSTICIABLE CONTROVERSY
Ability to supply relief, **1:69**
Declaratory judgment, **19:61**

JUSTIFICATION
Evidence, **8:35**

KESSLER DOCTRINE
Generally, **19:276**
Claim construction and interpretation, **19:309**

K-FEE SYSTEM GMBH V. NESPRESSO USA, INC.
2023, **11:91**

KICKER
Panduit guidelines, **13:72**

KNOWLEDGE
Notice and Knowledge (this index)

KNOWLEDGE ECONOMY
Sec. 101, **6:71**

KUEHL
Method of using versus method of making, **9:103**

LABELING
See also Marking (this index)
Patent license, **12:14**

LABORATORY CORPORATION OF AMERICA HOLDINGS V. QIAGEN SCIENCES, LLC
2025, **12:126**

LABORATORY EXPERIMENTATION
Diligence, **19:144**

LACHES OR DELAY
Generally, **9:272; 9:377; 19:252; 19:267; 19:296**
Apportionment, **23:27**
Blonder-Tongue, **1:13**
Burden of proof, **23:46**
Claim preamble, **19:210**
Compound interest, **4:24**
Contribution, **23:27**
Damages, **2:19; 3:180; 23:27**
Defense, **8:114**
Discretion of court, **14:11**
Elements, **7:30; 13:44; 23:45**
Equitable estoppel doctrine, **8:50**
Estoppel, **1:48; 19:38; 22:8**

LACHES OR DELAY—Cont'd
Evidence, **3:155; 23:27**
Exceptional case, **3:180**
FDA approval, **20:100**
Inequitable conduct, **3:149**
Interference, **16:9**
Intervening rights, evidence, **3:155**
Invalidity, **3:180**
Inventorship, **16:131**
Inventorship dispute, **12:109**
Jury verdict, **13:4**
Laches, **5:53; 13:36; 19:151**
Maintenance fees, **18:33**
More than six years delay, **8:32**
Notice of other proceeding, **8:16**
Ownership, **19:204**
Patent term adjustment, **23:69**
Period of delay, **5:53**
Plaintiff's, **14:9**
Prejudgment interest, **21:20**
Prejudice, **19:252**
Preliminary injunction, **20:12**
Presumption of validity, **12:9**
Prosecution laches doctrine, generally, **19:181**
PTO proceedings, **1:42**
Reasonably prudent person standard, **18:33**
Resulting prejudice, **13:44**
Review, standard of, **5:30; 5:53; 8:50**
Sale, **3:180**
Sale during laches period, **15:14**
Sec. 102(e) v. sec. 102(g), **19:41**
Sec. 271(a), **3:180**
Separately, each patent treated separately even if related, **19:76**
Simple v. compound interest, **4:24**
Standard, **19:154**
Summary judgment, **1:36; 8:140; 10:4; 23:45**
Totality of circumstances, **3:155**
Trademark infringement, willfulness, **18:112**
Two-elements required, **8:34**
Unclean hands, **19:204**
Undue delay, **9:241**
Unexplained delay, **19:151**
Unreasonable delay, **1:54; 3:149; 12:21; 13:36; 19:151**

LACHES OR DELAY—Cont'd
Waiver due to failure to file belated preliminary motion, **7:26**

LANGUAGE
See also Claim Language (this index)
Claim interpretation, **18:68; 20:71**
Claim preamble, **13:164**
Consisting of claim language, **13:7**
Indefiniteness, **16:47**
Rewrite claim language, **18:68**
Statutory construction and interpretation, **6:29; 11:33; 12:37; 19:67**

LANHAM ACT
Generally, **19:185**
Review, standard of, **9:249**
Sec. 43(a), **12:23**
Willful infringement, **3:26**

LAPSE
Excuse, **11:3**
Interference, **5:57**

LARGE NUMBER OF REFERENCES
Obviousness, effect on, **9:114**

LATCHES
Prosecution, **8:161**

LATE CLAIMING
CAFC, **18:3**
Interference, **3:25**

LATE FILINGS
Board, **18:56**

LATENT AMBIGUITY
Contract, **3:48**
Extrinsic evidence, **9:160**

LATENT PROPERTIES
Generally, **9:111**

LATE PAYMENT
Maintenance fees, **6:51**

LATER BROADER CLAIMS
Enablement, **1:78**

LATER DEVELOPMENTS
Double patenting, **20:92**
Skill, level of, **19:34**

LATER REFERENCE
Prior art reference relevant for all that it discloses, **9:117**

LATER SUBMISSION OF DATA
New interference rules, **8:3**

LATER SUBMISSION OF EVIDENCE
Good cause under 37 CFR Sec. 1.617(b) justifying, **8:35**

LAW-FACT QUESTION
Best mode, **3:31**
Claim construction, **13:78**

LAW FIRM
Disqualification of attorney, **5:12**

LAW OF OBVIOUSNESS
All-purpose criteria for applying, none, **9:99**

LAW OF THE CASE
Generally, **2:40; 3:8; 3:40; 19:57; 20:58**
Accounting phase, **11:15**
Appellate court need not explicate rationale for its ruling, **20:34**
Applicable, when, **8:56**
Applicable, when not, **12:59**
Better term than fraud, **19:14**
Cross-appeal, **7:28**
Damages, **20:23**
Evolving claim construction, **15:42**
Exceptions, **7:36; 13:61**
Finality, provides, **19:14**
Fraud, better term than, **19:14**
Inequitable conduct, **19:14**
Prima facie case, **20:114**
Reissuance, **1:276**
Sec. 102(b), **19:31**
Sec. 271(e)(1), **13:206**
Sec. 271(g), **13:206**
Special circumstances exception, **13:61**
Summary judgment, **2:29; 10:4**

LAW QUESTION
See also Fact Question; Fact-Law Question (this index)
Abandonment, **1:111**
Actual reduction to practice, **4:27**
All elements rule, **10:7**
Blonder-Tongue, **1:13**
CAFC jurisdiction, **20:2**
Claim construction, **1:50; 1:77; 4:23; 8:74; 13:45; 13:54; 13:78**
Claim differentiation, **11:2**
Claim identity, **9:90; 19:59**

LAW QUESTION—Cont'd
Claim interpretation, **2:52; 4:17; 5:22; 8:52; 9:131; 12:33; 13:29; 13:80; 16:40; 18:30; 19:56; 20:25; 23:16**
Claim preclusion, **2:159; 8:76**
Claims, scope of, **7:4**
Conception, **2:47; 2:96; 6:18; 6:20**
Contract construction and interpretation, **1:56; 1:57; 3:70; 4:41; 4:42; 8:33; 9:132; 9:145; 9:159; 11:29; 17:5; 23:36**
Count interpretation, **3:54; 4:31**
Court's jurisdiction, **19:66**
Declaratory judgment, **19:265**
Derivation vs. priority of invention, **16:36**
Double patenting, **9:134; 9:190**
Enablement, **1:80; 1:117; 1:127; 9:150; 9:154; 9:210; 16:47**
Identity, claim identity, **9:90**
Implied license, **3:56**
Indefiniteness, **9:328**
Infringement, **12:31; 13:64; 13:74**
Interference, **4:8**
Inventorship, **1:106; 3:83**
ITC, **13:20**
JNOV, **13:38; 22:4**
Jurisdiction, **16:43**
Jury, **1:14**
Means-plus-function claim, **11:47; 19:119**
Motion to compel discovery, **19:17**
Motion to dismiss, **2:54**
Obviousness
generally, **1:171; 7:46; 9:24; 9:172; 9:216; 10:15; 12:40; 14:2; 16:48; 18:23; 18:41; 19:36; 21:8; 22:1; 23:7**
determination, **2:141; 9:100**
double patenting, **9:134**
On-sale bar, **2:31; 7:71; 12:60**
Ownership, **11:33**
Personal jurisdiction, **8:69**
Priority, **3:53**
Procedural issue, **8:21**
Prosecution history estoppel, **13:63; 23:25**
Public use, **1:159; 2:57**
Reduction to practice, **2:96; 4:27; 5:34; 9:163; 19:70**
Reexamination, **20:43**

LAW QUESTION—Cont'd
Reissue, **9:188**
Repair, **4:1**
Res judicata, **21:29**
Sec. 145, **7:9**
Stare decisis, **13:53**
Statutory construction and interpretation, **1:74; 2:67; 4:40; 9:166; 9:200; 10:18; 13:49; 19:102**
Statutory terms, interpretation of, **9:120**
Stay pending clarification of law, **1:204**
Substantial evidence vs. clearly erroneous, **20:1**
Summary judgment, **1:35; 7:66; 20:10**
Undue experimentation, **5:45**
Validity, **14:8**

LEAHY-SMITH AMERICA INVENTS ACT
America Invents Act (this index)

LEAR
Generally, **6:45; 19:105**
Blonder-Tongue, **20:9**
Contract damages, breach of, **18:8**
Damages, breach of contract, **18:8**
Enforceability of settlement agreements when patent later held invalid, **8:11**

LEASE
Experimental use, **13:123**

LEGAL CONCLUSION
Definiteness, **1:118**
Indefiniteness, **9:253**
Printed publication, **3:101**

LEGAL TITLE
Standing to recover money damages, **1:46**

LEGISLATIVE HISTORY
Statutory construction, **7:35**

LEXICOGRAPHER
Generally, **2:81; 6:10; 9:254; 13:124**
Claim construction and interpretation, **1:132; 2:81; 9:254; 13:124; 26:1**
Dismissal, **3:19**
FRCP 52(a), **12:6**
Inventor as, **13:18**
Inventor as own, **14:20**
Ordinary meaning, **1:132**
Patentability standard, **13:18**

LEXICOGRAPHER—Cont'd
Patentee as own, **9:154; 10:13**
Summary judgment, **2:24; 10:13**

LICENSE AGREEMENT
Bona fide purchaser, **18:61**
Choice of forum clause, **23:2**
Contract law, **15:9**
Declaratory judgment, **7:79; 13:143; 19:192**
Defense, **6:102; 18:58**
ITC, litigation includes, **20:53**
Litigation includes ITC, **20:53**
On sale bar, **16:86**
Review, standard of, **19:104**
Sec. 1631, **19:2**
Subject matter jurisdiction, lack of, **1:7**
Third party making product, **3:70; 3:145**

LICENSE BACK
Assignor estoppel, **1:43**

LICENSE DEFENSE
Burden of proof, **3:56; 9:118**

LICENSES
Agreement. License Agreement (this index)
Antitrust violation, **7:25**
Assignment, **13:79; 13:87; 19:154**
Burden of proof, **19:48**
Co-inventors, **19:98**
Comparability to hypothetical license at issue in suit, **12:97**
Contempt, denial of, **16:23**
Continuation patent, **9:369**
Declaratory Judgments (this index)
Domestic industry requirement, **9:370**
Exclusive Licensee (this index)
FRCP 19, **9:71**
Implied License (this index)
Injunctions, **22:37**
International Trade Commission, **9:379**
Invalidity of patent, licensee, **13:132**
Irreparable harm, **8:46**
Jawboning at licensing negotiations, **19:61**
Labeling, licensee's manufacture with customer's labeling, **12:14**
Marking, **13:75**
Non-exclusive, **10:33**
Nunc pro tunc assignments, **13:87**

LICENSES—Cont'd
Patent misuse, **19:6**
Reasonable royalty rate, **19:38**
Review of decision on JNOV motion, **21:5**
Royalty as compulsory license, **16:106**
Sec. 262, **8:5**
Special master's decision, **13:24**
Standing, **9:301; 13:133; 13:157; 15:9; 16:64; 18:35; 19:174; 20:45**
Stay of patent action, **9:91**
Subject matter jurisdiction, lack of, **1:7**

LIFE AND MEANING
Claim preamble, **9:154; 22:41**

LIKELIHOOD OF SUCCESS
Generally, **18:32**
Preliminary injunctions, **1:169; 1:183**

LIMITATION OF ACTIONS
Administrative proceeding does not toll statute unless proceeding is mandatory prerequisite to suit, **13:62**
Claims court, **2:53; 3:55**
Equitable tolling thereof, **23:38**
Jurisdictional limitation versus, **8:44**
Limitations, jurisdictional limitation versus, **8:44**
Litigation misconduct, **9:284**
Relation back doctrine, **1:350**
Review, standard of, **12:46**
RICO, **1:47**
Sec. 286, **1:48; 19:27**

LIMITATIONS AND RESTRICTIONS
Generally, **1:80; 8:71**
Agency's authority limited by grant from congress, **11:26**
All claim limitations must be considered, **9:153**
Anticipation, **19:56**
Appealable interlocutory order, **22:2**
Appeal and review, **2:9; 7:2; 7:58; 9:59**
Certified appeal, **6:17**
Claim amendment, **13:27**
Claim Construction and Interpretation (this index)
Claim differentiation doctrine, **3:89; 9:370**
Claim preamble
generally, **1:119; 7:16**
life and meaning, **9:154; 22:41**

LIMITATIONS AND RESTRICTIONS —Cont'd
Claim preamble—Cont'd
reciting structural limitations, **1:198; 18:44**
series of limitations, **3:22**
Claim preclusion, **13:65**
Continuation-in-part applications, **16:112**
Damages for breach of contract limited to those reasonably foreseeable, **8:43**
Declaratory judgment, **10:6**
Description, **12:50**
Dismissal, **3:19**
Doctrine of Equivalents (this index)
"Each and every" limitation, **25:11**
Enforceability, **13:42**
Every claim limitation or substantial equivalent must be present, **23:35**
Extraneous claim limitation, **9:154**
FRAP 28(g), **12:22**
FRCP 59(e), **19:42; 19:58**
Implied license, **13:21**
Infringement, **23:40; 25:3**
Instructional limitation added to method, **11:64**
ITC, **8:28**
JNOV motion, denial of, **13:13**
Judicial review, **1:72**
Material, each claim limitation is, **12:28**
Materiality, **1:220**
Means-plus-function claim, **23:54**
Negative limitation, **9:412; 12:108**
Not raised below, **7:58**
Obviousness, **16:4**
Ordinary and accustomed meanings, terms given their, **12:33**
Patent claims, **14:79**
Patent Cooperation Treat (PCT), **8:70**
Post-trial motions, **18:3**
Present, not, **10:10**
Prior art, added to overcome, **11:22**
Prior art reference, **12:80**
Prosecution history, **21:9**
Prosecution history estoppel, **18:101; 19:115**
Reasonable royalty figures urged by parties, **19:53**
Reduction to practice, **3:82**
Reexamination, **9:194**

LIMITATIONS AND RESTRICTIONS —Cont'd
Reissue, **4:70; 22:15**
Sec. 112(6), **9:149; 22:10**
Sec. 121, **2:140; 7:16; 16:112**
Sec. 141-145, **9:59**
Sec. 171, **9:73**
Sec. 271(e)(1), **5:3**
Sec. 1491, **20:16**
Sec. 1821(b), **1:62**
Specification, limitation not required by, **9:118**
State immunity from suit under Eleventh Amendment, **10:11**
Statutory construction, **20:31**
Structural equivalency, **9:96**
Summary judgment, **20:13**
Validity, **4:68**
Written description, **9:412**

LIMITED EXCLUSION ORDER
ITC, **11:60**

LINGUISTICS
Motion, **9:233**

LINKING CLAIM
Reissue, **4:70**

LIQUIDATED DAMAGES
Challenges, **4:46**

LITERAL CLAIM SCOPE
Prosecution history estoppel, **2:77; 23:54**

LITERAL INFRINGEMENT
Claim construction, **2:139; 26:1**
Claim does not read exactly on accused device, **14:14**
Clearly erroneous standard, **19:23**
Exact corresponding, **12:33**
Fact question, **12:1**
Function not relevant to, **20:39**
Inventor's theory, **6:10**
Nonobvious, no requirement that accused device be, **2:49**
Summary judgment, **2:22; 20:13**
Willful infringement, **23:50**

LITERALLY MET
Doctrine of equivalents, **7:51**

LITERAL SCOPE
Doctrine of equivalents, **5:6**
Prosecution history estoppel, **13:95**

LITERATURE OF THE ART
Relative terms in claims given broadest reasonable interpretation during prosecution, **9:36**

LITIGATION MISCONDUCT
Bad faith behavior, **13:167; 18:29**
Exceptional case, **5:63; 13:197; 17:9; 18:64**
Inequitable conduct, **1:112; 1:180; 8:98**
Jurisdiction, **1:160**
Review, standard of, **1:112**
Sanctions, **1:193; 2:121; 13:85**
Statute of limitations, **9:284**

LIVING THINGS
Statutory subject matter, **16:63**

LKQ CORPORATION V. GM GLOBAL TECHNOLOGY OPERATIONS LLC
2024, **12:124**

LOCAL RULE
Generally, **15:23**
Attorneys' fees, costs, **1:260**
Patent-ineligibility defense, **13:217**
Privilege, **4:47**

LONG DELAY IN FILING
Interference, **16:9**

LONG-FELT NEED
Generally, **5:5; 20:29**
Burden on patent challenger, **16:12**
CCPA decisions, **9:74**
Obviousness, **21:8**
Review, standard of, **19:12**

LOST COUNT
Interference, **9:88**

LOST PROFITS
Generally, **7:88; 10:34; 13:223**
Acceptable noninfringing substitutes, **13:45**
Accounting phase, **11:15**
Anticipated profits, **13:131**
But for test, **5:54; 6:36; 7:47; 8:51; 11:32; 13:121; 16:40; 16:161; 18:35; 20:52**

LOST PROFITS—Cont'd
Causal relation must be shown, **5:71**
Causation, **3:96; 13:79; 15:10**
Convoyed sales, **1:174**
Damages, **1:20; 1:59; 2:19; 2:40; 3:8; 7:15; 7:63; 13:145; 13:157; 16:5; 16:135; 18:2; 19:52; 20:23; 23:3; 23:82**
Factual findings to support jury verdict presumed, **2:15**
Future lost profits, **19:137**
Infringement, **13:45; 26:4**
Issue preclusion, **4:9**
Market niche, **13:8**
Market share, **3:62; 21:18**
Obviousness, **18:23**
Panduit, **3:2; 11:28; 16:40; 19:56**
Price erosion, **2:34**
Reasonable royalty, **1:308; 23:81; 23:99**
Sec. 271(f), **23:82**
Sec. 284, **2:31**
Sec. 1498, **13:35**
Speculative, **21:35**
Standing, **23:82**
Subject matter jurisdiction, **25:1**
Substitutes, **13:45**
Two-supplier market, **6:26**

LOST SALES
Sears, **21:11**

LUMP SUM ROYALTY PAYMENT
Damages, **9:235**

LUV N' CARE, LTD. V. LAURAIN
2024, **12:125**

MACHINE
Damages, **16:5**
Definition, **9:290**
Means-plus-function claims, **19:112**
Prima facie obviousness, **9:17**
Sec. 101, **19:112**

MACHINE-OR-TRANSFORMATION TEST
Sec. 101, **3:164; 9:308; 16:123; 21:62**

MAGEMA TECHNOLOGY LLC V. PHILLIPS 66
2025, **13:264**

MAGNOLIA MEDICAL TECHNOLOGIES, INC. V. KURIN, INC.
2026, **13:271**

MAIL DELIVERY
Judicial notice, **11:24**

MAINTENANCE FEES
Delay
generally, **9:470**
unavoidable, **18:33**
Failure to pay, **2:131**
Inequitable conduct, **14:70; 21:40**
Late payment, **6:51**
Payment, late, **6:51**
Reinstatement of lapsed patent, **3:38**
Sec. 285, **9:470**
Small entity, **21:40**

MALPRACTICE
Generally, **14:76**
Alternative claim language disregarded, **13:184**
Negligence, **21:60**
Personal jurisdiction, filing patent application, **20:94**
State law claims, **12:96; 13:180; 21:60**
Subject matter jurisdiction, patent law issues, **23:71**

MALVERN PANALYTICAL INC. V. TA INSTRUMENTS-WATERS LLC
2023, **13:254**

MANDAMUS
Generally, **9:6; 9:229; 9:515**
Abandoned application, changing filing date on, **9:54**
Antitrust and patent claims separated for trial, **9:41**
Appealability, **2:2**
Appeal and review, **9:41; 9:63**
Attorney-client privilege, **9:184; 9:293**
Attorney fees award, **9:68**
Attorney misconduct, **9:57**
Attorneys, counsel misconduct, **9:57**
Burden, **9:193**
Business damage, suit for, **9:76**
CAFC jurisdiction, **9:54; 9:63**
Changing filing date on abandoned application, **9:54**
Clearly erroneous finding, **9:57**

MANDAMUS—Cont'd
Commissioner's decision, **9:54**
Consolidation, **19:284**
Custom, **9:57**
Damages, **9:76**
Discovery orders, review, **9:362; 9:430**
Discretionary exercise, **6:19; 9:430**
Dismiss or transfer infringement suit, **9:432**
Disregard law or ignore statute, courts not at liberty to, **9:57**
District court jurisdiction, **9:41**
Drastic remedy, **9:170; 9:180**
Evidence, same, **9:41**
Exceptional circumstances standard, **1:302; 9:63**
Exclusive jurisdiction, **9:63**
Filing date, **9:54**
FRCP 21, **9:359**
FRCP 42(b), **9:41**
Frivolity, **9:68**
Ignore statute or disregard law, courts not at liberty to, **9:57**
Inter partes review, **9:385; 9:469**
Jurisdiction, **9:41; 9:54; 9:63; 9:292; 23:92**
Mandate, **9:388**
Patent prosecution bar, **4:94**
Petitions, **2:2; 9:54**
Privilege, attorney-client privilege, **9:184**
Remand to state court, **9:68**
Remedial sanction, **9:57**
Review, standard of, **9:128**
Same evidence, **9:41**
Sanction, remedial sanction, **9:57**
Sec. 1651, **2:2; 9:41; 9:54; 9:68; 9:71; 9:76**
Sec. 1782, **9:406**
Separated for trial, antitrust and patent claims, **9:41**
Severance, **9:359**
Standing, **9:313**
State courts, **9:68; 9:76**
Strong medicine, **9:11**
Subject-matter jurisdiction, **9:68**
Threats to sue, **9:76**
Transfer venue, **9:76; 9:336; 14:60; 26:14**
Two juries, prohibition against, **9:41**

MANDAMUS—Cont'd
Untimely appeal, **3:5**
Venue, **9:445; 9:447; 9:457; 9:462; 9:472; 9:480; 9:490; 9:493; 9:498.50; 9:515**
Waiver, **9:447**
Writ, generally, **3:85**
Writ of mandamus, compelling production, **9:429; 9:490**

MANDATE
Appeal and review, **12:47**
Damages, **18:105**
Mandamus, **9:388**

MANDATORY STATUTES
Statutory construction, **5:17**

MANIFEST INJUSTICE
Attorney fees, **14:58**

MANIFEST OR CLEAR ERROR
Appellate role, **4:6**

MANUAL OF PATENT EXAMINING PROCEDURE (MPEP)
Admission or acquiescence in rejection, **16:6**
Anticipation, foreign publication, **16:6**
Binding force, none, **19:46**
CAFC, **9:10**
CIP, filing, **16:6**
Commercially available, **16:6**
Describes procedures on which public can rely, **16:8**
Devices, published, **16:6**
Disclosure, **16:6**
Filing CIP, **16:6**
Force of law, **18:1**
Foreign publication, efficacy as anticipation, **16:6**
Judicial notice, **9:374**
Publication, **16:6**
Published devices, **16:6**
Rejection, **16:6**
Reliance, **16:6**
Sec. 706, **9:114**
Sec. 711.01, **5:57**
Sec. 714.19, **5:57**
Sec. 717.05, **2:103**
Sec. 1302.10, **13:100**
Sec. 2001.06(a), **12:61**
Sec. 2152, **9:110**

MANUAL OF PATENT EXAMINING PROCEDURE (MPEP)—Cont'd
Sec. 2217, **17:2**
Standing to sue, **19:46**

MANUFACTURE
Definition, **9:290**
Infringement, **10:23**
Intervening rights, **13:168**
Jury verdict, **19:5**
Patent license, **12:14**
Reasonable royalty, **8:51**

MAQUET CARDIOVASCULAR LLC V. ABIOMED INC.
2025, **13:265**

MARKET DEMAND
Consumer behavior, **19:6**

MARKETING
Attorney, opinion of counsel, **3:72**

MARKET NICHE
Lost profits, **13:8**

MARKET POWER
Generally, **9:282**
Antitrust, **9:219; 13:133**

MARKET RATE
Attorney fees award, **16:24**

MARKET SHARE
Lost profits, **3:62; 14:9; 21:18**

MARKET SUCCESS
Ultimate recognition, **9:90**

MARKET VALUE
Anticipated collateral sales vs. reasonable royalty rate, **18:35**
Patented feature is reason for demand, **20:50**

MARKING
Generally, **16:178**
Apparatus and method claims, **3:146**
Briefs, confidentiality markings, **9:337**
Civil penalty, false marking, **6:72**
Claim construction, **18:118**
Claim interpretation, **19:15**
Constructive notice of infringement, **6:78**
Damages, **4:89; 14:24; 18:2**
Estoppel, **6:86**

MARKING—Cont'd
Fact question, **7:66**
Indications and usage, **2:152**
Licensees, **13:75**
Method claims, **3:146; 3:148**
No products to mark, **20:64**
Patent license, **12:14**
Rationale, **12:58**
Sec. 284, **14:24**
Sec. 287, **4:12; 8:4; 13:33**
Sec. 289, **14:24**
Sec. 292, **12:23**
Typographical error, manifestly obvious, **1:119**
Writ of mandamus, **9:329**

MARKUSH CLAIM
Claim construction, **13:218; 19:299**
Closed group, **1:122; 1:356**
Consisting, **7:85**
Co-pendency requirement, **9:105**
Defined, **13:218**
Infringement, **1:155**
Sec. 121, not proper under, **9:105**

MASK WORKS
SCPA, **2:34**

MASS PRODUCTION
Sec. 112(1), **23:19**

MASTER
Generally, **19:38**
Complex cases, **19:37**
Damages, **20:19**
Reliance upon his prior experience, **19:65**
Special Master (this index)

MATERIAL FACT
Executive Order 10096, **8:10**
Review, standard of, **19:120**
Summary judgment
generally, **3:81; 6:26**
absence of disputed issue of, **12:10**
disputed questions of, **5:36**
genuine issue, **1:103**
initial burden to show, **22:18**

MATERIALITY
Generally, **2:113; 6:60; 9:283; 15:24**
CFR 1.56(a), **9:43**
Cumulative reference, **19:59**

MATERIALITY—Cont'd
Design patent, **16:1**
Each claim limitation, **12:28**
Examiner, **12:43; 23:5**
FRCP 12(f), **4:13**
High degree of confidence and trust between PTO and patent applicants, **10:5**
Inequitable conduct
generally, **1:3; 1:10; 1:257; 1:261; 2:85; 7:1; 12:56; 13:80; 13:102; 13:141; 14:8; 19:122; 21:26**
but-for materiality, **20:106**
every material omission requires less evidence to show intent, **2:68**
intent, balancing, **6:5; 19:208**
intent as essential element even when materially false affidavit involved, **7:34**
misstatement, **12:93**
omission, **4:84; 12:93; 16:112**
per se materiality rule, none, **12:20**
reference, **6:80**
requirement, **20:35**
withheld art less material than cited prior art, **8:29**
Intent, **12:30; 12:43; 14:19**
Jury, **1:14**
Limitations, **1:220**
Post- and pre-critical date claims, **1:220**
Process Patent Amendment Act (PPAA), **2:60; 5:23**
Prosecuting similar claims in separate patent, **4:72**
PTO Rule 56, **13:158**
Reasonable examiner, **2:103; 12:43; 13:69**
Reference, **15:33; 19:59**
Relevant, less, **2:68**
Sec. 102(b), **13:35**
Sec. 102(g), **11:9**
Separate patent, **4:72**
Summary judgment, **3:13**
Surprising discovery, **16:105**
Unclean hands doctrine, **18:40**

MATHEMATICAL ALGORITHM
Generally, **1:95**
Definition, **9:42**
Means-plus-function claim, **1:176; 9:42**

MATHEMATICAL ALGORITHM —Cont'd
Performing function, does not cover all means for, **9:42**
Printed matter and substrate, **9:32**
Sec. 101, **1:290; 9:308**

MATTER OF LAW
Generally, **5:50**
Doctrine of equivalents, **5:44**
FRCP 50, **7:27**
Obviousness conclusion, **9:15**

MAXELL, LTD. V. AMPEREX TECHNOLOGY LIMITED
2024, **13:260**

MAXIM
Expressio unius, **4:30**

MAXIMUM RECOVERY RULE
Damages, **19:137**
Remittitur, **21:23**

MCOM IP, LLC V. CITY NATIONAL BANK OF FLORIDA
2026, **13:272**

MEANING
About claim terminology, **5:20**
Accustomed meaning. Ordinary and Accustomed Meaning (this index)
Claim Construction and Interpretation (this index)
Claim preamble, **9:154; 16:20; 22:41**
Contract Construction and Interpretation (this index)
Doctrine of equivalents, **3:51**
FRAP 38, **16:4**
FRCP 52(a), **12:6**
Jury instructions, **19:156**
Ordinary and Accustomed Meaning (this index)
Prosecution history, **8:74**
Statutory Construction (this index)
Words (this index)

MEANINGFULNESS
Claim interpretation, nonsensical result, **3:113**

MEANS-PLUS-FUNCTION
Generally, **1:130; 3:123; 4:120; 4:131; 5:32; 5:129; 5:148; 6:55; 7:83; 9:118; 13:239; 14:43; 16:94; 19:300; 20:81; 20:157.90; 22:30**
Accused device must perform identical function, **11:32**
Act, versus, **19:100**
Adequate disclosure, **1:99**
Adequate structure, **2:83**
All functions must be performed, **12:3**
Claim, generally, **3:176; 5:118; 13:221; 18:17**
Claim construction, **3:166; 5:110; 6:81; 9:199; 13:239; 16:138; 20:56; 20:149; 23:79**
Claim differentiation, **18:17; 23:54**
Claim language
express means-plus-function language, **2:137**
improper to narrow function beyond, **3:97**
Clearly erroneous standard, **19:23**
Clearly link structure with function, **13:118**
Combination, **3:89**
Component by component equivalence improper, **15:14**
Computer, general purpose, **1:176; 6:68; 20:116**
Continuation application with narrower claims, **4:51**
Contours of corresponding structure is law question, **19:119**
Corresponding function, **10:36; 18:48**
Corresponding structure, **1:114; 2:61; 2:123; 7:70; 11:42; 14:56; 19:119; 19:238**
Court must state burden of persuasion and quantum of proof required, **18:7**
Cross-appeal to reverse validity or infringement component of judgment, **18:2**
Definite structure, **6:36**
Determining meaning of means, **13:87**
Disavowal of claim scope, **3:140**
Disclosure, **2:134; 4:17**
Doctrine of equivalents versus, **1:125; 4:50; 9:215; 11:48**
Enablement, **5:124**
Equivalent structure, **9:96; 21:44**
Evidence, standard of proof, **3:83**
Extend to all means, does not, **10:28**

MEANS-PLUS-FUNCTION—Cont'd
First identify claimed function, **12:62; 13:100**
FRCP 51, **12:106**
Functional limitation, import, **23:54**
Function different from claim, improper to adopt, **3:102**
Identical function, **11:32**
Identify function, **1:125; 7:67; 7:79; 12:66**
Import functional limitations, **23:54**
Inconsistent construction, **20:56**
Indefiniteness, **5:112; 9:330; 13:200; 18:107; 18:129; 26:15**
Infringement, **1:289; 3:46**
Injunction, **20:149**
Inventorship, **23:55**
Invocation, **3:66**
Invoked, when, **25:3**
JNOV, **4:4**
Law question, **11:47; 19:119**
Limitation, functional, **11:66; 23:54**
Link structure in specification to recited function, **20:64**
Machine claims, **19:112**
Mathematical algorithm, **1:176; 9:42**
Means, generally, **19:116**
"Means" absent from claim, **16:138**
Means for generally invokes, **15:12; 21:28; 22:17**
Mechanism, **23:63**
Multiple claim interpretation, may include, **9:225**
Patentability, **4:97**
Performance, **12:3; 12:26**
Pioneer invention, **20:6**
Plain meaning of claim, **2:31**
Presumption with means, **1:134; 3:91; 5:51; 13:96; 18:107; 19:97; 23:51**
Prior art, **6:75**
"Program loading device," **18:107**
"Program recognition device," **18:107**
Proof, standard of, **3:83**
Prosecution history, **4:51**
Prosecution history estoppel, **3:84**
PTO, construed same way in PTO as in litigation, **9:199**
Review, standard of, **14:38**
Review function and structure, **22:26**
Scope, **3:78; 7:42; 13:84; 13:91**

MEANS-PLUS-FUNCTION—Cont'd
Sec. 101, **5:129**
Sec. 112, **2:123; 16:11; 20:6; 23:63**
Sec. 112(6), **1:51; 3:37; 9:130; 9:131; 9:149; 10:7; 10:13; 14:56; 18:107; 19:59; 22:10**
Secondary considerations, **13:17**
Specification, **6:36; 13:182; 20:64**
Statements during prosecution related to structure, **1:77**
Steps without function, **5:63**
Structural analysis, **6:75**
Structural equivalency, **9:96**
Structural support absent, **5:114**
Structure, **6:73; 7:70; 12:26; 22:26**
Structure performing function, **20:91**
Test, **23:50**
Two patents, **2:77**
Two-step analysis, **3:88**
Two-step approach, **15:21**
Use of means, **12:69; 16:51**
Whereby clause, **12:62**
Willful infringement, **18:17**
Written description, **1:262**

MEANS WITHOUT SUBSTANTIVE CHANGE
Identical claims, **12:25**

MEASUREMENT OF PHYSICAL PROPERTY
Patentability, **9:247**

MECHANICAL CONCEPTS
Judicial notice, **9:127**

MECHANICAL MISFIT
Sec. 103, **15:4**

MECHANISM
Means-plus-function, **23:63**

MEDICAL DEVICES
Sec. 271(e)(1), **5:13; 16:117**

MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, AND MODERNIZATION ACT
Case or controversy, **20:78**

MEDICINAL DRUG
Chemical, **9:60**

MEDTRONIC, INC. V. TELEFLEX INNOVATIONS S.A.R.L.
2023, **13:255; 13:256**

MEDTRONIC, INC. V. TELEFLEX LIFE SCIENCES LIMITED
2023, **13:257**

MEDYTOX, INC. V. GALDERMA S.A.
2023, **13:258**

MEETING OF THE MINDS
Generally, **23:21**

MEMORANDUM DECISION
Timeliness of appeal filing, **2:5**

MENTAL PROCESSES
Sec. 101 patentability. Abstract (this index)

MENTION, FAILURE TO
Inequitable conduct, **6:4**

MERCK SERONO S.A. V. HOPEWELL PHARMA VENTURES, INC.
2025, **13:266**

MERCK SHARP & DOHME B.V. V. AUROBINDO PHARMA USA, INC.
2025, **13:267**

MERE DENIAL
Intent to mislead, **19:128**

MERE DISSEMINATION
Generally, **13:52**

MERE KNOWLEDGE
Inequitable conduct, **13:101**

MERE PROCEDURAL DEVICE
Presumption of validity, **13:53**

MERGED FIRMS
Disqualification of counsel, **16:18**

MERIT SYSTEM
Review, standard of, **8:48**
Standard of review thereof, **4:39**

METAPHYSICAL DOUBT, MORE THAN
Summary judgment, **10:32**

METHOD
Certainty and definiteness, **9:280**
Claim interpretation, **9:280**
Damages, **19:154**
FDA use code, patented method of use, **14:68**
Indefiniteness, **9:280**
Instructional limitation added, **11:64**
Kuehl, **9:103**
On-sale bar, sec. 102(b), **4:16; 13:212**
Sec. 102(b) on-sale bar, **4:16; 13:212**
Sec. 287(a), **3:96**
Summary judgment, **21:7**

METHOD AND APPARATUS CLAIM
Claim construction, **8:123; 9:280**

METHOD CLAIMS
Claim construction, method and apparatus claim, **8:123**
Computer-facilitated processes, **6:71**
Construction, **13:195**
ordinarily construed an order, **9:223**
Direct infringement, performance of all steps, **1:222**
Durden, **9:98**
Government liability, **26:10**
Implied, order not implied, **9:234**
Infringement, **5:121; 13:53; 13:186**
JMOL, **13:195**
Joint infringement, **13:159; 13:160**
Make requirement, **7:99**
Marking, **3:146; 3:148**
Order not implied, **9:234**
Ordinarily construed an order, **9:223**
Sec. 271(a), **1:269**

METHODOLOGY
Damages, **1:105; 11:10; 12:90; 13:75**

MICROBIOLOGY FIELD
Deposit of cell sample line not required at time of filing, **9:53**

MICRON TECHNOLOGY, INC. V. LONGHORN IP LLC
2025, **13:268**

MILITARY AND STATE SECRETS PRIVILEGE
Generally, **3:122**

MILLER MENDEL, INC. V. CITY OF ANNA, TEXAS
2024, **13:261**

MINDS, MEETING OF
Generally, **23:21**

MINERVA SURGICAL, INC. V. HOLOGIC, INC.
2023, **13:259**

MINIMUM CONTACTS
Cease and desist letters, **18:45**
Personal jurisdiction, **1:70; 1:181; 5:67; 6:150; 20:94**

MINOR DIFFERENCES
Infringement, **16:33**

MINOR IMPROVEMENT
Surprising results, **9:118**

MINORITY
Claim interpretation, **5:71**

MIRROR WORLDS TECHNOLOGIES, LLC V. META PLATFORMS, INC.
2024, **13:262**

MISLEAD, INTENT TO
Generally, **13:80**
Disclosure, duty of, **14:19**
Materiality, **12:30**

MISLEADING CONDUCT
Equitable estoppel, **19:108**

MISREPRESENTATION
Conduct of counsel, **16:9**
Court's prior ruling, **19:57**
Exceptional case, **8:122**
Inequitable conduct, **8:85**
Intent to deceive, **6:28**
Prior art search, **7:29**

MISTAKE
Generally. Error (this index)

MISTAKE AT TRIAL
Jury verdict, **4:18**

MISTAKE OF FACT
Contract rescission, **4:34**

MISUSE OF PATENT
Patent Misuse (this index)

MITEK SYSTEMS, INC. V. UNITED SERVICES AUTOMOBILE ASSOCIATION
2025, **13:269**

MIXED QUESTION
Best mode, **3:31**
Claim construction, **13:78**
Infringement, **19:19**

MOBILE ACUITY LTD. V. BLIPPAR LTD.
2024, **13:263**

MODIFICATION
Combination, **9:51**
Damages, **1:20**
FRCP 60(b), **23:23**
FRCP 60(b)(6), **3:29**
Incentive, **9:51**
ITC, **3:73**
Obviousness, **9:51**
Prior art, **9:51**
References, **3:3; 9:51**
Secondary considerations, **9:82**
Summary judgment, **3:20**

MONDIS TECHNOLOGY LTD. V. LG ELECTRONICS INC.
2025, **13:270**

MONETARY DAMAGES
Harm to reputation, **18:32**
Preliminary injunction, **1:34**

MONETARY SANCTIONS
Abuse of discovery process, **13:6**
Discovery, abuse of discovery process, **13:6**

MONOPOLY
Antitrust, **7:73**
Double patenting, **9:45**
Power, **9:214**

MOOTNESS
Generally, **16:43**
Altvater, **13:46; 22:4**
Burden, **8:155**
Dismissal of complaint, **19:14; 19:200**
Equivalence, **5:7**
FRCP 59(e), **19:42**
Infringement, **9:118; 11:23; 25:9; 25:10**
ITC, **20:6**

MOOTNESS—Cont'd
Partial settlement, **7:8**
Possibility of, **13:41**
Post-filing events, effect of, **19:55**
Post-trial settlement of infringement issues, **11:23**
Settlement, **1:237**
Standing, **13:226**
Test thereof, **8:54; 14:16**
Vacation of judgment, **20:95**
Validity, **1:113**

MORE PERTINENT ART
Dismissal, **3:19**
Presumption of validity, **12:9**

MOTION IN LIMINE
FRCP 54(b), **21:41**
Precluding testimony on issue not raised before the Board, **7:26**

MOTIONS
Abuse of discretion, **19:17**
Add counts or parties, **3:43**
Amend pleadings, **3:24; 7:33; 19:6**
Amicus curiae, **9:67**
Choice of law, **20:17**
Claim interpretation, **8:84**
Confidential information, **19:17**
Conflict of laws, **19:45; 19:165**
Contempt, **11:17**
Default judgment, relief from, **9:144**
Denial, when appropriate, **7:33**
Directed verdict, **1:1; 4:32; 19:41**
Discovery, compel, **19:17**
Dismiss
generally, **7:36; 8:44**
FRCP 12(b)(6), **1:54; 1:248; 1:343**
FRCP 19(a), **22:8**
Question of law, **2:54**
Section 101, **1:343**
state a claim, failure to, **2:41**
state claim, failure to, FRCP 12(b)(6), **8:102; 19:237; 23:29**
subject matter jurisdiction, lack of, **1:7**
Dispositive motions with no material facts challenged, **8:10**
Disqualify trial judge, **8:12**
Dissolve, **16:7**
Employee's general knowledge, **19:45**
Execute on bond, **2:30**

MOTIONS—Cont'd
Executive Order 10096, **8:10**
Findings, **12:11**
FRCP 12(b)(6), **2:41; 8:102; 19:237; 23:29**
FRCP 15, **3:24**
FRCP 24, **3:38**
FRCP 24(b), **8:36**
FRCP 41(a)(1), **5:18**
FRCP 41(b), **12:11; 19:31**
FRCP 50, **7:27; 12:11**
FRCP 50(b), **2:33; 13:54**
FRCP 59(e), **10:14**
FRCP 60(b), **2:43; 6:22; 9:144**
FRCP 60(b)(6), **3:29**
FRCP 65.1, **2:30**
Inequitable conduct, **19:17**
Infringement, **12:36**
Interference, **13:3; 16:7**
Intervene, **1:68; 3:38; 8:36; 9:67**
JMOL, **1:101; 7:27; 13:54; 13:194**
Joint motion to vacate judgments below, **21:22**
Judgment, **2:33**
Judgment Notwithstanding Verdict (JNOV) (this index)
Jury, **9:125**
Jury verdict, **4:18**
Knowledge, trade secret in combination of known components, **19:45**
Law question, **19:17**
Limitation of review, **13:13; 18:3**
Linguistic, substance not linguistic form, **9:233**
Modify consent judgment, **3:29**
New Trial (this index)
Particularity, failing in, **18:25**
Pendency, **12:36**
Pending, **19:45**
Petition for rehearing pending, **19:45**
Prejudgment interest, **10:14**
Preliminary motions, **7:26**
Publish CAFC decision, **9:1**
Quash discovery subpoena, **20:17**
Rehearing, **19:45**
Reissue proceeding, **12:36**
Remand, **9:38; 19:45**
Review, standard of, **9:186; 19:60**
Sec. 102(b), **19:31**
Sec. 455(a), **8:12**

MOTIONS—Cont'd
Set aside judgment, **2:43; 6:22**
Settlement agreement, **21:22**
Stay, **11:1; 12:36**
Strike, **6:10**
Substance not linguistic form, **9:233; 19:86**
Summary judgment, **5:48; 9:215; 10:4; 13:82; 23:16**
Supplement record, **23:26**
Timeliness, **9:38; 16:37; 19:45**
Trade secret in combination of known components, **19:45**
Vacate, **16:19**
Voluntary dismissal when neither answer nor summary judgment motion filed, **5:18**
Waiver, **7:26; 10:15**

MOTIVATION
Generally, **9:114; 9:428**
Obviousness (this index)

MOT PERTINENT ART
Prior art, noting differences from, **4:6**

MOVABLE
Construction of term, **9:338**

MPEP
Manual of Patent Examining Procedure (MPEP) (this index)

MULTI-COMPONENT PRODUCTS
Damages, **22:47**

MULTIPLE APPLICATIONS
Claim construction and interpretation, **14:47**

MULTIPLE CLAIM INTERPRETATION
Means-plus-function claim, **9:225**

MULTIPLE DEFINITIONS OF PHRASE
Claim construction, **7:28**

MULTIPLE DICTIONARY DEFINITIONS
Claim interpretation, **9:253**

MULTIPLE EMBODIMENTS
Claim construction and interpretation, **22:30**

"MURDERING Y, X ON TRIAL FOR"
Specious argument, **18:24**

MUTUAL MISTAKE
Contract, **2:44**
Contract rescission, **4:34**

NARROW CLAIM CONSTRUCTION
Prejudicial error, **14:2**

NARROW CLAIMS
Implications, **13:39**
Manual of Patent Examining Procedure (MPEP) § 706, **9:114**

NARROW EXCEPTION
Experimental use, **5:50**

NARROWING AMENDMENT
Claim interpretation, **8:80; 12:83; 19:210**
Prosecution history estoppel, **2:128; 6:70; 7:69; 18:77**

NATERA, INC. V. NEOGENOMICS LABORATORIES, INC.
2024, **14:111**

NATURAL LAW
Generally, **1:355**

NDA
New Drug Application (this index)

NEGLIGENCE
Exceptional case, **18:9**
Inequitable conduct, **6:4; 14:8**
Intent to deceive, **19:59**
Malpractice, **21:60**

NEGOTIATIONS
Damages, **12:90; 12:97; 16:129; 20:23**
Jawboning at licensing, **19:61**
Refusal to engage in settlement negotiations, **15:37**
Settlement negotiation privilege, **9:362**

NETFLIX, INC. V. DIVX, LLC
2023, **14:109; 14:110**
2026, **14:113**

NEW ARGUMENT
Appeal, frivolous appeal, **13:46**
Frivolous appeal, **13:46**

NEW ART
Constitutionality, **16:8**

NEW BENEFIT OF OLD PRODUCT
Generally, **8:57**

NEW COMPOSITION
Prima facie obviousness, **9:17**

NEW CONSTRUCTION
JMOL, **8:84**

NEW COUNSEL
Reissue, **9:84**

NEW DRUG APPLICATION
Generally, **13:107; 14:33**
Abbreviated New Drug Application (ANDA) (this index)
CAPC, **3:132**

NEW EVIDENCE
Clearly erroneous, **6:9**
Rule 202, **9:288**
Sec. 145, **7:9; 8:118; 11:68**

NEW FACTUAL SITUATION
Squeezing into preestablished pigeonholes, **9:99**

NEW FEATURES
Accused machine's commercial success, **23:7**

NEW GROUND
Rejection, **9:15; 9:22; 9:37; 9:127; 9:372**

NEW INTERFERENCE RULES
Generally, **8:35**
Corroboration, **8:3**
Exhibit must be discussed, **8:3**
Good cause standard, **8:3**
Later submission of data, **8:3**
Prima facie showing, **8:3**
Reduction to practice, **8:3**
Right to make count, **3:53**
Sec. 1.671, **8:3**
Submissions, **8:3**
37 CFR Sec. 1.608, **8:3**
37 CFR Sec. 1.609, **8:3**
37 CFR Sec. 1.617, **8:3**

NEW ISSUE RAISED
PTO motion to remand, **9:130**

NEW JUDGMENT
Sec. 271(e)(1), **5:13**

NEW LEGAL TEST
Essential element test, **3:101**

NEWLY ADDED MATTER
CIP, **19:28**

NEWLY DISCOVERED EVIDENCE
Generally, **1:101**
New trial, **22:26**

NEWLY DISCOVERED PRIOR ART
Enhanced damages, **21:3**

NEWLY FOUND SEEDINGS
Plant patents, **9:355**

NEW MATTER
Generally, **19:121**
Sec. 132, **2:34**

NEW PRACTICE
Interference, **16:16**

NEW PRIOR ART
As whole, prior art as whole, **5:11**
Burden of proof more easily carried, **5:11**
Foreign references not well known, **5:11**
Operation of inventor's brain, **5:11**
Presumption of validity, **18:10**
Prior art as whole, **5:11**
Reference, **5:11**
Relevance, **5:11**
Secondary considerations, **5:11**

NEW PROPERTY
Claim construction, **5:2**
Discovery, **9:129**
Patentable, **9:104**

NEW QUESTION
Inter partes reexamination, substantial new question of patentability, **2:150**
Reexamination, **9:183; 9:314**

NEW RESULT
ITC, **1:17**

NEW RULES
Interference. New Interference Rules (this index)

NEW TRIAL
Generally, **3:123; 3:205; 18:14; 19:126; 19:156**

NEW TRIAL—Cont'd
Choice of law, **5:56; 5:65; 13:101; 19:126**
Claim interpretation, **19:16**
Conflict of laws, motion for new trial, **19:165**
Discovery, newly discovered evidence, **22:26**
District court has wide discretion, **13:34**
Evidence, newly discovered, **22:26**
Grounds thereof, **21:27**
Infringement, **8:51**
JNOV, **4:4; 13:4; 23:4**
Jury instruction, **5:60**
Jury verdict, **3:17; 4:18**
Motion
generally, **21:39**
abuse of discretion, reviewed for abuse of discretion, **23:10**
choice of law, **5:56; 5:65**
claim interpretation, **19:16**
fact question, **23:10**
infringement, **23:10**
reviewed for abuse of discretion, **23:10**
willful infringement, **16:22**
Newly discovered evidence, **22:26**
New trial, timely motion for new trial, **18:25**
Retrial of infringement not necessarily validity, **8:51**
Review, standard of, **2:99; 5:54; 13:85; 14:25; 16:87; 19:60**
Timeliness for JNOV, **19:16**
Timely motion for new trial, **19:165**
Validity, **8:51**
Willful infringement, **3:26; 16:22**

NEW UNAPPRECIATED PROPERTY OF PRIOR ART
Patentable subject matter, **5:56**

NEW USE
Generally, **9:201**
Discovery, **9:129**
Patentable subject matter, **2:82**
Prior art article, **9:48**

NEXSTEP, INC. V. COMCAST CABLE COMMUNICATIONS, LLC
2024, **14:112**

NEXUS
Burden on patent challenger, **16:12**
Claims construed, **9:77**
Commercial success, **2:76; 9:168; 18:28**
Objective evidence of nonobviousness, **1:292; 12:43; 18:53**
Obviousness, **1:292; 14:90; 18:15; 18:99**
Prejudice, **8:32**
Secondary considerations, **9:168; 9:331; 16:49; 19:36**
Summary judgment, **3:1**

9 CIR
Generally, **16:21; 19:6**
Appeal, scope of, **19:51**
Dismissal of pendent state law claim for unfair competition, **22:2**
Inconsistent verdicts, **18:14**
Summary judgment, **3:1**
Timeliness of appeal filing, **2:5**
Verdicts, inconsistent, **18:14**

9 USC § 3
Arbitration, **18:13**

1952 PATENT ACT
Doctrine of equivalents, **23:42**

NOERR
Generally, **9:219; 14:21**
Antitrust claim, **3:46; 20:127**
Exception to, **6:27**

NOMINAL DAMAGES
Sec. 284, **12:24**

NONANALOGOUS ART
Reference, **9:16**

NONASSERTED CLAIMS
JNOV motion, **6:6**

NON-EXCLUSIVE LICENSES
Generally, **10:33**

NON-PARTIES
Appeal, standing to appeal, none, **19:48**
Corroboration, **20:48**
Injunction, **1:75**
Issue preclusion, **9:296**
Motion to quash discovery subpoena, **20:17**
Sec. 102(g), **20:48**
Standing to appeal, none, **19:48**

NON-PARTIES—Cont'd
Standing to oppose, **21:22**

NONSTATUTORY DOUBLE PATENTING
Sec. 101, **5:103**

NONSTATUTORY SUBJECT MATTER
Sec. 101, **9:30; 13:210**

NORMAL ORDINARY SKILL IN THE ART
Inventive acts involved, **9:436; 19:72**

NOSE OF WAX
Jury verdict, **19:5**

NOTICE AND KNOWLEDGE
Generally, **13:89**
Administrative Procedure Act (APA), **9:344**
Amend defective notice, leave to, **4:25**
Anticipation, **23:48**
Appeal and review, **4:25; 9:169; 9:317; 10:14; 10:18**
Best mode, **7:47**
CAFC jurisdiction, **9:63**
Chemical, **9:60**
Claim interpretation, **8:112; 13:120**
Combining references, **9:126**
Constructive notice, **19:172**
Contributory infringement, **19:79**
Damages, **7:66; 19:154**
Discovery, **9:129**
Everyday mechanical concepts, **9:127**
Evidence, **10:18**
FRAP 3(c), **2:46**
FRAP 4(a)(4), **10:14**
FRCP 49(a), **19:21**
Good faith, **7:92**
Hypothetical person of ordinary skill, **9:65**
Inducing infringement, knowingly, **1:222; 7:103; 23:3**
Inequitable conduct, **13:101**
Infringement (this index)
Judicial Notice (this index)
Laches, **8:16**
Letters to customers as infringement threats, **13:41**
Operation, principle of, **14:4**

NOTICE AND KNOWLEDGE—Cont'd
Ordinary skill, hypothetical person of, **9:65**
Party's argument will not be addressed, **10:18**
Patentable, **9:104**
Preliminary injunction, **3:12**
Prior art, **9:114**
Reconsideration, request for, **20:21**
Reference
common knowledge of the art, **9:154**
materiality, **6:80**
Remand, motion to, **19:45**
Sec. 1.56, **8:29**
Sec. 271(b), **13:124**
Sec. 282, **1:92; 5:1; 20:15**
Sec. 285, **5:14**
Sec. 287, **2:6; 4:12; 7:92; 13:33; 21:53**
Specification need not disclose what is well known, **9:113**
Subject matter for judicial notice, **6:10**
Third persons, known or used by, **3:2**
35 USC § 282, pre-trial disclosure, **23:76**
Timeliness, **2:5; 4:25**
Willful infringement, **3:80; 14:24**
Willfulness, **3:51; 3:96**

NOVELTY
See also Point of Novelty (this index)
Design patent infringement, **1:165**
Gorham infringement test, **12:17**
Specifications, applies to claims not, **20:67**
Summary judgment, **21:7**

NULLIFICATION
Final judgment, **9:354**

NUMBER OF PREVAILING PARTIES
Award of costs, **19:219**

NUMBER OF UNITS SOLD
Commercial success, **9:181**

NUMERICAL RANGES
Doctrine of equivalents, **1:115**

NUNC PRO TUNC
Jurisdictional defect, cannot be used to cure, **13:59**
Licensee, **13:87**
Reduction to practice, **3:94**

OATH
Reissue, **4:69**

OBJECTION
Agency, **9:311**
Claim interpretation, **19:16**
JNOV, **6:6; 22:2; 23:4**
Jury and jury trials, **1:14; 2:61**
Jury instructions, **1:43; 13:38**
Partial summary judgment, **7:5**
Secondary considerations, **13:17**
Special verdict, **8:52**
Testing protocol, **14:4**

OBJECTIVE
Anticipation, **18:20**
Reasonable apprehension, **16:42**
Sec. 282, **6:10**
Secondary, **19:19**

OBJECTIVE CRITERIA
Obviousness, **11:55**

OBJECTIVE EVIDENCE
Generally, **9:168**
Must be commensurate with claimed invention, **9:100**
Nexus, **12:43; 18:53**
Obviousness, **3:30; 21:8**
Probative, often most, **7:46**
Valid, inappropriate to declare, **4:19**
Verbatim findings of counsel adopted, **8:22**

OBJECTIVE FACTORS
Prima facie obviousness, **9:86**

OBJECTIVE INDICIA
Secondary considerations, **14:2**

OBJECTIVE INTENT
Broadened reissue, **9:109**

OBJECTIVE STANDARD
Prosecution history estoppel, **1:96; 2:74; 13:80; 16:57**

OBSERVATION
Generally, **13:41**
Claims determine what infringes patent, **9:4**

OBSOLESCENCE
Presumption of validity, **9:21**

OBVIOUSNESS
Generally, **1:265; 1:348; 1:367; 1:378; 1:380; 2:182; 2:193; 3:78; 3:98; 3:184; 3:228; 4:81; 4:123; 5:135; 5:140; 5:154; 6:107; 7:83; 7:133; 9:243; 9:256; 9:260; 9:265; 9:413; 9:417; 9:439; 9:450; 9:456; 9:458; 9:460; 9:475; 9:514; 13:137; 13:189; 13:202; 13:225; 13:235; 13:246.70; 13:253; 14:42; 14:89; 14:100; 15:53; 15:55; 16:97; 16:158; 17:10; 18:15; 18:122; 18:126; 18:130; 19:251; 19:268; 19:273; 19:302; 19:310; 19:312; 19:319; 19:330; 20:126; 20:157.50; 21:79; 21:88; 22:57; 25:13; 25:14; 26:16**
Absolute predictability of success not required, **13:18**
Accepted wisdom, contrary to, **3:3**
Actual reports of failure, **2:101**
Adding features, **21:8**
Admission of prior art, **18:70**
Admissions, effect of inventor's, **9:125**
Advisory jury, **11:69**
All evidence to be considered, **1:80; 5:5; 18:15**
All-purpose criteria for applying, none, **9:99**
Analogous art, **4:127; 9:338; 11:70; 18:23**
ANDA, **6:91; 16:108; 19:271**
Anticipation, **1:255; 3:203; 4:15; 5:139; 9:442; 9:461; 10:8; 11:77; 13:204; 13:227; 20:67; 21:76**
Apparatus and obvious methods of use suggested, **4:74**
Appeal and review, **7:2; 9:56; 15:40**
Applicant's disclosure cannot be used to fill in gaps, **9:29**
As a whole, **2:8; 2:171; 5:111; 7:17; 9:46; 9:179**
Attorney, **3:104**
Blocking patent, **1:314**
Blonder-Tongue, **1:13**
Blueprint, **9:90**
Broadest reasonable interpretation, **3:201**
Burden, **1:30; 14:71**
Burden of persuasion and quantum of proof required, **9:357; 18:7**

OBVIOUSNESS—Cont'd
Cancellation of claims
generally, **16:154**
motion to amend to request, **14:78**
Case or controversy, **19:317**
Chemical cases, **9:44**
Chemical composition, **9:98**
Chemical compound, **5:90; 5:91**
Chemical process, **9:20**
Claim construction, **1:223; 2:183; 2:186; 3:178; 8:103; 9:397; 9:459; 19:11; 19:226; 19:243; 19:327; 20:8**
Claimed ranges, **9:277**
Claim preamble, **9:79**
Claims
generally, **2:171; 21:8**
as a whole, **1:166; 5:111; 18:71**
Clear and convincing evidence, **2:171; 14:9**
Clear error, **12:79**
Coextensiveness, **20:157.30**
Collateral estoppel, **10:3**
Combination
generally, **9:29; 13:15**
motivation to combine, **9:372; 23:68**
references, **1:4; 1:30; 3:138; 8:42; 9:121; 23:11**
suggestion to combine, **2:92**
Commercial embodiment, comparison with patentee's, **1:4**
Commercial success, **7:108; 9:154; 9:311; 13:166; 18:15; 18:83; 20:107; 23:75**
Common sense, **9:297; 9:450**
Comparative data, **9:56**
Composition claim, recitation in, **9:12**
Conclusion, **9:15**
Contemporaneous beliefs, **9:12**
Contrary to prior art teachings, **9:31**
Contributory infringement, **7:130**
Copying, **1:119; 12:116; 23:75**
Correctness, reviewed for, **9:15**
Corroboration, **5:133**
Covered business method review, **21:72**
Criticality of claimed range, **9:107**
Damages, **19:228**
Defenses, **16:4**
Dependent claim, **9:24; 16:4; 18:23; 19:245**

OBVIOUSNESS—Cont'd
Derivation of invention, **3:204**
Description, **6:99; 14:101; 20:47**
Designer of ordinary skill, **12:32**
Design patent, **8:128; 9:120; 9:135; 9:178; 9:227; 12:17; 13:198; 16:17**
Desirability
generally, **9:260**
prior art, combination proposed, must suggest desirability of, **9:29**
Device on sale more than one year, **20:72**
Differences, **3:3; 3:41; 18:15**
Disclaimers, **1:326**
Disclosure, **9:107; 16:4; 19:243**
DNA, **9:248**
Doctrine of equivalents, **3:178**
Double patenting
generally, **1:250; 5:49; 5:55; 9:110; 9:194; 9:203; 9:211; 9:488; 16:112; 16:147; 19:246; 21:76**
absolute predictability, not, **9:52**
claim comparison, **16:122**
claim consideration, **1:166**
claim construction, **19:226**
claims "as a whole," **5:111**
consonance, need for, **20:29**
disclosure, **9:45; 9:307; 19:226**
doctrines purpose is to prevent improper timewise extension of patent right, **9:112**
expectation, reference teaching requires only reasonable expectation of success, **9:52**
extension, doctrines purpose is to prevent improper timewise extension of patent right, **9:112**
fact vs. law questions, **9:52**
judicial notice of MPEP, **9:374**
law question, **9:134**
lead compound selection, **15:41**
obviated by terminal disclaimer, **17:2**
predictability, not absolute, **9:52**
prosecution rate, **6:69**
PTO, review of decisions, **9:52**
reasonable expectation, **9:52**
reference composition, **15:38**
reference teaching requires only reasonable expectation of success, **9:52**

OBVIOUSNESS—Cont'd
Double patenting—Cont'd
review of PTO decisions, **9:52**
same invention, **9:52**
Sec. 121, **19:59**
terminal disclaimer as concession, **15:6**
variation amount, **5:103**
Enablement, **14:101**
Established by factual evidence not argument, **9:15**
Evidence
all evidence must be considered, **5:5; 18:15**
commercial success and copying, **23:75**
established by factual evidence not argument, **9:15**
examiner, evidence not before, **11:42**
expert opinion, **13:53**
independent evidence of nonobviousness, **3:175; 13:185**
nexus, **1:292; 18:99**
objective evidence, **21:8**
strong evidence, **13:85**
substantial evidence, **3:208; 20:152**
weight and credibility of evidence, **1:30; 3:165; 13:84; 16:19; 16:137**
Examiner, evidence not before, **11:42**
Examiner's rejection, **9:427; 9:434**
Expectation, unexpected results, **1:168; 9:228; 9:250**
Expectation of success, reasonable, **12:55; 16:108; 16:109**
Expert testimony, **1:235; 13:53; 19:244**
Fact findings, **1:4**
Fact question, **9:182; 9:217; 23:52**
Facts needed, **3:104**
Factual evidence, **9:15**
Failure to satisfy burden of proving, **20:135**
FDA approval, **1:235; 1:236**
Four-part factual inquiry, **1:87; 1:92; 2:59; 3:83; 6:37; 9:181; 9:211; 9:231; 11:40; 13:90; 16:49; 18:47; 18:51; 18:53; 18:55; 19:119; 21:34; 23:47; 23:50; 25:7**
Four-part test, **1:126; 13:116; 22:27**
Fraud, **1:171; 22:1**
Functional relationship, **9:32**

OBVIOUSNESS—Cont'd
Genus, **3:167**
Graham factors, **2:8; 19:244**
Guidelines, **16:4; 18:23**
Hatch-Waxman Act, **21:76**
Heart of invention, **16:41**
Hindsight, **1:149; 3:103; 3:109; 5:47; 9:274; 13:185; 15:42; 16:4; 16:137; 19:92; 21:8**
Hypothetical person, **2:8**
Improvement, **18:23**
Incorporation by reference, **16:164**
Indefiniteness, **2:160**
Independent evidence of nonobviousness, **13:185**
Inducement, **7:130**
Inducing infringement, **8:24**
Inequitable conduct, **1:231; 18:84; 19:202; 22:1**
Infringement, **7:10; 18:23; 19:11; 19:19**
Inherency, **5:136; 8:147; 8:159; 16:140; 16:171; 19:303; 20:67**
Innovation is always invention, **18:15**
Interference, **18:89**
Inter partes reexamination, **12:101**
Inter partes review, **1:283; 1:295; 1:321; 1:326; 2:173; 3:201; 5:131; 5:134; 5:139; 8:139; 9:418; 9:426; 9:428; 11:86; 11:283; 13:222; 14:99; 14:104; 16:166; 20:153; 22:56**
Interrogatories, **5:7**
JMOL, **1:171; 1:178; 2:136**
JNOV, **13:38; 20:15**
Jurisdiction to review, **7:128; 9:425**
Jury and jury trials, **1:16; 3:153; 18:84; 19:37**
Known or used by others, **3:2**
Large number of references, **9:114**
Law question, **1:171; 2:141; 3:151; 7:46; 9:24; 9:100; 9:172; 9:216; 10:15; 11:75; 12:40; 14:2; 16:48; 18:23; 18:41; 19:36; 21:8; 22:1; 23:7**
Lead compound, **21:58**
Legal determination, **2:76**
Limitations, **6:101; 16:4; 16:137**
Literal infringement, **2:49**
Long-felt need, **21:8**
Lost profits, **18:23**
Marketplace response, **20:107**

OBVIOUSNESS—Cont'd
Matter of law, **9:15**
Minor changes, **9:166**
Modification, **9:51**
Motivation
generally, **9:207; 11:49; 16:140; 22:26**
combine, **7:127; 9:428**
expert testimony, **23:68**
fact question, **9:217; 23:52**
modify prior art reference, **9:124**
Multiple different patents, **16:156**
New ground of rejection, **9:15; 9:127; 9:372**
Nexus, **1:292; 6:101; 12:43; 14:90; 17:13; 18:15; 18:53; 18:99**
Non-enabling reference may qualify as prior art on obviousness, **19:59**
Non-technical arts, **13:166**
Objective criteria, **11:55**
Objective evidence, **1:255; 21:8**
Objective indicia of nonobviousness, **11:69**
Obvious to try, **9:66; 9:459; 14:37**
Obvious to try distinguished, **11:63**
On-sale bar, **20:50; 20:72**
Opinion testimony, **1:30**
Optimizing result-effective variable, **9:352**
Ordinary skill, **2:8; 12:32; 19:231; 20:126**
Others, failed attempts of, **1:101**
Papesch, **9:9**
Patentability, **9:66; 9:107; 19:59**
Patent marking, **1:307**
Patent term extension, **14:95**
Per se obviousness rejection, **9:173**
Petition for rehearing en banc, **19:287**
PHOSITA (person having ordinary skill in the art), **9:436**
Pick and choose, **2:8**
Policy, **16:4**
Potential claim unpatentable, **8:142**
Predictability of success not required, **1:255**
Prejudicial error, **18:15**
Prerequisite is determining pertinent references, **19:154**
Presumptions, **1:4; 1:30; 13:99; 16:4**
Prevailing party, **19:259**

OBVIOUSNESS—Cont'd
Prima facie cases
generally, **9:37; 9:167; 9:174; 9:197; 9:207; 9:245**
see also Prima Facie Obviousness (this index)
Prima facie showing, **1:283**
Printed matter, **16:169**
Printed matter and substrate, **9:32**
Prior art
generally, **2:157; 9:167; 9:371; 9:446; 15:43; 16:4**
admission of, **18:70**
combination proposed, must suggest desirability of, **9:29**
contrary to teachings, **9:31**
found or suggested, **19:59**
lack of suggestion, **9:148**
must be some teaching or suggestion in, **14:8**
reference, need for teaching, suggestion or motivation to modify, **9:124**
same as before PTO, **2:8**
scope and content, **18:92**
some suggestions or incentive in, **1:30**
specification, statement of purpose in, **9:19**
state of art at time invention made, **4:91**
suggestion, generally, **21:8**
teachings, generally, **9:19; 16:4**
though not, **1:30**
Prior suit, validity holding in, **7:17**
Privity, **11:14**
Process performable by person, **1:12**
Proposed substitute claims, **9:418**
Prosecution history estoppel, **19:275**
PTAB, **9:403**
Question
apparatus distinctions not claimed in process claims, **16:19**
attorneys, counsel arguments, **16:19**
burden, heavy, **16:19**
CAFC, **18:3**
credibility, **16:19**
evidence, objective, **3:30**
Graham, **3:30**
heavy burden, **16:19**
jury verdict, **3:17**
law question, above

OBVIOUSNESS—Cont'd
Question—Cont'd
objective evidence, **3:30**
reissue, **3:30**
reject witness' testimony, **16:19**
review, standard of, **16:19**
Sec. 103, **1:294; 16:19; 23:84**
skill in the art, level of, **3:30**
witnesses, reject of testimony, **16:19**
Ranges of obviousness, **5:134; 9:352; 22:63**
Reasonable expectation of success, **8:131; 9:52; 12:55; 15:58; 16:140**
Rebuttal evidence, **9:99**
Recitation in composition claim, **9:12**
Reexamination, **4:109; 9:329; 9:351; 9:442; 18:99**
Reference (this index)
Rehearing, **2:161**
Rehearing en banc, **13:214**
Rejection, **9:15; 9:56; 9:173; 9:333**
Remand and reassignment, **20:104**
Research, weight, **13:84**
Review, standard of, **2:59; 9:26; 9:168; 9:174; 9:195; 9:202; 22:13**
Routine optimization, **9:449**
Rule 131 affidavit, **7:19**
Same invention-type, **19:39**
Same way for validity and infringement, **19:11**
Sec. 101, **14:99**
Sec. 102, **3:168**
Sec. 103, **3:168; 13:225**
Sec. 314(d), **9:418**
Sec. 102(g), **11:9; 20:126**
Sec. 103, **9:27; 9:62; 9:103; 9:117; 9:139; 9:295; 15:4; 23:84**
Sec. 112, **9:86**
Sec. 171, **9:73**
Sec. 282, **1:4**
Secondary considerations, **3:175; 3:190; 6:99; 8:153; 9:331; 13:45; 13:253; 16:4; 16:168; 18:15; 19:11; 21:8; 23:66; 25:14**
Separately argued, **18:23**
Simultaneous inventions, **7:97**
Single reference, **19:123**
Skill in the art, level of, **2:197; 4:82; 15:19**
Sophisticated inventions, not limited to, **16:4**

OBVIOUSNESS—Cont'd
Special master's decision, **13:24**
Specification, **9:19; 9:56**
Specificity, need for, **12:64**
Standard of review, **9:418**
Standing, **1:334; 7:129**
Statement of purpose in specification not prior art, **9:19**
Strong evidence showing nonobviousness, **13:85**
Subject matter as a whole, **9:46; 9:436**
Substantial evidence test, **9:394; 19:43**
Substrate, **9:32**
Suggestion, **9:124; 9:148; 9:204; 11:49; 14:8; 21:8; 22:26**
Summary judgment, **8:14; 9:454; 12:15; 21:7**
Superior work, **18:23**
Teach away, **9:361; 19:234; 20:50**
Teaching-suggestion-motivation test, **3:153**
Test, **18:23**
Third persons, failure of, **21:8**
Time and timeliness, **4:91**
Time invention made, **12:43; 19:227**
Two-step analysis, **11:43**
Underlying factual inquiries, but based on, **9:197**
Unexpected properties, **8:147**
Unexpected results, **7:108; 8:40; 9:15; 9:228; 9:250; 9:295; 19:211; 19:214**
Unpatentable, **9:423**
Unpatentable claims, **2:173; 16:152**
Utility, **7:130**
Validity (this index)
Values, range of, **9:191**
Verdict, **16:14**
Vitiation, **3:178**
Waiver, **9:439**
Weight, years of research entitled to, **13:84**
Weight and credibility of evidence, **1:30; 3:165; 13:84; 16:19**
Willful infringement, **8:129; 18:23**
Work better, **18:23**

OBVIOUS TO TRY
Generally, **9:99; 13:18**
Chemical, **9:60**
Claim construction, **9:459**

OBVIOUS TO TRY—Cont'd
Conventional knowledge, **2:133**
Expectation of success, **1:44**
Lack of written description, **11:62**
Obviousness, **14:37; 16:107**
Obviousness distinguished, **11:63**
Standard, not, **9:26**
Standard of patentability, **9:66**
Test, improper, **9:167**
Verbatim findings of counsel adopted, **8:22**

ODYSSEY LOGISTICS & TECHNOLOGY CORP. V. STEWART
2025, **15:64**

OFFER FOR SALE
Generally, **6:61; 8:69; 19:137; 20:46**
Fine tuning, **19:130**
Sec. 102(b) on-sale bar, **1:216; 13:212; 18:8**
Sec. 271(a), **18:54; 20:46; 20:103**
Sham affidavit doctrine, **17:12**

OFFICERS
Sec. 102(b), **13:35**

OFFSHORE PATENTED PROCESS
Generally, **11:54**

OLD COMBINATION REJECTION
Cross-appeal, **18:2**

OLD COMPOSITION
Discovery of inherent properties, **20:11**

OLD PROCESS
Durden, **9:98**

OLD PRODUCT
Generally, **8:57**

OLLNOVA TECHNOLOGIES LTD. V. ECOBEE TECHNOLOGIES ULC
2026, **15:66**

OMISSIONS
Attorney, **4:36**
Best mode, unintentional omission, **8:87**
Inequitable conduct, **7:46**
Materiality, **12:93**
Reissue application, **9:294**
Statutory construction, **12:37**
Walker Process antitrust, **4:84**

180-DAY EXCLUSIVITY PERIOD
Abbreviated new drug application (ANDA), **4:98**

ONE MODE
Enablement, **1:131**

ONE OR MORE THAN ONE
A, **5:44**

ONESUBSEA IP UK LIMITED V. FMC TECHNOLOGIES, INC.
2023, **15:62**

ONE-TO-ONE CORRESPONDENCE
Doctrine of equivalents, **5:39; 6:39**

ONLY AS OF ISSUE DATE OF PATENT
Enablement, **9:53**

ONLY DISCLOSE WHAT AWARE OF
Best mode, **7:47**

ONLY GOD WORKS FROM NOTHING
Generally, **9:86**
Sec. 282, **6:10**

ON-SALE BAR
Generally, **3:96; 8:127; 8:145; 8:152; 9:279; 10:53; 13:204; 16:44; 16:103; 20:145; 21:45**
Assignment of invention as sale, **13:87**
Bright lie rule, none, **3:83**
Burden of proof, **9:171; 12:98**
Claim not invalid under, **13:215**
Clear and convincing evidence, **2:23**
Clearly erroneous definition, **2:23**
Commercial offer for sale, **13:102; 19:113**
Commercial offer to sell, **5:72; 19:179**
Commercial sale, **13:122; 19:133**
Contracts, **26:8**
Enforceability, **13:42**
Exception, supplier, **19:140**
Expectation, **5:35**
Experimental use, **1:59; 1:177; 1:179; 2:178; 5:64; 5:137**
Factors, **13:84; 18:42**
Filing date, **1:97; 4:93; 20:102**
Incidental to experimentation, **1:113**
Inequitable conduct, **5:137; 12:30**
Inherency, **19:113**

ON-SALE BAR—Cont'd
Invention submission organizations, **8:62**
Joint development exception, **2:23**
Joint inventors, between, **2:85**
Law question, **2:31; 7:71; 12:60**
License agreement, **16:86**
Method performed by hand, **4:16**
Obviousness, **20:50; 20:72**
Offer to sell, **18:8**
Pfaff test, **2:71**
Policy considerations, **16:49; 19:107**
Process, sale of, **11:52**
Public policy, **1:71**
Public use, **2:178**
Ready for patenting, **1:179; 1:216; 8:145; 9:310; 14:35; 19:139**
Reduction to practice, **16:52**
Research agreement, **5:76**
Review, standard of, **1:119; 22:20**
Sale contract, **26:8**
Sec. 102(b), **1:52; 2:7; 3:41; 3:142; 5:15; 5:64; 6:25; 9:5; 9:7; 9:93; 9:118; 9:279; 10:1; 11:10; 11:25; 13:212; 16:32; 19:7; 19:31; 19:54; 21:1; 21:16; 23:6**
Sec. 285, **5:137**
Submissions, **8:62**
Substantially completed with reason to expect it will work, **5:35**
Sufficiently complete is improper test, **19:91**
Summary judgment motion, **1:2**
Supplier exception, **19:140**
Totality of circumstances, **3:81**
Trademark declaration cannot establish on-sale date, **16:25**
Triggering bar, **1:216**
True sale, **13:123**
Two-part test, **8:71; 18:59; 23:47**

OPERATIONAL DIFFERENCES
Inducing infringement, **8:24**

OPERATION OF INVENTOR'S BRAIN
New prior art not considered by PTO, **5:11**

OPINION
Advisory opinion, **9:92; 20:2**
Attorneys (this index)

OPINION—Cont'd
CAFC, **17:2; 19:42**
Dann Amendment, **19:30**
Expert opinion. Expert or Opinion Evidence (this index)
Sec. 112, **9:40**
Summary judgment, **8:17**
Witnesses, **1:30; 3:1**

OPINION TESTIMONY
Expert or Opinion Testimony (this index)

OPPORTUNITY
Generally, **19:57**
Collateral estoppel, **16:57**

OPTIS CELLULAR TECHNOLOGY, LLC V. APPLE INC.
2025, **15:65**

"OR"
Claim interpretation, **2:86; 19:145**

ORAL FINDINGS
Sec. 291, **1:11**

ORAL TESTIMONY
Anticipation, **5:47**
Conception, **16:70; 19:151**
Contemporaneous documentary evidence, **3:49**
Corroboration, **10:31**
Prior use, **3:2**
Public use, **10:31**
Review, standard of, **19:12**
Validity, **23:48**

ORANGE BOOK
Generally, **10:54**
Case or controversy, **20:78**
Listing of patents, **1:135; 20:100**
Patent information, **14:62**
Tying, **16:121**

ORDERS
See also Judgments (this index)
Final judgment rule, **19:110**
FRCP 59, **19:50**
GVR order, **6:39**
ITC, **3:73**
Sec. 1.640, **1:60**
Transfer orders, **6:34**

"ORDINARILY AWARDED"
Prejudgment interest, **1:38; 13:72; 19:92**

"ORDINARILY CONSTRUED"
Method claims, **9:223**

ORDINARY AND ACCUSTOMED MEANING
Generally, **1:126; 2:101; 2:104; 3:51; 4:60; 8:74; 10:24; 11:61; 15:17; 19:157; 20:56; 20:64; 23:58**
All limitations considered meaning, **12:33**
Broadening ordinary meaning, **13:156**
Heavy presumption claim, **20:63**
Heavy presumption terms, **5:70; 18:67**
Jury verdict, **19:5**
Presumption of ordinary meaning, **11:48**
Statutory construction, **8:61**
Strong presumption, **4:73**
Surrounding words, **12:95**
Used differently by inventor, **3:91; 7:31**
Written description, **18:46**

ORDINARY DESIGNER STANDARD
Design patent, **4:48**

ORDINARY MEANING
Ordinary and Accustomed Meaning (this index)

ORDINARY OBSERVER TEST
Anticipation, **9:321**
Design patent infringement, **1:151; 1:165; 5:89; 6:88; 9:321; 18:96**
Point of novelty test, **3:100**

ORDINARY SKILL IN THE ART
Generally, **9:139**
Analogous art, **9:78**
Anticipation, **3:103**
Burden on patent challenger, **16:12**
Claim construction, **2:88; 5:110; 8:88; 8:112; 20:99**
Competency of Board, **9:65**
Conception, **19:124**
Factors, **9:168; 18:28**
Hypothetical inventor defined, **19:26**
Indefiniteness, **5:106**
Obviousness, **2:8; 12:32; 19:231**
Ordinary skill in the art, exercise of normal skill expected of person of, **9:436; 19:72**

ORDINARY SKILL IN THE ART —Cont'd
Prior art, **9:65; 9:114**
Reliance upon, **9:141**
Sec. 102(g), **11:9**
Technical qualifications, **9:65**

ORGANIZATION OF INFORMATION
Computer memory, **9:153**

ORIGINAL CLAIMS
Part of patent disclosure, **14:8**
Prior art, **9:90**

ORNAMENTALITY
Design patent, **2:58; 8:62; 18:87**
Summary judgment, **1:35**

OSSEO IMAGING, LLC V. PLANMECA USA INC.
2024, **15:63**

OVERALL SIMILARITY
Design patent, **2:63**

OVERBREADTH
Adequacy of support, **21:10**
Dominating patent, **21:10**
Principle of invention, **21:10**
Reverse doctrine of equivalents, **21:10**
Sec. 101, **21:10**
Utility, **21:10**

OVERLAPPING DATES
Interference, **3:54**

OVERRULING
Generally, **21:24**
Determining law, not appropriate source for, **4:16**

OVERSIGHT
Sec. 455, **8:14**

OVERTURN
Appeal and review, **23:33**
Claim construction, **16:13**
Sec. 112, **19:7**

OWNERSHIP
See also Title (this index)
Assignment of claim, **12:84**
Bright-line test, **6:23**
Claim preamble, **19:210**
Employer and employee, between, **2:73**
Executive Order 10096, **8:10**

OWNERSHIP—Cont'd
Foreign law, **1:172; 9:238**
Fraud in procurement, **13:150**
Inventorship, versus, **5:40; 9:303**
Joinder, **19:194**
Laches, **19:204**
Law question, **11:33**
Springs from invention, **20:40**
Standing, **1:172; 3:93; 9:303; 16:111**

OWN MERITS
Rule 147, **12:10**
Summary judgment, **5:48**

PACKET INTELLIGENCE LLC V. NETSCOUT SYSTEMS, INC.
2024, **16:193**

PAGE LIMIT
FRAP 28(g), **12:22**

PALO ALTO NETWORKS, INC. V. CENTRIPETAL NETWORKS, LLC
2024, **16:194**

PANDUIT
Generally, **6:26; 6:36; 18:35; 20:52**
Acceptable substitutes, **3:8; 4:90**
But for causation, not exclusive test for, **3:62**
Damages, lost profits damages award, guidelines for, **16:40**
Factual findings to support jury verdict presumed, **2:15**
Kicker, none, **13:72**
Lost profits, **3:2; 11:28; 16:40; 19:56**
Substitutes, acceptable, **3:8**
Two-supplier market test, **13:121**

PAPESCH
Improper, **9:9**
Obviousness, rebutting, **9:9**
Rebutting obviousness, **9:9**
Rejection, undue breadth, **9:9**
Undue breadth rejection, **9:9**

PARALLEL
Embodiment, **1:132**

PARDON
False patent marking, **19:262**

PARENT APPLICATION
Estoppel, **23:30**

PARENT APPLICATION—Cont'd
Sec. 120, **8:19**

PARENT CASE
Filing of CIP, **23:30**
Prosecution history, **13:100**

PARKERVISION, INC. V. QUALCOMM INCORPORATED
2024, **16:195**

PARKERVISION, INC. V. VIDAL
2023, **16:188**

PAROL EVIDENCE
Integration, **13:76**

PARTIAL JUDGMENT
Appealability, **7:16**

PARTIAL SETTLEMENT
Generally, **7:8**

PARTIAL SUMMARY JUDGMENT
Appealability, **3:9**
Final judgment rule, **3:86**
FRCP 56(d), **7:5**
Object, failure to, **7:5**
Preliminary injunction, **19:32**

PARTICULARITY
Incorporation by reference, **26:12**
Interference, **7:48**
Pleading, **9:329**
Timely motion for new trial, **18:25**

PARTICULAR LANGUAGE
Statutory construction, **12:37**

PARTIES
Customer end user as parties at trial, no necessity to have—contributory vs.direct infringement, **18:11**
Non-Parties (this index)
Prevailing party, **9:266**
Real party in interest, inter partes review, **1:324; 23:97**
Sec. 315(b), **1:324**
Standing (this index)

PARUS HOLDINGS, INC. V. GOOGLE LLC
2023, **16:189**

PATENTABILITY
Generally, **3:172; 9:127; 9:129; 9:133**

PATENTABILITY—Cont'd
Abstract ideas, **1:95; 9:286**
Claim interpretation, **11:49**
Claims, **2:173**
Design patent, **9:137; 11:25**
Doctrine of equivalents, **8:60; 12:51**
Inequitable conduct, **18:116**
Interference, **9:230; 16:16; 18:44; 23:44**
Inter partes review, **2:173**
Jury, fact findings of, **19:9**
Lexicographer, inventor as, **13:18**
Man-made organisms, **1:228**
Means-plus-function claim, **4:97**
Measurement of physical property, **9:247**
New unappreciated property of prior art, **5:56**
New use known process, **2:82**
Not dependent on how invention was made, **12:55**
Obviousness, **2:173; 9:66; 9:107; 19:59**
Physical property, measurement of, **9:247**
Prima facie obviousness, **9:17**
Printed matter, **9:32; 11:64; 13:232**
Product-by-process claims, **9:81**
Prosecution history estoppel, **9:199; 16:69**
Reexamination, **9:183; 9:314**
Sec. 1.1641, **9:141**
Sec. 135(a), **9:116**
Signal, **9:290**

PATENTABLE
Is obvious, **18:22**

PATENT ACT OF 1952
Generally, **9:136**
Doctrine of equivalents, **23:42**

PATENT AGENTS
Writ of mandamus, compelling production, **9:429**

PATENT AND TRADEMARK OFFICE (PTO)
Generally, **1:3; 1:60; 9:1; 9:150; 10:5; 11:11; 12:31; 13:45; 18:19**
Appeal and review, **9:2; 13:162; 16:134**
Articulated reason for decision, **12:64**
Assignee failing to record assignment, **1:60**

PATENT AND TRADEMARK OFFICE (PTO)—Cont'd
Attorneys, **12:75**
Authority limited by grant from Congress, **11:26**
Claim construction, **9:199**
Claim differentiation, **11:2**
Clearly erroneous standard, **12:2**
Construction and interpretation, **1:81; 9:337**
Controlling unless plainly erroneous or inconsistent with regulation, **22:9**
Deference, entitled to, **9:337; 11:27**
Defined, relationship, **9:34**
Delay in prosecution, **23:69**
Design Patent (this index)
Discipline, **2:121**
Entitled to deference, **11:27**
Examiners (this index)
Excuse, **11:3**
Fact findings, **9:80**
Good faith belief, **1:43**
Hearsay, **9:150**
Identity of invention, **20:20**
Inconsistency, **22:9**
Inequitable conduct, **1:203; 7:19; 9:43; 10:2; 12:55; 12:85; 16:114; 19:118**
Initial rejection, **7:19**
Interference, **7:102**
Inter partes review, **19:282**
Issue preclusion, **20:41**
Judicial review of PTO decision under Administrative Procedure Act, **16:134**
Jurisdiction, **19:46**
Materiality, standard of, **9:43**
Means-plus-function claim, **9:199**
Motion to remand, **9:130**
Objection to agency, **9:311**
Obviousness, **9:52; 9:56**
Own regulations, **12:75**
Plainly erroneous, **22:9**
Presumption of validity, **19:235**
Prima facie obviousness, **9:140; 9:153**
Prior art, noting differences from, **4:6**
Regulation, **19:63**
Reissue, **19:110**
Relationship defined, **9:34**
Res judicata, **2:60**

PATENT AND TRADEMARK OFFICE (PTO)—Cont'd
Review, standard of, **3:50; 4:56; 4:69; 9:165; 9:196**
Rule making, **12:37**
Sec. 2(b)(2)(D), **2:121**
Sec. 32, **23:15**
Sec. 41(a)(7), **13:32**
Sec. 102(b), **9:7**
Sec. 103, **9:140**
Sec. 282, **12:6**
Statutory Construction and Interpretation (this index)
Subject matter jurisdiction, lack of, **6:19**
37 CFR Sec. 1.56, duty of candor and good faith to PTO, **1:203**
Timing requirement, failure to observe, **9:187; 11:31**
Treaties. Patent Cooperation Treaty (this index)
Weight given thereto, **20:28**

PATENT COOPERATION TREATY (PCT)
Interference, **6:66**
Jurisdiction, **2:116**
Revival, **5:127**
Time limits, **8:70**

PATENT MARKING
Generally, **1:352**
Obviousness, **1:307**

PATENT MISUSE
Generally, **13:130; 21:51**
Affirmative defense, **23:9**
Anticompetitive effects, **16:126; 19:227**
Claims, **23:9**
Commercial embodiment, **23:9**
Contributory infringement, **8:14**
Dismissal for failure to state claim, **10:42**
Industry standard, **16:126**
Injunction against small infringer, **23:9**
Intervening rights, **23:9**
Lawsuit brought for improper purpose, **7:33**
Licensing, **19:6**
Scope of patent exceeded, **19:227**
Sec. 2, **20:2**
Trademark generic, **23:9**
Tying, **16:121**

PATENT MISUSE—Cont'd
Unenforceable until misuse purged, **2:61**

PATENT POLICY
Obviousness, **16:4**

PATENT POOLS
Tying, **16:121**

PATENT PROPERTY
Sec. 261, **10:4**

PATENT PROSECUTION
Bar, generally, **4:94**
Fraud, **3:83**
Inequitable conduct, **6:42**

PATENT RIGHT CLAUSE
Performance of government contract, **8:8**

PATENT TERM
Adjustment of Patent Term (this index)
Computation of extension, **13:144; 23:70**
Deference to agency's interpretation, **8:25**
Drug Price Competition Act (DPCA), **7:18**
Drug Price Competition and Patent Term Restoration Act (DPCPTRA), **3:109; 13:77**
Extension, **14:95; 19:339**
Extension, generally, **6:3; 7:18; 13:77; 13:120; 16:149**
Hatch-Waxman amendment, **13:144**
Obviousness, **14:95**
Restoration, **16:84**
Sec. 154(b), **23:69**
Sec. 156, **6:3; 21:6**
Sec. 156(a)(4), **8:25; 16:125**
Sec. 156(e)(2), **19:197**
Sec. 156(f), **16:125**
Statutory construction rules, **8:25**

PATENT TERM RESTORATION ACT (PTRA)
Generally, **4:40; 7:55**
Extensions, **13:77**

PATENT TRIAL AND APPEAL BOARD (PTAB)
Obviousness, **9:403**

PATENT TYING
Generally, **9:276; 21:51**
Choice of law, **9:276**

PCT
Patent Cooperation Treaty (PCT) (this index)

PENALTIES
Sanctions (this index)

PEN AND PENCIL ANALOGY
Doctrine of equivalents, **18:29**

PENDENT JURISDICTION
Appeal of unquantified sanctions order, **15:39**
Lack of, **19:9**

PENDING ACTS AND MATTERS
Generally, **5:2; 11:20; 16:19**
Choice of law, co-pending actions, **12:67**
Considerations involved, **19:49**
Declaratory judgment, **23:9**
Document retention policy, **13:168**
Interference, **13:31**
ITC, **19:25**
Motion, **12:36; 19:45**
9 Cir, **22:2**
Reexamination, **22:23**
Sec. 2201, **13:41**
Stay, **8:52**
Suspension of proceedings on appeal, **1:24**
Willfulness, **3:51**

PER ARTICLE
Sec. 292 penalty, **6:72**

PERFORMANCE
Generally, **8:43**
Administrative law, **13:70**
Constructive reduction to practice, **8:8**
Equitable estoppel, **8:8**
Filing of application is constructive reduction to practice, **8:8**
Four elements, **8:8**
Intent, **8:8**
Mathematical algorithm, **9:42**
Means-plus-function claim, **12:3; 12:26**
Patent right clause, **8:8**
Probability, invention performs its intended function beyond prob-

PERFORMANCE—Cont'd
ability of failure, **8:8**
Product-by-process claims, **9:81**
Reduction to practice, **8:8**
Sec. 102(g), **19:10**

PERMANENT IDEAS
Conception, **13:72; 20:65**

PERMANENT INJUNCTION
Generally, **10:54**
Abuse of discretion, **1:219; 9:315; 14:84**
Anticipation, **1:219**
Causation, **7:122**
Drive demand, **7:122**
Interlocutory decision, **12:41**
Irreparable injury, **7:122; 18:93**
Sec. 271(e)(1), **5:13**
Sunset provision, **1:219**

PERMISSIBLE
Facilitation, **20:54**
Interference, **5:68**
Statutory construction, **8:54; 12:34**

PER SE MATERIALITY RULE
Inequitable conduct, **12:20**

PER SE OBVIOUSNESS REJECTION
Obviousness, **9:173**

PER SE RULE
Clearly erroneous standard, **19:23**

PERSONALIZED MEDIA COMMUNICATIONS, LLC V. APPLE INC.
2023, **16:190**

PERSONAL JURISDICTION
Generally, **3:120; 3:181; 7:53; 7:107; 12:57; 13:230; 14:81; 18:73; 20:82; 20:158; 21:91; 24:5**
Additional activities beyond warning letter, **1:181; 3:131**
Attorney-client relationship, **18:90**
Cease and desist letters, **24:5**
Choice of law, **1:70; 4:49; 8:69; 8:79; 9:226; 18:45**
Consent, **8:79; 13:114**
Contractual consent or waiver, **13:114**
Federal circuit law, **19:215**

PERSONAL JURISDICTION—Cont'd
Foreign countries, **1:181; 1:186; 1:189; 2:142; 8:79; 14:15**
Foreseeability, **1:374**
FRCP 4(k)(2), **13:234**
Law question, **8:69**
Malpractice claim based on filing patent application, **20:94**
Minimum contacts, **1:70; 5:67; 6:150; 20:94**
Negation requirement, **19:215**
Nonconsenting party outside forum state, **8:79; 16:124**
Review, standard of, **6:50**
Rule 4(k), **13:181; 19:212; 19:215**
Specific jurisdiction, **20:46**
Stream of commerce plus theory, **1:221**
Stream of commerce theory, **1:181; 2:46**
Use, **13:153**
Venue, **8:69**
Waiver, contractual consent or, **13:114**

PERSONAL LIABILITY
Generally, **12:119**
FRCP 15(c), **6:11**
Inducing infringement, **19:92**
Motion for directed verdict, **1:1**
Sec. 102(b), **13:35**
Sec. 112, **15:2**

PERSPECTIVE
Doctrine of equivalents, **12:69**

PERSUASION
Burden of Persuasion and Quantum of Proof (this index)

PERTINENCY OF WITHHELD INFORMATION
Known or used by others, **3:2**

PETITIONS
Mandamus, **2:2; 9:54**
Motion to remand, **19:45**
Panel hearing or rehearing en banc, **11:67**
Special, petition to make
generally, **7:57; 12:56**
claim interpretation, **7:57**
inequitable conduct, **7:29**
prosecution history estoppel, **7:57**

PFAFF TEST
Generally, **22:20**
On-sale bar, **2:71**

PFIZER INC. V. SANOFI PASTEUR INC.
2024, **16:196**

PHANTOM COUNT
Interference estoppel, **9:49**

PHILIP MORRIS PRODUCTS S.A. V. INTERNATIONAL TRADE COMMISSION
2023, **16:191**

PHOSITA
Obviousness, person having ordinary skill in the art, **9:436; 19:72**

PHRASE, MULTIPLE DEFINITIONS OF
Claim construction, **7:28**

PHYSICAL EMBODIMENT
Interference, **3:25**

PHYSICAL EVIDENCE
Claim interpretation, **6:37**

PHYSICAL EXHIBIT
Corroboration, **2:96**
Drawing, **16:36**

PHYSICALLY COMBINABLE
Claims construed, **9:77**
Presumption of validity, **9:21**
Sec. 103, **15:4**

PHYSICALLY WORK TOGETHER
Co-inventors, **20:68**

PHYSICAL PROPERTY
Patentability, **9:247**

PHYSICAL SUBSTITUTION
Reexamination, **9:87**

PICK AND CHOOSE
Nonobviousness, **2:8**
Prima facie case, **9:37**

PIERCING CORPORATE VEIL
Generally, **8:53**
Alter ego doctrine, **13:50**
FRCP 25(a), **13:25**

PIONEER
Generally, **1:115**
Claim interpretation, **20:8**
Combinations, virtually all inventions are, **13:1**
Enablement, **16:80**
Infringement, **20:6**
Inspection of patentee's product, **16:15**
Means-plus-function claim, **20:6**
Sec. 102(e) v. sec. 102(g), **19:41**
Sec. 120, **8:19**

PLAIN LANGUAGE
Claim differentiation doctrine, **13:105**

PLAINLY ERRONEOUS
Agency's interpretation of own regulations, **22:9**

PLAIN MEANING
Claim construction or interpretation, **19:167; 21:9**
Clear and unambiguous, where contract provisions are, **1:56**
Means-plus-function claim, **2:31**
Sec. 156, **6:3**
Statutory construction and interpretation, **1:69; 3:50; 6:14; 9:138; 9:149; 10:19; 12:19; 13:48; 17:5; 20:26; 23:32**

PLANT PATENTS
Newly found seedlings, **9:355**
Public use, **4:107; 94:106**
Sec. 161, **9:355**

PLANTS
Enablement, **9:259**
Sec. 271, **10:17**
Single claim, **9:162**

PLANT VARIETY PROTECTION ACT (PVPA)
Generally, **4:55; 13:114; 19:173**
Sec. 101, versus, **16:63**
Sexually reproduced variety, **9:162**

PLATINUM OPTICS TECHNOLOGY INC. V. VIAVI SOLUTIONS INC.
2024, **16:197**

PLEADED, MUST BE
Collateral estoppel, **4:3**

PLEADING
Form 18, **9:356; 19:237**
Infringement, **9:356**

PLURALITY
Can mean more than two, **4:61**
Mean more than two, can, **20:29**
At least two, **18:67**

POINT OF NOVELTY
Generally, **23:18**
Design patent, **2:106; 9:325**
Ordinary observer test, **3:100**

POSSESSION
Best mode, **5:55**
Description, **13:124**
Sec. 102(b), **9:18**

POST- AND PRE-CRITICAL DATE CLAIMS
Materiality, **1:220**

POST-GRANT REVIEW
Standing, **1:320**

POST-JUDGMENT INTEREST
Generally, **20:49**
Choice of law, **20:49**
Sec. 1961(a), **7:27**
Sovereign immunity, **1:55**

POST-JUDGMENT MOTION
FRCP 59(e), **2:46; 4:25**

POST-JUDGMENT RELIEF
FRCP 60(b) vs. FRCP 60(a), **16:37**

POST-TRIAL INJUNCTION
Jurisdiction, lack of, **19:9**

POST-TRIAL MOTIONS
Claim interpretation, **8:84**
Evidence, no requirement to prove validity, **18:3**
JNOV, **1:50**
Limitations, review limited, **18:3**
Review limited, **18:3**
Validity, no requirement to prove, **18:3**

POST-TRIAL SETTLEMENT
Mootness, **11:23**

POST VERDICT MOTIONS
Preserve ground, failure to, **5:22**

POWERBLOCK HOLDINGS, INC. V. IFIT, INC.
2025, **16:201**

POWER GRIDS
Sec. 101, abstract ideas, **5:128**

PRACTICAL UTILITY
Generally, **6:33**
Sec. 101, **9:143**

PRACTICE
Enablement, **9:177**
Reduction. Reduction to Practice (this index)
Sec. 287, **4:12**

PREAMBLE
Claim Preamble (this index)

PRECEDENTS
Stare Decisis (this index)

PRECISE PROPORTIONS
Drawings, **8:74**

PRECISION
Description, **6:33**
Primary reference, **8:62**

PRE-CLINICAL RESEARCH
Sec. 271(e)(1), **9:251**

PRECLUSION
See also Claim Preclusion (this index)
Infringement, **16:35**
Issue Preclusion (this index)
Motion in limine, **7:26**
Res judicata, **6:14**

PREDICTABILITY
Obviousness, **13:18**
Obviousness-type double patenting, **9:52**

PREEMPTION OF LAWS
Generally, **8:66; 12:123; 21:49**
Biologics Price Competition and Innovation Act of 2009, **1:303**
CAFC, **21:42**
Competition, **26:7**
Conflict preemption, **11:50**
Disclosure, **21:30**
Federal patent code and UCC, **3:68**
Federal unfair competition claims, **26:7**

PREEMPTION OF LAWS—Cont'd
Fraudulent non-disclosure state inventorship law, **21:30**
State law, **21:30; 21:42**
State law tort liability, **7:81**
Tort liability, state law tort liability, **7:81**
UCC, federal patent code and, **3:68**

PREFERENCE
Claim interpretation, **1:116; 5:31; 6:56; 7:57; 7:77; 16:54; 22:12; 23:49**
Claims, scope of, **1:79**
Comparing claims with accused device, **13:9**
Summary judgment, **10:4**

PREJUDGMENT INTEREST
Generally, **5:54; 11:21; 19:38; 19:324; 20:49**
Abuse of discretion, **3:96; 8:20**
Award against government requires either contract or Act of Congress, **19:83**
Compensatory purpose, **15:10; 23:73**
Compound vs. simple interest, **18:35**
Congress, **19:83**
Damages, **2:15; 7:15; 16:5; 18:2**
Delay in bringing suit, **21:20**
Enhanced damages, **21:3**
FRCP 59(e) motion to alter or amend judgment, **10:14**
Government, **19:83**
Ordinarily awarded, **1:38; 13:72; 19:92**
Presumption of validity, **12:9**
Prevailing party, **19:259**
Purpose, **2:30**
Rate, **21:18**
Reviewed only for abuse of discretion, **8:20**
Sec. 284, **4:7**
Simple interest, **18:35**
Time, withheld, when, **12:20**
Withheld, when, **12:20**
Witnesses, **14:5**

PREJUDICE
Generally, **1:54; 10:15; 18:39**
Change in economic position, **7:30**
Choice of law, **8:82**
Complaint dismissed for mootness in view of settlement of controversy, **19:14**

PREJUDICE—Cont'd
Damages to proper focus, **8:50**
Economic position, change in, **7:30**
Economic prejudice, **1:67**
Equitable estoppel, **19:252**
Final decision, **8:82**
Laches or delay, **19:252**
Nexus required, **8:32**
Reliance on delay not required, **13:44**

PREJUDICIAL ERROR
Jury instructions, **2:31**
Narrow claim construction, **14:2**
Obviousness, **18:15**

PRELIMINARY AMENDMENT
Four-factor test, **1:110**

PRELIMINARY INJUNCTIONS
As to injunctions, generally. Injunctions (this index)
Generally, **1:366; 2:199; 5:8; 7:85; 11:89; 12:123; 13:226; 13:245; 14:41; 19:183; 20:124; 20:128; 20:140; 20:155**
Abuse of discretion, **1:155; 1:169; 13:89**
ANDA filing, **1:202**
Appealability, **11:19**
Appeal and review, **2:16; 3:12; 7:81; 8:2**
Attorney, proposed by, **12:16**
Balance of hardships, **1:169**
Biosimilar products, **1:291**
Burden of proof, **3:76; 5:92; 14:20; 19:235**
Causal nexus requirement, **1:225**
Choice of law, **13:89; 16:33**
Claim construction and interpretation, **1:241; 3:135**
Concurrent litigation, stay of concurrent litigation, **11:19**
Confidential business information is property, **6:7**
Counsel, proposed by, **12:16**
Delay, **20:12**
Denial, **4:5; 10:41; 14:10; 18:75; 20:12**
Design patent, **1:226; 3:34; 20:93**
Discretion of court, **1:220; 2:60; 6:21; 8:81; 12:29; 23:20**
District court's discretion, **1:220; 8:81**
Doctrine of equivalents, **13:229**

PRELIMINARY INJUNCTIONS —Cont'd
Drastic remedy, **9:95**
Employee mobility, **12:16**
Equal, not equal to same thing, **4:5**
Equal, things equal to each other, **4:5**
Escrow, **3:21**
Evidence, **8:2**
Exclusionary rights, **12:111**
Exhaustion of patent rights, **12:102**
Factors, **6:15**
Final judgment, **9:304**
Findings, **12:16**
Foreign patent in foreign court, **19:32**
Four-factor test, **1:133; 3:34; 7:69; 8:2; 9:145; 10:26; 10:29; 13:88; 13:107; 13:114; 14:9; 15:20; 16:70; 18:26; 18:32; 18:65; 19:94**
FRCP 52(a), **3:12; 15:5; 16:26**
Functionality, **2:16; 3:34**
Infringement suit presumed in good faith, **1:40**
Initial consideration of evidence, **8:2**
Interlocutory decision, **12:41**
Interlocutory order, **11:19**
Irreparable harm, **1:169; 1:225; 3:34; 19:14; 20:12**
Irreparable injury, **18:21**
Issuance, standard for, **11:67**
Jurisdiction, **3:12**
Lawsuits, against filing, **1:40**
Likelihood of success on merits, **1:169; 1:183; 11:67**
Money damages, **1:34**
Notice and knowledge, **3:12**
Partial summary judgment, denial of, **19:32**
Preserve status quo, **1:34**
Presumption, **3:34; 20:12**
Priority filing date, **1:199; 5:88**
Procedural issue, **8:21**
Property, confidential business information is, **6:7**
Reissue, **1:259**
Restraining against use of stolen trade secrets, **6:7**
Review, standard of, **7:70; 8:46; 13:89; 20:61**
Review on appeal, standard of, **2:62; 7:50; 8:71; 12:16; 16:46; 20:53; 22:16**

PRELIMINARY INJUNCTIONS —Cont'd
RICO, **6:7**
Same thing, not equal to, **4:5**
Sec. 1292(a)(1), **23:13**
Serious question, **1:40**
Stay of concurrent litigation, **11:19**
Stolen trade secrets, **6:7**
Summary judgment, **19:32**
Threshold issue, **12:16**
Trademark, **2:16**
Trade secrets, restraining against use of stolen secrets, **6:7**
Validity, **1:169; 18:21; 20:12**

PRELIMINARY MOTIONS
Generally, **7:26**

PRELIMINARY STATEMENT
Interference, **3:54**
Purpose thereof, **7:26**

PREPONDERANCE OF EVIDENCE
Defined, **4:33**
Reexamination, **5:9**

PRESUMPTIONS
See also Burden of Proof (this index)
Attorney disqualification, **16:3**
Claim construction and interpretation, **1:161; 4:73; 4:74; 5:70; 9:94; 11:48; 18:67; 20:63**
Claim differentiation doctrine, **1:162; 3:80; 19:171**
Co-inventors, naming properly, **7:79**
Commercial success, **23:52**
Common law, **9:154**
Design patent, **19:8**
Different scope, **3:80; 11:48**
Doctrine of equivalents, **8:60; 21:11**
Evidence, **18:26**
Inequitable conduct, **13:19**
Inventor's admission of invention by another, **1:8**
Inventorship, **6:35**
Irreparable harm, **1:110; 18:26; 18:32; 19:94; 20:12**
Judge and jury roles, **10:15**
Means-plus-function claims, **1:134; 3:91; 5:51; 13:96; 18:107; 19:97; 23:51**
No presumption re uncited art, **12:13**
Notice and knowledge, **9:114**

PRESUMPTIONS—Cont'd
Obviousness, **16:4**
Ordinary meaning, **11:48**
Preliminary injunction, **3:34; 20:12**
Prosecution history estoppel, **2:66; 5:115; 6:39; 12:53; 19:146; 23:42**
Public officer perform their duties correctly, **1:55**
Regularity, **1:55**
Sec. 102(b), **9:7**
Sec. 282, **6:10; 8:23**
Special verdict, **20:50**
Summary judgment, **10:4**
Validity
generally, **1:80; 3:41; 8:119; 19:37; 19:129; 19:189**
admission as prior art, **18:10**
anticipation, **19:37**
Blonder-Tongue, **1:13**
combining references, criterion for, **9:21**
criterion for combining references, **9:21**
delay, **12:9**
destroyed, **13:81**
equivalence, **5:7**
evidence to be weighed, **14:10**
irreparable harm, **14:9**
ITC, **19:25**
JNOV, **22:2**
jury, **1:16**
laches, **12:9**
mere procedural device, **13:53**
more pertinent art, effect of, **12:9**
new prior art, effect of, **18:10**
obsolescence need not necessarily defeat reference, **9:21**
obviousness, **1:4; 1:30; 13:99**
physically combined, not whether they can be, **9:21**
prejudgment interest, **12:9**
prior art, **18:10**
process performable by person, **1:12**
publication, **18:10**
reference, **9:21**
Sec. 102(e), **1:22**
Sec. 282, **9:21; 9:57; 9:80; 12:6; 13:87; 16:4; 18:6**
substantive law, **19:36**
summary judgment, **3:13**

PRESUMPTIONS—Cont'd
Validity—Cont'd
verbatim findings of counsel adopted, **8:22**
weakened or destroyed, never, **13:81**
Warner-Jenkinson, **9:209**
Well-established common law principles not changed, **9:154**

PRETRIAL ORDER
Choice of law, **19:149**
FRCP 16, **19:14**

PRETRIAL PROCEEDINGS
Judicial Panel on Multi-District Litigation (JPMDL), **7:6**

PRETRIAL STIPULATION
Effect thereof, **11:28**

PREVAILING PARTY
Generally, **9:266; 15:60**
Costs, **2:179**
JMOL, **3:161**
Number of prevailing parties, **19:219**
Obviousness, **19:259**
Voluntary dismissal, **18:76**
Willful infringement, **19:259**

"PREVIOUSLY DONE, SOMETHING NOT"
Sec. 145, **7:9**

PRICE
Selling lower priced product does not justify infringement, **16:33**

PRICE EROSION
Damages, **22:26**
Lost profits, **2:34**

PRIMA FACIE CASE
See also Prima Facie Obviousness (this index)
Appeal and review, **9:37**
Experimental use, **1:71**
Explained, **9:104**
FRE 705, **19:59**
Interference, **7:13**
Lack of written description rejection, **8:101**
New ground of rejection, **9:37; 9:127**
Obviousness. Prima Facie Obviousness (this index)
Pick and choose, cannot, **9:37**

PRIMA FACIE CASE—Cont'd
Prior art teachings, among, **9:37**
Rebuttal, **9:150**
Rejection, **9:37; 9:127**
Sec. 112, **16:10**

PRIMA FACIE OBVIOUSNESS
Generally, **9:37; 9:50; 9:167; 9:174; 9:197; 9:207; 9:245**
As a whole, **9:86**
Broadest possible construction, **2:25**
Chemical composition, **9:98**
Claims not argued separately, **9:98**
Combining references, **9:123**
Composition, **9:17**
De novo review, **2:133**
DNA, **9:133**
Establish, burden to, **9:140**
Evidence, **9:99; 9:152**
Expectation, unexpected results, **9:86**
Experts, disbelief by, **2:25**
Factors in determining patentability of claims to new composition and its method of use, **9:17**
Few machines have no utility, **9:17**
Inventor, problem facing, **9:17**
Law of the case, **20:114**
Machines, **9:17**
New composition, **9:17**
Objective factors, **9:86**
Patentability, **9:17**
PTO's burden, **9:140; 9:153; 9:387**
Rebuttal, **2:25; 9:99; 9:119; 9:152**
References, combining, **9:123**
Sec. 103, **9:115**
Structural obviousness, **9:50**
Structural similarity, **1:183; 9:126**
Unexpected results, **9:86**
Utility, few machines have no, **9:17**

PRIMA FACIE SHOWING
New interference rules, **8:3**

PRIMARILY FACTUAL
Description, **21:33**

PRIMARILY FUNCTIONAL
Design patent, **16:21**
Validity, **12:8**

PRIMARY REFERENCE
Absence of precision in verdict, **8:62**

PRINCIPAL CONSIDERATIONS
Enhanced damages award, **19:101**

PRINTED MATTER
Generally, **9:402**
As a whole, **9:32**
Claim to be read as a whole, **9:32**
Mathematical algorithm, **9:32**
Need for substrate relationship, **9:153**
Obviousness, **9:32; 16:169**
Patentability, **9:32; 11:64; 13:232**
Sec. 101, also extends to, **9:32; 11:64**

PRINTED PUBLICATION
Generally, **7:125; 10:48; 13:246**
Anticipation, **9:322; 9:327; 14:94**
"Arranged as in the claim," **14:56**
Burden of proof, **13:72**
Claim construction, **1:313**
Claim preamble, **1:313**
Corroboration, **14:94**
Dismissal, **3:19**
Inequitable conduct, **15:34**
Legal conclusion, **3:101**
Publicly accessible, **9:261; 9:386; 19:266**
Sec. 102(b), **9:14; 9:18; 9:33; 11:60; 12:89; 14:8; 16:25**
Technical paper, **13:11**

PRINTER MATTER REJECTION
Generally, **9:262**

PRIOR ACTIONS
Generally, **13:53**
Issue preclusion, **9:151**
Obviousness, **7:17**

PRIOR ADJUDICATION
Collateral estoppel, **9:90**

PRIOR APPLICATION
Continuation application, **19:105**

PRIOR ART
Generally, **3:39; 4:6; 7:29; 9:48; 9:96; 9:103; 9:110; 9:114; 13:18; 13:28; 13:45; 16:97; 17:2; 19:34; 22:66**
Admission of own work, **18:70**
Analogous art, **1:329**
Anticipation (this index)
Burden less easily carried, **4:6**
Burden of proof more easily carried, **5:11**

PRIOR ART—Cont'd
Chemical, **9:60**
Claim interpretation, **1:103; 8:57; 13:63; 19:15**
Claim preamble, **9:79**
Collateral estoppel, **8:73; 13:105**
Combining references, **9:126; 9:127; 16:109**
Combining teachings, **9:74**
Commercialization, lack of, **4:6**
Cumulative references, **12:61**
Disclaimer, **19:216**
Disclose potential priority conflicts, **7:68**
Dismissal, **3:19**
Doctrine of equivalents, **7:40; 9:118; 12:78; 13:93; 20:61**
Double patenting, **9:45**
Embellishment, **4:6**
Enablement, **9:305; 19:59; 19:207**
Enhanced damages, **21:3**
Enhancement, **4:6**
Foreign country, patented in, **9:120**
Highly Relevant Prior Art (this index)
Improper, **1:10**
Inducing infringement, **8:24**
Inequitable conduct, **7:1; 8:29; 8:62; 12:30; 19:128**
Information disclosure statement, **1:122; 18:86**
Infringement, **5:60; 7:10; 19:19**
Intrinsic, cited art as, **22:31**
Inventor's admission of invention by another, **1:8**
Jepson format, **13:15**
Jury verdict, **3:17**
Later reference, discredited by, **9:117**
Limitations added to overcome prior art, **11:22**
Litigated, claims not, **4:6**
Means-plus-function claims, **6:75**
Modification, **9:51**
New prior art not considered by PTO, **5:11**
New use for an old structure, **9:48**
Not pertinent art before PTO, **4:6**
Obviousness (this index)
Ordinary skill, hypothetical person of ordinary skill, **9:65**
Original versus reissue claims, **9:90**

PRIOR ART—Cont'd
Own work, admission of own work, **18:70**
Patentable subject matter, **5:56**
Presumption of validity, **18:10**
Prima facie case, **9:37**
Priority, disclose potential priority conflicts, **7:68**
Product-by-process claim, **9:58**
Prosecution history estoppel, **6:39; 20:29; 23:42**
PTO, generally, **4:6**
Public accessibility, **19:207; 22:42**
Reexamination, **9:194; 9:200**
Reference (this index)
Reissue, **9:90**
Relevancy of foreign patent prosecution, **13:69**
Scientific formula, **9:48**
Sec. 102, **19:257**
Sec. 102(b), **4:84; 9:46; 9:150**
Sec. 102(g), **5:2**
Sec. 112(6), **1:91; 9:118; 11:28**
Sec. 282, **6:10**
Secondary considerations, **4:10**
Secret Prior Art (this index)
Structure, new use for an old structure, **9:48**
Suggestion or motivation to modify, must be, **9:101**
Summary judgment, **3:1; 3:20; 6:1; 21:7**
Teaching or suggestion must appear in reference, **9:140**
Technical paper, **13:11**
Uncited, **3:90**
Validity, **3:77; 4:6**
Weight, must be given, **13:53**

PRIOR DECISION
Res judicata, **13:22**

PRIOR DISMISSAL
ITC, **25:2**

PRIOR EXPERIENCE
Attorneys' fees, award by special master, **19:65**

PRIOR FILING
Earlier Filing Date (this index)

PRIOR INTERFERENCE
Subsequent litigation, effect of prior interference on, **2:36**

PRIOR INVENTION
Sec. 102(g), **9:158**
Third party, **12:55**

PRIOR INVENTOR
Sec. 102(g)(2), **4:65**

PRIORITY
Generally, **18:1; 19:152**
Anticipation, **5:142; 25:12**
Claim, **25:12**
Claim construction, **5:142**
Description, written description required, **19:120**
Enablement and enablement requirement, **19:304**
Estoppel, **23:30**
Foreign application filed earlier, **2:125**
Inherent disclosure, **25:12**
Interference, **2:107; 3:6; 3:82; 6:20; 6:66; 7:13; 7:100; 8:30; 8:78; 9:88; 11:65; 13:31; 15:1; 16:16; 18:49; 19:90; 19:240; 23:14**
Law questions, **3:53; 16:36**
Prior art, **7:68**
Reduction to practice, **8:108**
Reexamination, **9:340; 19:110**
Reissue, **9:294**
Sec. 111, **19:32**
Sec. 119, **9:143**
Sec. 119(a), **2:125**
Sec. 120, **20:88**
Sec. 135(a), **9:116**
Stay order, **11:1**
Written description required, **19:120**

PRIORITY FILING DATE
Generally, **1:376; 9:258**
On-sale bar, **20:102**
Preliminary injunction, **1:199; 5:88**
Sec. 120, **2:142**
Written description, **4:117**

PRIOR JUDGMENT
Damages, **20:23**

PRIOR MUST BE ENABLING
Inconsistent jury findings, **2:10**

PRIOR NOTICE
FRAP 4(a)(4), **10:14**

PRIOR POSSESSION
Interference, **4:11**

PRIOR RULING
Generally, **5:9; 19:57**
Factual differences must be material to prevent operation of collateral estoppel doctrine, **1:63**

PRIOR TO MARKETING
Opinion of counsel, **3:72**

PRIOR USE
Generally, **3:2**

PRIVATE FIRM
Attorney fees award, **16:24**

PRIVATE PARTY
Antitrust, **5:30**

PRIVILEGE
Generally, **11:56**
Appellate review, appropriate for, **9:184**
Attorney-Client Privilege (this index)
Local rule compliance, **4:47**
Mandamus writ, **9:184**
Settlement negotiation privilege, **9:362**

PRIVITY
Assignor estoppel, **9:118; 13:88; 19:47**
Attorneys fees, **11:14**
Bound by related party's acts, **5:4**
Inherent property, **11:14**
Inter partes review, **23:86; 23:94**
Obviousness, **11:14**
Related party, **5:4; 11:14**
Res judicata, **9:224**
Time-bar, **16:176**
Willful infringement, **11:14**

PROBABILITY
Performance of government contract, **8:8**

PROCEDURAL ERRORS
Harmful error must be shown, **4:37**

PROCEDURAL ISSUE
Choice of law, **8:21; 19:42; 20:4**
Inconsistent positions, **8:21**
Irreparable harm, **8:21**
Law question, **8:21**

PROCEDURAL ISSUE—Cont'd
Preliminary injunction, **8:21**
Sec. 112, **8:21**

PROCEDURAL LAPSE
Interference, **5:57**

PROCEDURAL PRESUMPTION
Sec. 282, **6:10**

PROCEDURAL RULE
CIT, **5:18**

PROCESS
Abstract mental process, Sec. 101 patentability. Abstract (this index)
Chemical process, **9:20**
Claim construction, **21:61**
Costs on appeal, **1:20**
Damages, **19:154**
Definition, **9:20; 18:85**
Equivalence, **3:87**
Inequitable conduct, **10:2**
Infringement, **4:51**
International Trade Commission, **1:184**
Obviousness question, **16:19**
On-sale bar, **11:52**
Performable by person
generally, **1:12**
abstract mental process, Sec. 101 patentability. Abstract (this index)
circumstantial evidence, **1:12**
infringement, **1:12**
inquiry essential into secondary considerations, **1:12**
obviousness, most probative on, **1:12**
presumption of validity, effect on, **1:12**
uncited prior art, **1:12**
Product-by-process claim, **1:52**
Sec. 101, **3:164; 6:71; 9:308**
Sec. 102(g), **19:10**
Sec. 271, **10:17**
Sec. 271(a), **18:79**
Sec. 271(g), **2:97**
Sec. 287, **8:4**
Sec. 287(a), **3:96**
Subject matter jurisdiction, process claim, generally, **3:164**

PROCESS PATENT AMENDMENT ACT (PPAA)
Import, sell, or use, **14:20**
Materially changed, **2:60; 5:23**

PROCUREMENT
Inequitable conduct, **13:19**

PRODUCT-BY-PROCESS
Generally, **9:466; 11:87; 19:51; 19:186; 19:187**
Claim limitations, **1:52**
How product is made not how it is used, **13:54**
Identical, performances of compounds, **9:81**
Patentability determined by product itself, **9:81**
Performances of compounds identical, **9:81**
Prior art product identical, **9:58**
Sec. 295, **14:31**
Structures not necessarily identical, **9:81**

PRODUCTION DOCUMENTS
Generally, **3:14**

PRODUCTION SPECIFICATIONS
Interference, **4:8**

PROFESSIONAL CONDUCT
Settlement agreement, **19:40**

PROFITS
Design patent, **3:98**
Lost Profits (this index)
Sec. 289 election, **2:33**

PRO HAC VICE
Sanctions, **2:55**

PROMPTU SYSTEMS CORPORATION V. COMCAST CORPORATION
2024, **16:198**

PROPER CLAIM CONSTRUCTION FIRST
Anticipation, **20:67**

PROPER NOTICE
Conversion of FRCP 12(b) motion into a FRCP 56 motion for summary judgment, **2:41**

PROPER STANDARD
Jury verdict, **3:75**

PROPERTY
Constitutionality, **16:8**
Each patent establishes independent right, **11:35**
Independent, each patent establishes independent right, **11:35**
Preliminary injunction, **6:7**

PRO SE APPEARANCE
Generally, **6:16**

PROSECUTION ESTOPPEL
Earlier patent, **12:3**

PROSECUTION HISTORY
Generally, **1:107; 13:28; 13:111; 19:146; 19:171; 21:91**
Additional components, **12:18**
Ambiguous, improper, **9:246**
Amendments, **5:44**
Arguments made therein, **3:75; 16:66; 19:111**
Arguments same weight as claim amendments, **5:44**
Claim construction, **1:298; 14:57**
Claim differentiation, **1:162**
Claim interpretation, **1:77; 2:77; 11:12; 12:31; 19:84; 23:51**
Continuation, parent case in construing, **13:100**
Disavowal of particular aspect of claim meaning, **8:74; 16:151**
Disclaimer, **2:155; 5:94; 13:209; 19:169; 19:193; 22:35**
Doctrine of equivalents, **9:108**
Error in record, **22:23**
Estoppel. Prosecution History Estoppel (this index)
Failure to satisfy burden of proving, **20:135**
Foreign prosecution, claim construction, **1:209**
Hatch-Waxman Act, **9:438**
Infringement, **13:126**
Limitations not present in issued claims, **21:9**
Meaning, disavowal of particular aspect of claim meaning, **8:74; 21:70**
Means-plus-function, **4:51**
Other patents, relevance of, **13:128**

PROSECUTION HISTORY—Cont'd
Parent case, **13:100**
Prior art, unpatentable in view of, **19:281**
Reissued patent, **6:37**
Relevance of other patents, **13:128**
Sec. 102(g) prior work, **5:2**
Sec. 1498, **12:11**
Subject matter relinquished or disclaimed, **1:116**
Wilson hypothetical claim, **19:84**

PROSECUTION HISTORY ESTOPPEL
Generally, **1:131; 1:135; 1:142; 2:84; 2:109; 3:99; 4:51; 5:115; 5:144; 7:80; 7:107; 16:56; 19:84; 19:94**
Amendment, **2:9; 2:66; 2:128; 3:130; 4:73; 6:48; 7:69; 8:13; 8:47; 18:40; 19:146; 20:29**
Any claim amendment, **6:48**
Appeal and review, **2:9**
Argument based estoppel vs. amendment based estoppel, **4:73**
Cancellation of broader claim, **5:36**
Claim construction and interpretation, **15:30; 20:118; 26:1**
Claims statement made regarding, not limited to, **1:84**
Clarity, **6:39; 19:153**
Clear, presumption to overcome prior art if unclear, **23:42**
Close examination of reason for amendment, **8:13**
Commonly owned patents, **1:115**
Competition, **8:38; 23:41**
Consisting of claim language, **13:7**
Defining claim terms, distinguished from, **19:84**
Definition, **19:84**
Dependent claims, **8:105**
Design patents, **16:139**
Disclaimer with clarity, **19:153**
Distinguished from prosecution history defining claim terms, **19:84**
Doctrine of equivalents, **1:164; 6:48; 6:64; 9:186; 9:377; 12:1; 12:62; 15:29; 16:27; 16:174; 20:69; 20:89; 21:77; 22:37**
Estoppel context, **9:186**
Examination, **8:13; 8:47; 18:40**
Examiner's reliance unnecessary, **12:49**

PROSECUTION HISTORY ESTOPPEL—Cont'd
Explanation, prosecution only where no explanation, **9:209**
File wrapper estoppel, **4:26**
Foreseeability, **4:96**
Indefiniteness, **1:21**
Infringement determination, **22:8**
Jury case, **6:26**
Law question, **13:63; 23:25**
Limitations, **19:115**
Literal claim scope, **2:77; 13:95; 23:54**
Means-plus-function, **3:84**
Narrowing amendment, **2:128; 6:70; 7:69; 18:77**
Objective standard, **1:96; 2:74; 13:80; 16:57**
Obviousness, **19:275**
Patentability, **9:199; 16:69**
Petition to make special, **7:57**
Policy-oriented limitations, **19:115**
Presumption, **2:66; 5:115; 6:39; 12:53; 19:146; 23:42**
Prior art, **6:39; 20:29; 23:42**
Purpose, **3:86; 8:47**
Reasonable competition, **8:38; 23:41**
Reasons for allowance, **19:168**
Rebuttable presumption, **12:53**
Recapture, **16:40**
Reexamination, **9:237**
Relevance, **2:31; 23:54**
Replacing claims, **13:105**
Scope of claim limitations, **18:101**
Sec. 102(e) v. sec. 102(g), **19:41**
Sec. 120, **8:19**
Similar limitation, applies to all claims with, **5:59**
Source, **3:84**
Special, petition to make special, **7:57**
Specification, effect of advantages in, **22:16**
Statutory requirements, related to, **12:59**
Subject matter, prevents recapture of, **8:72**
Substantial reason for related to patentability, **6:41**
Summary judgment, **20:13**
Summary judgment of non-infringement, **8:40**
Surrender, **16:40**

PROSECUTION HISTORY ESTOPPEL—Cont'd
Tangentially rebuttable, **3:130; 9:326; 18:77**
Vague assertions of patentability, **9:199**
Viewed from standpoint of reasonable competitor, **8:38; 23:41**
Voluntary, **16:79**
Wilson hypothetical claim, **7:28**

PROSECUTION IRREGULARITIES
Generally, **13:81**
Inequitable conduct, **13:81**

PROSECUTION LACHES DOCTRINE
Generally, **19:181**
Laches or Delay (this index)

PROSECUTION RATE
Double patenting, **6:69**

PRO SE LAWYER
FRCP 37, **16:71**

PRO SE LITIGANT
Failure to state claim, **13:142**
Frivolous appeal, **2:38**

PROTECTIVE ORDER
Confidential information, **13:40**
unsealing, appeal and review, **1:239**
Discovery of confidential information, **13:40**
Patent prosecution bar, **4:94**

PROTESTED REISSUE
Affidavit, **9:23**

PROVISIONAL APPLICATION
Inventorship, **5:88**
Written description as related to nonprovisional, **14:36**

PROVISIONAL REJECTION
Sec. 102(e), **9:110**

PROVISUR TECHNOLOGIES, INC. V. WEBER, INC.
2024, **16:199**

PS PRODUCTS INC. V. PANTHER TRADING CO. INC.
2024, **16:200**

PTO
Patent and Trademark Office (PTO) (this index)

PUBLIC ACCESSIBILITY
Indexing, **22:42**
Printed Publication (this index)
Sec 102(b) printed publication, **11:60**
Sec 112 written description, **3:144**
Standing, **19:316**

PUBLICATION
Claim interpretation, **20:8**
Motion to publish CAFC decision, **9:1**
MPEP, **16:6**
Pre-issuance damages with no actual notice of patent, **18:113**
Presumption of validity, **18:10**
Printed Publication (this index)

PUBLIC CONCERN
Constitutionality, **16:8**
Validity of patent is matter of, **6:22**

PUBLIC DISCLOSURE
Interference, **3:25**

PUBLIC INTEREST
Generally, **3:229**
Forum non conveniens, **13:58**
Preliminary injunction, **1:169**
Sec. 282, **12:5**
Vacation of judgment, **15:36**

PUBLICLY ACCESSIBLE
Generally, **9:261; 20:150**
Indexing, **22:42**

PUBLIC OFFICER
Presumption of regularity, **1:55**

PUBLIC POLICY
Assignor estoppel bars validity challenge, **4:13**
Interference, **7:13**
On-sale, **1:71**
Public use bars, **12:45**
Reexamination, **2:64; 9:200**

PUBLIC SERVICE
Attorney fees, **10:2**

PUBLIC USE
Generally, **9:279; 12:72**
Anticipation, **16:167; 26:13**
Commercial use, secret commercial use, **11:12**
Confidentiality agreement, **1:174; 2:106**

PUBLIC USE—Cont'd
Experimental use exception, **2:178; 8:98; 14:35**
Implied license, **26:13**
Inventor testing claimed features, **14:36**
Law question, **2:57**
On-sale bar, **2:178; 13:28**
Oral testimony, **10:31**
Plant patents, **4:107; 94:106**
Policy, **2:57**
Printed publication, publicly accessible, **9:261**
Proof, standard of, **1:71**
Public policy, **12:45**
Rule of reason, **1:159**
Sale, **7:21**
Sec. 102(b), **2:1; 2:45; 3:16; 4:84; 4:101; 8:23; 9:34; 9:75; 10:31; 13:35; 13:149; 20:14; 23:11**
Sec. 262, **8:5**
Sec. 284, **16:167**
Secret commercial use, **11:12**
Third party, **4:101**
Totality of circumstances, **12:45; 16:44**
Validity, **16:167**
Witnesses, oral testimony, **10:31**

PUBLIC UTILITIES
Power grid monitoring, abstract ideas, **5:128**

PUBLISHED DEVICES
MPEP, **16:6**

PUNISHMENT
Damages, **1:20**

PUNITIVE DAMAGES
Generally, **18:14**
Constitutionality of large award, **20:58**
Review, standard of, **18:58**
State law punitive damages, **9:161**

PURDUE PHARMA L.P. V. COLLEGIUM PHARMACEUTICAL, INC.
2023, **16:192**

PURELY LEGAL QUESTION
Claim interpretation, **3:84**

PURELY PROCEDURAL ISSUES
Choice of law, **12:58**

PVPA
Plant Variety Protection Act (this index)

QUALCOMM INCORPORATED V. APPLE INC.
2025, **17:14**

QUALIFICATION
Attorneys (this index)
Judge, **8:12; 8:14**
Judicial disqualification, **16:19**
Prior art on obviousness, non-enabling reference may qualify as, **19:59**
Technical qualifications, **9:65**

QUANTUM OF EVIDENCE
Generally, **14:2**
Burden of Persuasion and Quantum of Proof (this index)
Court must state, **18:7**

QUASHAL
Appealability, **8:9**
Choice of law, **20:17**
FRCP 45, **11:24**

QUASI-ESTOPPEL
Generally, **9:216**

QUESTION CERTIFIED
Interlocutory order, **21:24**

QUESTIONS
Fact Question (this index)
Law Question (this index)

QUI TAM ACTION
Retroactive elimination under AIA, **2:151**
Sec. 292 (this index)

RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS ACT
RICO (this index)

RAISING ISSUES
Ambiguity, patent, **9:132**
Appeal and review, **2:87; 7:58; 8:44; 13:85**
Argument not raised at trial, **13:45**
Collateral estoppel, **7:65**
FRAP 30(b), **6:10**
Inequitable conduct, **23:47**
Interference, **13:3**

RAISING ISSUES—Cont'd
JMOL, **8:84**
Jurisdiction, **2:56**
Motion in limine, **7:26**
PTO motion to remand, **9:130**
Sec. 282, **4:58**
Secondary considerations, **9:82**
Summary judgment, **2:71**
Waiver, **4:58; 6:16; 23:25**

RAI STRATEGIC HOLDINGS, INC. V. PHILIP MORRIS PRODUCTS S.A.
2024, **18:137**

RANGE OF MOTION PRODUCTS, LLC V. ARMAID COMPANY INC.
2026, **18:147**

RANGES
Inter partes review, **5:134**
Obviousness, **5:134**

READY FOR PATENTING
Experimental use, **5:64**
On-sale bar, **1:179; 8:145; 9:310; 14:35; 19:139**

REALTEK SEMICONDUCTOR CORPORATION V. INTERNATIONAL TRADE COMMISSION
2025, **18:139; 18:140**

REAL WORLD CONSIDERATIONS
Generally, **13:45**

REASONABLE APPREHENSION
Generally, **6:35**
Objective, **16:42**

REASONABLE COMPETITION
Prosecution history estoppel, **8:38; 23:41**

REASONABLE DEBATE
Certificate of correction, **14:39**

REASONABLE DELAY
Laches, **19:151**

REASONABLE DILIGENCE
Generally, **13:105**
Interference, **2:13**
Inter partes review, **1:338**
Preamble, **1:338**

REASONABLE DILIGENCE—Cont'd
Rule 131 affidavit, **1:344**

REASONABLE EXAMINER STANDARD
Incorporation by reference language, **8:124**
Materiality, **12:43; 13:69**

REASONABLE EXPECTATION
Obviousness, **8:131; 9:52; 12:55; 16:140**

REASONABLE INTERPRETATION
Broadest Reasonable Interpretation (this index)
Only one, **16:60**
Statutory construction, **13:83; 20:42**

REASONABLENESS OF EXAMINER'S REJECTION
Inequitable conduct, **1:3**

REASONABLE PATENT EXAMINER
Materiality, **2:103**

REASONABLE PRECISION
Description, **6:33**

REASONABLE ROYALTY
Generally, **1:152; 2:84; 24:7**
ANDA, **1:280**
Anticipated profit, **13:131**
Appeal is review and not trial de novo, **6:12**
Apportionment of damages, **14:5**
Claim construction, **19:279**
Common sense estimation, **9:213**
Damages (this index)
Determined, when, **21:23**
Eminent domain, **8:56**
Entire market value rule, **12:97; 18:35; 22:43**
Established royalty as measure, **13:72**
Expert or opinion evidence, **19:279**
Heavy burden if no manufacture to exceed, **8:51**
Industry-wide licensing agreement, **1:38**
License, willing licensor, **19:38**
Limitations, court not limited to figures urged by parties, **19:53**
Lost profits, **1:308; 23:81; 23:99**
Sec. 284, **2:6**
Waiver, **19:279**

REASONABLE ROYALTY—Cont'd
Willing licensor, **19:38**

REASONABLY APPRISED
Indefiniteness, **15:21**

REASONABLY CONTEMPORANEOUS
Evidence of level of skill in the art, **9:23**

REASONABLY FORESEEABLE
Damages, **8:43; 13:79**

REASONABLY PRUDENT PERSON STANDARD
Delay, unavoidable, **18:33**

REASONABLY RELATED
Safe harbor provision of Hatch-Waxman, **13:187**

REASONS OF ALLOWANCE
Prosecution history estoppel, **19:168**

REASSIGNMENT
Articulation of reasoning, **20:104**

REBUTTABLE PRESUMPTION
Prosecution history estoppel, **3:130; 12:53; 18:77**

REBUTTAL
Attorney disqualification, **16:3**
Inventor's admission of invention by another, **1:8**
Obviousness, prima facie obviousness, **9:99**
Papesch, **9:9**
Prima facie obviousness, **2:25; 9:99; 9:119**

RECAPTURE
Generally, **16:67**
Disclaimer, **8:96**
Doctrine of equivalents, **13:63**
Prosecution history estoppel, **16:40**
Reissue, **7:106; 9:335; 9:368; 13:54; 13:140; 13:165; 23:16**

RECAPTURE RULE
Certificate of correction, **3:187**
Written description, **3:187**

RECEIVERS
Standing, **13:148**

RECENTIVE ANALYTICS, INC. V. FOX CORP.
2025, **18:141**

RECOMBINANT DNA
As to DNA, generally. DNA (this index)
Generally, **7:28; 9:128; 9:167; 18:40; 19:121**
Deposit of DNA, **19:121**
Encoding protein sequence, **9:167**

RECONSIDERATION
Infringement, new theory, **7:113**
New ground of rejection, **9:22**
Rejection, new ground of, **9:22**
Summary judgment, **10:4**
Timely notice of appeal, **20:21**

RECONSTRUCTION
Claim differentiation, **11:2**
Exhaustion of patent rights, **10:27**
Implied license to repair with sale, **11:36**
Repair (this index)
Replacement of worn part, **16:20**
Template, use as template, **9:114**
Use as template, **9:114**

RECTIFY
Patent license, **12:14**

RECUSAL
Generally, **2:55**
Choice of law, **2:55**
Judicial disqualification, **1:65**

REDEFINING
Claim interpretation, **5:48**
Claim terms during prosecution, **1:136**

REDRAFTING CLAIM
Claim construction, **18:91**
Claim preamble, **3:22**

REDUCTION TO PRACTICE
Generally, **2:118; 11:10**
Burden of production, **12:63**
Conception, **9:407; 13:105; 19:124**
Constructive interference, **8:67**
Elements, **7:64; 13:105**
Embodied in tangible form, **19:144**
Evidence, standard of, **13:110**
Experimental use, **7:12**
Intended purpose, need to show device works for, **13:72**

REDUCTION TO PRACTICE—Cont'd
Interference, **3:25; 12:2; 14:3**
Invention of claims, **16:70**
Law question, **2:96; 4:27; 5:34; 9:163; 19:70**
Limitations, includes all, **3:82**
New interference rules, **8:3**
Nunc pro tunc, **3:94**
On-sale bar, **16:52**
Performance of government contract, **8:8**
Priority of invention, **8:108**
Reasonable diligence, **1:344**
Reference, antedate, **9:341**
Requirements, **20:70**
Review, standard of, **19:90**
Rule 131, **1:344**
Sec. 102(g), **6:83; 19:10**
Sec. 120, **9:13**
Sec. 131, **9:407**
Tangible form, embodied in, **19:144**
Testing, **26:11**
Two prong test, **5:46**
Verbatim findings of counsel adopted, **8:22**

REDUNDANT JUDGMENT
Declaratory judgment suit or counterclaim as, **13:46**

REEXAMINATION
Generally, **18:108**
Amendment of claims, **3:102; 6:8; 16:115; 17:6; 20:4**
Anticipation, **9:314; 9:340; 19:225**
Broadening uses, reissue test, **8:68**
Broaden term is not fatal, **1:90**
Broadest reasonable interpretation, **9:87; 9:154; 9:255**
CAFC jurisdiction, **7:8**
Certificate, **9:239**
Claim preclusion, **19:255**
Commissioner not limited to prior art, **9:194**
Completed upon issuance of reexamination certificate, **9:239**
Constitutionality, **10:16; 16:8**
Court review of decision to institute, **9:206**
Damages, **12:50**
District court cannot order party to file, **9:180**

REEXAMINATION—Cont'd
Effective date, **13:79**
Enlargement of claims question of law, **20:43**
Estoppel, **1:369**
Expiration of patent, **9:424**
Extrinsic evidence, **20:120**
Filing, district court cannot order party to, **9:180**
Final judgment rule, **5:25; 6:84; 6:85**
Identical to original claim, **6:8**
Incremental, **9:501**
Interference, **4:8**
Inter Partes Reexamination (this index)
Intervention, **13:176**
Issuance of certificate, **9:239**
Jurisdiction, **19:46**
Law question, **20:43**
Limitations, commissioner not limited to prior art, **9:194**
Manual of Patent Examining Procedure (MPEP) § 2217, **17:2**
New claims, **19:255**
New question, **2:150; 9:183**
Obviousness, **4:109; 9:329; 9:351; 9:442; 18:99**
Parties, **9:180**
Patentability, **9:183**
Pending litigation, stay as result of, **22:23**
Physical substitution of one reference into structure of another, **9:87**
Possibility, **9:87**
Preponderance of the evidence standard, **5:9**
Prior art, **9:194; 9:200**
Priority, **9:340; 19:110**
Priority cannot be determined, **19:110**
Prosecution history estoppel, **9:237**
Public policy, **2:64; 9:200**
Reference, **9:87**
Reissue, **6:8; 8:68; 11:5**
Reissue versus, **9:151**
Rejection, adding new grounds, **9:344**
Request not litigation suit in court, **10:9**
Review of decision to institute, **9:206**
Rule 131 affidavit, **7:19**
Sec. 252, **12:25**
Sec. 282, **9:80**
Sec. 304, **19:46**

REEXAMINATION—Cont'd
Sec. 305, **9:151**
Stay, **8:52; 16:116; 19:49; 22:23**
Substantial new question of patentability, **2:150; 9:183; 9:314**
Substantively identical, amended claims, **6:8**
Substitution, **9:87**
Summary judgment, **3:192**
Termination, **1:282**
Third-party requester, **1:287**
35 USC § 252, **6:8**

REFERENCE
Admission from failed attempt to antedate reference, **3:54**
All that it fairly suggests, **9:148**
All that it teaches, **9:123**
Analogous art, **9:16; 9:78; 19:36**
Antedating Reference (this index)
Anticipation, **5:66; 7:48; 7:94; 7:99; 9:291; 13:85; 19:38; 19:201**
Chemical, **9:60**
Claims construed, **9:77**
Combination patent, **13:15**
Combining references
express teaching, **9:119**
obviousness, **3:138; 8:42; 9:121; 16:109**
prima facie obviousness, **9:123**
prior art, teaching or suggestion in, **9:126; 9:127**
showing only components not overall appearance of design, **9:137**
Combining teachings, **9:74**
Commissioner's brief not prior art, **9:140**
Common knowledge of the art, **9:154**
Cumulative reference, **5:16; 18:40; 19:51; 19:59**
Design patent, **9:137**
Disclosure document, **15:28**
Earlier filing date, **5:104**
Effective date, **9:110**
Enabling reference may qualify as prior art on obviousness, **19:59**
Fact findings of PTO, **9:80**
Fact question, teachings of, **9:119; 9:133; 9:148; 9:166; 9:169; 19:56**
First-filed patent as prior art, **17:2**
Foreign countries, **9:120; 17:1**

REFERENCE—Cont'd
Hindsight analysis improper, **9:16**
Incorporation by Reference (this index)
Inequitable conduct, **13:101**
In their entireties, **16:4**
Intentionally withheld, cannot be, if PTO considers, **12:43**
Later reference, discredited by, **9:117**
Modification, **3:3; 9:51**
New prior art not considered by PTO, **5:11**
Notice and knowledge
common knowledge of the art, **9:154**
materiality, **6:80**
Obviousness
generally, **9:16**
combining references, **3:138; 23:11**
entirety, considered in its, **2:8**
establishment, teaches away from claimed invention as a general rule cannot be used to, **9:152**
large number of, **9:114**
prerequisite is determining pertinent references, **19:154**
prior art, **9:124; 19:59**
reasonable expectation of success, **9:52**
reference composition, **15:38**
single reference, **19:123**
teaching away, **3:151; 9:289; 9:361**
Presumption of validity, **9:21**
Prior art
generally, **9:59; 12:61**
combining references, **9:126; 9:127**
combining teachings, **9:74**
Commissioner's brief, **9:140**
enabling reference, **19:59**
first-filed patent, **17:2**
later reference, discredited by, **9:117**
limitations, **12:80**
new prior art not considered by PTO, **5:11**
obviousness, **9:124; 19:59**
relevancy of foreign patent prosecution, **13:69**
Reexamination, **9:87**
Relative terms, **9:36**
Relevancy of foreign patent prosecution, **13:69**
Rule 131 affidavit, **7:19**

REFERENCE—Cont'd
Sec. 1.56, **8:29**
Sec. 102(b), **9:18**
Sec. 103, **15:4**
Sec. 103 rejection, **9:101**
Sec. 112, foreign references, **17:1**
Sec. 282, **5:1**
Special master's decision, **13:24**

REFINING
Improving device, **13:8**

REGENERON PHARMACEUTICALS, INC. V. MYLAN PHARMACEUTICALS INC.
2025, **18:142; 18:143**

REGENTS OF THE UNIVERSITY OF CALIFORNIA V. BROAD INSTITUTE, INC
2025, **18:144**

REGENTS OF THE UNIVERSITY OF MINNESOTA V. GILEAD SCIENCES, INC.
2023, **18:134**

REGENXBIO INC. V. SAREPTA THERAPEUTICS, INC.
2026, **18:148**

REGIONAL CIRCUIT COURT
Choice of law, **24:1**

REGIONAL CIRCUIT LAW
Declaratory judgment, **19:22**

REGIONAL LAW
Motion to vacate, **16:19**

REGISTRATION
Declaratory judgment, **23:9**
Sec. 32, **23:15**
Statutory invention registration, **8:67**

REHEARING
Frivolous, **9:97**
Motion to remand, **19:45**
Obviousness, **2:161**

REINSTATEMENT
License agreement, **16:23**
Maintenance fee, failure to pay, **3:38**

REISSUE
Generally, **14:51**

REISSUE—Cont'd
Affidavit describing work of third party at reasonably contemporaneous time, **9:23**
Application, **9:47**
Attorney fees award, **16:24; 18:82**
Attorneys, **9:84; 9:294**
Broadened claims, **9:192; 9:365; 17:6**
Cancelled original claim, **6:85; 9:364; 12:31**
Change, **9:10**
Claim construction in foreign prosecution, **1:209**
Claims construed, **6:100; 9:77**
Copying before patent issued, **11:5**
Dann Amendment, **19:30**
Dependent claims, **9:336**
Disclaimer filed and two-year limit, **22:15**
Double patenting, **7:115**
Error, **8:64; 19:110; 19:137**
Filing, **9:3; 22:15**
Foreign prosecution, claim construction, **1:209**
Ignorance of inventor, **9:84**
Inequitable conduct, **8:26**
Insight, new counsel's, **9:84**
Intervening rights to manufacture, **13:168**
Inventorship, **3:83**
Inventor's ignorance, **9:84**
JMOL, **4:64**
Jury, **1:16**
Law of the case, **1:276**
Law question, **9:188**
Limitation, disclaimer filed and two-year limit, **22:15**
Linking claim, **4:70**
Motion, **12:36**
New counsel's insight, **9:84**
Oath invalidating, **4:69**
Objective intent to claim is not criterion, **9:109**
Obviousness question, **3:30; 9:366**
Omissions, **9:294**
Preliminary injunctions, **1:259**
Prior art, **9:90**
Priority, **9:294**
Prosecution history, **6:37**
PTO error in two patents for same invention, **19:110**

REISSUE—Cont'd
Recapture rule, **7:106; 9:335; 9:368; 9:507; 13:54; 13:140; 13:165; 23:16**
Reexamination, **6:8; 8:68; 11:5**
Reexamination versus, **9:151**
Remedial statutes, **9:3**
Requirements, **14:23**
Restriction, **4:70**
Same invention, **19:110**
Sec. 26, **9:3**
Sec. 116, **9:3**
Sec. 121, **7:115**
Sec. 251
generally, **2:4; 8:12; 9:69; 9:84; 9:85; 9:105; 9:138; 19:51**
compelling patentee to seek no defect reissue, **7:21**
Sec. 252, **19:4; 19:13; 19:55; 23:26**
Sec. 252(2), **2:40**
Specify every different, **4:63**
Summary judgment, **8:17**
Suspend proceedings, **3:72**
Terminal disclaimer, withdrawal, **9:367**
37 CFR Sec. 1.175(a)(4), **9:25**
Two patents, **19:110**
Unrelated claims, **9:365**
Validity, oath, **4:69**
Willful infringement, **11:5**
Written description, **9:479**

REJECTION
Acquiescence of applicant, **12:31**
Appellate review, **9:64**
Common occurrence, **17:4**
Cross-appeal, **18:2**
Evidence of validity, **7:19**
Factfinder not obliged, **8:31**
FRCP 56(f), **2:80**
Grounds, **9:344**
Intent to claim, **9:39**
MPEP, **16:6**
New ground, **9:15; 9:22; 9:37; 9:127**
Obviousness, **9:56; 9:173; 9:333; 16:19; 17:2**
Papesch, **9:9**
Sec. 1.192(c)(7), **8:107; 13:108**
Sec. 1.196(a), **9:140**
Sec. 102(b), **9:18**
Sec. 102(e), **9:110**
Sec. 103, **9:101**

REJECTION—Cont'd
Sec. 112, **16:10**
Sec. 132, **3:32**
Sec. 145, **7:9**
37 CFR Sec. 1.196(a), **9:106**
Timeliness, **9:38**
Validity, evidence of, **7:19**

RELATED APPLICATIONS
Sec. 120, **12:10**

RELATED LITIGATION
Generally, **19:61**

RELATED PARTY
Privity, **5:4; 11:14**

RELATIVE TERMS
Generally, **9:36**

RELEVANCE
All that it teaches, **9:123**
Anticipation, **19:154**
Claim interpretation, **3:75**
Due process clause, **18:69**
Facts to be found by trial court, **18:25**
Foreign patent prosecution, **13:69**
Inequitable conduct, **8:62**
Jury verdict, **18:25**
Later reference, discredited by, **9:117**
Materiality, **2:68**
New prior art not considered by PTO, **5:11**
Sec. 1498, **12:11; 15:4**
Selection of transferee forum, **9:128**
Subsequent patent, **8:40**
Substantial evidence, **16:39**
Transfer, selection of transferee forum, **9:128**

RELEVANT MARKET
Jury, **1:16**

RELITIGATING
Consent judgment, **5:8**

REMAND
Appealable, **9:31**
Appropriateness, **7:37; 12:26**
Assignor estoppel, **6:96**
Attorney fees, **3:46**
Clarification, **10:38**
Damages, **18:105**
Faulty jury instruction, **7:27**

REMAND—Cont'd
FRCP 52(a), **1:59**
Jury instructions, faulty, **7:27**
Mandamus, **9:68**
Necessity of, **3:35**
Non-party, **9:116**
Notice and knowledge, **19:45**
Scope, **5:43**
Sec. 284, **2:31**
Sec. 1367, **8:97**
Sec. 1447, **8:97**
Senior party introduces no evidence, **2:26**
Timeliness, **9:38**

REMBRANDT DIAGNOSTICS, LP V. ALERE, INC.
2023, **18:135**

REMEDIAL SANCTION
Mandamus, **9:57**

REMEDIAL STATUTES
Reissue, broadening, **9:3**

REMITTITUR
Maximum recovery rule, **21:23**
Review, standard of, **15:10**

REMOVAL
Assignor estoppel, **6:96**
Expert opinion testimony, **2:80**
Sec. 141, **9:116; 9:496**
Sec. 1447(d), appeal and review, **22:46**

RENEWAL
Directed verdict, **14:1**

REPAIR
ARO, **19:56**
Blonder-Tongue, **1:13**
Combination, when component effectively spent, **19:79**
Implied license defense, **4:1**
Law question, **4:1**
Reconstruction versus
generally, **1:86; 4:1; 8:59; 10:27; 12:20; 13:42**
bright-line test, none therefore, **2:75**
exhaustion of patent rights, **10:27**
extent of change not its purpose, **19:143**
implied license to repair with sale, **11:36**

REPAIR—Cont'd
Reconstruction versus—Cont'd
replacement of worn part, **6:67; 16:20**
Three situations, **8:83**

REPEAL
CAFC, **6:30**
Implication, by, **18:34**
Statutory construction, **6:30; 19:80**

REPEATED BITES AT THE APPLE, NO SUPPORT FOR
Repose, law reaches for, **2:26**

REPLACEMENT
Doctrine of equivalents, **13:106**
Prosecution history estoppel, **13:105**
Reconstruction vs. repair, **6:67; 16:20**

REPLICATION OF PATENTED TECHNOLOGY
Infringement, **13:173**

REPLY BRIEF
Generally, **1:351**
Fraud allegation, **12:3**
Raising issue for first time, **1:79; 12:3; 23:23**

REPOSE
Repeated bites at the apple, no support for, **2:26**

REPREHENSIBLE CONDUCT
Appellant's demeaning trial court, **9:159**

REPRESENTATIVE CLAIMS
Generally, **2:57**
FRAP 38, **16:4**
Sec. 1.192(c)(7), **8:107**
Valid, inappropriate to declare, **4:19**

REPUDIATION
Generally, **4:59**

REPUTATION
Adequacy of monetary damages, **18:32**

RESALE
Review of decision on JNOV motion, **21:5**

RESCISSION
Generally, **4:59**

RESEARCH
FNERDA, **6:18**

RESEARCH—Cont'd
Obviousness, **13:84**
On sale bar, research agreement, **5:76**
Sec. 271(e)(1), **9:251; 9:299**

RESEARCH JOINT VENTURES
Patent misuse, **16:126**

RES JUDICATA
Generally, **8:92; 19:332**
Agency decision, effect of, **2:60**
Agreement, effect of, **4:71**
Application to patents not in complaint, **11:35**
Claim preclusion, **19:255**
Collateral estoppel, **9:122; 16:35**
Complaint, application to patents not in, **11:35**
Consent decree on validity and enforceability, **6:17**
Continuing conduct, **1:229**
Enforcement, consent decree on, **6:17**
Issue preclusion, **4:9; 13:51**
Law question, **21:29**
Material differences in claim limitation, **14:64**
Preclusion, **4:9; 6:14; 13:51**
Prior state court decision, **13:22**
Privity, **9:224**
Sec. 337, **3:23**
State court decision, prior, **13:22**
Summary judgment, **1:78**
Validity, consent decree on, **6:17**

RESPONSE
Discovery sanctions, **13:25**
Document request, **2:27**

RESTEM, LLC V. JADI CELL, LLC
2025, **18:145**

RESTITUTION
Attorney fees award improperly granted, **19:58**
Equitable remedy, **20:34**

RESTORATION OF PATENT TERM
Generally, **16:84**

RESTRICTIONS
Limitations and Restrictions (this index)

RESUBMITTING REFERENCES
Inequitable conduct, **1:92**

RESULTING PREJUDICE
Delay, **13:44**

RETENTION OF DOCUMENTS
Preservation of evidence, **13:168**

RETIRED
Evidence, loss of, **14:11**

RETRIAL
Infringement, **8:51**

RETROACTIVITY
Constitutionality, **16:8**
Judicial decision, **23:33**
Not favored, **2:32**
Order, **1:46**
Standing, **8:63**
Statutory construction, **15:7**

RETROSPECTIVE EFFECT
Change in law, **7:25**

REVERSAL
Appropriateness, **12:26**
Damages award, **5:102**
Declaratory judgment, **9:92**
District Court decision, **9:1**
Jury and jury trials, **5:41**
State immunity from suit under Eleventh Amendment, **10:11**
Summary judgment, **8:17**
Validity, **7:8**
Willful infringement, **3:26**

REVERSE DOCTRINE OF EQUIVALENTS
Generally, **1:131; 9:149; 13:9; 20:61**
Abbreviated new drug application (ANDA), **18:80**
Additional components, **12:18**
Burden of proof, **19:24**
Claim construction and interpretation, **3:7; 19:24; 19:51**
Claim differentiation, **11:2; 19:24**
Claim preclusion, **18:80**
Commercial embodiment, comparison with, **19:24**
Complexity exception, **19:24**
Exception, complexity, **19:24**
Jury, **19:24**
Lethal weapon, **19:24**
Overbreadth, **21:10**
Specification, **19:24**

REVERSE DOCTRINE OF EQUIVALENTS—Cont'd
Summary judgment, **19:24**

REVERSE PAYMENT
Settlement agreement, **9:309**

REVERSE SETTLEMENT AGREEMENT
Antitrust, **6:87**

REVERSE VALIDITY
Cross-appeal, **18:2**

REVERSIBLE ERROR
Difficulty of showing, **19:57**

REVIEWABILITY
Appealability (this index)

REVIVAL
Abandoned patent, **1:177**
Patent cooperation treaty (PCT), **5:127**

REWRITTEN ACTS AND MATTERS
Claim interpretation, **16:91; 18:68**
Claims, rewritten to suit needs, **14:14**
Doctrine of equivalents, **18:65**
Validity, **1:119**

REX MEDICAL, L.P. V. INTUITIVE SURGICAL, INC.
2025, **18:146**

RICO
Preliminary injunction, **6:7**
Statute of limitations, **1:47**

RIGHT TO SUE
Standing, **19:154**

ROAD TRYOUT
FRCP 15(c), **6:11**

ROKU, INC. V. INTERNATIONAL TRADE COMMISSION
2024, **18:138**

ROKU, INC. V. UNIVERSAL ELECTRONICS, INC.
2023, **18:136**

ROOTS
Half the practice of a decent lawyer, **1:20; 12:24; 16:4**

ROUTINE
Well-understood, Routine and Conventional (this index)

ROUTINE ASSESSMENT
Attorney fees, **18:12**

ROUTINELY BUILT
Conclusory statements, **9:113**

ROUTINE OPTIMIZATION
Obviousness, **9:449**

ROYALTIES
Appeal is review and not trial de novo, **6:12**
Blonder-Tongue, **1:13**
Damages, **8:20; 9:235**
Escrow, **3:21**
Expired patent, **11:79**
Factual findings to support jury verdict presumed, **2:15**
FRCP 52(a), **1:18**
In lieu of injunction, **16:106**
Reasonable Royalty (this index)
Running royalty agreement, **23:73**
Sales to subsidiary, **9:159**
Sec. 1631, **19:2**
Stay of patent action, **9:91**
Unpatented components, may be based on, **5:26**

RUBIK'S CUBE CASE
Generally, **13:28**

RULE 11
Generally, **19:258**

RULE 27(1)
Generally, **6:57**

RULE 28(D)
Confidentiality markings in brief, **9:337**

RULE 60(b)
Discretion of court, **12:100**

RULE 129(B)(1)(II)
Generally, **8:165**

RULE 131 AFFIDAVIT
Generally, **17:2**
Antedating reference, **7:19**
Four-part Graham inquiry, **7:19**
Graham inquiry, four-part, **7:19**
Obvious determination, **7:19**

RULE 131 AFFIDAVIT—Cont'd
Reasonable diligence, **1:344**
Reduction to practice, **1:344**
Reexamination, **7:19**
Reference, antedating, **7:19**

RULE 147
Generally, **12:10**
Own merits, each claim considered on, **12:10**

RULE 196
Rule 198, **9:31**

RULE 198
Rule 196, **9:31**

RULE 202
New evidence, **9:288**

RULE OF REASON
Corroboration, **9:288; 11:41; 12:92; 13:72; 19:132**
Sufficient circumstantial evidence, **3:82**

RUMORS
Appellate jurisdiction, **3:11**

RUSCC 60(B) MOTION
Claims court, **3:40**

SAFE HARBOR
ANDA, Hatch-Waxman safe harbor, **13:187**
Drug product importation, **1:175; 16:117**
Sec. 121, **2:140; 19:246**
URAA, **2:54; 4:40**

SAGE PRODUCTS, LLC V. STEWART
2025, **19:358**

SALAZAR V. AT&T MOBILITY LLC
2023, **19:344**

SALES
Adjudicated infringer, **11:10**
Commercial success, **9:111**
Damages, future lost sales, **6:74**
Infringement, **8:129**
Infringement, selling lower priced product does not justify, **16:33**
Laches, **15:14**
Offer for sale, infringement, **8:129**
Public use, **7:21**
Royalty calculation, **9:159**

SALES—Cont'd
Sec. 271, **10:17**
Summary judgment motion, **1:2**

SALES CONTRACT
On-sale bar, **26:8**

SALIX PHARMACEUTICALS, LTD. V. NORWICH PHARMACEUTICALS INC.
2024, **19:353**

SAME BURDEN
Sec. 1498, **12:11**

SAME CLAIM
Claim interpretation, **1:106**

SAME CLAIM INTERPRETATION
Used for validity and infringement, **2:45**

SAME CONCEPTS
Sec. 287, **13:33**

SAME DESIGN
Sec. 171, **9:73**

SAME EVIDENCE
Identity of invention, **20:20**
Mandamus, **9:41**

SAME INVENTION
Double patenting, **7:75; 9:52**
Expiration of patent right is not guarantee of right to use, **19:39**
Jury instructions, **10:4**
Obviousness-type, **19:39**
Obviousness-type double patenting, **9:52**
Reissue, **19:110**

SAME ISSUES
Enjoining concurrent litigation, **9:116**

SAME LOCATION
Doctrine of equivalents, **26:4**

SAME MEANING
Claim interpretation, **19:15**
JNOV motion, denial of, **13:13**

SAME PARTIES
Enjoining concurrent litigation, **9:116**

SAME PHRASES
Sec. 287, **13:33**

SAME RESULT
Graver Tank, **20:6**

SAME TERMS
Claim interpretation, **1:106; 5:63; 6:43**

SAME THING, NOT EQUAL TO
Preliminary injunction, **4:5**

SAME TIME
Co-inventors, **20:68**

SAME WAY
Construed same say, **11:9; 23:11**
Obviousness, **19:11**
Sec. 102(g), **11:9**

SAMPLE AS WITNESS
Claims determine what infringes patent, **9:4**

SANCTIONS
Generally, **1:364; 13:131; 13:135; 19:188**
Antitrust, **11:16**
Appeal and review, **13:71; 19:64**
Attorney fees, **12:36; 19:42; 20:115**
Choice of law, **19:114**
Confidentiality markings in briefs filed, **9:337**
Demand therefor must be supported, **17:2**
Discovery violation, **2:27; 18:94**
Dismissal without prejudice, **12:36**
Enforcement order, **4:20**
FRAP 38, **9:102; 23:89**
FRCP 11, **1:41; 3:150; 5:109; 9:125; 18:24; 18:95**
FRCP 37(b), **14:14; 20:4**
Frivolous appeal, **3:150; 5:96; 13:71**
Improper behavior in courtroom, **14:19**
Infringement, neither intent nor preparation constitutes, **12:22**
Inter partes review, **2:174**
ITC orders, violations, **14:65; 15:52**
Jurisdiction, **20:129**
Litigation misconduct, **1:193; 13:85; 20:87**
Mandamus, **9:57**
Patent and Trademark Office (PTO), **2:121**
Pro hac vice, **2:55**
Respond, failure to, **13:25**

SANCTIONS—Cont'd
Review, standard of, **9:161**
Sec. 1.287(d)(2), **23:14**
Sec. 1.616, **1:60**
Sec. 284, **2:31**
Sec. 285, **19:57**
Sec. 292, **6:72**
Sec. 455, **8:14**
Sec. 1292(c)(2), **9:6**

SANDERLING MANAGEMENT LTD. V. SNAP INC.
2023, **19:345**

SANHO CORP. V. KAIJET TECHNOLOGY INTERNATIONAL LIMITED, INC
2024, **19:354**

SANOFI-AVENTIS DEUTSCHLAND GMBH V. MYLAN PHARMACEUTICALS INC.
2023, **19:346**

SATELLITE LITIGATION
Generally, **3:42**

SCATTERGUN APPROACH
FRCP 15(c), **6:11**

SCHOOL, EXPERT STILL IN
Generally, **23:11**

SCHWENDIMANN V. NEENAH, INC.
2023, **19:347**

SCIENCE
Validity, **5:56**

SCIENTIFIC FORMULA
Prior art article, **9:48**

SCIENTIFIC OPINION
Evidence, **2:79**

SCIENTIFIC PRINCIPLES
Inventor's theory, **6:10**

SCIENTIFIC THEORY
Generally, **26:2**

SCIENTIST
Test results, **8:30**

SCPA
Mask works, **2:34**

SCREENING
Attorney disqualification, **16:3**

SEAGATE TEST
Enhanced damages, **8:137**

SEAGEN INC. V. DAIICHI SANKYO COMPANY, LTD.
2025, **19:359**

SEALED DOCUMENTS
Generally, **21:89**

SEARCH
Misrepresentation re prior art search, **7:29**

SEARS
Compco, **21:11**
Copying an article, **7:3**
Damages, **7:3; 21:11**
Lost sales caused by introduction of competitive product, **21:11**

SEC. 1.
Generally, **3:241; 8:67**

SEC. 1.11(b)
Sec. 1.195, **9:74**

SEC. 1.28
Generally, **4:52**

SEC. 1.48
Sec. 256, **19:76**

SEC. 1.51(a)
Generally, **5:57**

SEC. 1.54(d)(1)
Generally, **19:163**

SEC. 1.54(d)(2)
Generally, **19:163**

SEC. 1.56
Generally, **19:180**
Disclose references showing each known step, no obligation to, **8:29**

SEC. 1.84
Heavy lines show light direction, **9:137**

SEC. 1.137
Generally, **4:52**

SEC. 1.153
Form-of-claim requirement, **9:137**

SEC. 1.192(a)
Affidavit, **9:142**

SEC. 1.192(c)
Dependent claims not separately argued, **9:154**

SEC. 1.192(c)(7)
Generally, **13:108**
Representative claim, **8:107**

SEC. 1.195
Sec. 1.11(b), **9:74**

SEC. 1.196(a)
Rejection, grounds not specifically addressed by Board, **9:140**

SEC. 1.287(d)(2)
Sanctions, **23:14**

SEC. 1.324
Evidence, **23:55**

SEC. 1.601
Generally, **9:240**

SEC. 1.601(c)
Sec. 135(b), versus, **9:240**

SEC. 1.601(i)
Generally, **1:107; 9:163**

SEC. 1.601(n)
Generally, **1:107**

SEC. 1.616
Sanctions, **1:60**

SEC. 1.633(a)
Generally, **18:44**

SEC. 1.633(g)
Interference, **11:27**

SEC. 1.640
Interference, **3:32**
Order to show cause, **1:60**

SEC. 1.640(b)
Generally, **2:93**

SEC. 1.645(b)
EIC has broad discretion on late filings, **1:60**

SEC. 1.657(a)
Generally, **2:96**

SEC. 1.662(b)
Interference, **7:23**

SEC. 1.671
New interference rules, **8:3**

SEC. 1.671(f)
Generally, **2:96**

SEC. 1.1641
Patentability considered, **9:141**

SEC. 2
"Before the Office," **2:121**
Patent misuse, **20:2**

SEC. 2(b)(2)(D)
Generally, **11:50**
Disciplinary action, **2:121**

SEC. 6(a)
Commissioner's regulation if not inconsistent have force of law, **23:15**

SEC. 10.57(b)
Propriety of nondisclosure by attorney of another client's application, **13:69**

SEC. 13(b) CONDITION PRECEDENT
Interference, **2:93**

SEC. 26
Reissue, broadening, **9:3**

SEC. 32
Generally, **11:50**
"Before the Office," **2:121**
PTO registration of attorneys, **23:15**

SEC. 41(a)(7)
Agency's interpretation of statute, **13:32**
Commissioner's jurisdiction, **13:32**
Complaint, well-pleaded, **13:32**
Deference, entitled to, **13:32**
District court, **13:32**
Interpretation of statute, agency's, **13:32**
Jurisdiction, commissioner's, **13:32**
Well-pleaded complaint, **13:32**

SEC. 41(c)(1)
Generally, **7:87**

SEC. 43(a)
Competition, unfair, **15:5; 16:21**
8 Cir, **10:15**
Lanham Act, **12:23**

SEC. 43(a)—Cont'd
Summary judgment, **3:1**
Unfair competition, **15:5; 16:21**
Willful infringement, **3:26**

SEC. 85
Attorney fees award in contract action, **9:159**

SEC. 100
Generally, **19:174**

SEC. 100(d)
Generally, **1:68**
Patentee, **1:46**

SEC. 101
Generally, **1:277; 1:286; 1:322; 1:349; 1:368; 2:177; 2:191; 3:172; 3:213; 3:219 to 3:221; 3:232.70; 3:235; 3:239; 4:118; 5:146; 5:150; 5:153; 6:105; 9:393; 9:414; 9:416; 9:451; 9:465; 9:474; 9:487; 9:497; 9:498; 9:506; 9:511; 13:188; 14:98; 15:46; 16:178; 18:115; 18:125; 19:257; 19:306; 19:307; 19:328; 20:139; 21:81; 21:82; 21:86; 23:102; 24:8**
Abstract ideas, **1:95; 1:253; 1:285; 1:286; 1:290; 2:163; 3:143; 4:104; 5:128; 6:94; 9:286; 9:308; 13:188; 19:298; 19:301; 19:331; 20:143; 22:58**
Animals as patentable subject matter, **1:45**
Anticipation, **3:207**
Claim construction, **13:241; 19:320**
Computer-aided, **6:80; 19:292**
Computer-related limitations to significant part of invention, **1:251; 1:286; 2:147**
Correctness of inventor's theories, **18:6**
Covered business method review, **18:119; 20:154**
Damages, **6:97**
Definitions, **9:290**
Dismiss, motion to, **1:343**
DNA, **1:228; 1:245; 9:383**
Double patenting, **9:463**
Economic practice, **19:331**
Enablement, **18:6**
Estoppel, **19:320**
Failure to claim patent-eligible subject matter, **9:433**

SEC. 101—Cont'd
Failure to state a claim, **2:167**
Indefiniteness, **2:175**
Infringement allegations, **7:118**
Internet, abstract ideas, **1:285; 4:104; 9:437**
Inter partes review, **14:99**
Issue preclusion, **22:61**
Machine, **19:112**
Machine-or-transformation test, **9:308; 16:123; 21:62**
Man-made organisms, **1:228**
Mathematical algorithm, **9:308**
Means-plus-function claim, **4:97**
Nonstatutory subject matter, **9:30**
Obviousness, **14:99**
Overbreadth, **21:10**
Patent-ineligibility defense, **13:217**
Patent-ineligible subject matter, **1:310; 3:219; 3:227; 6:94; 9:431; 9:437; 13:210; 18:109**
Power grid monitoring, **5:128**
Practical utility requirement, **9:143**
Printed matter and substrate, **3:219; 9:32; 11:64**
Process claim, **3:164; 6:71; 9:308**
PVPA, **16:63**
Sec. 112, **18:6**
Sec. 285, **9:455**
Sovereign immunity, **21:78**
Standing, **9:452**
Statutory subject matter, **1:51; 3:164; 4:105; 6:82; 9:30; 9:154; 9:155; 9:286; 9:437; 13:178; 21:62**
Subject matter, **11:83**
Summary judgment, **2:175**
Utility, **2:34; 3:37; 5:7; 13:55; 14:4; 18:6; 20:25**
Vacation of summary judgment based on anticipation, **5:129**

SEC. 102
Anticipation, **9:104**
Classic test, **12:12**
Corroboration, **6:40**
Obviousness, **3:168**
Prior art, **19:257**
Public accessibility, **19:207**

SEC. 102(a)
Generally, **13:72; 13:122; 23:48**
First inventor, **7:98**

SEC. 102(a)—Cont'd
Foreign country, patented in, **9:120**
Known or used by others, **3:2**
Prior art reference, **9:120**
Third parties, **3:2**

SEC. 102(b)
Generally, **1:71; 3:96; 5:21; 5:77; 9:171; 13:122; 14:35; 14:44; 19:161; 23:48**
Additional references can be used for anticipation rejection to show possession by public, **9:18**
Analogous art, **19:7**
Anticipation, **7:99; 9:18; 9:129; 21:73**
Appeal, de novo review from PTO, **9:7**
Applicability, **19:31**
Complaint charging infringement of only certain claims, **19:31**
Court's role, **19:31**
Dates, obscuring, **2:1**
De novo review from PTO, **9:7**
Design patent, **20:32**
Disclosure, **9:18**
Enablement, **9:18**
Evidence, **9:7; 9:18**
Exception, supplier, **19:140**
Exceptional case, **9:93**
Experimental use, **7:12; 12:30**
Fatal wound, staunching, **4:16**
FRCP 41(b) motion, **19:31**
Incorporation by reference, **1:101**
Inequitable conduct, **9:7; 13:35; 21:73**
Infringement, **19:31**
Inventorship, **19:7**
Law of the case doctrine, **19:31**
Materiality, **13:35**
Method performed by hand, **4:16**
Motion, FRCP 41(b) motion, **19:31**
Offer to sell, **18:8**
Officers, **13:35**
On-sale bar, **1:52; 2:7; 3:41; 4:16; 5:15; 5:64; 6:25; 8:127; 9:5; 9:7; 9:93; 9:118; 9:279; 10:1; 11:10; 11:25; 16:32; 19:7; 19:31; 19:54; 21:1; 21:16; 23:6**
Patent applications not entitled to presumption of validity, **9:7**
Personal liability, **13:35**
Possession by public, **9:18**
Presumption of validity, **9:7**

SEC. 102(b)—Cont'd
Printed publication, **9:14; 9:18; 9:33; 12:89; 14:8; 16:25**
Prior art, **9:46; 9:150**
PTO, de novo review from, **9:7**
Public, possession of, **9:18**
Public use, **2:1; 2:45; 3:16; 8:23; 9:34; 9:75; 10:31; 13:35; 13:149; 20:14; 23:11**
References, **9:18**
Rejection, **9:18**
Sec. 1.195, **6:57**
Sec. 103, **2:1; 9:46**
Sec. 262, **8:5**
Skilled in art, failure by those, **9:18**
Staunching the fatal wound, **4:16**
Summary judgment, **1:2; 19:62**
Supplier exception, **19:140**
Technical paper, **13:11**
Third persons, activities of, **19:7**
Unfair competition, not, **3:16**
Validity, **9:7**

SEC. 102(c)
Anticipation, **5:65**

SEC. 102(d)
Generally, **2:90**
Filing date, **9:136**
Policy, **9:136**
Statutory bar, **9:136**

SEC. 102(e)
Generally, **9:212**
Actual commercial consequences, **19:41**
Anticipation, **20:115**
Commercial consequences, actual, **19:41**
Damages, jury damages award, **19:41**
Delay, **19:41**
Different inventive entities sharing common inventor, **1:22**
Disclosure of species anticipates generic claim, **9:28**
Effective date, **9:110**
Evidence before PTO on validity was material, **1:22**
Jury damages award, **19:41**
Laches, **19:41**
Pioneer, **19:41**
Presumption of validity, **1:22**
Prosecution history estoppel, **19:41**

SEC. 102(e)—Cont'd
Provisional rejection, **9:110**
Sec. 103 provisional rejection practice, **9:110**
Secret prior art, **19:41**
Separate steps, **19:41**

SEC. 102(f)
Generally, **3:117; 9:471; 12:40; 15:11; 16:50; 19:125**
Derivation of invention, **14:10**
Sec. 103, **15:11**

SEC. 102(g)
Generally, **3:59; 3:94; 5:77; 13:72; 13:103; 18:63; 21:39**
Arguments, **5:2**
As a whole, **11:9**
Bad axiom, **11:9**
Claims construed same way, **11:9**
Companies, **14:7**
Corroboration of non-party inventors, **20:48**
Design around, **11:9**
Diligence irrelevant when not first to conceive, **14:7; 16:148**
Foreign country, imported product produced by process performed in, **19:10**
Heart of process invention, process is, **19:10**
Intent, **11:9**
In this country, **1:111**
Materiality, **11:9**
Necessary, when, **19:10**
Non-party inventors, corroboration of, **20:48**
Obviousness, **11:9; 20:126**
Ordinary skill, hypothetical person of, **11:9; 20:126**
People conceive, **14:7**
Performance, **19:10**
Prior art, **5:2; 20:126**
Prior invention, **9:158**
Priority, **26:11**
Process, **19:10**
Prosecution history, **5:2**
Reduction in practice in U.S., **19:10**
Reduction to practice, **6:83**
Same, claims construed same way, **11:9**
Sec. 103, **11:9**
Sec. 103 prior art, as, **5:2; 20:126**

SEC. 102(g)—Cont'd
Sec. 104, **19:10**
Secret prior art, **19:41**
Sufficient, **19:10**
Suppression or concealment, **16:9**
Tests, **19:10**
Third party invention, **14:7**
Utility for any purpose, **19:10**

SEC. 102(g)(2)
Generally, **13:103; 13:105; 18:63; 19:132**
Prior inventor, **4:65**

SEC. 103
Amendment of 1984, **11:23**
Claim interpretation, **20:8**
Design patent, **9:8**
Mechanical misfit, **15:4**
Obviousness, **1:294; 3:168; 9:27; 9:62; 9:103; 9:117; 9:139; 9:295; 13:225; 15:4; 16:19; 23:84**
Physically combining references, **15:4**
Prima facie obviousness, **9:115**
Prior art, **5:2; 9:46**
PTO's burden to establish, **9:140**
References, **9:101; 15:4**
Rejection on single reference device capable of being operated like claimed apparatus, **9:101**
Sec. 102(b), **2:1**
Sec. 102(e), **9:110**
Sec. 102(f), **15:11**
Sec. 102(g), **11:9**

SEC. 103(2)
Prior art, exclusion of, **9:110**

SEC. 104
Foreign activity, **8:30**
Sec. 102(g), **19:10**

SEC. 111
Claims not in patent, **19:32**
Priority filing date, **19:32**

SEC. 112
Generally, **5:57; 11:8; 16:89**
Able to produce standard, **15:2**
Abstract ideas, **18:85**
Amend claims, **20:6**
Appealed, decisions are, **9:40**

SEC. 112—Cont'd
Best mode, **1:161; 1:194; 2:14; 4:2; 5:16; 19:21; 19:60**
Burden on patent challenger, **18:4**
Challenger, burden on, **18:4**
Chemical interference, **2:14**
Claim construction and interpretation, **4:23; 9:40; 9:339; 20:6**
Claim differentiation, **16:2**
Claim language itself, **9:72**
Claims too broadly written, **9:104**
Clear and concise, **15:2**
Competitor's product, to cover, **20:6**
Continuation case, effective filing date of, **18:4**
Corporate officer, **15:2**
Damages, **8:7; 19:7**
Date, effective filing date of continuation case, **18:4**
Definiteness, **1:161; 8:103; 16:114; 19:4**
Description, **9:46; 9:85; 18:4; 18:40; 20:6**
Detail required, **19:7**
Disclosure, **13:10**
Distinctiveness, **12:28; 16:2; 19:26; 21:17**
Doctrine of equivalents, distinct from, **16:2**
Effective filing date of continuation case, **18:4**
Enablement, **1:167; 1:304; 2:34; 3:14; 9:83; 13:56; 14:8; 17:1; 21:14; 23:8**
English grammar, read with precepts of, **9:40**
Equity powers, **19:4**
Equivalents, **8:7; 11:10; 20:6**
Evidence, **19:7; 19:125**
Fact question, **8:7**
Factual finding, **8:7**
Filing date, **18:4; 23:11**
Finding, factual, **8:7**
Foreign references, ignorance of, **17:1**
Functionality, construction, **2:154**
Indefiniteness, **1:21; 1:44**
Inequitable conduct, **8:7**
Injunctive relief, **1:304; 19:4**
Interference, **3:6; 3:28**
Issue date, only as of issue date of patent, **9:53**

SEC. 112—Cont'd
JNOV, **4:4**
Jury, **17:1**
Means-plus-function claims, **2:123; 16:11; 20:6; 23:63**
Obviousness, **9:86**
Only as of issue date of patent, **9:53**
Opinions, not, **9:40**
Overturn, easy, **19:7**
Paragraphs 1, 2, 6 contrasted, **1:99**
Personal liability, **15:2**
Prima facie case of acquiescence in examiner's rejection for inadequate disclosure, **16:10**
Procedural issue, **8:21**
Records, failure to keep, **8:7**
References, foreign references, ignorance of, **17:1**
Sec. 101, **18:6**
Sec. 120, **8:19**
Single means claim, **9:40**
Special verdict, **17:1**
Statements out of context, improper to take, **9:86**
Support, lack of, **9:86**
Totality of circumstances, **15:2**
Validity, claims construed to preserve, **20:6**
Willful infringement, **15:2; 19:7**
Written description, **1:252; 1:258; 8:101; 9:46; 18:4**

SEC. 112(1)
Generally, **2:90; 5:69; 7:57; 9:189; 10:24; 12:73**
Best mode, **7:34; 20:33; 23:19**
Description, written, **1:200; 9:125; 9:130; 19:254; 22:7; 23:25**
Disclosure, sufficiency of, **23:30**
DNA, **18:40**
Enablement, **6:20; 9:113; 9:115; 9:134; 9:142; 9:143; 13:55; 16:141; 19:51**
Experiment, undue experimentation, **10:23**
Indefiniteness, **3:54**
Inherently present, **18:52**
Mass production specifications, inventor not required to supply, **23:19**
Sources and techniques, **23:19**
Specification, **3:54; 23:19**

SEC. 112(1)—Cont'd
Undue experimentation, **10:23**
Utility, **9:165**
Written description, **1:200; 9:125; 9:130; 19:254; 22:7; 23:25**

SEC. 112(2)
Generally, **5:58; 9:189; 15:20; 19:131**
Certainty and definiteness, **5:106**
Clam indefiniteness, **2:45**
Definiteness, **3:37; 14:66; 14:72**
Evidence beyond specification, **19:125**
Indefiniteness, **13:55; 14:12**
Need to particularly point out and distinctly claim, **9:149**
Review, standard of, **9:240**
Specification, evidence beyond specification, **19:125**

SEC. 112(6)
Generally, **1:130; 9:130; 9:189; 12:66; 13:111; 19:131; 20:59**
Argument, **10:7**
Claim construction, means-plus-function claim, **6:81; 23:79**
Claim differentiation doctrine versus, **12:26**
Claim interpretation, prior art, effect on, **11:28**
Corresponding structure, **14:38; 14:56**
Doctrine of equivalents distinguished, **9:149**
Infringement, **9:215; 16:51**
Interpretation of means-plus-function claim limitation, **22:10**
Limitations and restrictions, **9:149; 22:10**
Means-plus-function, **1:51; 3:37; 6:81; 9:131; 9:149; 10:7; 10:13; 14:56; 14:66; 18:107; 19:59; 22:10; 23:79**
Prior art, **1:91; 9:118; 11:28**

SEC. 116
Generally, **16:50; 19:102**
Amendment of 1984, **11:23**
Claim broadened if broader in any respect, **9:3**
Claim interpretation, **19:15**
Inventorship, **8:115**
Joint inventorship, **2:48; 22:39**
Purpose of reissue statute, **9:3**

SEC. 116—Cont'd
Reissue, purpose of reissue statute, **9:3**
Sec. 256, **9:3**

SEC. 117
Generally, **23:57**

SEC. 119
Acting on behalf of, **2:125**
Activity outside U.S., **19:144**
Benefit of filing date of foreign priority application, **9:143**
Foreign countries, **6:66; 9:143; 19:144**
Sec. 120, **9:28**

SEC. 120
Generally, **2:90; 5:20; 9:205; 9:243; 13:193; 18:52**
Amendments, **8:19**
Application, **8:19; 12:10**
Benefit of earlier filing date, **12:99; 20:33**
Best mode, **8:19**
Chain of related applications, **12:10**
CIP, **9:73**
Computer, **8:19**
Constructive reduction to practice, **9:13**
Disclosure, sufficiency of, **11:8**
Earlier filing date, **2:142; 5:104; 12:99; 18:85; 20:33; 20:88; 26:12**
Election of species, **12:10**
Entitlement to earlier filing date, **11:8**
Filing date, **11:8; 20:33**
Incorporation by reference, **4:122; 26:12**
Inherent property, **11:8**
Parent application, **8:19**
Pioneer, **8:19**
Post-invention technology, **8:19**
Prosecution history estoppel, **8:19**
Reduction to practice, constructive, **9:13**
Related applications, chain of, **12:10**
Sec. 112, **8:19**
Sec. 119, **9:28**
Sec. 121, **18:1**
Serve different functions, **8:19**
Species, election of species, **12:10**
Submit claims, failure to, **2:68**

SEC. 121
Clear demarcation required, **7:75**
Double patenting, **7:115**

SEC. 121—Cont'd
Markush claim rejection, **9:105**
Obviousness-type double patenting, **19:59**
Reissue, **7:115**
Restriction, requirement for, **2:140; 7:16; 16:112**
Sec. 120, **18:1**

SEC. 121(1)
Generally, **1:80**

SEC. 121(2)
Generally, **1:80**

SEC. 121(3)
Generally, **1:80**

SEC. 121(4)
Generally, **1:80**

SEC. 122(a)
Special circumstances exception, **8:135**

SEC. 131
Conception, **9:407**
Reduction to practice, **9:407**

SEC. 132
Generally, **20:59**
New matter, **2:34**
Rejection, reasons for, **3:32**

SEC. 135(a)
Board can decide both priority and patentability, **9:116**

SEC. 135(b)
Generally, **1:107; 2:93; 9:198**
Interference, **1:219; 1:220**
Sec. 1.601(c), **9:240**

SEC. 135(c)
Certiorari possibility, **3:29**
Interference settlement agreement, failure to file, **3:29**

SEC. 136
Interference, **4:27**

SEC. 141
Generally, **13:115**
Appeal and review, **9:59; 16:173; 22:44**
District court, **6:9**
Estoppel, **2:165**
Interference, **2:165**

SEC. 141—Cont'd
Removal procedure, **9:116**
Sec. 146, **2:165; 9:116**

SEC. 142
Appellate review, no restriction on scope of, **9:59**

SEC. 143
Appellate review, no restriction on scope of, **9:59**
Brief required, **9:116**

SEC. 144
Appellate review, no restriction on scope of, **9:59**

SEC. 145
Generally, **13:115; 14:92**
Admissibility of evidence, **8:111**
Appeal and review, **6:9; 9:59**
Assessment of costs on appeal, **14:4**
Attorneys fees, **8:162; 14:80**
CAFC, **6:9**
Costs of action imposed on patentee, **10:16**
Costs on appeal, assessment of, **14:4**
Crediting expert, **7:9**
De novo determination, **14:4**
Direct appeal, **6:9**
Disclosure, reject, **7:9**
Enablement, **7:9**
Expert, crediting, **7:9**
How to do it, **7:9**
Jurisdiction, **9:394**
Law question, **7:9**
New evidence, **7:9; 8:118; 11:68**
Previously done, something not, **7:9**
Reject disclosure of how to do it, improper to, **7:9**
Review, standard of, **13:115**
Sec. 146 actions, **20:11; 20:125**
Skilled at time of invention, **7:9**
Standing, **2:18**

SEC. 146
Generally, **23:44; 23:52**
Estoppel, **2:165**
Interference, **1:42; 2:165; 3:6; 3:53; 7:26**
Review, standard of, **20:125; 23:52**
Sec. 141, **2:165; 9:116**
Sec. 145, **20:11; 20:125**

SEC. 151
Generally, **4:52**

SEC. 153
Issue date, whether patent was validly issued on, **5:17**

SEC. 154
Generally, **4:106**

SEC. 154(b)
Patent term adjustment, **23:69**

SEC. 156
Generally, **2:187; 8:61; 13:120**
Ambiguity, **21:6**
Congress, policy for, not courts, **6:3**
Extension of patent term, **6:3**
Patent term extension, **21:6**
Plain meaning rule, **6:3**
Statutory construction and interpretation, **6:3; 21:6**
Summary judgment, **1:139**
Term, extension of, **6:3**
Terminal disclaimers, **13:144**

SEC. 156(a)
Generally, **3:72**

SEC. 156(a)(4)
Extension of term, **16:125**
Patent term extension, **8:25; 15:35**

SEC. 156(d)(1)
Generally, **1:74**

SEC. 156(e)(2)
Patent term extension, **19:197**

SEC. 156(f)
Generally, **13:120**
Extension of term, **16:125**

SEC. 156(g)
Patent term extension, **23:70**

SEC. 161
Plant patents, **9:355**

SEC. 171
Aesthetics determination, **9:73**
Complete articles, not limited to designs for, **9:73**
Design, **9:73; 9:106**
Differences, whether are significant, **9:73**

SEC. 171—Cont'd
Limitations, **9:73**
Obviousness, **9:73**
Same, designs same, **9:73**

SEC. 172(b)
Inducing infringement, **26:2**

SEC. 183
Use of invention, **8:117**

SEC. 207(a)(2)
Government as necessary party to suit by its exclusive licensee, **14:9**

SEC. 210.30
Generally, **7:52**

SEC. 210.36
Generally, **7:52**

SEC. 211.54(a)
ITC, **1:15**

SEC. 236
Generally, **16:50**

SEC. 251
Generally, **8:64**
Broadening reissue, **1:52**
Compelling patentee to seek no defect reissue, **7:21**
Reissue, **2:4; 7:21; 8:12; 9:69; 9:84; 9:85; 9:105; 9:138; 19:51**
Sec. 255, versus, **19:142**

SEC. 252
Discretion of trial court, **19:4**
Enhanced damages, **21:3**
Evidence not considered de novo, **19:4**
Expert witnesses, **19:4**
Reexamination, **12:25**
Reissue, **19:4; 19:13; 19:55; 23:26**
Sec. 255, versus, **19:142**
Summary judgment, **8:17**

SEC. 252(2)
Reissue patent, **2:40**

SEC. 254
Generally, **7:87; 14:39**
Certificate of correction, **19:56**

SEC. 255
Generally, **6:44; 14:39**

SEC. 255—Cont'd
Clerical or typographical mistake, **19:142**
Sec. 251 versus, **19:142**
Sec. 252 versus, **19:142**

SEC. 256
Generally, **6:35; 6:44; 19:102; 23:55**
Correction of inventorship, **16:131**
Joint inventors, **22:54**
Sec. 1.48, **19:76**
Sec. 116, **9:3**

SEC. 261
Federal law, **18:58**
Patent property, **10:4**
Validity, patent not to be found valid, **10:4**

SEC. 262
Enforcement and enforceability, **19:264**
Joint inventor's freedom to license, **8:5**
License, joint inventor's freedom to, **8:5**
Public use, **8:5**
Sec. 102(b), **8:5**

SEC. 263
Each claim must be evaluated, **15:6**

SEC. 271
Generally, **9:268**
Sale of plant embodying patented process not sale of invention, **10:17**

SEC. 271(a)
Generally, **14:47**
Damages, **1:270; 3:180; 8:138**
Divided infringement, **1:270**
Exceptional case, **3:180**
Extraterritorial activities, **13:135**
Inducement, **19:322**
Infringement, testing, **23:53**
Invalidity, **3:180**
Laches or delay, **3:180**
Method claim, **1:269**
Offer for sale, **18:54; 20:46; 20:103**
Process, **18:79**
Sale, **3:180; 8:138**
Sec. 271(e), **18:18**

SEC. 271(b)
Generally, **13:122; 13:136; 19:92; 20:54**

SEC. 271(b)—Cont'd
Inducing infringement, **7:103; 8:24; 11:60; 16:22**
Knowingly, **13:124**

SEC. 271(c)
Contempt, **16:25**
Contributory infringement, **6:23; 18:79**
Damages, **20:23**
Inducing infringement, **8:24**

SEC. 271(d)(5)
Generally, **21:51**

SEC. 271(e)
Infringement, **6:65**
Sec. 271(a), **18:18**

SEC. 271(e)(1)
Generally, **1:85**
Abuse of discretion, **5:3**
Appealability, **5:13**
DPCA, **20:26**
Drugs, restricted to drugs alone, not, **5:3**
FDCA, **3:182**
Findings, new judgment as negating, **5:13**
Generic drugs, **3:159**
Infringement, **5:13**
Injunction, **5:3; 5:13**
International Trade Commission, **1:184**
Law of the case, **13:206**
Medical devices, infringement exception for, **5:13; 16:117**
New judgment as negating prior findings, **5:13**
Permanent injunction, when proper, **5:13**
Pre-clinical research, **9:251**
Premarketing approval of generic drugs, **3:159**
Research, pre-clinical, **9:251**
Research tool exception, **9:299**
Restricted to drugs alone, not, **5:3**
Reviewed under abuse of discretion standard, **5:3**
Safe harbor for drug products, **1:175; 16:117**
Sec. 271(g), **13:206**
Threat of sale, **5:13**
Willful contempt order, **5:13**

SEC. 271(e)(2)
Generally, **1:128; 7:55; 7:69; 20:78**

SEC. 271(e)(2)(A)
Generally, **2:74; 7:55; 13:137; 14:33**
Abbreviated new drug application, **9:312**

SEC. 271(e)(4)
Generally, **1:128; 7:81**

SEC. 271(f)
Generally, **5:77; 18:54**
Combination, Sec. 271(f)(2), **16:141; 23:53**
"Component" of patented invention, **1:146**
Damages, **23:82**
Lost profits, **23:82**
Outside United States, **21:52**
Standing, **23:82**

SEC. 271(f)(1)
Generally, **16:83**

SEC. 271(f)(2)
Actual combination, not require, **23:53**
Extraterritoriality, **23:93**

SEC. 271(g)
Generally, **1:102; 2:60; 11:54**
Importation, prohibits, **2:80**
Inducement, **19:322**
Infringement, when, **13:105**
Law of the case, **13:206**
Process patented, product which is made by, **2:97**
Sec. 271(e)(1), **13:206**

SEC. 272
Generally, **14:41**

SEC. 281
Generally, **1:68**
Patentee's civil action for infringement, **1:222**
Standing, **4:116**

SEC. 282
Born valid, patents are, **6:10**
Burden of proof, **9:80**
Cited art considered by PTO, **12:6**
Combination, **18:6**
Combination of old elements, **6:10**
Congress, intent as clear, **12:5**

SEC. 282—Cont'd
Defenses available, **16:50**
Disclosure, statutory outer limits, **23:76**
Each claim treated independently, **13:55**
Elements, combination of, **6:10**
Equivalency finding, **18:6**
Experiment, failed, **6:10**
Fraud, **8:23**
Independently, each claim treated, **13:55**
Inequitable conduct, **8:23**
Intent of Congress is clear, **12:5**
Inventor's admission of invention by another, **1:8**
ITC, **19:25**
Notice and knowledge, **1:92; 5:1; 20:15**
Objective, **6:10**
Obviousness, **1:4**
Only God works from nothing, **6:10**
Presumption, **6:10; 8:23; 9:21; 9:57; 9:80; 12:6; 13:87; 16:4; 18:6**
Prior art, not, **6:10**
Procedural presumption, **6:10**
PTO, cited art considered by, **12:6**
Public interest not involved, **12:5**
Raised or waived, **4:58**
Reexamination, **9:80**
Reference, failure to notice, **5:1**
Review, standard of, **18:6**
Secondary considerations, **6:10**
Statutory construction, **12:5**
30-day notice, **20:15**
Valid, patent born valid, **12:5**
Validity
generally, **6:10**
presumption of, **9:21; 9:57; 9:80; 12:6; 13:87; 18:6**
reexamination, **9:80**
Waived or raised, **4:58**
Waiver, **20:15**

SEC. 283
Generally, **10:23**
Contempt, **11:17**
Discretion of court, **18:18**
Injunction, **10:17; 18:18**
Issuance of injunction is discretionary, **18:18**

SEC. 284
Generally, **3:96; 10:21; 13:72; 13:79; 19:92; 21:23**

SEC. 284—Cont'd
Anticipation, **16:167**
Convoyed sales, **2:31**
Cost savings, estimated cost savings, **8:4**
Damages, generally, **2:31; 4:6; 4:7; 8:4; 11:21; 12:4; 13:157; 19:29; 19:35; 19:53; 20:23**
Design patent, **3:98**
Enhanced damages, **1:62; 2:30; 2:40; 8:123; 18:29**
Estimated cost savings, **8:4**
Exclusive vendor as co-plaintiff, damages, **11:18**
Hypothetical negotiation, **1:296**
Infringement, willful, **4:32; 7:27**
JNOV, **23:4**
Judge, assignment of different, **2:31**
Lost profits, **2:31**
Marking statute, **14:24**
Nominal damages, **12:24**
Precision, not ascertainable with, **2:30**
Prejudgment interest, **4:7**
Public use, **16:167**
Reasonable royalty, **2:6**
Records, failure to keep, **2:30**
Remanded cases, **2:31**
Sanctions, **2:31**
Sec. 285, **18:22**
Sec. 1927, **2:31**
Settlement agreement, breach of, **7:54**
Validity, **16:167**
Weight and credibility of evidence, **2:31**
Willful infringement, **4:32; 5:19; 7:12; 7:27; 8:123; 19:57**

SEC. 285
Generally, **2:55; 3:221; 5:155; 6:53; 7:57; 7:114; 9:266; 11:10; 13:72; 15:60; 15:62; 19:311**
Abuse of discretion, **2:170; 7:20**
Appeal, award of attorney fees on, **4:16**
Attorneys' fees, **2:170; 3:42; 3:196; 4:16; 4:32; 5:137; 7:20; 7:27; 8:18; 8:38; 8:130; 12:4; 13:38; 16:5; 18:121; 18:123; 19:3; 19:33; 19:35; 19:51; 19:58; 19:313; 23:6**
Choice of law, **23:57**
Claim construction, **1:5; 19:320**
Dismissal of action, **3:42; 19:200**
Estoppel, **19:320**

SEC. 285—Cont'd
Exceptional case, **1:299; 2:9; 2:33; 5:14; 5:109; 5:151; 6:13; 8:130; 9:316; 13:2; 13:175; 14:88; 15:3; 15:45; 19:52; 19:269; 20:151; 21:75**
Experimental use, **5:137**
Expert's report, **5:14**
Fraud, exceptional case for reasons other than, **15:3**
Inequitable conduct, **5:137; 16:59; 18:43**
Inference drawn from party's failure to offer its expert's report, **5:14**
Infringement, **2:170; 3:42; 7:20**
Intent, **5:14**
Jury trial, **1:300**
Maintenance fees, **9:470**
Notice and knowledge, **5:14**
On-sale bar, **5:137**
Purpose, **2:27**
Sanctions, **19:57**
Sec. 101, **9:455**
Sec. 284, **18:22**
Settlement agreement, breach of, **7:54**
Should have known, **5:14**
Willful infringement, **1:201; 2:170; 7:20; 15:6; 19:28**
Willfulness, **2:34**

SEC. 286
Damages, **1:47**
Future acts of others, **19:27**
Liability arises when acts are committed, **19:27**
Limitation of actions, **19:27**
Statute of limitations, not, **1:48**
Third persons, future acts of others, **19:27**

SEC. 287
Bifurcation, **4:12**
Damages-notice, **4:12**
Documents not marked, **4:12**
Error harmless where no evidentiary basis for contrary verdict, **4:12**
Excludable, **4:12**
Implied license, **4:12**
Marking, **4:12; 8:4; 13:33**
Notice and knowledge, **2:6; 4:12; 7:92; 13:33**
Patent marking notice, **13:33**

SEC. 287—Cont'd
Practice, **4:12**
Process, marking not necessary for, **8:4**
Same concepts, **13:33**
Same phrases, **13:33**

SEC. 287(a)
Generally, **12:58; 13:75**
Actual notice requirement, **21:53**
Method or process, not applying to, **3:96**
Patent marking, **1:58; 1:62**
Process or method, not applying to, **3:96**

SEC. 287(b)(5)
Letters to customers as infringement threats, **13:41**

SEC. 289
Damages, **14:77; 19:293**
Marking statute, **14:24**
Profits, **2:33**

SEC. 291
Change of circumstances, not defeated by, **1:11**
Claim construction, **1:5**
Federal question jurisdiction, **1:11**
Interference, **19:149**
Interfering patents, **1:11; 7:102; 11:23**
Oral findings sufficient, **1:11**
Subject-matter jurisdiction, lack of, **1:11**

SEC. 292
Generally, **3:118**
Constitutionality of AIA elimination of qui tam provision, **2:151; 3:195**
False patent marking, **1:23; 3:118; 9:329; 12:23; 19:224; 19:262**
Per article interpretation, **6:72**

SEC. 295
Generally, **14:31**
Product by process, **14:31**

SEC. 303
Constitutionality of procedures, **16:8**

SEC. 304
Reexamination in subsequent litigation, effect of, **19:46**
Sec. 305, **19:46**

SEC. 305
Reexamination, **9:151; 16:115**
Sec. 304, **19:46**

SEC. 314(d)
Appeal dismissal, **2:180**
Jurisdiction to review, **9:425**
Obviousness, **9:418**
Scope of review, **9:418; 13:236; 19:260**
Standard of review, **9:418**

SEC. 315(b)
Inter partes review, **1:324**
Real party in interest, **1:324**

SEC. 315(c)
Generally, **13:240**

SEC. 316(a)(3)
Inter partes review, **21:74**

SEC. 329
Covered business method review, **7:117**

SEC. 335B(a)(1)
Generally, **2:74**

SEC. 337
Generally, **19:106; 19:176; 19:177**
Appellate function, **3:23**
Commission findings, **3:23**
Contributory infringement, **19:222**
Defined, substantial evidence, **3:23**
Exclusion orders, **3:23; 25:9; 25:10**
Imports, exclusion order against, **3:23**
Infringement, no injury despite, **3:23**
Injunctions, **19:222**
Inventor's admission of invention by another, **1:8**
ITC, **1:15; 2:12; 3:23; 5:98; 12:5; 18:26; 19:25; 20:105; 21:64**
No injury despite patent infringement, **3:23**
Purpose, **3:23**
Res judicata, not, **3:23**
Substantial evidence, **3:23**

SEC. 337(a)
Generally, **13:107**
ITC, **1:39**

SEC. 337(c)
ITC, **6:14**

SEC. 355(j)
Generally, **1:128**

SEC. 355(j)(2)
Generally, **1:128**

SEC. 355(j)(2)(A)(vii)
Generally, **1:128**

SEC. 355(j)(2)(A)(viiii)
Generally, **1:128**

SEC. 355(j)(5)(B)(iii)(iii)
Generally, **13:107**

SEC. 455
Judge disqualification, **8:14**
Sanctions reserved for matters more serious than mere oversight, **8:14**
Statute is self-enforcing and self-executing, **1:65**

SEC. 455(a)
Motion to disqualify trial judge, **8:12**

SEC. 553
APA, **1:45**

SEC. 703(c)
APA, **13:51**

SEC. 706(2)
APA, **13:50**

SEC. 1117(a)
Attorneys' fees, **18:121**

SEC. 1267
Supplemental jurisdiction, **7:25**

SEC. 1291
Increasing supersedeas bond, **19:42**

SEC. 1292
Appellate jurisdiction, lack of, **1:31**

SEC. 1292(a)(1)
Appealability, **18:11; 23:13**
Beginning of patent term, needed more at, **23:13**
Continue, evidence that status quo can, **23:13**
Evidence that status quo can continue, **23:13**
Immediately appealable interlocutory order denying injunction, **23:13**
Injunctive relief, **16:116; 23:13**
Interlocutory order, **18:16; 23:13**
Jurisdiction, **14:6**
Preliminary injunction, failure to seek, **23:13**

SEC. 1292(b)
Generally, **21:41**
Appeal from interlocutory order, **9:97**
Interlocutory appeal, **10:43; 14:9**
Interlocutory order, appeal from, **9:97**
Sec. 1292(c) certification, **17:3**

SEC. 1292(c)
Sec. 1292(b), **17:3**

SEC. 1292(c)(1)
CAFC has exclusive jurisdiction of appeals involving preliminary injunctions in patent cases, **5:8**
Federal patent policy, **6:17**
Sec. 1292(a), **16:116**

SEC. 1292(c)(2)
Appeal, interlocutory appeal, **9:6**
Appealability of interlocutory order, **10:12**
Appealable judgment, **13:5**
Attorney, sanctioning counsel, **9:6**
Final judgment, **13:8**
Interlocutory appeal, **9:6; 13:61**
Interlocutory order, appealability of, **10:12**
Sanctioning counsel, **9:6**

SEC. 1292(d)(2)
Escrow, **3:21**

SEC. 1337
Generally, **16:51**
ITC, **3:154; 25:2**

SEC. 1337(a)
Imported drug products, **1:175**

SEC. 1337(c)
Generally, **11:54**
ITC, **8:28**

SEC. 1337(d)
ITC, **8:28**
Limited exclusion order, **11:60**

SEC. 1337(e)
ITC, **8:28**

SEC. 1338
Generally, **22:5**
Arising under jurisdiction, **3:14**
Subject matter jurisdiction, **1:49; 11:20**

SEC. 1338(a)
Antitrust claim, **21:13**
Arising under subject matter jurisdiction of distinct court, **1:53**
Jurisdiction, **1:160; 4:22; 4:92**
Subject matter jurisdiction, **1:7; 5:17**

SEC. 1338(b)
Dismissal for lack of subject matter jurisdiction, **13:58**

SEC. 1346(b)
Interference, **3:6**

SEC. 1355
Generally, **19:106**

SEC. 1367
Supplemental jurisdiction, **8:97; 13:58; 14:82; 22:36**

SEC. 1391(c)
Sec. 1400(b), **22:6**

SEC. 1400(b)
Assuming control of litigation does not waive venue, **9:11**
Sec. 1391(c), **22:6**
Venue, **9:11; 9:445**
Waiver, **9:11**

SEC. 1406(a)
Venue, **9:447**

SEC. 1407(a)
Judicial Panel on Multi-District Litigation (JPMDL), **7:6**

SEC. 1447
Assignor estoppel, **6:96; 22:46**

SEC. 1491
Limited to claim court, **20:16**

SEC. 1498
Generally, **7:47; 15:4**
Claims court, **16:38**
Damages, **13:35**
Each claim element essential, **12:11**
FRCP 41(a)(1)(B), **1:279**
Government, acting by or for, **9:398; 20:18**
Inducement, **1:279**
Lost profits, **13:35**
Paramount, **20:16**
Prosecution history, **12:11**

SEC. 1498—Cont'd
Relevant, always, **12:11**
Relevant art field, **15:4**
Sales to government, **13:35**
Same burden, **12:11**
Skill, level of, **15:4**

SEC. 1498(a)
Generally, **8:56; 13:109**

SEC. 1500
Subject matter jurisdiction, **21:15**

SEC. 1631
Counterclaims, **19:2**
Defenses, **19:2**
Dismiss or transfer, **19:2**
License agreement, suit for royalties due under, **19:2**

SEC. 1651
All Writs Act, **9:157**
CAFC jurisdiction over JPML consolidation order, **9:128**
Interest of justice, **3:14**
Mandamus, **2:2; 9:41; 9:54; 9:68; 9:71; 9:76**

SEC. 1657(b)
Generally, **2:96**

SEC. 1659
Stay, **9:292**

SEC. 1782
Generally, **9:193**
Mandamus, **9:406**

SEC. 1821(b)
Limitation on award of expert witness fees, **1:62**

SEC. 1927
Generally, **7:126**
Comply with court rules, failure to, **10:10**
FRAP, **1:41**
Sec. 284, **2:31**

SEC. 1961(a)
Post-judgment interest, **7:27**

SEC. 2201
Declaratory judgment, **7:25; 9:89; 9:92; 10:6; 12:23; 13:41; 19:22; 19:55; 23:9**

SEC. 2201—Cont'd
Dismissal, **7:25; 13:41**

SEC. 2201(a)
Generally, **19:81**

SEC. 2412(b)
Costs and attorney fees award against government in Claims Court, **13:48**

SEC. 2501
Generally, **2:53**

SEC. 2516(a)
Generally, **19:83**

SEC. 2568(a)
Generally, **19:173**

SEC. 7703
APA, **2:32**

SEC. 7703(c)
APA, **8:31; 11:26**

SECOND ACTION
Claim preclusion, **8:76**

SECONDARY
Objective, **19:19**

SECONDARY CONSIDERATIONS
Generally, **1:87; 2:59; 13:253; 16:48**
Afterthought, **9:82**
Anticipation definition, **4:15**
Appeal, theory raised for first time on, **9:82**
CCPA decisions, **9:74**
Commercial success, **3:41; 9:82; 9:331**
Cross-appeal to reverse validity or infringement component of judgment, **18:2**
Description, **6:99**
Due entirely to improvements and modifications made by others, **9:82**
Evidence, **13:17; 13:45**
Exclusion, **13:17**
Expectation, unexpected result, **16:4**
Function of patent claims, **9:82**
Improvements, **9:82**
Inequitable conduct, **4:10; 11:4**
Instructions, **13:17**
Means-plus-function claims, **13:17**
Modification, **9:82**

SECONDARY CONSIDERATIONS —Cont'd
Must always be considered when present, **9:82**
Must be considered, **9:70**
Neutral factor, absence of, **13:17**
New prior art not considered by PTO, **5:11**
Nexus, **9:168; 9:331; 16:49; 19:36**
Nonparty's motion to quash discovery subpoena, **20:17**
Object, failure to, **13:17**
Objective indicia, **14:2**
Obviousness, **3:175; 3:190; 5:131; 6:99; 8:153; 9:331; 13:45; 16:4; 16:168; 18:15; 19:11; 21:8; 23:66**
Prior art, invention need not be superior to, **4:10**
Raising issues, **9:82**
Review, standard of, **9:207; 19:12**
Sec. 282, **6:10**
Settlement evidence excluded, **13:17**
Summary judgment, **3:1; 8:14; 21:7**
Theory raised for first time on appeal, **9:82**
Third persons, **9:82**
Unexpected results, **12:13; 16:4**
Valid, inappropriate to declare, **4:19**
Weight given thereto, **18:28**

SECOND BITE AT APPLE
Generally, **12:31**

SECOND PROCEEDING
Collateral estoppel, **7:65**

SECRET COMMERCIAL USE
Public use bar, **11:12**

SECRET PRIOR ART
Sec. 102(e) v. sec. 102(g), **19:41**

SEIZURE
Enforcement order, **4:20**

SELECTION OF TRANSFEREE FORUM
Relevant factors, **9:128**

SELF-EXECUTING STATUTES
Due process, **18:33**

SELF-INITIATED INVESTIGATION
ITC decision, **2:17**

SEMICONDUCTOR CHIP
Foundry arrangement, **9:145**

SEMICONDUCTOR CHIP PROTECTION ACT (SCPA)
Mask works, **2:34**

SENIOR PARTY
Interference, **2:96; 15:1**
Remand, when appropriate, **2:26**
Testimony, right to stand on its position and take no, **2:47**

SENIOR SCIENTIST
Test results, **8:30**

"SEPARATE"
Appellate jurisdiction, lack of, **1:31**
Argued, claims not, **9:119**
Argued separately, **9:30; 9:173**
Claim differentiation doctrine, **1:92**
Compound and its properties are inseparable, **9:103**
Dependent claims not separately argued on appeal, **9:100**
Doctrine of equivalents, **7:77**
Double patenting, **7:22**
Each claim, **10:8**
Equivalence, **6:42**
FRCP 79(a), **5:45**
Inequitable conduct, **7:1**
Infringement, **8:52**
Laches, **19:76**
Mandamus, **9:41**
Materiality, **4:72**
Obviousness, **18:23**
Sec. 1.192(c), **9:154**
Sec. 102(e) v. sec. 102(g), **19:41**
Stand or fall together, claims not argued separately, **9:117**
Statutory construction, **1:72**
Statutory interpretation, **8:43**
Treated separately, **16:25**

SEPARATION OF POWERS
Generally, **1:376**

SEQUOIA TECHNOLOGY, LLC V. DELL, INC.
2023, **19:348**

SERIES OF LEGAL PROCEEDINGS
Sham litigation, **5:108**

SERIOUS QUESTION
Preliminary injunction, **1:40**

SET ASIDE
FRCP 60(b), **6:22**
Jury verdict, **3:173; 14:47**
New evidence introduced, **6:9**

SETTLEMENT AND SETTLEMENT AGREEMENT
Generally, **19:1; 19:326; 20:80**
Antitrust, **9:309**
Attorney, disqualification of counsel, **19:40**
Bad faith not requirement for breach thereto, **12:39**
Breach thereof, **7:54**
Choice of law, **1:100; 7:54; 16:99**
Complaint dismissed for mootness, **19:14**
Contracts, **3:107**
Discovery, settlement negotiation privilege, **9:362**
Disqualification of counsel, **19:40**
Enforcement thereof, **2:138; 8:48; 9:159**
FRAP 38, **19:1**
Frauds, Statute of, **19:40**
Frivolous appeal, **19:1**
Infringement, **16:40**
Interpretation, **10:9**
Joint motion to vacate judgments below, **21:22**
Judgment, joint motion to vacate, **21:22**
Judicial estoppel, **23:21**
Jurisdiction, **7:54**
Lear distinguished, **8:11**
Mootness, **11:23**
Motion, joint motion to vacate judgments below, **21:22**
Partial settlement may moot appeal, **7:8**
Professional conduct, local bar standards of, **19:40**
Refusal to engage in settlement negotiations, **15:37**
Reverse settlement, **6:87**
Sec. 284, **7:54**
Sec. 285, **7:54**
Secondary considerations, **13:17**
Vacation, **21:22**

SEVENTH AMENDMENT
Jury trial, right to, **1:58; 3:71; 9:170; 13:64; 13:74; 16:8; 19:195**

SEVERAL COMMON MEANINGS
Claim interpretation, **9:246**

SEVERAL PATENTS, ONE OF
Inequitable conduct, **12:3**

SEVERANCE
Mandamus, **9:359**

SEVERE REMEDY
Civil contempt, **13:1**

SEXUALLY REPRODUCED VARIETY
Plant Variety Protection Act (PVPA), **9:162**

SHAM LITIGATION
Generally, **3:83; 14:25**
Affidavit doctrine, **17:12**
Inequitable conduct, **8:98**
Offer for sale, **17:12**
Series of legal proceedings, **5:108**
Two-tiered test, **6:27**
Winning lawsuit, **21:24**

SHOCKWAVE MEDICAL, INC. V. CARDIOVASCULAR SYSTEMS, INC.
2025, **19:360**

SHOP RIGHTS
Generally, **12:27**
Totality of circumstances evaluated, **13:52**

SHOULD HAVE KNOWN
Sec. 285, **5:14**

SHOWING OF NONOBVIOUSNESS
Chemical cases, **9:44**
Expectation, unexpected results, **9:44**
Independent evidence of nonobviousness, **13:185**
Relative effectiveness, **9:44**

SIERRA WIRELESS, ULC V. SISVEL S.P.A.
2025, **19:361**

SIGNAL CLAIMS
Patentable subject matter, **9:290**

SIGNIFICANCE
Developments occurring after filing date, **9:142**

SIGRAY, INC. V. CARL ZEISS X-RAY MICROSCOPY, INC.
2025, **19:362**

SILENCE
Copying, **1:48**
Statutory construction, **6:24**

SIMILARITY
Chemical, **9:60**
Evidence of similar properties, **9:29**
Prima facie obviousness and structural similarity, **1:183**
Prosecution history estoppel, **5:59**

SIMPLE INTEREST
Damages, delay, **4:24**
Delay damages, **4:24**
Prejudgment interest, **18:35**

SIMPLE NEGLIGENCE NOT ENOUGH
Exceptional case, **18:9**

SIMPLICITY
Generally, **9:127**

SIMPLIFICATION OF REFERENCE
Combination patent, **13:15**

SIMULTANEOUS ACTS AND MATTERS
Generally, **5:5; 12:13**
Appealability of sanctions, **19:64**
Conception, **13:105**
Obviousness, **7:97**

SINGLE CLAIM
Plant patents, **9:162**

SINGLE INVENTION
Generally, **9:103**

SINGLE MEANS CLAIM
Sec. 112, **9:40**

SINGLE REFERENCE
Obviousness, **19:123**

SINGLE USE
Contributory infringement, **19:79**
Enforceability, **13:42**
Inducing infringement, **19:79**

SISVEL INTERNATIONAL S.A. V. SIERRA WIRELESS, INC.
2023, **19:349; 19:350**

SIXTH CIRCUIT
Choice of law, **1:42**

SKILL
Actual skill of inventor not pertinent, **19:34**
Computer programmer, **14:8**
Inequitable conduct, **15:3**
Later developments not evidence, **19:34**
Patent attorney, **19:36**
Sec. 1498, **15:4**
Summary judgment, **12:15; 21:7**

SKILLED ARTISAN
Fact question, well-understood, routine and conventional, **1:311**

SKILLED IN THE ART
Claim interpretation, **3:75; 4:61; 4:66; 9:232; 20:8**
Claims speak to those, **5:19**
Disclosure of corresponding structure, **2:123**
Exceptional skill in the art, **14:67**
Factors, **5:5**
Indefiniteness, **9:156**
Inventor's theory, **6:10**
Obviousness, **4:82; 15:19**
Obviousness question, **3:30**
Sec. 102(b), **9:18**
Specification directed to, **9:125**

SMALL ENTITY
Issue fee, **4:52**
Maintenance fees, **21:40**

SMARTREND MANUFACTURING GROUP, INC. V. OPTI-LUXX INC.
2025, **19:363**

SMOOTH
Generally, **23:43**

SNAPPOWER V. LIGHTING DEFENSE GROUP
2024, **19:355**

SNIPR TECHNOLOGIES LIMITED V. ROCKEFELLER UNIVERSITY
2023, **19:351**

SOFTVIEW LLC V. APPLE INC.
2024, **19:356**

SOLE INVENTORSHIP
Interference, **19:72**

SOPHISTICATION
Combination patent, **13:15**
Obviousness, **16:4**

SO THAT
Generally, **23:43**

SOUND VIEW INNOVATIONS, LLC V. HULU, LLC
2026, **19:365**

SOUTH
Generally, **20:34**
Precedent, **23:28**

SOVEREIGN ACT DOCTRINE
Inherent element of every government contract, **8:41**

SOVEREIGN ACTS
Defenses, **15:8**

SOVEREIGN IMMUNITY
Generally, **3:79; 3:115; 26:10**
Declaratory judgment suit, **7:25**
Federal government, **3:95**
Inter partes review, **18:128; 19:305**
Joinder, **7:134**
Jurisdictional grants, **2:190; 13:66**
Narrowly construed, **19:75**
Post-judgment interest, **1:55**
Sec. 101, **21:78**
State immunity from declaratory judgment suit, **7:25**
State universities, **21:63**
Strictly construed, **10:19**
Waiver, **13:48; 23:28**

SPECIAL, PETITION TO MAKE
Generally, **7:57; 12:56**
Claim interpretation, **7:57**
Inequitable conduct, **7:29**
Prosecution history estoppel, **7:57**

SPECIAL CIRCUMSTANCES EXCEPTION
Law of the case doctrine, **13:61**
Sec. 122(a), **8:135**

SPECIAL DEFINITION
Claim interpretation, **14:30**

SPECIAL DISPATCH
CAFC jurisdiction, **7:8**

SPECIAL INTERROGATORIES
Generally, **11:28; 14:1**
Appellate review, aid in, **8:84**
Jury, **1:16**
Unresolved deadlock, **2:49**

SPECIAL MASTER
As a whole, reference must suggest invention, **13:24**
Authority to amend decision, **16:37**
Claims court, **3:49**
Damages, **20:19**
Deference, **13:24**
Improvement, **13:24**
Infringement determination, **1:207; 13:24**
Judgments not opinions are reviewed, **13:24**
License, need for, **13:24**
Obviousness, **13:24**
Reference as a whole must suggest invention, **13:24**
Reliance upon his prior experience, **19:65**

SPECIAL PROVINCE OF TRIER OF FACT
Weight and credibility of evidence, **18:12**

SPECIAL VERDICT
Generally, **13:53**
Advantage thereof, **18:41**
Erroneous jury instructions, **14:7**
Form, **12:20**
Forms, **19:9**
FRCP 49(a), **19:37; 23:1**
Hypothesize, **13:85**
Inferior infringement, **23:1**
Infringement, inferior infringement, **23:1**
Jury instructions, **6:88; 14:7**
Objections, waiver of objections, **8:52**
Presume jury resolved facts in favor of verdict winner, **20:50**
Review, standard of, **20:35**
Sec. 112, **17:1**

SPECIAL VERDICT—Cont'd
Waiver of objections, **8:52**

SPECIES
Claim preamble, **3:22**
Disclosure of species, **2:107; 9:126**
Genus, **2:107; 18:40**
Sec. 102(e), **9:28**
Sec. 120, **12:10**
Written description, **3:106**

SPECIFICATIONS
Admissions, **16:109**
Application, **9:189**
Best mode, **9:357**
Claim construction and interpretation, **1:134; 3:80; 5:2; 9:94; 12:68; 13:86; 13:104; 14:57; 18:68; 19:191; 19:196; 20:61; 21:9; 25:4**
Declaratory judgment, **10:6**
Disavowal of scope, **5:97**
Disclosure, **5:16; 9:113**
Dismissal, **3:19**
Embodiments appearing in specification will not be read into claims, **5:19**
Enablement, **23:77**
FRCP 52(a), **12:6**
Incorporation by reference, **16:128**
Interference, **1:182; 2:172; 4:8; 19:151**
Limitation not required by, **9:118**
Means-plus-function claim, **6:36; 13:182; 20:64**
Mere dissemination of invention's specifications is not infringement, **13:52**
Novelty, **20:67**
Obviousness, **9:19; 9:56**
Only as of issue date of patent, **9:53**
Primary basis for construing claims, **19:26**
Prosecution history estoppel, **22:16**
Reverse doctrine of equivalents, **19:24**
Review, standard of, **19:12**
Sec. 112(1), **3:54**
Sec. 112(2), **19:125**
Skilled in the art, **9:125**

SPECIFIC CLAIMS
Exhaustion of patent rights, reservation, **11:72**

SPECIFIC DEVICES
Issue preclusion, **11:35**

SPECIFIC FACTUAL FINDINGS
FRCP 52(a), **13:16**

SPECIFIC INTENT
Active inducement of infringement, **1:157**

SPECIFIC INTENT TO DECEIVE
Fraud, **6:28**

SPECIFICITY
Jury verdict, **8:52**
Obviousness, **12:64**

SPECIFIC JURISDICTION
Generally, **2:46**
Personal jurisdiction, **20:46**

SPECIFY EVERY DIFFERENT
Reissue, **4:63**

SPECIOUS ARGUMENT
Murder, x on trial for murdering Y, **18:24**

SPECK V. BATES
2024, **19:357**

SPECTRUM OF EFFECT
Doctrine of equivalents, **9:108**

SPECULATIVE
Lost profits, **21:35**

SPIRIT
Federal Rules, **3:24**

SPRINGS FROM INVENTION
Ownership, **20:40**

SSI TECHNOLOGIES, LLC V. DONGGUAN ZHENGYANG ELECTRONIC MECHANICAL LTD.
2023, **19:352**

STANDARD ESSENTIAL PATENTS
Damages, **3:186**

STANDARD OF REVIEW
Appeal and Review (this index)
Jurisdiction to review, **9:425**

STANDARD SETTING ORGANIZATIONS
Disclosure, **17:9**
Implied waiver, **3:206; 8:120**

STANDING
Generally, **1:317; 1:353; 1:363; 1:363.50; 3:230; 5:79; 7:137; 16:74; 16:159; 19:174; 19:251**
All co-owners, **5:40**
All substantial rights, **9:233**
Antitrust claim, **9:89**
Appeal and review, **7:39; 19:48; 20:75**
Assignment, **1:153; 1:191; 1:196; 1:218; 1:264; 5:38; 13:87**
Bankruptcy, **13:148**
Claim construction and interpretation, **1:264**
Consent, **19:263**
Constitutionality, **13:191**
Co-owners, all, **5:40; 19:221**
Damages, **23:82**
Declaratory judgment, **16:113**
De novo review, **7:39**
Dismissal without prejudice, **20:96**
Divorce, **5:105**
Exclusive licensee, **1:190; 1:196; 13:157; 19:223; 23:67**
Exclusive ownership, **20:134**
Exclusive rights, licensee with exclusive right to sell abroad, **15:9**
Exclusive territorial license, **16:64**
Expired patent, **11:78**
False patent marking, **19:262**
Hard termination date, **1:153**
Hired to invent, **10:47**
Holder of legal title must be joined in action, **1:68**
Infringement, **13:170; 19:154**
Injury, **1:45; 3:177; 4:116**
Inter partes review, **10:50; 16:157**
Inventorship, **19:272**
Joining involuntarily, **9:302**
Legal title vs. equitable title, **1:46**
Licenses and licensees, **1:153; 9:301; 13:133; 15:9; 16:64; 18:35; 20:45**
Lost profits, **23:82**
Mootness, **13:226**
MPEP, **19:46**
Non-parties, **19:48; 21:22**
Obviousness, **1:334; 1:355; 7:129**
Ownership, **1:172; 3:93; 9:303; 16:111**
Patentee, **1:272**
Post-grant review, **1:320**
Preliminary injunction, **12:111**

STANDING—Cont'd
Public accessibility, **19:316**
Qui tam plaintiff, **19:224; 19:262**
Receivers and trustees, **13:148**
Retroactive, **8:63**
Review, de novo review, **7:39**
Sec. 101, **9:452**
Sec. 145 review, parties entitled to, **2:18**
Sec. 271(f), **23:82**
Sec. 281, **4:116**
Substantial rights, **6:54; 12:117; 19:128**
Territorial license, exclusive territorial license, **16:64**
Three elements, **16:75**
Title, **12:58; 19:154**
Vesting title and right to sue infringer, **19:154**
Virtual assignment, **5:38**
Waived, cannot be, **2:18**

"STAND OR FALL TOGETHER"
Generally, **9:117**

STARE DECISIS
Appropriate, when, **2:50**
Law question, application is, **13:53**

STARTING POINT
Inequitable conduct, **7:1**
Statutory construction, **11:33; 20:30**

"START WITH STATUTE ITSELF"
Statutory construction, **19:73**

STATE CLAIM, FAILURE TO
Dismissal, **3:19; 4:121; 7:36; 20:44**
Form 18, **12:114**
FRCP 12(b)(6), **2:41; 7:99; 8:102; 12:112; 12:114; 19:237; 23:29**
Pro se litigant, **13:142**
Review, standard of, **4:29**

STATE COURT
Eleventh Amendment, **10:11**
Judgment, **19:45**
Mandamus, **9:68; 9:76; 26:14**
Patent questions, **3:14**
Res judicata, **13:22**
Sec. 1447, **8:97; 22:46**

STATE OF MIND
Best mode, **3:31**

STATES
Abuse of process, **1:42**
Choice of law, **18:64; 18:66**
Damages, **9:161**
Dismissal, **22:2**
Eleventh Amendment, **10:11; 18:40**
Immunity
declaratory judgment suit, **7:25**
Eleventh Amendment, **2:120; 9:128; 10:11**
Jurisdiction in state law contract dispute, **12:91**
Preemption, **21:30; 21:42**
Stay of patent action, **9:91**
Summary judgment, **12:15**

STATE SECRETS PRIVILEGE
Generally, **3:95**

STATE UNIVERSITIES
Jurisdiction, federal courts, **21:63**

STATUTE OF LIMITATIONS
Limitation of Actions (this index)

STATUTE OF MONOPOLIES
Statutory subject matter, **9:308**

STATUTORY CLAIM
Chemical process, **9:20**

STATUTORY CONSTRUCTION AND INTERPRETATION
Generally, **1:39**
Absurd results to be avoided, **2:39**
Administrative agency, **19:74**
Ambiguity, **6:24; 7:55; 8:45**
Appellate subject matter jurisdiction, **1:37**
Applicable rules, **22:6**
Application, **15:7**
As a whole, **3:63; 19:77**
Begins with, **6:29; 23:29**
Broad statutory language, **20:31**
Chevron deference, **4:45; 6:31; 13:77; 26:3**
Conflicts, **2:35; 9:183; 20:36**
Deference, **2:51; 4:30; 4:43; 6:24; 11:30; 11:39; 14:17; 14:22; 19:74; 19:82; 23:31**
Definition, **8:61**
Directory vs. mandatory statutes, **5:17**
Expressio unius, **1:57**

STATUTORY CONSTRUCTION AND INTERPRETATION—Cont'd
Headings, effect of, **7:25**
Implication, repeals by, **18:34**
Implicit repeals disfavored, **6:30; 19:80**
Intent, **1:61; 7:24; 7:55; 8:39; 8:45; 13:60; 19:75**
Judicial not agency function, **11:26**
Jurisdictional statute begins with its language, **3:60**
Language, **6:29; 11:33; 12:37; 19:67**
Law question, **1:74; 2:67; 4:40; 9:166; 9:200; 10:18; 13:49; 19:102**
Legislative history, **7:35**
Mandatory vs. directory statutes, **5:17**
Meaning and effect, to give to all its parts, **19:69**
Omissions, **12:37**
Ordinary meaning, **8:61**
Particular language in statutory sec. omitted in another, **12:37**
Patent term extension, **8:25**
Permissible construction, **1:81; 8:54; 12:34**
Plain meaning rule, **1:69; 3:50; 6:14; 9:138; 9:149; 10:19; 12:19; 13:48; 14:9; 17:5; 20:26; 23:32**
Question at issue, **20:37**
Reasonable interpretation, **13:83; 20:42**
Regulations, conflict with, **9:183**
Repeals, **6:30; 18:34; 19:80**
Restrictive, **20:31**
Retroactive application, **15:7**
Review, standard of, **2:54; 3:58; 6:44; 9:162; 9:176; 13:59; 16:30; 19:88**
Sec. 156, **6:3; 21:6**
Sec. 282, **12:5**
Separate provisions to be construed together, **1:72; 8:43**
Silent statute, **6:24**
Starting point, **11:33; 19:73; 20:30**
Summary judgment, written description and enablement requirement, **21:46**
Terms, **8:61**
Tools therefore, **18:36**
Undefined terms given their ordinarily understood meaning, **8:61**

STATUTORY DISCLAIMER
Interference, **7:45**

STATUTORY INVENTION
Registration, **8:67**

STATUTORY NOTICE
Letters to customers as infringement threats, **13:41**

STATUTORY SUBJECT MATTER
Generally, **13:178**
Abstract principles, **21:57**
Business methods, **3:202; 9:308; 19:297**
Business methods exception, **19:112**
Computer software, **9:175**
Living things, **16:63**
Sec. 101, **1:51; 3:164; 4:105; 9:30; 9:154; 9:155; 9:286; 9:437; 13:178; 21:62**
Signals, **9:290**

STATUTORY TERMS
Law question, **9:120**

STATUTORY TIME PERIODS
Two types, **23:28**

STAUNCHING THE FATAL WOUND
Sec. 102(b) on-sale bar, **4:16**

STAY
See also Vacation of Judgment (this index)
Clarification of law, **1:204**
Covered business method review, **2:158; 9:415; 22:48; 22:52**
Execution of judgment and injunction pending appeal
considerations involved, **19:49**
court actions, **19:49**
judicial notice of fact, **19:49**
reexamination, **19:49**
37 CFR Sec. 1.11(b), **19:49**
Final judgment, **9:415**
Final judgment rule, **19:110**
Injunction pending appeal, **5:2**
Interlocutory review, **19:230**
Jurisdiction, lack of, **19:9**
Motion, **12:36**
Order, **11:1; 14:40**
Patent action, **9:91**
Pending reexamination, **8:52**
Preliminary injunction, **11:19**
Reexamination, **8:52; 16:116; 22:23**
Sec. 1659, **9:292**

STEPS WITHOUT FUNCTION
Means-plus-function claim, **5:63**

STEP-TWO ANALYSIS
Infringement, **20:63**

STEUBEN FOODS, INC. V. SHIBUYA HOPPMANN CORPORATION
2025, **19:364**

STIMULATION OF INVENTIONS
Generally, **1:45**

STIPULATED JUDGMENT
Claim construction, **10:37**
Consent decree, **8:6**

STIPULATION
Generally, **1:379**
Appealability, **10:37; 10:38**
CAFC jurisdiction, **20:2**
Fictitious facts, may not stipulate, **13:68**
Willful infringement, **12:24**

STOCK ACQUISITION
Motion for directed verdict, **1:1**

STOLEN TRADE SECRETS
Preliminary injunction, **6:7**

STREAM-OF-COMMERCE PLUS THEORY
Personal jurisdiction plus something more, **1:221**

STREAM OF COMMERCE THEORY
Personal jurisdiction over nonresident foreign defendant, **1:181; 2:46**

STRICT LIABILITY OFFENSE
Infringement, **10:21**

STRICTLY CONSTRUED
Waiver of sovereign immunity, **10:19**

STRIKE, MOTION TO
Addenda, **6:10**

STRIKING PLEADING
Appealability, **20:5**

STRONG EVIDENCE
Obviousness, **13:85**

"STRONG MEDICINE"
Mandamus, **9:11**

STRONG PRESUMPTION
Claim interpretation, **4:73**

STRUCTURAL EQUIVALENCY
Means-plus-function claim limitation, **9:96**

STRUCTURAL LIMITATIONS
Claim preamble, **18:44**

STRUCTURAL OBVIOUSNESS
Prima facie obviousness, **9:50**

STRUCTURAL SIMILARITY
Chemical, **9:60**
Prima facie obviousness, **1:183; 9:126**

STRUCTURE
Infringement, **7:57**
Means-plus-function claim, **5:114; 6:73; 7:70; 12:26; 20:91; 22:26**
Prior art article, **9:48**
Product-by-process claims, **9:81**

SUA SPONTE
Summary judgment, **9:146**

SUBJECTIVE GOOD FAITH
Anticipation, **18:20**
Blonder-Tongue, **1:13**

SUBJECT MATTER
Generally, **20:25; 21:17**
ANDA, **20:100**
Inventorship, conception, **21:55**
Judicial notice, **6:10**
Jurisdiction, **7:36; 13:66; 13:196**
Obviousness, **9:46; 9:436**
Prosecution history, **1:116**
Prosecution history estoppel, **8:72**
Statutory Subject Matter (this index)
Summary judgment, **3:13**

SUBJECT MATTER JURISDICTION
Generally, **7:36; 8:151; 13:66; 13:196; 16:162**
Actual case or controversy, **12:22; 19:250**
Anticipation of defense, asserted in, **1:7**
Appeal and review, **6:19**
Arising under, **3:18**
Arose out of agreement, **18:13**
Choice of law, **20:66**
Claims court, **2:41; 20:27; 21:21**
Contracting parties, **25:1**

SUBJECT MATTER JURISDICTION —Cont'd
Covenant not to sue, **4:95**
Declaratory judgment, **1:297; 1:301; 8:109; 16:130; 19:250**
Design around, **25:1**
Dismissal, **12:38**
Enhanced damages, **25:1**
Examination, **6:19**
Extraterritorial activities, **12:82**
Federal, **22:5**
FRCP 12(b)(1), **1:7**
Hatch Waxman amendments, **3:159**
Imported product, **12:81**
Incentive, **25:1**
Isolated DNA molecules, **1:214**
License, **1:7**
Lost profits, **25:1**
Malpractice, **23:71**
Mandamus, **9:68**
Motion to dismiss, **1:7**
Process claim, **3:164**
Sec. 291, **1:11**
Sec. 1338, **1:49; 11:20**
Sec. 1338(a), **1:7; 5:17**
Sec. 1338(b), **13:58**
Sec. 1500, **21:15**

SUBMISSIONS
CAFC, **18:3**
Doctrine of equivalents, **7:51**
FRCP 56(f), **2:80**
Good cause under 37 CFR Sec. 1.617(b) justifying, **8:35**
JNOV, **23:4**
New interference rules, **8:3**
On-sale bar, **8:62**
Sec. 120, **2:68**

SUBORDINATE
Appeal, Board failure to review all claims on, **9:2**

SUBPOENA
Choice of law, **20:17**
Inter partes reexamination, **1:232**

SUBSEQUENT LITIGATION
Generally, **2:36**
Sec. 304, **19:46**

SUBSEQUENT PATENT
Generally, **8:40**

SUBSTANCE NOT LINGUISTIC FORM
Motion, **9:233; 19:86**

SUBSTANTIAL DIFFERENCE
Doctrine of equivalents, **16:40**

SUBSTANTIAL EQUIVALENT
Generally, **12:1**

SUBSTANTIAL EVIDENCE
Generally, **1:117; 2:31; 2:34; 7:131; 13:103; 15:19; 20:1; 20:25**
Advisory jury, **18:14**
APA, **8:34**
Claim interpretation, **20:1**
Defined, **2:37; 4:33; 6:31; 6:32; 7:43; 7:44; 8:31; 9:231; 13:68; 20:22**
Definition, **10:31**
Independent substantiation, **19:43**
Infringement, **25:10**
ITC, **8:28**
JMOL, **10:40**
JNOV, **6:6; 15:2**
Jury verdict, **7:29**
Law question, **20:1**
Obviousness, **19:43**
Relationship between, **11:13**
Relevance, **16:39**
Review, standard of, **16:31**
Sec. 337, **3:23**
Test devised, **19:43**

SUBSTANTIALITY
Claim interpretation, **12:70**
Doctrine of equivalents, **1:82; 6:26; 8:47; 18:39; 19:94; 23:40**

SUBSTANTIALLY
Generally, **22:25; 26:9**
Claim interpretation, **12:61; 13:134**
Jury instructions, **10:4**
On-sale bar, **5:35**

SUBSTANTIAL NEW QUESTION
Reexamination, **2:150; 9:183; 9:314**

SUBSTANTIAL OPEN ISSUES
Contempt, **1:88**

SUBSTANTIAL QUESTION
Success on merits, likelihood of, **16:70**

SUBSTANTIAL REASON
Doctrine of equivalents, **6:41; 8:60**

SUBSTANTIAL REASON—Cont'd
Prosecution history estoppel, **6:41**

SUBSTANTIAL RIGHTS
JNOV motion, **6:6**
Standing, **6:54; 12:117; 19:128**

SUBSTATION OF FEATURES
Doctrine of equivalents, **14:45**

SUBSTITUTE
Acceptable substitutes, **19:96**
Appellate brief is no substitute for notice of appeal, **10:14**
Applicant's disclosure cannot be used to fill in gaps, **9:29**
Availability of acceptable noninfringing substitutes, **19:53**
Disclosure, **9:29**
Doctrine of equivalents, **26:4**
Infringement, **7:63**
Lost profits, **13:45**
Panduit, **3:8; 4:90**
Reexamination, **9:87**
Untimely appeal, **3:5**

SUBSTRATE
Obviousness, **9:32**

SUCCESS
Attorney fees, **10:2**
Commercial Success (this index)
Reasonable expectation, **9:352; 12:55; 16:108; 16:109**
Testing, **5:34**

SUCCESS ON MERITS, LIKELIHOOD OF
Infringement, nonmovant infringes, **7:50**
Nonmovant infringes, **7:50**
Preliminary injunction, **1:169; 11:67**
Substantial question, **16:70**
Validity and enforcement challenges, withstand, **1:110**

SUCCESSOR
Motion for directed verdict, **1:1**

SUFFICIENCY
Jury instructions, **2:143**
Testimonial evidence alone, **7:11**
Written description, **1:185**

SUFFICIENCY OF DISCLOSURE
Interference, **3:25**

SUFFICIENT CIRCUMSTANTIAL EVIDENCE
Rule of reason, **3:82**

SUFFICIENT EXPLANATION
Board, **9:218**

SUFFICIENTLY COMPLETE
On-sale bar, **19:91**

SUFFICIENTLY SPECIFIC
Directed verdict motion, **23:17**

SUGGESTION
Generally, **9:96; 9:114; 9:148**
Claim interpretation, **19:15**
Claim preamble, **16:58**
Combining references, **9:126; 9:127**
Commissioner's brief not prior art, **9:140**
Device, prior art, **9:101**
Functional characteristic, **9:101**
Modification, **9:51**
Obviousness, **9:124; 9:148; 9:204; 11:49; 14:8; 21:8; 22:26**
Prior art device, **9:101**
References, combining, **9:126**
Special master's decision, **13:24**
Summary judgment, **3:20**

SUMMARY DETERMINATION
Collateral estoppel, **16:160**
ITC, **8:58**

SUMMARY DISPOSITION OF APPEAL
FRAP 2, **10:20**

SUMMARY JUDGMENT
Generally, **1:141; 3:89; 7:86; 9:220; 9:237; 9:252; 9:267; 9:281; 12:71; 13:104; 13:123; 15:17; 16:77; 19:100; 19:159; 19:189; 21:48; 23:51**
Abandonment as law question, **1:111**
Abbreviated new drug application (ANDA), **2:88**
Adjustment of patent term, **1:315**
Affidavits, **19:99**
Ambiguity, claim construction, **2:98**
Analogous art, **21:7**
Analogous prior art, **6:1**
Appeal and review, **1:288; 2:29; 8:17; 21:29**

SUMMARY JUDGMENT—Cont'd
Appropriateness, **1:6; 3:44; 4:34; 7:30; 13:63; 14:14; 19:79; 19:91; 20:32; 20:39; 21:25; 23:35; 25:4**
As a whole, invention considered, **12:15**
Attorneys' fees, **1:2; 2:71**
Bankruptcy discharge, **2:21**
Broadened reissue, **20:10**
Burden, viewed with trial burden, **13:90; 18:47**
Burden of production, **12:63**
Burden of proof, **1:35; 10:4**
Burden to show, **22:18**
Care, approached with, **13:27**
Case or controversy, **7:7**
Claim construction or interpretation, **1:108; 1:256; 2:24; 2:78; 8:17; 11:53; 19:161; 20:10; 23:58**
Claim differentiation, **11:44**
Claim management, **2:153**
Claims court, **16:30**
Combine references, suggestion to, **3:1**
Competition, state unfair competition claim, **12:15**
Conclusory, **3:13; 20:62**
Conflicting views, **8:14**
Contributory or indirect infringement, **3:36**
Court of International Trade standard, **20:38**
Covenant not to sue, **1:306**
Cross-motions, **2:36**
Decision, justifies and detracts from, **1:126**
Declaratory judgment, **7:7**
Defined, **20:10**
Dependent claims, **2:29**
Design patent, **1:35; 16:17**
Devoid, **13:98**
Directed verdict, JNOV over, **10:4**
Disclosure dedication, **20:74**
Discovery, right to, **1:35**
Discretion of court not to proceed, **7:7**
Dismissal, **3:19**
Disputed questions of material facts, **5:36**
Divided infringement, **13:211**
Doctrine of equivalents, **2:20; 2:66; 2:114; 4:62; 8:40; 11:46; 12:42; 20:13; 22:21; 23:64**
Documents, trial by, **19:51**

SUMMARY JUDGMENT—Cont'd
Doubt resolved in favor of nonmovant, **9:215**
Due care, duty of, **1:35**
Each motion on own merits, **5:48**
Eliminate factually unsupported claims, **15:15**
Enablement, **1:127; 2:82; 2:90; 14:75; 15:26**
Enforcement of judgments, court's power, **1:83**
Equitable estoppel, **19:108**
Estoppel, **1:48; 10:4**
Evidence, infringer provides evidence of noninfringement, **14:33**
Exceptional case, **18:55**
Executive Order 10096, **8:10**
Ex parte test, **3:10**
Experts, **3:1; 8:14**
Expert testimony, **1:6; 3:20; 3:150**
Facts viewed most favorably for nonmovant, **23:16**
File wrapper, infringement, **10:13**
Final judgment, appeal after, **21:29**
Final order rule, **12:41**
Foreign countries, Court of International Trade standard, **20:38**
FRAP 47.6(b), **2:72**
FRCP 41(a)(1), **5:18**
FRCP 52(a), **20:26**
FRCP 56, **2:29; 9:89; 13:36; 16:28; 16:32; 19:44**
FRCP 56(c), **3:36; 3:52; 4:26; 8:27; 9:131; 11:25; 16:35; 18:28; 21:13**
FRCP 56(e), **3:1**
FRCP 56(f), **11:7; 19:20**
Good faith dispute regarding claims, **16:54**
Gorham test, **1:35**
Granted by court sua sponte, **9:146**
Granting, standard for, **6:1**
Harmless error, **3:1**
Heavy presumption terms, **5:70**
Hypothetical vs. real person, **8:14**
Identify facts, **22:21**
Indefiniteness, **2:175; 5:141; 19:131**
Indirect infringement, **4:75**
Indirect or contributory infringement, **3:36**
Inequitable conduct, **2:24**

SUMMARY JUDGMENT—Cont'd
Infringement, **1:79; 1:137; 3:189; 16:20; 21:28**
Inherent anticipation, **19:154**
Initial burden to show no material fact, **22:18**
Interplay of prosecution history estoppel and doctrine of equivalents, **8:40**
Interpretation, **8:17**
Invalidity, **3:20**
Inventorship, **2:99**
JNOV over directed verdict, **10:4**
Judicial redrafting, **2:29**
Laches, **1:36; 10:4; 23:45**
Law of the case, **2:29; 10:4**
Law question, **1:35; 7:66; 20:10**
Lexicographer, **2:24; 10:13**
License agreement, **3:70**
Limitations, **20:13**
Literal infringement, **2:22; 20:13**
Material, unnecessary fact not, **3:13**
Material Fact (this index)
Metaphysical doubt, more than, **10:32**
Method patentable even though device using it is not, **21:7**
Modification of prior art device, **3:20**
Motion, **5:48; 9:215; 10:4; 13:82; 23:16**
Nexus, **3:1**
9 Cir, **3:1**
Noninfringement, **2:22**
Noninfringement of asserted claims, **4:113**
Nonmovant, **13:82**
Novel combination, **21:7**
Obviousness, **8:14; 9:274; 9:454; 12:15; 21:7**
Only facts affect outcome, **13:102**
On-sale bar, **1:2; 7:71**
Opinion, **8:17**
Opinion testimony, **3:1**
Ordinary and accustomed meaning, **2:104; 4:60**
Ornamental v. functional obviousness, **1:35**
Ownership, employer and employee, **2:73**
Own merits, each motion on, **5:48**
Partial Summary Judgment (this index)
Patentee as own lexicographer, **10:13**
Preference, **10:4**

SUMMARY JUDGMENT—Cont'd
Preliminary injunction, **19:32**
Presumption of validity, **3:13**
Presumptions, **10:4**
Prior art, **3:1; 3:20; 6:1; 21:7**
Proper, when, **19:76**
Prosecution history, **1:116**
Prosecution history estoppel, **2:74; 8:40; 8:72; 12:59; 16:79; 20:13**
Purpose, **3:41**
Raising attorney fees claim, **2:71**
Real vs. hypothetical person, **8:14**
Reconsidering motion, **10:4**
Reconstruction versus repair, **19:143**
Reexamination, **3:192**
Reissue statute, **8:17**
Res judicata, **1:78**
Reversal, when required, **8:17**
Reverse doctrine of equivalents, **19:24**
Review, standard of, **1:67; 1:82; 1:87; 2:44; 2:52; 2:63; 4:29; 7:7; 7:35; 9:162; 15:12; 17:5; 18:33; 19:84; 22:7; 23:36; 23:43**
"Rewritten" claims, **16:91**
Sales, **1:2**
Sec. 43(a), **3:1**
Sec. 101, **2:175**
Sec. 102(b), **1:2; 19:62**
Sec. 156, **1:139**
Sec. 252, **8:17**
Secondary considerations, **3:1; 8:14; 21:7**
Skill, level of, **12:15; 21:7**
Standards for granting, **1:26; 6:1**
Standing, **20:75**
State unfair competition claim, **12:15**
Statutory construction and interpretation, **1:74**
Sua sponte, granted by court, **9:146**
Subject matter easily discernible, **3:13**
Suggested, must be, **3:20**
Supplanting prior art device, **21:7**
Synergism, **3:13**
Taxable costs, **3:13**
Tenets, **8:14**
Testimony on claim terms, **12:25**
Time, when appropriate, **2:153; 13:63**
Transcript, **3:13**
Trial by documents, **19:51**
Unfair competition, **12:15**

SUMMARY JUDGMENT—Cont'd
Validity, **1:35; 3:13; 20:10; 21:46**
Validity, presumption of, **13:99; 19:129**
Viewed with trial burden, **18:47**
Walker Process, **12:15**
Willfulness, **1:35; 1:222; 1:230**
Witnesses, **12:25; 21:7**

SUNSET PROVISION
Permanent injunction, **1:219**

SUPERIORITY
Infringement not avoided, **19:38**
Obviousness, **18:23**

SUPERSEDEAS BOND
Surety, **2:30**

SUPERVISORY AUTHORITY
Design patent, **16:17**

SUPPLANTING PRIOR ART DEVICE
Summary judgment, **21:7**

SUPPLEMENTAL INFORMATION
Inter partes review, **21:74**

SUPPLEMENTAL JURISDICTION
Discretion of court declined, **7:39**
Sec. 1267, **7:25**
Sec. 1367, **8:97; 13:58; 14:82; 22:36**

SUPPLEMENT RECORD
Generally, **23:26**

SUPPLIER EXCEPTION
On-sale bar, **19:140**
Sec. 102(b), **19:140**

SUPPORT, LACK OF
Sec. 112, **9:86**

SUPPRESSION
Generally, **6:62**
Abandonment, **3:59; 6:33**
Purpose of patent system, **16:9**
Sec. 102(g), **16:9**
Unreasonable delay, **12:21**
Vacuum, does not operate in, **16:9**

SUPREME COURT
Generally, **1:52**

SURETY
Supersedeas bond, **2:30**

SURPRISING RESULTS
Improvement, minor improvement, **9:118**
Inequitable conduct, **11:4**
Minor improvement, **9:118**

SURRENDER
Doctrine of equivalents, **13:63; 13:95**
Prosecution history estoppel, **13:140; 16:40**

SUSPENSION
Pendency of earlier case involving same patent, **1:24**
Reissue, **3:72**

SYNERGISM
Appellate standard of review, **7:2**
Combination, **19:36**
Declaratory judgment, **10:6**
Inequitable conduct, **11:4**
Jury, **1:16**
Summary judgment, **3:13**

TANGENTIAL
Doctrine of equivalents, **3:130; 9:377; 18:74; 18:77**

TANGENTIALLY
Prosecution history estoppel, **3:130; 18:77**

TANGIBLE FORM
Computer program, **9:164**
Reduction to practice, **19:144**

TARIFF ACT
ITC, **13:11**

TAXABLE COSTS
Summary judgment, **3:13**

TEACHING
Combining references, **9:119**
Commissioner's brief not prior art, **9:140**
New prior art not considered by PTO, **5:11**
Obviousness, **3:153**
Prior art, **9:96; 9:140**
Reference, **9:289**
Reference, must appear in, **9:140**
Requirement, **9:114**

TECHNICAL EXPERT
Infringement, **9:125**
Testimony, **16:11**

TECHNICAL PAPER
Prior art printed publication under Sec. 102(b), **13:11**

TECHNICAL QUALIFICATIONS
Ordinary skill, hypothetical person of, **9:65**

TECHNICAL TERMS
Claim integration, **13:91**
Claim interpretation, **14:44; 16:56**
Dictionary, **1:109**
Indefiniteness, **13:80**

TECHNOLOGICAL ADVANCE
Infringement, **22:32**

TECHNOLOGICAL ARTS TEST
Statutory subject matter, **9:308**

TECHNOLOGICAL EVIDENCE
Generally, **14:32**

TECHNOLOGIC EQUIVALENCY
Infringement, **8:51**

TELEFONAKTIEBOLAGET LM ERICSSON V. LENOVO (UNITED STATES), INC.
2024, **20:166**

TEMPLATE
Hindsight reconstruction, **9:114**
Instructional manual, **9:123**

TEMPORARY RESTRAINING ORDER (TRO)
Generally, **12:16**

10-DAY LIMIT
FRCP 59(e), **19:42**

TERM
Generally. Patent Term (this index)
Contract construction, **16:34**
FRCP 56(c), **8:27**

TERMINAL DISCLAIMER
Certificate of correction, **10:44**
Double patenting, **9:384; 15:6**
Purpose, **9:110**
Reissue, withdrawal of disclaimer, **9:367**
Rejection, **17:2**

TERMINAL DISCLAIMER—Cont'd
URAA, **2:89**

TERMS
See also Claim Terms; Patent Term (this index)
Law question, **9:120**
Statutory construction, **8:61**

TERRITORIAL LICENSE
Standing, **9:301; 16:64**

TERSE CLAIM LANGUAGE
Claim interpretation, **5:50**

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. V. AMNEAL PHARMACEUTICALS OF NEW YORK, LLC
2024, **20:167**

TEVA PHARMACEUTICALS INTERNATIONAL GMBH V. LILLY
2026, **20:169**

THESIS
Documentary evidence, weight accorded testimony in conflict with, **13:34**

THIRD PARTIES
Generally, **9:118**
Attorney-client privilege, **19:60**
Contempt, **20:54**
Evidence of level of skill in the art, **9:23**
Implied license, **3:147**
Injunction, **1:296**
Interference, **3:6**
Inter partes reexamination, **3:138**
Invention, **19:34**
Inventorship, **1:102**
License agreement, **3:70; 3:145**
Obviousness, **21:8**
Prior invention by, **12:55**
Public use, **4:101**
Reexamination, third-party requester, **1:287; 3:194**
Sec. 102(a), **3:2**
Sec. 102(b), **19:7**
Sec. 102(g), **14:7**
Sec. 286, **19:27**
Secondary considerations, **9:82**

30-DAY NOTICE
Sec. 282, **20:15**

30-MONTH PERIOD
ANDA, **1:120; 5:95**

30-PERCENT REASONABLE ROYALTY
Damages, **20:19**

35 USC § 101
Abstract ideas, **1:333**
Laws of nature, **1:333**
Natural phenomena, **1:333**

35 USC § 146
Civil action for interference, **19:232**

35 USC § 252
Reexamination, **6:8**

35 USC § 282
Disclosure, statutory outer limit, **23:76**

35 USC § 1124(4)
Generally, **16:100**

37 CFR SEC. 1.6(c)
Generally, **7:45**

37 CFR SEC. 1.11(b)
Stay of execution of judgment and injunction pending appeal, **19:49**

37 CFR SEC. 1.56
Generally, **19:180**
Disclose references showing each known step, no obligation to, **8:29**
Duty of candor and good faith to PTO, **1:203**

37 CFR SEC. 1.56(a)
Generally, **2:113; 16:98**
Materiality, **9:43**

37 CFR SEC. 1.105 (a)(1)
Generally, **19:180**

37 CFR SEC. 1.142
Generally, **7:75**

37 CFR SEC. 1.145
Generally, **7:75**

37 CFR SEC. 1.175
Generally, **14:23**

37 CFR SEC. 1.175(a)(4)
No defect reissue application, **9:25**

37 CFR SEC. 1.191
Board failure to review all claims on appeal, **9:2**

37 CFR SEC. 1.196(a)
Examiner, ground of rejection not part of Examiner's decision, **9:106**

37 CFR SEC. 1.321
ITC, **13:20**

37 CFR SEC. 1.608
New interference rules, **8:3**

37 CFR SEC. 1.609
New interference rules, **8:3**

37 CFR SEC. 1.617
New interference rules, **8:3**

37 CFR SEC. 1.617(b)
Good cause, **8:35**

THREATENED INFRINGEMENT
Appellate jurisdiction, **3:11**

THREAT OF SALE
Sec. 271(e)(1), **5:13**

THREATS TO SUE
Mandamus, **9:76**

THREE-JUDGE PANEL
State immunity from suit under Eleventh Amendment, **10:11**

THREE-PART INQUIRY
Doctrine of equivalents, **22:10**

THREE-PART TEST
Equitable estoppel, **2:61; 5:53**
Estoppel, **8:32**

THREE REQUISITE ELEMENTS
Estoppel, **1:67**

"THREE SITUATIONS"
Repair, **8:83**

THRESHOLD INTENT
Inequitable conduct, **6:4**

THRESHOLD ISSUE
Preliminary injunction, denial of, **12:16**

THRESHOLD LEVEL
Inequitable conduct, **1:44; 21:36**

THRESHOLD QUESTION
CAFC jurisdiction, **23:15**

TIE
Interference, **15:1**

TIME AND TIMELINESS
Generally, **18:1**
Abandonment, **4:65**
Agency, **9:187; 11:31**
Antedating Reference (this index)
Antitrust, **11:16**
Appeal and review, **4:25; 9:38; 9:317; 10:3; 11:38; 13:162; 16:37**
Appellate jurisdiction, **2:5; 13:8**
Application entitled to benefit of earlier filing date, **13:53**
Attorney fees award, **7:54**
Barred, inter partes review, **12:115; 23:94**
Best mode belief, **1:246**
Broadening reissue, **9:3**
Business day, **23:28**
CIP, **20:35; 20:59**
Claim construction, **3:123; 22:18**
Concealment, **4:65**
Damages, date of hypothetical negotiation, **1:296; 12:97**
Declaratory judgment, **3:134; 13:177; 19:250**
Description, **19:120**
Doctrine of equivalents, **23:63**
Enablement, **5:45; 21:39**
Equitable estoppel, **2:5**
Estoppel, **23:30**
Exceptional case, **2:5; 18:9**
Factual findings to support jury verdict presumed, **2:15**
False marking, civil penalty, **6:72**
Filing Date (this index)
First sale doctrine, **2:5**
Foreign activities, **9:61**
FRAP 4(a), **2:5**
Implied license, **2:5**
Interference, **8:122; 13:3; 16:132; 19:144**
Inter partes review, **23:94**
JNOV, **6:6; 22:2**
Judicial notice, **11:24**

TIME AND TIMELINESS—Cont'd
Jurisdiction, **7:38; 13:8; 15:8**
Jury instructions, **13:38**
Memorandum decision, **2:5**
Motion to remand, **9:38; 19:45**
New trial, **19:16**
9 Cir, **2:5**
Notice of appeal, **4:25; 9:317**
Notice of patent, **2:5**
Obviousness, **4:91; 9:112; 12:43**
Particularity, failing in, **18:25**
Permanent injunction, sunset provision, **1:219**
Priority analysis, **9:340**
PTO motion to remand, **9:130**
Raising argument, **3:32**
Reconsideration, request for, **20:21**
Reduction to practice, antedate of reference, **9:341**
Rejection, **9:38**
Remand, **9:38**
Sec. 102(b), **2:1**
Sec. 111, **19:32**
Sec. 112, **18:4**
Sec. 120, **12:99; 20:33**
Trademark, **2:5**
Trademark declaration cannot establish on-sale date, **16:25**
Waiver, **10:15**
Weekend or holiday, **23:28**

TIME LIMITS
FRCP 59(e), **19:58**
Patent Cooperation Treaty (PCT), **8:70**

TIME PERIOD
Interference, **15:1**

TITLE
See also Ownership (this index)
Automatically vests in United States, **6:18**
Employer-employee, **6:15**
Standing, **5:105; 12:58; 19:154**

TOLLING
Appeal, of time for, **7:32**

TOP BRAND LLC V. COZY COMFORT COMPANY LLC
2025, **20:168**

TORT
Occurs at place where sales are made, **14:15**

TORTIOUS INTERFERENCE
Generally, **19:185**
Inducing infringement, **18:48**

TORT LIABILITY
Preemption of laws, state law tort liability, **7:81**

TOTALITY OF CIRCUMSTANCES
Experimental use, **2:57; 12:45; 16:44**
On-sale bar, **3:81**
Public use, **12:45; 16:44**
Sec. 112, **15:2**
Shop rights, **13:52**
Willful infringement, **1:58; 11:18; 11:56; 19:38**

TOUCHSTONE
Inventorship, **2:99**

TRADE DRESS
Choice of law, **9:161; 15:11**
Gorham infringement test, **12:17**

TRADEMARK
Declaration cannot establish on-sale date, **16:25**
Declaratory judgment, **23:9**
Patent misuse, **23:9**
Preliminary injunction, **2:16**
Timeliness of appeal filing, **2:5**

TRADE NAME
Best mode, **18:5**
Disclose supplier, failure to, **20:33**

TRADE SECRETS
Generally, **15:22; 16:103**
Choice of law, **12:65; 18:39**
Contract, **18:14**
Defined, **12:27**
Motion to remand, **19:45**
Preliminary injunction, **6:7**

TRANSCRIPT
Summary judgment, **3:13**

TRANSFER
Dismiss or transfer infringement suit, **9:432**

"TRANSFER FROM"
Claim construction, **7:104**

TRANSFERS
Action, transfer of, **18:40**
Appeal and Review (this index)
Choice of law, **24:1**
Clear abuse of discretion, **9:381; 9:382**
Judicial Panel on Multi-District Litigation (JPMDL), **7:6**
Jurisdiction declined, **21:12**
Orders, **6:34**
Ownership, **9:303**
Relevant factors, **9:128**
Sec. 1631, **19:2**
Stay order, **11:1**
Venue, **7:93; 8:69; 8:110; 9:334; 9:336; 9:395; 14:60; 22:38; 26:14**

TREBLE DAMAGES
Appeal is review and not trial de novo, **6:12**

TRIAL BY DOCUMENTS
Summary judgment, **19:51**

TRIAL CONDUCT
CAFC, **18:3**

TRIAL DE NOVO
Appeal is review and not trial de novo, **6:12**

TRIAL JUDGE
Sec. 455(a), **8:12**
Weight and credibility of testimony, **19:54**

TRIER OF FACT
Weight and credibility of evidence, **18:12**

TRINITY INFO MEDIA, LLC V. COVALENT, INC.
2023, **20:165**

TRO (TEMPORARY RESTRAINING ORDER)
Generally, **12:16**

TRUE INVENTOR
Claim interpretation, **19:15**

TRUE SALE
On-sale bar, **13:123**

TRUSTEES
Standing, **13:148**

TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK V. GEN DIGITAL INC.
2026, **20:170**

21 CFR 314.53(c)(3)
Generally, **1:135**

21 CFR 314.53(f)
Generally, **1:135**

21 CFR 355(c)(2)
Generally, **1:135**

21 CFR 355(j)(2)(A)(vii)
Generally, **1:135**

21 USC § 355
Generally, **13:120**

28 USC § 1291
Generally, **14:40**
Immediate appeal, **11:10**

28 USC § 1292(b)
Discretionary, **14:40**

28 USC § 1295
Inter partes review, disclaimers, **1:327**
Stay orders not final, **14:40**

28 USC § 1338
Generally, **14:40**
Arising under jurisdiction, **2:3**
Jurisdiction, **20:83**

28 USC § 1361
Generally, **8:92**

28 USC § 1498(a)
Generally, **20:66**

28 USC § 1920
Cost award, **9:342**

28 USC § 2202
Generally, **16:81**
FRCP 13(a), **16:81**

TWO-STEP ANALYSIS
Infringement (this index)

TYING ARRANGEMENTS
Generally, **9:282**

TYPOGRAPHICAL ERROR
Marking, **1:119; 16:183**

UCB, INC. V. ACTAVIS LABORATORIES UT, INC.
2023, **21:92**

ULTIMATE ARBITER
CAFC, **18:3**

ULTIMATE LEGAL ISSUE
Expert's opinion, **9:113**

ULTIMATE RECOGNITION
Market success, **9:90**

UNCITED PRIOR ART
Claim differentiation, **11:2**
Prior art, **3:90**
Process performable by person, **1:12**

UNCLAIMED DISCLOSED MATERIAL
Doctrine of equivalents, **13:75**

UNCLAIMED ELEMENTS
Claim interpretation, **6:58**

UNCLAIMED SUBJECT MATTER
Best mode, **13:101**
Dedication, intent, **20:74**
Doctrine of equivalents, **10:30**

UNCLEAN HANDS DOCTRINE
Generally, **7:124**
Inequitable conduct, **3:35**
Inventorship dispute, **16:131**
Laches, **19:204**
Materiality required, **18:40**

UNCONTRADICTED EXPERT TESTIMONY
Generally, **21:13**

UNDEFINED TERMS
Statutory construction, **8:61**

UNDERLYING FACTS
Interference, **4:11**
Obviousness, **9:197**

UNDERSTANDING
CAFC jurisdiction, **9:63**
Claim interpretation, **22:25**
Discovery of new property or use of known composition, **9:104**
Indefiniteness, **19:131**

UNDUE BREADTH REJECTION
Papesch, **9:9**

UNDUE DELAY
Laches, **9:241**

UNDUE EXPERIMENTATION
Generally, **16:181; 23:11**
Enablement, **1:44; 2:99; 9:177; 9:305; 19:201**
Law question with facts, **5:45**
Quantitative, not merely, **10:23**
Sec. 112(1), **10:23**

UNEXPECTED BENEFIT
Generally, **9:100**

UNEXPECTED PROPERTIES
Obviousness, **8:147**

UNEXPECTED RESULTS
Generally, **9:191**
Closest art, compared with, **9:111**
Established by factual evidence not argument, **9:174**
Factual evidence, **9:174; 9:197**
Finding tantamount to nonobviousness, **7:108; 8:40**
Obviousness, **1:168; 9:15; 9:228; 9:250; 9:295; 19:211; 19:214**
Prima facie obviousness, **9:86**
Secondary considerations, **12:13; 16:4**

UNEXPECTED SETTLEMENT
Judicial estoppel, **23:21**

UNFAIR COMPETITION
Generally, **15:25**
Choice of law, **7:55; 16:48**
Inducing infringement, **18:48**
Inequitable conduct as, **16:48**
Infringement, **19:87**
Sec. 43(a), **15:5; 16:21**
Sec. 102(b), **3:16**
Sec. 337 (this index)
Summary judgment, **12:15**

UNFOUNDED DEFENSES
Anticipation, **18:20**

UNIFORM COMMERCIAL CODE (UCC)
Preemption, **3:68**

UNIFORMITY OBJECTIVE
Choice of law, **23:37**

UNILATERAL CONTRACT
Contract law, **23:39**

UNITED CANNABIS CORPORATION V. PURE HEMP COLLECTIVE INC.
2023, **21:93**

UNITED SERVICES AUTOMOBILE ASSOCIATION V. PNC BANK N.A.
2025, **21:96**

UNITED STATES
Site of infringement, **12:81**
Sovereign interests, qui tam actions, **19:224**
Title automatically vests in, **6:18**

UNITED STATES COURT OF INTERNATIONAL TRADE (CIT)
Procedural rule corresponds to FRCP, **5:18**

UNITED THERAPEUTICS CORPORATION V. LIQUIDIA TECHNOLOGIES, INC.
2023, **21:94**

UNJUST ENRICHMENT
Generally, **21:49**

UNPATENTED ACCESSORY SALES
Generally, **11:21**

UNPUBLISHED CAFC OPINION
Effect thereof, **17:2**

UNREASONABLE DELAY
Abandonment, suppression or concealment, **12:21**
Laches, **1:54; 13:36**

UNRELATED APPLICATIONS
Prosecution, **13:108**

UNRESOLVED DEADLOCK
Special interrogatories, **2:49**

UNSUPPORTED ALLEGATION
Frivolous appeal, **1:52**

URAA (URUGUAY ROUND AGREEMENTS ACT)
Generally, **13:77; 14:36**

URAA (URUGUAY ROUND AGREEMENTS ACT)—Cont'd
Offer to sell in United States, **20:103**
Safe harbor provision, **2:54; 4:40**
Terminal disclaimer, **2:89**

USE
Infringement, **9:453**
Not covered by patent, **14:63**
Personal jurisdiction, **13:153**
System use, infringement by, **3:156**
Written description, **9:453**

USE CODE OF FDA
Counterclaim to force correction, **14:68**

US FOOD AND DRUG ADMINISTRATION
FDA (this index)

US INVENTOR, INC. V. UNITED STATES PATENT AND TRADEMARK OFFICE
2025, **21:97**

US PATENT NO. 7,679,637 LLC V. GOOGLE LLC
2026, **21:99**

US SYNTHETIC CORP. V. INTERNATIONAL TRADE COMMISSION
2025, **21:98**

UTILITY
Application, **18:1**
Collateral estoppel, **9:143**
Contributory infringement, **7:130**
Design patent, **1:356**
Enablement, **9:319; 16:60**
Fact question, **13:28**
Inducement, **7:130**
Inoperable, **5:56**
Inoperative, **6:9; 9:222**
Interference, **6:33**
Obviousness, **7:130**
Overbreadth, **21:10**
Practical, **6:33**
Prima facie obviousness, **9:17**
Public Utilities (this index)
Sec. 101, **2:34; 3:37; 5:7; 13:55; 14:4; 18:6; 20:25**
Sec. 102(g), **19:10**
Sec. 112(1), **9:165**

VACATION OF JUDGMENT
See also Stay (this index)
Altvater, **13:46**
Claim construction, **1:5**
FRCP 59(e), **19:42**
Judgment of patent invalidity, **3:188**
Mootness of case, **20:95**
Public interest, **15:36**
Regional law controls, **16:19**
Settlement agreement, **21:22**
Summary judgment based on anticipation, **5:129**
Validity, **7:8; 10:10; 23:18**

VACATUR
Generally, **3:236**

VACUUM, CLAIMS NOT INTERPRETED IN
Generally, **9:58; 19:13**

VAGUE ASSERTIONS OF PATENTABILITY
Prosecution history estoppel, **9:199**

VAGUENESS
See index topics Ambiguity; Certainty and Definiteness (this index)

VALIDITY
Generally, **2:199; 3:59; 8:93; 9:253; 16:87; 21:32; 22:23**
Altvater, **13:46**
Anticipation, **1:340; 1:341; 16:167**
Appeal and review, **7:61; 8:49; 8:62; 18:39; 21:26**
Assignor estoppel, **21:38**
Attorney fees, **10:2**
Burden, heavy, **23:48**
Burden of persuasion, **15:15**
Burden of proof, **14:21; 20:35; 20:39; 21:25**
Challenging each claim, **3:114**
Claim by claim basis, **1:110**
Claim construction and interpretation
generally, **21:33**
declared valid, **4:23**
domestic industry requirement, **19:206**
each claim presumed valid, **4:74**
infringement, construed same way for, **1:131; 2:82**
preserve validity, **18:50; 23:16**

VALIDITY—Cont'd
Claim construction and interpretation —Cont'd
uphold if possible, **12:12**
Claim itself recites incorrect science, **5:56**
Claim preclusion, **8:76**
Clear and convincing evidence, **5:49; 5:64; 19:132; 19:142**
Collateral estoppel, **4:3; 8:73; 13:105**
Consent judgment, **5:8**
Copending application, **8:7**
Counterclaim, **13:91**
Cross-appeal, **18:2**
Damages, **3:180; 12:45**
Declaratory judgment, **1:312**
Declare, inappropriate to
evidence, objective, **4:19**
objective evidence, **4:19**
representative, unless claim is, **4:19**
secondary consideration, **4:19**
Dependent, independent versus, **8:7**
Dependent claims as hedge against invalidity, **9:345**
Design patent, **19:8**
Determination to be vacated when infringement not present, **23:18**
Dismissal, **16:54**
Doctrine of equivalents, **5:6**
Domestic industry requirement, **19:206**
Double patenting, **8:7**
Each claim has independent validity presumption, **3:41**
Each patent independent, **5:45**
Enforceability issue, **12:40**
Equivalence, **5:7**
Examiner, prior art before, **3:77**
Exceptional case, **3:180**
FRCP 49(a), **19:21**
FRCP 56, **16:32**
FRCP 59(e), **19:42**
Heavy burden when only oral testimony, **23:48**
Identity of invention, **20:20**
Indefiniteness, **2:169**
Independent, each patent as, **5:45**
Independent of infringement, **19:86**
Independent vs. dependent claim, **8:7**

VALIDITY—Cont'd
Infringement
access validity not examiner's potential act, **20:72**
appeal and review, **7:61; 8:49; 18:39**
burden of persuasion, **15:15**
eliminates need to consider, **12:45**
independent of, **16:74; 19:86**
lack of written description, **19:249**
validity, effect on, **1:113**
Judgment, **2:169; 14:1**
Jury verdict, **4:18; 8:62; 12:94; 21:26**
Laches or delay, **3:180**
Lack of written description, infringement, **19:249**
Law question, **14:8**
Lear distinguished, **8:11**
Licensee, **13:132**
Limitations, must construe dispute limitations first, **4:68**
Mootness, **1:113**
New trial, **8:51**
Obviousness
generally, **18:47**
dependent claims, **9:24**
dependent claim validity, **16:4**
eliminates need to consider, **12:45**
holding in prior suit, **7:17**
same way for validity and infringement, **19:11**
Oral testimony, **23:48**
Patents born valid, **4:6**
Post-trial motions, **18:3**
Preliminary injunction, **18:21; 20:12**
Presumption of
generally, **1:80; 19:37; 19:129**
irreparable harm, **14:9**
ITC, **19:25**
JNOV, **22:2**
mere procedural device, **13:53**
new prior art, effect of, **18:10**
obviousness, **13:99**
prejudgment interest, **12:9**
PTO, **19:235**
Sec. 282, **8:119; 9:21; 9:57; 9:80; 12:6; 13:87; 16:4; 18:6**
substantive law, **19:36**
summary judgment, **3:13**
verbatim findings of counsel adopted, **8:22**

VALIDITY—Cont'd
Primarily functional, **12:8**
Prior art, **3:77; 4:6**
Prior ruling upholding patent validity, **5:9**
PTO initial rejection, **7:19**
Public concern, matter of, **6:22**
Public policy, **4:13**
Public use, **16:167**
Reexamination, **6:85**
Regulation invalid when contrary to purposes of statute, **7:24**
Reissue, **4:69**
Rejection, **7:19**
Remand and reassignment, **20:104**
Res judicata effect, **6:17**
Rewrite claim to preserve validity, not court's function to, **1:119**
Science, claim itself recites incorrect science, **5:56**
Sec. 271(a), **3:180**
Sec. 102(b), **9:7**
Sec. 112, **20:6**
Sec. 153, **5:17**
Sec. 261, **10:4**
Sec. 282, **6:10; 9:80; 12:5**
Sec. 284, **16:167**
Standard of proof, **13:169**
State immunity from suit under Eleventh Amendment, **10:11**
Success on merits, likelihood of, **1:110**
Summary judgment, **1:35; 20:10; 20:107; 21:46**
Two-step analysis, **19:119**
Vacation of judgment, **7:8; 10:10**
Witnesses, **19:145; 23:48**

VALUE AND VALUATION
Anticipated collateral sales vs. reasonable royalty rate, **18:35**
Bona fide purchaser, **8:63**
Demand, patented feature is reason for, **20:50**
Eminent domain, **8:56**
Entire market value rule, **6:36**
Obviousness, **9:191**

VARIED USE OF A TERM
Claim interpretation, **2:78**

VASCULAR SOLUTIONS LLC V. MEDTRONIC, INC.
2024, **22:70**

VENUE
Generally, **1:362.50; 2:196; 3:229.50; 9:499; 9:505; 9:508; 9:515; 10:46; 20:82; 22:64**
Corporation, domestic, **20:137**
Dismiss or transfer infringement suit, **9:432**
Domestic corporation, **20:137**
Frcp 12(g)(2), **9:447**
Frcp 12(h)(1)(a), **9:447**
FRCP 25(a), **13:25**
Frivolous appeal, **23:98**
Infringement, **8:53**
Mandamus, **9:445; 9:447; 9:449; 9:457; 9:462; 9:472; 9:480; 9:491; 9:493; 9:510; 9:515**
Personal jurisdiction, lack of, not properly transfer, **8:69**
Sec. 1400(b), **9:11**
Transfers, **7:93; 8:69; 8:110; 9:334; 9:336; 9:395; 9:447; 14:60; 22:38; 26:14**
Waiver, **9:447**

VERBAL DIFFERENCES
Appellate standard of review, **7:2**

VERBATIM FINDINGS OF COUNSEL ADOPTED
Generally, **8:22**
Anticipation, **8:22**
Best mode, **8:22**
Conception, **8:22**
Enablement, **8:22**
Evidence, objective, **8:22**
Fact question, **8:22**
It would be obvious, **8:22**
Objective evidence, **8:22**
Obvious to try, **8:22**
Presumption of validity, **8:22**
Reduction to practice, **8:22**
Validity, presumption of, **8:22**

VERDICT
Generally, **12:74; 14:44**
Advisory jury still need findings of fact, **20:39**
Alternate legal theories, **13:97**
Appeal and Review (this index)

VERDICT—Cont'd
Choice of law, **13:105**
Claim interpretation, **19:5**
Claim preamble, **16:14**
Combination patent, **3:17**
Commercial embodiment comparison, **16:14**
Conflict, **4:18**
Defenses, **3:75**
Delay, excusable, **13:4**
Dimensions, **19:5**
Directed Verdict (this index)
Doctrine of equivalents, **8:47; 16:14**
Equitable estoppel, **13:4**
Equivalents, range of, **19:5**
Evidence, **3:75; 4:18; 7:29**
Exact identity, **16:14**
Excusable delay, **13:4**
Findings of fact, **20:39**
Form, **22:4**
FRAP 38, **3:17**
FRCP 49(a), **19:5**
FRCP 49(b), **13:4**
Frivolous appeal, **3:17**
Identity. exact identity, **16:14**
Improper, **16:14**
Indirect infringement, **16:153**
Infringement, **8:47; 19:5; 20:25**
Instruction, **4:18**
Insufficient, **3:17**
Inventor's claim interpretation, **19:5**
JMOL, **11:28**
JNOV, **3:17; 5:7; 13:17; 19:56; 20:15**
JNOV motion, **16:14**
Judgments reviewed, **16:14**
Jury trial, **16:14; 19:60**
Laches, **13:4**
Manufacturing tolerances, **19:5**
Mistakes at trial, not to cure, **4:18**
Motion, **4:18; 5:7**
New trial, **3:17; 4:18**
9 Cir law, **18:14**
Noninfringement, **1:50**
Nose of wax, **19:5**
Obviousness, **3:17; 3:153; 16:14**
Ordinary meaning, term given its, **19:5**
Primary reference, **8:62**
Prior art, distinguishing features in, **3:17**
Proper standard, **3:75**

VERDICT—Cont'd
Relevant facts to be found by trial court, **18:25**
Review, standard of, **2:49; 6:26; 8:51; 21:27**
Sec. 287, **4:12**
Set aside, **3:173; 14:47**
Special Verdict (this index)
Specificity thereof, **8:52**
Substantial evidence, **7:29**
Validity, **4:18; 8:62; 21:26**

VERSATA SOFTWARE, LLC V. FORD MOTOR COMPANY
2026, **22:73**

VESTING OF TITLE
Infringement, **19:154**
United States, **6:18**

VICARIOUS LIABILITY
Infringement, **4:75**
Joint infringement, **13:159; 13:160**

VIDEOTAPE
FRE 403, **13:4**

VIRTEK VISION INTERNATIONAL ULC V. ASSEMBLY GUIDANCE SYSTEMS, INC.
2024, **22:71**

VIRTUAL ASSIGNMENT
Standing, **5:38**

VISIBLE, NOT REQUIRED TO BE
Design patent, **19:118**

VISUAL APPEARANCE AS A WHOLE
Infringement, **3:100**

VITALNESS
Administrative law, **4:38**

VITIATION
Claim construction, **3:178**
Doctrine of equivalents, **1:267; 3:178; 18:106**
Obviousness, **3:178**

VLSI TECHNOLOGY LLC V. INTEL CORPORATION
2023, **22:68**
2026, **22:74**

VOICE TECH CORP. V. UNIFIED PATENTS, LLC
2024, **22:72**

VOIDING
Election, **3:61**

VOLUNTARY AND INVOLUNTARY ACTS AND MATTERS
Dismissal, **18:76**
FRCP 19(a), **11:19; 19:264**
FRCP 41(a)(1), **5:18**
Joinder, **9:302; 14:9; 15:9**
Prosecution history estoppel, **16:79**

VOLUNTEER
Amicus curiae, **1:41**

VOLVO PENTA OF THE AMERICAS, LLC V. BRUNSWICK CORPORATION
2023, **22:69**

WAIVER
Generally, **1:363; 9:246; 9:492; 18:66**
See also Estoppel (this index)
Belated preliminary motion, **7:26**
Claim construction and interpretation, **3:174; 3:200; 4:99; 9:234; 15:29; 19:16; 19:279**
Constitutional immunity, **3:33**
Defenses, **9:159**
Directed verdict, failure to timely move for, **10:15**
Eleventh amendment waiver, **18:66**
Expert or opinion evidence, **19:279**
FRCP 49(a), **19:21**
Implied waiver, standards setting organization, **3:206; 8:120**
Jury trial, **20:39**
Legal issues not raised at trial, **6:16**
Obviousness, **9:439**
Opening brief, raising issue in, **23:25**
Patent term extensions, **16:149**
Personal jurisdiction, **13:114**
Reasonable royalty, **19:279**
Sec. 282, **4:58; 20:15**
Sec. 1400(b), **9:11**
Sovereign immunity, **10:19; 13:48; 19:75; 23:28**
Special verdict, **8:52**
Standing, **2:18**
Time bar, **1:350**

WAIVER—Cont'd
Transfers, **9:447**
Venue, **9:447**

WALKER PROCESS
Generally, **3:69; 3:83; 3:230; 8:102; 9:221; 14:21; 14:25**
Antitrust, **1:25; 1:42; 4:84; 11:16; 18:97**
Inequitable conduct, **3:71; 14:21; 14:25**
Invalidity and noninfringement, declaratory judgment, **20:133**
Jurisdiction, **24:6**
Summary judgment, **12:15**

WARNER-JENKINSON
Presumption, **9:209**

WARRANTY, BREACH OF
Interference, **1:58**

WASH WORLD INC. V. BELANGER INC.
2025, **23:105**

WATERMAN
Generally, **15:9**

WEAKENED
Presumption of validity, **13:81**

WEBER, INC. V. PROVISUR TECHNOLOGIES, INC.
2024, **23:103**

WEEKEND OR HOLIDAY
Timely appeal, failure to file, **23:28**

WEIGHT AND CREDIBILITY OF EVIDENCE
Generally, **19:57; 22:27**
Agency regulations and pronouncements, **20:28**
Determinations, **4:41; 6:28**
Obviousness, **1:30; 3:165; 13:84; 16:19**
Reviewability, **8:31**
Sec. 284, **2:31**
Secondary considerations, **18:28**
Special province of trier of fact, **18:12**
Trial court, **14:10**
Trial judge, **19:54**
Trier of fact, special province of, **18:12**

WELL-ESTABLISHED COMMON LAW PRINCIPLES
Presumption, **9:154**

WELL-KNOWN AND ROUTINELY BUILT
Conclusory statements, **9:113**

WELL-PLEADED COMPLAINT
Generally, **1:76; 8:66; 12:44; 13:107; 19:55**
Counterclaim included, **2:31**
Jurisdiction, **1:135; 1:160**
Sec. 41(a)(7), **13:32**
Transfer of appeal, **7:14**

WELL-UNDERSTOOD, ROUTINE AND CONVENTIONAL
Fact question, skilled artisan, **1:311**

WHEREBY CLAUSE
Claim construction, **8:91; 20:29**
Means-plus-function claim, **12:62**

WHOLE INVENTION
Claim interpretation, statements describing whole invention, **22:32**

WHOLE OF STATUTE TO BE CONSIDERED
Statutory construction, **19:77**

WIDE DISCRETION
JMOL, **26:9**

WILLFUL BLINDNESS
Inducement, **7:103**

WILLFUL CONTEMPT ORDER
Sec. 271(e)(1), **5:13**

WILLFUL INFRINGEMENT
Generally, **1:152; 2:33; 3:2; 6:59; 8:133; 13:126**
Actual knowledge of infringer, **14:24**
Actual notice creates affirmative duty, **3:80**
Advice of counsel, **14:5; 19:154**
Affirmative duty, **18:29**
Appealable issue, **3:26**
Attorneys (this index)
Avoidance of literal infringement factor, **23:50**
Bad faith not required, **10:21**
Burden, **16:22**